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Abstract
The lymphatic system provides a conduit for the delivery of antigen-presenting 
cells from peripheral tissues to draining lymph nodes, both constitutively and 
during inflammation, when a dramatic increase in the number of trafficking 
events occurs. This thesis is concerned with the role played by the lymphatic 
endothelium under pro-inflammatory conditions and the mechanisms regulating 
entry of leukocytes into the lymphatic capillaries.
Monoclonal antibodies against the lymphatic vessel endothelial-specific receptor 
for hyaluronan, LYVE-1, were raised in rat against the mouse orthologue, for use 
both as a marker for lymphatics in mouse tissue and to investigate the 
physiological role of this protein. LYVE-1 was found to be dramatically and 
specifically down-regulated by TNFa and TNFp, by rapid internalisation and 
transcriptional down-regulation in primary lymphatic endothelial cells. A 
significant reduction in LYVE-1 expression was also recorded in intact lymphatic 
vessels in response to TNFa and in an allergen-induced mouse model of skin 
inflammation. Furthermore, lymphatic endothelial cells were found to respond 
to this pro-inflammatory cytokine by instigating a distinct expression 
programme characterised by up-regulation of the key leukocyte adhesion 
receptors VCAM-1, ICAM-1 and E-selectin; chemokines and other potential 
regulators of leukocyte entry. Moreover, the major components of this 
programme were confirmed in dermal lymphatic vessels in the allergen-induced 
mouse model of skin inflammation, simultaneous with the down-modulation of 
LYVE-1 and lymphatic accumulation of migrating leukocytes. The results 
described in this thesis provide the first evidence that lymphatic endothelial cells 
play an active role in inflammation. In addition these data indicate that the 
lymphatic and blood vascular systems share components of the same address 
code for specific vascular targeting.
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Chapter 1 General Introduction 1.1 The Lymphatic System
1.1 The Lymphatic System
1.1.1 The discovery of the lymphatics
The early history of the research into the lymphatics is contemporary with the 
founding of modem medicine. The ancient Greeks first recorded the observation 
of vessels containing colourless fluid: Hippocrates spoke of "white blood" circa 
400BC and the Greek physician Herophilus recorded vasa chylifera or lacteals in 
the mesenteries of the live criminals he dissected (Robinson, 1907). Another 
Greek physician, Erasistratus (340-280 B. C.) also observed such vessels but 
mistakenly believed them to be arteries. However the important physiological 
functions they perform were unreported. No further progress was made until 
1622 when an Italian professor of anatomy and surgery, Gasparo Aselli observed 
white fluid-filled vessels in the mesentery of a well-fed dog. He termed these 
vessels "milky veins", lacteis venis in a descriptive paper published 
posthumously in 1627 (figure 1.1). The following year the efforts of Nicolas 
Peiresc, a liberal senator of Aix, resulted in these observations being confirmed in 
a human subject, a felon who had eaten copiously before execution and whose 
body was inspected an hour and a half later.
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B
Figure 1.1 Illustrations from the descriptive paper on mesenteric lymphatics by Gasparo 
Aselli (1627). Upper panel depicts the branching “lacteis venis” in canine mesentery. Lower panel 
shows the highly decorative front cover of this extensive study.
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The discovery of the thoracic duct by Jacques Mentel in 1629 and again in 1651 
by Jean Pecquet lead to the recognition that lymph drains from the thoracic duct 
into the blood instead of to the liver, as was previously suggested by Aselli, who 
postulated that lymph would transform into blood in the liver. However the 
importance of the lymphatics was not initially acknowledged and it was 
assumed that their primary role was to enable absorption of food. This concept 
was revised following the observation of the extensive network of the lymphatics 
throughout the body, by Olaus Rudbeck in 1651, a young Swede working in 
Upssala and at the same time by George Joyliffe, an English anatomist and then 
again in 1653 independently by Thomas Barholin in Copenhagen, who first 
introduced the term lymphaticus (Robinson, 1907). The lymphatics of the large 
intestine were traced to the thoracic duct, which was found to lead into the 
subclavian veins.
Development of the technique of intralymphatic injection of mercury, first by 
Nuck (1692), then modified by Macagni (1784), Cruikshank (1798) and Gerota 
(1896), permitted the lymphatic system to be outlined in greater detail than was 
previously possible. Monro primus (1732) and Monro secundus (1788) were 
responsible for various accounts of the lymphatic system and detailed plates 
indicating the location of major lymphatic vessels in the body (figure 1.2), as 
revealed by the injection of mercury (reviewed by Kaufman, 1999). The modem  
era of understanding lymphatic function was heralded in 1746 in London, when 
William Hunter with his brother John Hunter and pupils at the School of 
Anatomy were able to show that the lymphatic vessels are responsible for 
absorption throughout the body, instead of only from the gut, as was initially 
believed. By the end of the century, the anatomy of the larger lymphatic network 
was correctly elucidated. The fine lymphatic capillaries had to linger on in 
obscurity until 1862, when the advent of a discovery by von Recklinghausen 
revolutionised the field. He found that following the application of silver nitrate
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to tissues, the borders of endothelial cells stained black (reviewed by Skobe and 
Detmar, 2000). He went on to disprove the popular theory of the time that 
lymph passed from the blood stream into the lymphatics through a fine tubular 
system and demonstrated that the two systems were not directly connected. 
Instead he theorised that lymphatic capillaries have open endings into which 
fluid passes from the interstitial space. He was responsible for an accurate 
description of the network of lymphatic capillaries and revealed that they are 
lined by a single layer of endothelial cells.
Figure 1.2 Engraving of the lymphatic system, based on the cadaver of a male subject, 
dissected and injected with mercury in 1788 by Monro secundus. Adapted from Kaufman, 1999.
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The first suggestion that lymph was a filtrate of blood was by Ludwig in the late 
19th century and confirmed by Starling in 1896. Although Starling had realized 
that capillaries leak protein, the concept was further developed in the early 20th 
century by Drinker (Skobe and Detmar, 2000). Thus the lymphatic system was 
recognised as constituting highly permeable absorbing vessels which return fluid 
and proteins to the blood stream and a cease in this recirculation results in death, 
(Adair and Guyton, 1985).
The role played by the lymphatics in absorbing digested fats from the intestine 
was characterised more fully by Allen (1967), who identified the presence of 
lacteals within the villi of the small intestine, so called due to the milky (lacte) 
white appearance, first observed and recorded 2000 years earlier.
The important immunological functions performed by the lymphatics were not 
recognised until the 20th century, with the characterisation of lymph nodes and 
understanding of antigen presentation. The pioneering works of Gowans (1957 
and 1964) and later Morris (1961-1972) are credited with paving the way for our 
modem understanding (reviewed by Young, 1999), as although the presence of 
cells (ilymphocytes) within the lymphatics had been noted, it was initially believed 
that these were newly formed cells. Gowans demonstrated that the cannulation 
of the thoracic duct in a rat resulted in a progressive loss of lymphocytes in the 
thoracic duct lymph but that this loss could be reversed by returning the 
collecting cells to the animal by intravenous injection. He also observed that cells 
collected and labelled with radioactive tracking agents could later be recovered 
from the thoracic duct lymph and thus the recirculation of lymph-bome cells was 
demonstrated. Morris and colleagues continued the studies in sheep, which as a 
large animal permitted the lymphatic vessels draining individual lymph nodes to 
be accessed surgically. The other advantage of the ovine model was that sheep 
lymph nodes do not occur in chains as in humans, where the efferent lymph of
6
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one node contributes to the afferent supply of a second node. Instead, each node 
is drained by only a single efferent lymphatic. Thus this simplified model has 
permitted many subsequent researchers to track lymphocyte traffick through a 
variety of lymphoid and non-lymphoid organs, in normal and pathological 
conditions (reviewed by Young, 1999).
Over the last 2000 years the inhumane and brutal early anatomical studies of the 
lymphatics have launched methodical scientific research into furthering 
understanding of the role of this fascinating circulatory system. With the 
relatively new discovery of novel, specific markers for lymphatic vessels 
(described in sections 1.2.5 and 1.3 of this chapter), the next few years can be 
anticipated to be an exciting time in the chronicles of research into the 
lymphatics.
1.1.2 Anatomy and Physiology
1.1.2.1 Lymphatic vessels
Lymphatic vessels are present in all tissues except for the central nervous system, 
bone and bone marrow (Mortimer, 1997). They can be broadly classified as 
either lymph capillaries (also termed initial capillaries), pre-collectors, collectors 
or lymphatic trunks. The initial capillaries within the superficial dermis of the 
skin originate as blind-ended endothelial-lined tubes and drain through a series 
of enlarging vessels, diminishing in number until they reach the thoracic duct. 
The initial lymphatics form an extensive network between the papillary and 
reticular dermis, overlaid by further plexi of arterioles and venules which lie 
directly beneath the epidermis.
When viewed in histological sections, lymphatic vessels often appear collapsed 
and distended, with thin attenuated walls of loosely overlapping endothelial
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cells and nuclei bulging into the lumen (figure 1.3). Unlike blood vessels they 
lack a basement membrane or zona occludens (Fawcett, 1986) and possess no 
fenestrations. Collagen fibres tether the lymphatic vessels to the surrounding 
matrix and prevent vessel collapse when the fluid pressure in the surrounding 
interstitium exceeds that within the vessels. The overlaps of cells create valves 
which prevent fluid leaking back into the tissue once the pressure has increased 
within the vessel (figure 1.3). In larger vessels, specialised valves composed of 
endothelium and matrix also assist in the one-way movement of lymph, as do 
local tissue pressure due to muscular activity and local arterial pulsation (Parson 
and McMaster,. 1938; reviewed by Swartz, 2001). Lymph fluid must be 
transported through the vessels against a hydrostatic pressure gradient and 
against a protein concentration gradient (reviewed by von der Weid and Zawieja, 
2003). Collector vessels are surrounded by lymphatic smooth muscles, as are 
larger lymphatic vessels. These muscles are arranged into one to three layers, 
interwoven with collagen and elastin fibres and surrounded by an adventitia of 
fibroblasts, connective tissue and nerve endings. As the vessels progress 
centrally the amount of smooth muscle increases, with the layers more 
distinguishable. This smooth muscle exhibits spontaneous and phasic 
contractions which enable the valve-delineated chambers of the vessel to act as 
pumps or "primitive hearts". The spontaneous transient depolarisation events 
which lead to contraction are believed to be of a myogenic origin (von der Weid 
and Zawieja, 2003). Impaired lymphatic smooth muscle function has been linked 
to various pathologies including lymphoedema (tissue swelling due to 
accumulation of protein-rich interstitial fluid resulting from low lymphatic 
output); interstitial oedema (increased leakage of fluid and protein from the 
blood, compounded by the inability to increase lymphatic clearance); and 
potentially inflammatory bowel disease. A study by Kaiserling et al., 2003 used 
the lymphatic marker podoplanin to demonstrate an increase in the number of
8
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intestinal lymphatic capillaries which may lead to abnormal lymphatic 
contractile function and impaired lymph flow (von der Weid and Zawieja, 2003).
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Figure 1.3 Transverse section of a dermal lymphatic capillary. Lymphatic endothelial cells are
firmly attached to the collagen and elastin fibres in tissues by anchoring filaments. An increase in 
interstitial fluid pressure expands the tissue and stretches the fibres. This expansion opens the 
intercellular junctions between overlapping endothelial cells, allowing passage of fluid and 
macromolecules into the distended lumen. Adapted from Skobe and Detmar, 2000.
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1.1.2.2 Lymph nodes
Lymphatic vessels deliver lymph fluid to the lymph nodes, which are responsible 
for filtering the fluid to remove cell debris and foreign matter for immune 
surveillance. There are hundreds of lymph nodes throughout the human body, 
varying in size from 1 to 10 mm in diameter (reviewed by Swartz, 2001). These 
are organised in clusters in regions such as the neck (cervical), near the jaw 
(submaxillary), armpits (axillary), in between the lungs (mediastinary), the 
abdominal cavity (mesenteric) and groin (inguinal), (figure 1.4).
Each lymph node is bounded by a collagenous capsule but a cross-sectional view 
reveals that it consists of several layers: the cortex, containing B-cells; the 
paracortex, rich in T-cells; and a central medulla (figure 1.5). The cortex in larger 
animals is subdivided into lobules, each separated by fibrous radial bands 
termed trabeculae (Gretz et al., 1997) whilst the lymph nodes of smaller animals 
such as mice typically contain only one lobule. B-cells aggregate in the lymphoid 
follicle of each lobule, with high endothelial venules (HEVs) and cortical sinuses 
situated in the surrounding cortex area. Macrophages are resident within the 
node to engulf cell debris and particulate matter and remove it from the lymph. 
This region is also rich in professional antigen presenting cells (APCs) which 
have entered through the afferent lymph as lymph node sinuses are the 
continuation of the lymphatic vessels entering the node. These branch into 
smaller subcapsular sinuses and the lymph fluid passes on to cortical sinuses 
within the cortex to reach the underlying sinuses of the medulla (Gretz et al., 
1997). Medullary sinuses drain into the terminal sinus and the filtered fluid 
leaves the node at the hilum via the efferent lymphatic vessel.
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Figure 1.4 Schematic representation of the lymphatic system and lymph nodes.
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Figure 1.5 Structure of a lymph node. Schematic diagram of a lymph node illustrating the cortex, 
containing the lymphoid follicles (rich in B lymphocytes) and the surrounding parafollicular cortex 
which contains T lymphocytes. The inner medulla contains large numbers of macrophages and 
dendritic cells, with some scattered lymphocytes. Lymph fluid enters from afferent lymphatic 
vessels and enters the subcapsular sinus. After passing through the node, the filtrate exits through 
the single efferent lymphatic vessel at the hilus.
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The migration of cells through the lymph node is by no means random but rather 
a carefully orchestrated process known as ecotaxis. This is dependent upon 
cellular interactions, gradients of soluble factors such as chemokines and the 
expression of specific structural proteins within the node (reviewed by Young, 
1999). The majority of lymphocytes enter the lymph node directly from the 
bloodstream by extravasation at HEVs (discussed more thoroughly in section
1.5.4 of this chapter) and are localised within B- and T-cell areas. Originally it 
was believed that lymph-borne antigens percolated through the lymph node 
cortex but Gretz et al. (2000) demonstrated that a functional barrier exists which 
restricts access to the cortex. In this study tracers of known molecular weight 
were injected subcutaneously into rats and mice to demonstrate that high 
molecular weight tracers were abundant in the subcapsular sinus but absent in 
the adjacent cortex, whereas low molecular weight tracers were only partially 
excluded. The authors suggest that this barrier could be significant during 
microbial infections, where it would isolate the cortex from the microbes 
themselves and their soluble products, which could perturb immune responses. 
They also showed that it remained intact even during viral-induced swelling of 
the lymph node. However such a barrier could restrict the ability of antigen 
presenting cells (APCs) already in the cortex to acquire lymph-borne antigen. 
The authors found high molecular weight tracer within the cortex after a delay of 
four hours from the time of subcutaneous injection and suggest that this is due to 
cellular uptake and would allow contact with APCs. Restriction of lymph-borne 
material to HEVs did not occur as low molecular weight tracers were found to 
highlight the reticular network and HEVs in the cortex. Thus lymph moves from 
the subcapsular sinus towards HEVs through the reticular network. Each 
reticular fibre is ensheathed by fibroblastic reticular cells and constitutes an 
extracellular space distinct from the interstitial space of the parenchyma and 
continuous with the fibres in the floor of the subcapsular sinus and those 
enwrapping the HEVs (Moe et al., 1963). Incoming lymphocytes pass from the
13
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HEV lumen to the cortical parenchyma and are bathed in the low molecular 
weight lymph-borne molecules that arrive via the reticular network. Gretz et al. 
(2000) speculate that this could be the site where antigen-specific B cells could 
capture their soluble antigen and transport it to the cortex for presentation to T 
cells. Chemokines were also found to travel through the reticular network to 
HEVs and may be immobilised on the endothelium to play a role in the 
lymphocyte recruitment. This route could also be utilised by pro-inflammatory 
cytokines, produced within inflamed tissue and passed through the lymph to the 
draining lymph node to stimulate endothelium at HEVs and perhaps up-regulate 
adhesion molecules to enhance leukocyte recruitment from the blood.
1.1.3 The origins and development of the lymphatics during embryogenesis
Until 1999, there were two theories concerning the origin of the lymphatics in the 
developing embryo. Injection experiments carried out by Sabin (1902, 1904) led 
her to propose that isolated primitive lymphatic sacs originate from endothelial 
budding from the veins (figure 1.6). An alternative theory, less widely accepted, 
was put forward by Huntington and McClure in 1910, whereby the initial lymph 
sacs arise in the mesenchyme and independent to the veins. In 1999, Wigle and 
Oliver proved Sabin's theory correct. They found that the transcription factor 
Proxl is a specific marker for the subpopulation of endothelial cells that bud and 
sprout from the vasculature of the developing mouse embryo.
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Figure 1.6 Schematic diagram to show the relative positions of primary lymph sacs, as
described by Sabin.
At E9.5 in the mouse, a few cells in the region anterior to the developing forelimb 
were Proxl positive, becoming more apparent and abundant by E10.5. Proxl 
positive cells were found lining one area of the anterior cardinal vein and these 
cells bud and spread in a clearly polarised manner, moving dorsoanteriorly. 
Expression of CD31 and VE-cadherin revealed that these cells were of endothelial 
origin. Thus an initial step must require the formation of endothelial cell 
precursors before specific growth factors and transcription factors induce arterial 
and venous formation. The initial budding of lymphatic endothelial cells from 
the veins is Proxl independent and may be regulated by the haematopoietic
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intracellular signalling proteins SLP-76 and Syk, the loss of which confer an 
angiogenic phenotype on haematopoietic cells (Abtahian et al., 2003). However 
Proxl is required to maintain budding and sprouting of the restricted 
subpopulation. Also it has been shown that ectopic expression of Prox-1 in 
cultured primary blood vascular endothelial cells induces lymphatic endothelial 
cell-specific genes and downregulated blood vessel-specific genes (Petrova et al., 
2002; Hong et al., 2002). Once the cells are committed to the lymphatic 
endothelial lineages, lymphatic vessel sprouting from embryonic veins is 
dependent upon paracrine VEGF-C signalling through VEGFR-3 and the first 
lymphatic endothelial cells are believed to migrate to form lymph sacs towards a 
VEGF-C concentration gradient (Karkkainen et al., 2003). The involvement of 
VEGFR-3 had been demonstrated earlier by Makinen et al. (2001a), who found 
that expression of soluble VEGFR-3 in transgenic mice during embryonic 
development inhibited lymphangiogenesis and lead to regression of existing 
foetal lymphatic vessels. The dermis and subcutaneous fat layer thickened, as in 
human lymphoedema and a lack of macromolecular transport in the dermis with 
fluid accumulation in the skin was also observed. However angiogenesis and the 
blood vascular endothelium were unaffected.
Budding from the cardinal vein gives rise to the jugular lymph sacs, from where 
capillary plexuses spread to the neck, head, forelimbs and thorax (Wigle and 
Oliver, 1999). From E12.5 onwards, additional posterior lymph sacs form, 
probably due to endothelial budding from other veins. Proxl-positive cells arise 
around other veins of the body, in the trachea, oesophagus, lungs and from the 
posterior cardinal vein By E14.5, these endothelial cells begin to grow out 
towards the periphery of the embryo to form lymphatic capillaries. At E15.5 an 
extensive lymphatic capillary network has developed, covering the dermis of the 
skin and intermingling with the blood capillaries throughout the entire embryo.
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Lymph nodes develop from an accumulation of CD45+ CD4+ CD3- cells which 
are in close proximity to MAdCAM-1, VCAM-1 and ICAM-1 expressing cells, 
seen enclosed within a layer of LYVE-1+ MECA32+ endothelial cells by E16.5 
(Cupedo et al., 2004). Such expression of both lymphatic and blood vascular 
markers reflects the fact that these cells have recently sprouted from the large 
veins and are still undergoing transition from a vascular to a lymphatic 
phenotype. This endothelial cell layer eventually differentiates to form the 
subcapsular sinus of the lymph node.
1.1.4 Functions of the lymphatics
The functions of lymphatics within the skin can be divided into three broad 
categories. Firstly it is responsible for carrying triacylglycerols and cholesterol 
from the intestines to the tissues (Voet and Voet, 1995), the function which 
originally lead to its discovery. Secondly it has an important immunological 
function (discussed in more detail in section 1.5 of this chapter). The lymphatics 
provide a major exit route from the skin for circulating cells such as T- 
lymphocytes and macrophages, as well as professional antigen presentating cells 
like dendritic cells. Antigens are transported to the regional lymph node and a 
primary immune response is initiated as naive lymphocytes are brought into 
contact with antigen-presenting cells. The third vital function of the lymphatics 
is the regulation of homeostasis in the skin, draining excess fluid from the 
interstitium to maintain constant interstitial volume, returning macromolecules 
to the circulation to maintain constant colloid osmotic pressure, transporting 
extracellular matrix components, eliminating unwanted cellular by-products and 
removing foreign organic and inorganic material (Berne et al., 1998). Each day 
approximately 50% of the total circulating protein escapes from the blood vessels 
and as it cannot be reabsorbed through the same route, it is the responsibility of 
the lymphatic system to return extravasated fluid and macromolecules to the 
circulation (Skobe and Detmar, 2000).
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1.2 Hyaluronan and its Receptors: CD44 and LYVE-1
One of the extracellular matrix components transported by the lymphatics is 
hyaluronan (HA), a large glycosaminoglycan linear copolymer of D-glucuronic 
acid and N-acetyl-D-glucosamine (Figure 1.7), up to 105-1 0 7 Da in size (reviewed 
by Toole, 2004). Other glycosaminoglycans (such as chondroitin sulphate, 
heparan sulphate and keratan sulphate) are bound to a core protein to form a 
glycosylated protein, or proteoglycan. However HA is not covalently bound in 
such a molecule but is secreted as a free polysaccharide.
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Figure 1.7 Schematic diagram of the structure of hyaluronan. The repeating disaccharide unit 
consists of alternating units of glucuronic acid and N-acetyl glucosamine (adapted from Laurent 
and Fraser, 1992).
Karl Meyer is credited with the discovery of HA in 1934, which was found to 
consist of "a uronic acid and an amino sugar". Thus, as it was isolated from 
bovine vitreous humour it was named hyaluronic acid from the Greek hyalos 
meaning vitreous (Meyer and Palmer, 1934). The name was later modified to 
hyaluronan, (Balasz et al., 1986) partly because it is the accepted terminology that 
names of polysaccharides have the suffix -an. The other reason was a chemical
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one: at physiological pH this molecule exists with dissociated carboxyl groups 
and should thus be termed hyaluronate but the counter ion in vivo could not be 
specified.
Subsequent studies found that HA was present in other soft connective tissues, 
such as umbilical cord, skin and rooster comb and the latter became a major 
source for HA (reviewed by Laurent and Fraser, 1992).
1.2.1 Functions of HA
HA is implicated in a wide range of physiological roles, as a structural 
component and also through its interactions with a cohort of HA binding 
proteins, discussed in section 1.2.3 of this chapter. HA plays an important 
structural role in cartilage where it provides support and lubrication. At 
physiological pH, HA is highly acidic due the presence of carboxyl groups and 
therefore has a net negative charge. This attracts many positively charged ions, 
which in turn attract large numbers of water molecules to form a highly hydrated 
gel. When bound by cartilage Link protein and large proteoglycans such as 
aggrecan and versican (reviewed by Knudson and Knudson, 1993), the HA- 
proteoglycan complex forms a porous, hydrated, space-filling gel in the 
extracellular matrix. Such an HA matrix has been found around cells as a 
pericellular coat (Knudson et al., 1993), which has been shown to aid cell 
movement (Evanko et al., 1999). The importance of HA in cell migration is 
indicated by its up-regulation during embryogenesis, wound healing and 
inflammation (Knudson and Knudson, 1993). The mechanism by which this 
occurs is thought to be due to reduced intercellular adhesion, enhancing cell 
division or migration. An increase in the amount of HA in some cancers has also 
been noted (reviewed by Toole, 2004), where it correlates with a more aggressive 
tumour.
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Interaction of HA with one of its principal receptors CD44 (described in more 
detail in section 1.2.4 of this chapter) has been found to promote signal 
transduction, eliciting a range of responses such as production of pro- 
inflammatory cytokines and rearrangement of the cytoskeleton.
HA is not restricted to eukaryotes and has also been identified in certain 
pathogenic bacteria, such as Streptococcus pyogenes and Pasteurella multocida, 
which use their hyaluronan coat to evade the host's immune system.
1.2.2 HA metabolism and turnover
HA is synthesised on the inner side of the cell membrane, unlike other GAGs 
which become covalently linked to a protein backbone within the Golgi complex 
(Toole et al., 2004). To date, three HA synthase genes, termed Hast, Has2 and 
Has3, have been identified in both mouse and human, spanning the membrane 
four times with both the C and N-termini located intracellularly. Has2 exhibits 
more restricted expression in the adult than Hasl or Has3. However, a study by 
Camenisch et al. (2000) found that Has2 is crucial for normal embryonic 
development, as the Has2_/_ phenotype is embryonic lethal, unlike either Hasl or 
Has3, with severe defects in vasculature development and a highly compact 
extracellular matrix, lacking the hydrating and expanding properties of HA.
HA turnover is surprisingly rapid in comparison to most extracellular matrix 
components, with approximately one third of the body's HA content turned over 
per day (Fraser et al., 1997). Only one third of this HA is degraded locally 
(Laurent and Fraser, 1992), by internalisation followed by degradation by 
intracellular hyaluronidases. The majority of HA is transported through the 
lymphatic vessels for degradation within the draining lymph nodes. The 
concentration of HA within the lymph was measured by Laurent and Fraser 
(1992) as between 8.5 and 18 jig/ml. Serum concentrations of HA are maintained
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at very low levels, typically 0.01 to 0.1 pg/ml, in sharp contrast to the 
concentrations found in certain tissues such as cartilage (1200 pg/ml) and in the 
dermis of the skin (200 pg/ml). Any HA present within the blood is rapidly 
transported to either the liver, spleen or kidneys, thus avoiding an increased 
viscosity of the blood.
The mechanism by which HA is taken into the lymphatics and transported 
remains unknown. However it may involve receptor-mediated transcytosis or be 
a case of simple diffusion between gaps in the intercellular junctions. 
Approximately 90% of HA in the afferent lymph is degraded within the lymph 
node, but the mechanism by which this occurs is largely uncharacterised (Fraser 
et al., 1997).
Degradation of HA occurs within lysosomes by the hyaluronidases HYAL1, 
HYAL2, HYAL3, HYAL4, PH20 and HYALP1. These enzymes are all endo-p-N- 
acetylhexosaminidases and cleave HA into small oligosaccharides of either 4 or 
10 repeating units in length (reviewed by Csoka et al., 2001). Expression of these 
enzymes varies between tissues. Degradation is completed by two 
exoglycosidases, p-glucuronidase and p-N-acetylglucosaminidase, which 
sequentially remove saccharides from the reducing end of the short HA chain.
1.2.3 Hyaluronan receptors
The majority of HA-binding proteins, or hyaladherins within the tissues belong 
to the Link protein superfamily, characterised by one or more copies of the Link 
domain (reviewed by Day and Prestwich, 2002). The Link domain acquired its 
name as it was first identified in Link protein, a component of cartilage, 
following a report that cartilage proteoglycans interacted with HA (Hardingham 
and Muir, 1972). The domain is approximately 100 amino acid residues in length 
and contains four cysteine residues which form two disulphide bridges.
21
Chapter 1 General Introduction 1.2 HA and its Receptors
The majority of Link protein superfamily members are components of the 
extracellular matrix and form a subfamily known as the hyalectans. These 
include aggrecan, versican, brevican and neurocan. They may be characterised 
by the G1 domain, containing an Ig fold and two Link modules, a central GAG 
attachment domain and a G3 domain. Other Link superfamily members include 
Link protein itself; BRAL1 (brain Link protein-1), identified by a BLAST 
homology search using brevican sequence; and TSG6 (tumour necrosis factor- 
stimulated gene-6), a small 277 residue protein which was originally isolated 
from TNF-treated fibroblasts (reviewed by Day and Prestwich, 2002).
The cell surface Link family members identified to date are CD44, LYVE-1, 
Stabilin-1 (also known as FEL-1, CLEVER-1 and FEEL-1) and HARE (FEL-2, 
Stabilin-2 or FEEL-2). CLEVER-1 and HARE are both large transmembrane 
proteins containing motifs for clathrin-mediated endocytosis. The extracellular 
domains are composed of alternating EGF-repeat regions and tandem Fasciclin 
domains with a membrane-proximal Link module.
CD44 has been well characterised over a number of years and plays a variety of 
roles in diverse physiological settings. LYVE-1 is in a much earlier stage of 
characterisation and much of the work done to date has been within the 
laboratory of Prof. David Jackson. However both receptors share a high degree 
of structural similarity and thus any study on LYVE-1 could not be undertaken 
without first reviewing CD44 (figure 1.8).
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Figure 1.8 Schematic diagram of CD44 and LYVE-1. Both proteins are type I transmembrane 
receptors with the Link module situated at the N-terminus (indicated by a black box), a glycosylated 
domain adjacent to the transmembrane domain and a cytoplasmic domain at the C-terminus. The 
Link module contains two di-sulphide bridges, but both CD44 and LYVE-1 contain an additional 
cysteine pair which form an extra disulphide bridge outside the Link module and an unpaired 
cysteine residue within the transmembrane domain.
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1.2.4 CD44
CD44 attained its name at the Third International Workshop on Leukocyte 
Differentiation Antigens (reviewed by Haynes et al., 1989), after repeated 
discoveries over the previous nine years under several different names. Dalchau 
et al. (1980) are credited with the first discovery of CD44, when they detected 
reactivity of a monoclonal antibody, F10.44.2, towards a then unknown antigen 
on T-cells, granulocytes, cortical thymocytes and in brain homogenate. 
Subsequent researchers characterised the antigen under various names including 
Pgp-1 (phagocytic glycoprotein-1), on macrophages and granulocytes; 
Extracellular Matrix Receptor type III (ECM-III), expressed on fibroblasts and 
found to bind to collagen types I and VI and fibronectin; and Hermes antigen, 
identified using the Hermes-3 mAb by Jalkanen et al. (1988) which was found to 
block the binding of lymphocytes to high endothelial venules (HEVs). The same 
molecule was found to be recognised by the "cluster" of antibodies used in all 
these studies and thus attained a "cluster of differentiation" number, CD44.
The reasons behind a long period of independent studies on what were 
considered different molecules within distinct functional contexts lie in the 
supremely polymorphic nature of CD44. Alternative splicing and heavy 
modification by glycosylation permits the molecule to exert a wide range of 
functions through each of its domains.
1.2.4.1 Structure of CD44
Cloning of CD44 cDNA from lymphoid cell lines by two independent groups in 
1989 confirmed that the multitude of antigens originally studied as different 
proteins were truly products of the same gene (Goldstein et al., 1989; 
Stamenkovic et al., 1989). Discrepancies between the sequences published are 
due to the former group cloning a variant isoform with a truncated cytoplasmic
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tail and the latter describing what is now considered the standard form. This 
type I transmembrane protein is 314 amino acid residues in length, following 
cleavage of the 19 amino acid signal peptide. The extracellular domain is 248 
amino acids in length and contains the Link module at the N-terminus, with the 
characteristic two disulphide bridges. Unlike most other Link superfamily 
members, CD44 (and also LYVE-1) contain a third disulphide bridge. The 
extracellular domain is followed by a stretch of 21 hydrophobic residues which 
make up the transmembrane domain and a 72-residue cytoplasmic tail precedes 
the carboxy terminus.
The extracellular domain contains six putative N-linked- and six putative O- 
linked- glycosylation sites (Goldstein et al., 1989), which accounts for the 
discrepancy between the predicted molecular weight of only 37 kD and observed 
molecular weight which exceeds 85 kD. The presence of four SG motifs 
represent potential GAG attachment sites, which may be modified with 
chondroitin or heparan sulphate (reviewed by Lesley et al., 1993)
1.2.4.2 Expression and functions of CD44
CD44 is widely expressed on cells of epithelial, mesothelial and haematopoietic 
origin. The few tissues that have been consistently reported as CD44-negative 
are cardiac muscle, renal tubular epithelium, testis and portions of the skin 
(Lesley et al., 1993). Given that it is so extensively expressed, it is quite 
astonishing that the CD44'/_ mouse did not exhibit some developmental defect 
which would cause its demise whilst still an embryo. Instead no embryonic 
lethality was reported and such mice developed normally, albeit with impaired 
homing of lymphocytes to the thymus and lymph nodes (Protin et al., 1999) and 
altered tissue distribution of myeloid progenitors (Schmits et al., 1997). This 
contrasted considerably with other studies which had shown that CD44 plays a 
critical role in development and tissue homeostasis. For example the injection of
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function blocking CD44 antibodies significantly reduced limb outgrowth 
(Sherman et al., 1998) and the disruption of CD44 expression in the skin resulted 
in severe accumulation of HA (Kaya et al., 1997). The absence of such a 
phenotype in the CD44 deficient mice would suggest that compensatory 
mechanisms come into play, such as up-regulation of other HA receptors. 
However the subsequent examination of the knock-out mouse and other studies 
on function blocking have shed more light on the many varied functions that 
CD44 performs, both in a normal physiological state and under pathological 
conditions
The mechanism by which leukocytes extravasate from the blood stream into the 
tissues is described in detail in section 1.5.3 of this chapter. Interactions between 
the leukocyte and blood vascular endothelium may be broadly divided into three 
phases of 1. rolling and initial attachment, mediated by selectins, 2. firmer 
attachement via integrins and 3. transmigration. The involvement of CD44 in the 
earlier stage of rolling was demonstrated by Clark et al. (1996), using CD44- 
positive lymphocytes within a flow chamber coated with hyaluronan or tonsillar 
stromal cells and by DeGrendele et al. (1996) using a substrate of SV40- 
transformed lymph node endothelial cells. DeGrendele et al. (1997b) later 
showed that CD44-HA interactions are of critical importance in the migration of 
T-cells to sites of inflammation. Numerous studies have shown that anti-CD44 
treatment, for example by promoting monoclonal antibody-induced shedding 
(Zheng et al., 1995) lead to a reduction of inflammation due to the lack of 
leukocyte infiltrate. More recent studies using the knock-out mouse have 
confirmed this and have found that this animal does not enjoy the normal 
healthy phenotype initially believed. Teder et al. (2002) demonstrated that such 
mice are unable to resolve lung inflammation following bleomycin-induced non- 
infectious lung injury, due to impaired clearance of apoptotic neutrophils, 
persistent accumulation of HA fragments and impaired activation of TGFpl. A
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partial reversal of this inflammatory phenotype was performed by reconstituting 
CD44 deficient mice with bone marrow from CD44+ mice and thus demonstrated 
a critical role for CD44 in resolving the inflammatory response. It is now 
generally believed that CD44 plays a role in the regulation of lymphocytes 
specifically during inflammatory conditions rather than in normal lymphocyte 
trafficking. Stoop et al. (2002) showed that the increased resistance of CD44 
deficient mice to collagen-induced arthritis was most likely due to impaired 
migration of leukocytes to the inflamed joints. Whereas CD44-positive 
lymphocytes in arthritic mice migrated to the site of inflammation, lymphocytes 
from CD44 deficient mice preferentially migrated to the lymph nodes.
CD44 is also believed to play a vital role in maintaining homeostasis within the 
extracellular matrix, where HA is known to form large complexes with 
proteoglycans. Transfection of CD44 into COS-7 cells and addition of exogenous 
HA lead to assembly of a pericellular matrix (Knudson et al., 1993), in a similar 
manner to that by chondrocytes, which naturally express CD44. CD44 has also 
been shown to mediate internalisation of HA in a number of cells such as 
chondrocytes, fibroblasts, macrophages and keratinocytes, via a clathrin- and 
caveolae-independent pathway (Culty et al., 1992; Hua et al., 1993; Kaya et al., 
1997; Tammi et al., 2001). Moreover Kaya et al. (1997) demonstrated that 
targeted suppression of CD44 in keratinocytes leads to the accumulation of HA 
in the skin of transgenic mice, which exhibited abnormal epidermal structure and 
delayed wound healing.
The importance of the cytoplasmic tail to the function of CD44 is becoming 
increasingly appreciated and the roles in signal transduction dissected out. 
Bourguignon et al. (1993) demonstrated that binding of HA to CD44 induces an 
increase in intracellular free calcium concentrations in T-lymphoma cells and 
thus could trigger signal transduction events within the cell. Association of
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CD44 with Src family tyrosine kinases and RhoA has been shown, as have 
interactions with GTP exchange factors Tiaml and Vav2, promoting signalling 
through Racl (reviewed by Turley et al., 2002). Such signalling pathways are 
known to regulate actin assembly that is associated with membrane ruffling, 
cellular projections and cell motility.
In addition to recruitment of other signalling molecules, signalling activity of the 
intracellular domain itself has been shown. This domain is proteolytically 
released from the rest of the molecule in response to stimulation with phorbol 
ester (Okamoto et al., 2001). The fragment has been shown to translocate to the 
nucleus and activate transcription via the 12-O-tetradecanoylphorbol 13-acetate- 
responsive element, found in numerous genes including CD44, which is induced.
Interactions of the cytoplasmic tail with other proteins have also been reported. 
The ERM proteins ezrin, radixin and moesin are closely related to each other, 
sharing approximately 75% homology but are encoded by different genes 
(Bretscher and Berryman, 1999). They are involved in the attachment of 
microfilaments to the plasma membrane and are capable of regulated homotypic 
and heterotypic interactions through their N- and C-terminal domains. The N- 
termini have been shown to bind in vitro to a motif of charged amino acids in the 
cytoplasmic portion of CD44 (Legg and Isacke, 1998), thus potentially connecting 
the cytoskeleton with the extracellular matrix.
Thus CD44 plays a critical role in cell adhesion, both in maintaining contact with 
the extracellular matrix and with other cells. Moreover this cell adhesion may 
trigger a range of responses within the cell, from activation of gene transcription 
to intracellular signal transduction cascades and the rearrangement of 
cytoskeletal proteins.
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1.2.5 LYVE-1
Despite the diverse functions of CD44, deletion of this gene in mice produced no 
immediately obvious abnormalities. Clearly the identities of HA receptors 
involved in HA homeostasis remained to be identified, prompting Banerji et al.
(1999) to search Human Genome Sciences/TIGR expression sequence tag (EST) 
databases for cDNAs homologous to the full length CD44H. A 2,313-bp EST 
from a HUVEC library was found to contain an open reading frame encoding a 
novel type I transmembrane receptor containing an N-terminal Link domain. 
Upon transfection of this cDNA into fibroblasts, the cells were found to bind HA, 
demonstrating that this CD44 homologue was a genuine HA receptor and the 
second cell surface receptor within the Link module superfamily. A soluble 
fusion protein of the novel homologue was generated and used to raise 
polyclonal antibodies in rabbits, to determine the expression pattern in tissue. 
Immunohistochemistry revealed that in sharp contrast to the widely expressed 
CD44, this protein was exclusively expressed on lymphatic vessels and was 
hence named LYVE-1 (lymphatic vessel endothelial HA receptor-1).
1.2.5.1 Structure of LYVE-1
The amino acid sequence of LYVE-1 encodes a 322-residue polypeptide, with the 
typical characteristics of a type I integral membrane glycoprotein (Banerji et al., 
1999). Kyte-Doolittle and Goldman hydropathy plots revealed that a sequence of 
26 largely hydrophobic residues reside at the NH2 terminus and probably 
constitute the leader peptide. These are followed by a hydrophilic sequence of 
212 amino acids which encode the extracellular domain. A sequence of 21 
hydrophobic residues correspond to the transmembrane anchor, followed by the 
dibasic motif KR and a highly charged stretch forming the 63-residue 
cytoplasmic tail. A heavily O-glycosylated serine/threonine-rich region, 
comprising 71 residues lies within the extracellular domain, as do two motifs for
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N-linked glycosylation, NFT and NSS, centred on residues 54 and 131 
respectively. LYVE-1 shares an overall 43% homology with CD44, although the 
sequence is more tightly conserved around the HA-binding Link domain. Both 
LYVE-1 and CD44 contain a single Link domain, composed of two P sheets 
flanked by two short a helices encapsulating a hydrophobic core (Kohda et al., 
1996). The domain is stabilised by four central cysteine residues (C2-C5), with a 
flanking pair (Cl and C6) spaced at exactly the same distances in both LYVE-1 
and CD44 and the two molecules share a much higher sequence homology of 
57% between these flanking cysteines. Both molecules also have a cysteine 
residue within the transmembrane sequence which is believed to be involved in 
covalent dimerisation of CD44 (Liu et al., 1997) and LYVE-1 (Nightingale and 
Jackson, unpublished).
Sequence alignment of LYVE-1 from five different species has shown that the 
cytoplasmic tail is remarkably well conserved (figure 1.9), suggesting that in 
addition to HA binding, LYVE-1 may perform other functions via this domain.
1.2.5.2 Cloning of the mouse orthologue
Human LYVE-1 amino acid sequence was used to identify the mouse orthologue 
by BLAST searching the mouse EST data base (Prevo et al., 2001). The cDNA 
was subsequently cloned from mouse lung and found to contain an open reading 
frame encoding 318 residues, i.e. 4 residues shorter than the human sequence, 
due to three amino acids less in the leader peptide and one less in the 
extracellular domain. Overall the LYVE-1 sequences from the two species share 
74% homology, with 79% homology within the Link domain. As in the human, 
two glycosylation sites exist within the extracellular domain, at N52 and N129, as 
does the heavily O-glycosylated serine/threonine-rich tract between residues 144 
and 188. The cysteine residues within the extracellular domain are conserved, as 
is the impaired cysteine within the transmembrane domain
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1.2.53 LYVE-l-mediated HA binding and internalisation
HA binding by LYVE-1 was first demonstrated in the human by Banerji et al., 
1999. They expressed the extracellular domain and leader peptide as a soluble 
fusion protein with the hinge, CH2 and CH3 domains of human IgGl and 
showed that LYVE-1 Fc bound immobilised HA in a concentration dependent 
manner which was virtually identical to that of CD44 Fc. Control fusion proteins 
of CD33 Fc and ICAM2 Fc displayed no significant binding. The LYVE-1- 
immobilised HA interaction was shown to be very sensitive to competition with 
soluble HA, whereas neither chondroitin -4 -S0 4 , chondroitin -6 -SO4 or heparin 
sulphate could compete for HA binding. Thus HA binding by LYVE-1 was 
shown to be highly specific. Evidence to suggest binding of HA by LYVE-1 in 
vivo was also shown. LYVE-1 was found to associate on the luminal face of tissue 
lymphatics with HA, in immunofluorescence studies using the HA probe 
biotinylated HABC (composed of bovine aggrecan and Link protein).
HA binding by mouse LYVE-1 was demonstrated by Prevo et al., 2001, using 
both transient 293T transfectants and soluble mouse LYVE-1 Fc fusion protein in 
microplate binding assays. The specificity of murine LYVE-1 for HA was shown, 
with no detectable binding to chondroitin -4 -SO4, chondroitin -6 -SO4 or heparin 
sulphate.
Prevo et al. (2001) also demonstrated that both mouse and human LYVE-1 
mediate the internalisation of HA in 293T transfectants, through receptor- 
mediated endocytosis. Immunoelectron microscopy was also used to reveal that 
murine LYVE-1 is located on both the luminal and abluminal surfaces of 
lymphatic endothelium. This would suggest an involvement of LYVE-1 in the 
transport of HA across lymphatic endothelium. The uptake of HA by LYVE-1 is 
considerably slower than that by the professional scavenger receptor HARE (HA
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receptor for endocytosis, Zhou et al., 2000), which would suggest that LYVE-1 
does not play a role in the rapid uptake and degradation of lymphatic HA.
More recent work by Tom Nightingale (DPhil thesis, University of Oxford, 2004) 
has sought to address the molecular mechanism by which LYVE-1 binds HA. 
Curiously the default binding state of LYVE-1 on lymphatic endothelium, both in 
the mouse and human, is "off". Removal of terminal sialic acid residues from 
carbohydrate chains linked to the protein via N-glycosidic linkages is required 
before LYVE-1 can bind HA. Moreover the LYVE-1 knockout mouse did not 
show any obvious abnormality of the lymphatics or HA metabolism. It is 
possible that more HA receptors remain to be identified and these play 
compensatory roles in both the CD44-/- and LYVE-1-/- mice. However it is also 
highly possible that LYVE-1 may have another physiological function besides 
that of an HA binding molecule. This would explain why HA binding requires a 
specific mechanism whereby it is "switched off", instead of just simply down- 
regulating protein expression. If LYVE-1 is to serve as a highly specific marker 
for the lymphatics, expression under various physiological and pathological 
conditions must be carefully characterised. Such studies require the use of a 
second lymphatic marker, to demonstrate that the vessels expressing LYVE-1 are 
truly lymphatic and not blood capillaries.
1.3 Other Endothelium Markers
The study of the lymphatics demands the ability to discriminate between 
lymphatic vessels and blood vasculature in tissue sections as well as in cultured 
cells. Research into identifying specific and reliable markers for both blood and 
lymphatic endothelium has advanced at a rapid pace over the last six years and
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although each marker may have its virtues and shortcomings, their use in concert 
has permitted a variety of exciting, novel studies.
1.3.1 Proxl
The homeobox transcription factor Proxl was cloned in 1993 by Oliver et al. by 
homology to the Drosophila melanogaster gene, prospero, where it controls axonal 
outgrowth. Functional inactivation of Proxl in mice proved to confer embryonic 
lethality, with phenotypic alterations to the lens and liver (Wigle et al., 1999). 
However its importance as a specific marker for the lymphatics was first 
reported by Wigle and Oliver (1999). Heterozygous Proxl+/- mice were generated 
with an in-frame insertion of the p-galactosidase (lacZ) gene which permitted 
detections of Proxl expression throughout development. Proxl+!- mice died 
between two and three days after birth, with their intestines filled with chyle, the 
milky-white fluid transported by lymphatic vessels of the small intestine. Such a 
phenotype indicated haploinsufficiency and suggested that the development of 
the enteric lymphatic system was dependent upon the presence of two copies of 
Proxl. The important role that this transcription factor plays during the 
development of the lymphatics was further demonstrated by studying p-gal 
expression in the heterozygous embryos. Proxl was found to be expressed in a 
subpopulation of endothelial cells which bud off from the cardinal vein and give 
rise to the lymphatic system. Moreover in the homozygous Proxl-!-, although the 
development of the vasculature proved unaffected, budding and sprouting of the 
lymphatics did not occur. Thus Proxl was shown to be a specific and essential 
regulator of the development of the lymphatic system.
Proxl was later shown to be required in maintaining the budding and sprouting 
of a restricted subpopulation of these endothelial cells rather than responsible for 
initiating it, (Wigle et al., 2002). The default phenotype of budding endothelial 
cells was shown to be that of blood vasculature and such cells require Proxl
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before a lymphatic vasculature phenotype can be adopted. A subsequent study 
by Petrova et al. (2002) found that Proxl is capable of reprogramming endothelial 
cells, up-regulating lymphatic endothelium-specific genes and inducing 
proliferation whilst suppressing blood vasculature endothelial genes.
Proxl has proved a very useful marker for lymphatics in tissues and in cultured 
lymphatic endothelial cells, with a distinct nuclear localisation.
1.3.2 Podoplanin
Podoplanin is one of the most highly expressed lymphatic-specific genes 
(Petrova et al., 2002; Hirakawa et al., 2003). It was first cloned from phorbol 
ester-treated osteoblastic cells and named OTS-8 (Nose et al., 1990). In vivo 
expression in lymphatic endothelium but not on blood vascular endothelium was 
first reported by Wetterwald et al. (1996) who named it E ll antigen due to its 
recognition by E ll antibody, a marker for cells of the late osteogenic lineage 
which binds to osteoblasts and osteocytes. An identical sequence termed Tla 
was found to be selectively expressed at the apical surface of alveolar epithelial 
type I cells in rat lung (Dobbs et al., 1988; Rishi et al., 1995). Tla expression was 
also detected in the choroid plexus, ciliary epithelium of the eye, intestine, 
kidney, thyroid and oesophagus of the foetal rat (Williams et al., 1996). Most 
recently the same gene was cloned as podoplanin by Breiteneder-Geleff et al. 
(1997) who identified it as a 43kDa membrane protein expressed on glomerular 
epithelial cells in rat kidneys. The researchers found that podoplanin was down- 
regulated in puromycin aminonucleoside nephrosis (PAN), a rat model of 
human minimal change nephropathy. Podoplanin acquired its name due to 
association with this pathological condition, where the arborised foot processes 
of podocytes are transformed into "flat feet", the Latin term for which is pes 
planus.
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Podoplanin is first expressed in the mouse embryonic vascular system between 
days E10.5 and E11.5 (Schacht et al., 2003) in endothelial cells of the cardinal vein 
and in the Proxl-positive lymphatic progenitor cells. By parturition, expression 
was found to be almost completely restricted to lymphatic endothelium, 
predominantly localised to the luminal plasma membrane of lymphatic vessel 
endothelial cells. Podoplanin-/- mice died immediately after birth due to 
respiratory failure, precipitated by impaired formation of alveolar airspace which 
was associated with a reduction in the number of differentiated type I alveolar 
epithelial cells in the lung (Ramirez et al., 2003). Such neonates also exhibited 
cutaneous lymphoedema, dilated cutaneous and intestinal lymphatic vessels and 
impaired lymphatic transport. However their blood vasculature was unaffected. 
Schacht et al. (2003) also found that over-expression of podoplanin in cultured 
vascular endothelial cells promoted the formation of elongated cell extensions. 
Cell adhesion, migration and tube formation were also found to be significantly 
increased. Thus podoplanin was shown to be a key regulator of lymphatic 
vascular formation.
Podoplanin has proved an extremely useful and reliable marker, both in the 
identification of lymphatic vessels in tissues and in isolating and characterising 
cultured cells (Kriehuber et al., 2001; Hong et al., 2002 and Petrova et al., 2002, to 
mention but a few).
1.3.3 VEGFR-3
Vascular endothelial growth factor receptor-3 (VEGFR-3), a tyrosine kinase 
receptor was first cloned by Aprelikova et al. (1992) from human leukaemia cells 
and named FLT4 as the tyrosine kinase domain shared 79% homology with the 
haematopoietic growth factor FLT1 (later re-named VEGFR-1). FLT4 expression 
was detected in human placenta, lung, heart and kidney. Subsequent studies 
revealed that both FLT1 and FLT4 contain seven immunoglobulin-like
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extracellular domains (Galland et al., 1993; Pajusola et al., 1992), with 12 potential 
glycosylation sites and two different transcript sizes of 5.8kb and 4.5kb, which 
differed in their carboxy terminal tails. These two isoforms, termed FLT4s (short) 
and FLT41 (long) were found to be generated by alternative polyadenylation and 
subsequent alternative splicing (Padjusola et al., 1993). Borg et al. (1995) 
demonstrated that FLT4 is highly glycosylated with a molecular weight of 
approximately 180kDa and provided some evidence that the two forms have 
different signalling properties.
VEGF-C was identified as a ligand for FLT4 by Joukov et al. (1996), who re­
named it VEGFR-3. In the same study VEGF-C binding to VEGFR-3 was found 
to induce tyrosine autophosphorylation of the receptor. VEGF-D was later 
identified as a second ligand for VEGFR-3 by Achen et al. (1998). Both ligands 
are able to induce the proliferation, migration and survival of VEGFR-3-positive 
cells in vitro (Makinen et al., 2001b) and are implicated in lymphangiogenesis, 
discussed in section 1.4.1 of this chapter.
Early studies suggested that VEGFR-3 was absent from blood vascular 
endothelium (Padjusola et al., 1992). However Kukk et al. (1997) showed that 
VEGFR-3 is widely expressed in the vascular endothelium in the early stages of 
development. Also disruption of the VEGFR-3 gene was found to cause 
disorganization in the large blood vessels (Dumont et al., 1998). The defective 
lumens of these vessels lead to fluid accumulation in the pericardial cavity and 
cardiovascular failure at embryonic day 9.5. Clearly the receptor plays an 
essential role in the development of the embryonic cardiovascular system before 
the lymphatic system has formed. The importance of VEGFR-3 within the 
lymphatic system was shown in a study by Irrthum et al., 2000, who identified an 
intragenic polymorphism in VEGFR-3 as responsible for Milroy disease, an 
autosomal dominant, congenital lymphoedema, characterised by a chronic
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swelling of limbs. This mis-sense mutation was found to inhibit the 
autophosphorylation of the receptor. Thus the loss of adequate VEGFR-3 
signalling appears to cause diminished or delayed development of lymphatic 
channels.
Although VEGFR-3 cannot serve as a specific marker for lymphatic endothelium 
in the embryo, it has been used extensively in studies on both normal and 
pathogenic adult tissue, for example Lymboussaki et al., 1998. Antibodies 
against the extracellular domain have also been used to isolate lymphatic 
endothelial cells from human primary microvascular endothelium, (Makinen et 
al., 2001b). However, in a study by Partanen et al. (2000), although VEGFR-3 was 
mainly confined to lymphatic endothelium within the adult and absent from 
large blood vessel endothelium, expression was detected on the endothelium of 
specific subsets of capillary. Such capillaries were typically found in tissues 
associated with extensive molecular exchange across the blood vessel wall, such 
as endocrine glands and the kidney glomeruli. The researchers found that 
continuous endothelia were usually negative for VEGFR-3 whilst discontinuous 
endothelia were positive. Thus it was suggested that VEGFR-3 plays a role in the 
transport functions of more permeable endothelia. Expression of VEGFR-3 at 
major sites of haematopoiesis or blood cell trafficking was also observed, in the 
sinusoids of the liver, spleen and bone marrow, implying a role for the receptor 
in regulating the translocation of cells.
Expression of VEGFR-3 on blood capillaries has also been observed during the 
neovascularisation of tumours and in chronic inflammatory wounds. Kubo et al.
(2000) found that VEGFR-3 is induced in murine vascular endothelial cells upon 
implantation of tumour cells where it is essential for maintaining the integrity of 
the endothelium. A study on wound healing in pigs and humans by Paavonen et 
al. (2000) revealed weak expression on vascular endothelium in chronic wounds
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such as within the neovasculature of ulcers and in lower extremity decubitus 
lesions.
VEGFR-3 is probably the most well-characterised of lymphatic endothelium 
markers detailed here. However exact sets of circumstances under which 
VEGFR-3 is expressed on blood capillary endothelium remain to be fully 
elucidated and therefore as a marker VEGFR-3 must be used with prudence. As 
many of the studies carried out in this thesis concern inflammation and the 
administration of inflammatory stimuli, VEGFR-3 is not employed as a marker in 
any of these experiments. Nevertheless its extensive use in other studies and its 
emerging role in a variety of physiological and pathological processes mean that 
this introductory chapter would not be complete without alluding to it.
1.3.4 CD34
The sialomucin CD34 is a heavily glycosylated type I transmembrane protein, 
expressed on developmentally early lymphohaematopoietic stem and progenitor 
cells, small-vessel endothelial cells and embryonic fibroblasts (reviewed by 
Krause et al., 1996). Its molecular weight is estimated at 116 kDa but due to 
extensive post-translational modifications, the molecular mobility is strongly 
influenced by its charge and remarkably the amino acid sequence deduced from 
the human CD34 gene sequence predicts a polypeptide of only 40 kDa (Simmons 
et al., 1992).
CD34 was first identified in a study by Civin et al. (1984), who sought to analyse 
and enrich haematopoietic progenitor cells using a mAb they had generated 
against the KGla myeloid leukaemia. The gene was cloned in 1992 by Simmons 
et al. who identified nine potential N-linked glycosylation sites and numerous 
potential O-linked glycosylation sites within the extracellular domain. Within 
the cytoplasmic portion they found two consensus protein kinase C
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phosphorylation sites and one potential tyrosine kinase phosphorylation site. 
The CD34 gene was found to span 26kb and possess nine exons (Satterthwaite et 
al., 1992). Two forms of CD34 have been identified, arising due to alternative 
splicing. One species contains exons 1 through to 8 and forms the full-length 
form; alternative splicing results in the insertion of an addional exon, termed 
exon X, between exons 7 and 8 which introduces a translational stop codon. This 
results in a truncated form of CD34, with a shorter cytoplasmic domain but 
identical transmembrane and extracellular regions to the full length protein.
Later studies revealed more about the structural nature of CD34 (reviewed by 
Krause et al., 1996). The extracellular region is dominated by an amino-terminal 
mucin-like domain, which is densely substituted with sialylated O-linked 
carbohydrates (Baumhueter et al., 1993), rendering CD34 highly stable and 
resistant to proteases. Due to this extensive glycosylation, the mucin domain is 
forced to adopt an extended, rod-like structure. Adjacent to this domain is a 
globular domain which contains six evenly spaced cysteine residues and could 
potentially fold into an Ig-like structure (Brown et al., 1991). The cytoplasmic 
domain is highly conserved between species orthologues, with over 90% amino 
acid residue homology). This domain also shares the most homology with other 
members of the growing CD34 family of sialomucins, namely podocalyxin and 
endoglycan (Sassetti et al., 2000). Such a high degree of conservation implies that 
this domain is responsible for a vital functional role and due to the presence of 
potential phosphorylation sites, would suggest that CD34 is involved in cell 
signalling.
Expression of CD34 on vascular endothelial cells was first identified and 
published by Fina et al. (1990). In this study, seven CD34 mAb already known to 
recognise epitopes on human haemopoietic progenitor cells were also found to 
bind to vascular endothelium. The researchers found that the majority of
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capillaries in most tissues were CD34 positive, as was umbilical artery. Less 
staining was observed on vein endothelium, whilst large vessels and placental 
sinuses were negative. CD34 was found to be concentrated on membrane 
processes, particularly at the interdigitations between adjacent endothelial cells. 
However none was observed on well established cell-cell contacts at tight 
junctions. Thus it was suggested that CD34 functions as an adhesion molecule 
on both endothelial cells and haematopoietic progenitors. A study by 
Schlingemann et al. (1990) very shortly afterwards, found that CD34 was 
localised at the luminal endothelial membrane but not the abluminal membrane, 
which was either negative or very weakly positive. However the abluminal 
microprocesses within tumour stroma were strongly positive and suggestive that 
CD34 could be used for such microprocesses during neovascularisation.
Expression of CD34 in freshly isolated umbilical vessel endothelial cells was 
reported by Fina et al., 1990. However they found that with continuous culture, 
although message could still be detected, CD34 protein could not be. They 
concluded that this was either due to downregulation or the possibility that the 
protein was being processed into another form which the antibodies they 
employed could not recognise. Maintaining expression of CD34 in cultured cells 
was later found to be possible by restraining cell proliferation and promoting cell 
contact (Deha et al., 1993), suggesting that CD34 might have a negative 
modulatory role on adhesion function within endothelial cells.
Within undifferentiated haematopoietic progenitors it would appear that full 
length CD34 plays a role in the maintenance of a phenotypically plastic state, 
thus inhibiting differentiation. Fackler et al. (1995) carried out a study on murine 
myeloid leukaemia cells and found that cytokine-induced differentiation resulted 
in the down-regulation of CD34. Constitutive expression of recombinant full 
length CD34 prevented differentiation, although leukaemia cells expressing the
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truncated form were found to complete differentiation. Thus inappropriate 
expression of full-length CD34 in leukaemic cells could contribute to their 
undifferentiated phenotype.
CD34 at high endothelial venules (HEV) has been identified as a ligand for L- 
selectin, but only when appropriately glycosylated and thus has a putative role 
in L-selectin-mediated leukocyte trafficking (Baumhueter et al., 1993; 
Baumhueter et al., 1994). L-selectin has been shown to bind directly to GlyCAM- 
1 on murine HEV, to form a chimeric protein which in turn binds to CD34 in a 
sialic acid-specific and Ca2+-dependent manner. Satomaa et al. (2002) identified 
the carbohydrate moieties on CD34 extracted from human tonsils and suggested 
that the sialated O-glycans could potentially form multiglycan binding epitopes 
for L-selectin. No L-selectin binding has been reported on either non-HEV 
endothelial tissues or haematopoietic progenitor cells, implying that differential 
glycosylation of CD34 across cell types may affect adhesive interactions, as may 
expression of different accessory molecules like GlyCAM-1.
Since the early 1990s, CD34 has served as a reliable marker for blood vascular 
endothelium in tissue sections. Traweek et al., 1991 found that CD34 gave 
quantitatively and qualitatively stronger staining in vascular neoplasia than von 
Willebrand Factor, vWf, an alternative marker for vascular endothelium, 
synthesised in Weibel-Palade bodies. Similarly Miettinen et al., 1994 found that 
CD34 was a specific and sensitive marker for the diagnosis of angiosarcomas, 
whereas vWf was less reliable. CD34 is employed in some of the experiments of 
this thesis in phenotyping cultured endothelial cells, as its expression has been 
shown to be restricted to prox-l-negative blood vessels in human skin and absent 
from lymphatic endothelium (Hirakawa et al., 2003). However, it has a 
limitation as a marker for blood endothelial cells in culture as there is evidence 
outlined above to suggest that CD34 expression decreases with continuous 
culturing. Therefore for this reason the absence of CD34 from an endothelial cell
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alone cannot be interpreted as an indication that the cell is lymphatic endothelial. 
Lymphatic endothelial cell markers were used much more extensively to avoid 
such potential artefacts.
1.3.5 CD31
CD31 or platelet endothelial cell adhesion molecule-1 (PECAM-1) was first 
identified in a search for novel endothelial cell adhesion molecules (Muller et al,
1989). This immunoglobulin (Ig) superfamily member is widely expressed on 
haemopoietic and endothelial cells, (reviewed by Jackson, 2003) and was found 
to be heavily glycosylated, with a relative molecular mass of approximately 130 
kDa, up to 40% of which is believed to consist of carbohydrate (Newman et al.,
1990). Expression occurs at a high density in endothelial cells where it 
concentrates at cell-cell borders and up to a million copies of CD31 have been 
found on such cells (Newman et al., 1994). Much lower expression is found on 
haematopoietic and immune cells such as macrophages, neutrophils, monocytes, 
mast cells, natural killer cells, platelets and naive B and T cells. No CD31 has 
been detected on fibroblasts, epithelial cells or red blood cells. The open reading 
frame, encoded on human chromosome 17q23 and mouse chromosome 6 
(Gumina et al., 1996) consists of 16 exons encoding a signal peptide, six C2-type 
Ig domains, a transmembrane region and a cytoplasmic C-terminal. CD31 
message is highly expressed in lung, heart and kidney and to a lesser extent in 
brain and liver. Several alternative splice variants occur, which are expressed in 
a cell-, tissue- and species-specific pattern and arise as a result of alternative 
splicing of either the transmembrane or cytoplasmic domain exons. The delta- 
exon 14 form (Kirschbaum et al., 1994) and delta-exon 13 form (Osawa et al., 
1997) may be generated in endothelial cells.
The ligand interactions of CD31 have attracted much interest for research over a 
number of years as this molecule is capable of both homophilic interactions with
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another corresponding CD31 molecule on an adjacent cell and also heterophilic 
binding to several other ligands. Homophilic interactions have been shown to be 
mediated by the NH2 terminal Ig domains 1 and 2, with the other Ig domains and 
the transmembrane proximal region responsible for maintaining these binding 
domains in the correct spacial organisation (J. Sim et al., 1996; Newton et al., 
1997). Human-mouse chimeric studies by Q. H. Sun et al. (1996) demonstrated 
the species specificity of these homophilic interactions. CD31 can also dimerise 
(Newton et al., 1999) and it is believed that the formation of primary cis 
interactions promotes efficient trans interactions with CD31 molecules on the 
neighbouring cell. A zipper model was proposed by Newton et al. (1997), 
whereby CD31 dimers interdigitate with other dimers on an apposing cell 
surface. Thus each CD31 molecule interacts with two others in this homophilic 
manner, with contribution from residues on both faces of the first Ig fold.
Heterophilic interactions with avp3 integrin have been found in both the mouse 
(Piali et al., 1995) and human (Buckley et al., 1996). In the latter publication, the 
binding was found to be mediated predominantly by the Ig domain 1, with some 
contribution from domain 2. CD31 binding to CD38 and an unidentified 120 kDa 
ligand on T cells have also been demonstrated (reviewed by D. E. Jackson, 2003).
As CD31 is capable of both heterophilic and homophilic binding of ligand, tight 
regulation of binding specificity is essential. J. Sun et al. (1996) suggested that 
the local level of surface expression of CD31 can alter ligand binding properties: 
where CD31 expression is high, typically at endothelial cell-cell junctions, 
homophilic ligand interactions occur. On leukocytes, where CD31 expression is 
lower and more diffuse, heterophilic interactions are more commonly mediated. 
A possible molecular mechanism by which this could be occurring was identified 
in a publication from the same research group, by Yan et al. (1995a). They 
transfected a series of mouse CD31 splice variants into mouse L cells and
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analysed the adhesive properties in an aggregation assay whereby transfectants 
were mixed with non-transfectants and allowed to aggregate. They found that 
full length CD31 and all isoforms containing peptide sequences encoded in 
cytoplasmic exon 14 mediated heterophilic aggregation via a non-CD31 ligand. 
Deletion of exon 14 resulted in homophilic aggregation. The researchers also 
found that heterophilic aggregation was sensitive to deglycosylation of CD31, 
whereas homophilic aggregation was not.
The region of exon 14 responsible for ligand specificity was identified by a series 
of deletion mutants as a conserved 5 residue motif, VYSEI in the mouse sequence 
or VYSEV in the human sequence (Famiglietti et al., 1997). The tyrosine residue 
within this motif was found to be key in determining the mode of aggregation. A 
construct in which the tyrosine was mutated to a phenylalanine residue was 
found to induced aggregation in a homophilic manner rather than the 
heterophilic aggregation observed by the wild-type. Homophilic aggregation 
was also induced following high levels of tyrosine phosphorylation within the 
cell. Thus the cell could potentially determine whether CD31 functions as a 
homophilic or heterophilic adhesion molecule by alternative splicing during 
synthesis and by the state of phosphorylation in the translated protein.
On endothelial cells CD31 is localised primarily at the cell-cell junctions but 
research by Bird et al. (1999) have lead to the suggestion that this adhesion 
molecule does not support strong adhesive interactions but rather acts as an 
adhesion-dependent signalling receptor and promotes cell adhesion and 
survival. In a study carried out by J. Sun et al. (2000), the localisation of CD31 to 
cell-cell junctions was found to be dependent on homophilic binding between 
adjacent cells and thus intact extracellular and transmembrane domains. A small 
group of highly charged amino acids (599RKAKAK604) in a membrane proximal 
region of the cytoplasmic domain were also found to be crucial. These provide
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putative docking sites for the recruitment of cytosolic signalling molecules and 
perhaps also cytoskeletal proteins.
In a study by Bogen et al. (1992) using immunoperoxidase and immunoelectron 
microsopic techniques, high levels of CD31 were found to be expressed on 
endothelium-adherent lymphocytes transmigrating across sinusoidal or venular 
vascular boundaries. Such expression was also detected in draining lymph 
nodes during the immune response following challenge with a protein antigen, 
where there are many transmigrating lymphocytes. They also found that 
leukocyte CD31 was predominantly localised on the surface which was in contact 
with endothelial cells and postulated that CD31 may play a role in lymphocyte 
recruitment and transmigration. The requirement for CD31 in transendothelial 
migration of leukocytes was shown by Muller et al. (1993). They found that anti- 
CD31 antibodies blocked transmigration when bound to either CD31 on 
monocytes or to CD31 at the endothelial junction, both in resting cells and 
following stimulation with proinflammatory cytokines. Neutrophil migration 
was also found to be blocked by these antibodies, although such migration only 
occurred across stimulated endothelial cells. As soluble CD31 also blocked 
migration, the interaction was deemed to be most probably homophilic and thus 
binding of leukocyte to endothelium was direct. Also, the epitope of the 
blocking antibody used lay within Ig domains 1 and 2 and was not found to 
block heterophilic aggregation. Heterophilic aggregation in L-cells was mapped 
to either Ig domain 2 or Ig domain 6 (Yan et al., 1995b) whilst again the N- 
terminal Ig domains were shown to be involved in transmigration.
Following stimulation of endothelium with the pro-inflammatory cytokines IFNy 
and TNFa, CD31 is redistributed from the intercellular junctions, perhaps as a 
means of regulating the transmigration of leukocytes (Romer et al., 1995). Also 
the gene expression decreases (Neubauer et al., 2000), shown in sinusoidal
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endothelial cells and monocytes following inflammation in the liver and also in 
cells in vitro. However these phenomena were not shown to reduce monocyte or 
neutrophil transmigration under flow (Shaw et al., 2001). A study using CD31- 
deficient mice demonstrated that although no differences in levels of leukocyte 
rolling or firm adhesion were observed in response to IL-ip, there was a delay in 
leukocyte transmigration (Thompson et al., 2001). Thus CD31 was shown to play 
a critical regulatory role in leukocyte migration through vessel walls at sites of 
inflammation. Such a delay in transmigration in these mice did not occur 
following TNFa elicitation as this cytokine was found to stimulate leukocytes 
directly. Thus CD31-independent leukocyte migration may also occur.
In addition to direct interactions as an adhesion molecule, CD31 plays pivotal 
roles in cell signalling pathways as an agonist receptor. Dangerfield et al. (2002) 
showed that homophilic interactions between neutrophil CD31 and CD31 at 
endothelial cell junctions stimulated enhanced expression of a6pl integrin on the 
cell surface of transmigrating neutrophils. This is believed to aid their migration 
through the perivascular basement membrane via interactions with laminin, a 
major constituent of this barrier. Such up-regulation of the surface expression of 
this integrin may be due to translocation from granules and degranulation. 
Other research groups have found that engagement of CD31 can up-regulate pi, 
P2 and p3 integrin function, (Tanaka et al., 1992; Berman and Muller, 1995; and 
Varon et al., 1998).
Other functions of CD31 in endothelial cells include the maintenance of a 
vascular permeability barrier, as shown by enhanced permeability changes in 
response to histamine by endothelial cells which do not express CD31, (Graesser 
et al., 2002). A role for CD31 in angiogenesis has also been found by several 
groups. In a recent study by Solowiej et al. (2003), a sterile and inert object was 
implanted into mice subcutaneously and the neutrophil infiltrate measured. An
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attenuated infiltrate was observed in CD31 knock-out mice and this was found to 
be due to a decrease in angiogenesis and thereby diminished delivery of 
leukocytes to the region.
Thus the different domains of CD31 permit this Ig superfamily member to carry 
out a vast repertoire of diverse function. This protein also serves as an effective 
marker for endothelial cells, both of the blood vasculature and of the lymphatics, 
allowing discrimination from epithelial cells and fibroblasts in culture.
Of the endothelial cell markers described above, podoplanin has been used the 
most extensively in this PhD as its high expression on the surface of lymphatic 
endothelium makes it ideal for investigating possible variations in LYVE-1 
expression. The availability of specific antibodies against both mouse and 
human podoplanin has permitted the study of LYVE-1 expression on both mouse 
and human tissue, in cell lines and also in models of pathological conditions 
within tissues.
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1.4 Pathological Conditions of the Lymphatics
1.4.1 Metastasis of tumour cells and lymphangiogenesis
The role of the lymphatics as a conduit for metastasising tumours has been 
recognised since the early 1700s when Louis Petit reported the spread of breast 
cancer to axillary lymph nodes (reviewed by Swartz, 2001). Tumours of the 
breast, lung and gastrointestinal tract are known to result frequently in 
secondary tumours within draining regional lymph nodes (reviewed by 
Saharinen et al., 2004); however the mechanism by which this dissemination 
occurs remains poorly characterised.
An increased expression of VEGF-C has been detected in many human tumours 
and has been found to correlate with lymph node metastasis in thyroid, prostate, 
gastric, colorectal and lung cancers. VEGF-C is also implicated in inducing 
lymphangiogenesis. A model used extensively to investigate this is that of 
transgenic mice overexpressing VEGF-C under the control of the keratin 14 (K14) 
promoter, which directs transgene expression to the basal keratinocytes of the 
skin. Jeltsch et al. (1997) found that K14-VEGF-C mice display a pronounced 
hyperplasia of cutaneous lymphatic vessels but exhibit no variation in the 
growth of blood vessels. A later study by Veikkola et al. (2001) generated 
transgenic mice with K14-VEGF-D and K14-VEGF-C156S, a mutant factor which 
is a selective agonist of VEGFR-3 and showed that VEGF-D is also 
lymphangiogenic. In addition they demonstrated that VEGFR-3 alone was 
responsible for the signal transduction. At around the same time Enholm et al.
(2001) used an adenoviral system to show that subcutaneous expression of 
VEGF-C induces proliferation and enlargement of lymphatic vessels in mice and 
also strongly up-regulates VEGFR-2 and VEGFR-3 expression in blood vessels. 
They found that VEGF, in contrast, only induces angiogenesis and the up-
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regulation of VEGFR-2. Mandriota et al. (2001) demonstrated that VEGF-C 
overexpression in pancreatic p-cells of transgenic mice results in extensive 
lymphatic channel formation around the islets of Langerhans which, as islets are 
very rarely in direct contact with lymphatics in wild-type mice, indicates de novo 
formation of lymphatics. These mice were crossed with mice from a transgenic 
model of p-cell carcinogenesis, which develop numerous B-cell tumours that are 
capable of local invasion but not metastasis. In contrast to the single transgenics, 
37% of the mice crossed with those overexpressing VEGF-C developed 
metastases in the draining regional mesenteric lymph nodes of the pancreata, 
thus providing evidence for a causal role for VEGF-C-mediated 
lymphangiogenesis and the dissemination of tumour cells.
The importance of VEGF-C in promoting lymphangiogenesis and metastasis to 
lymph nodes and lungs has also been shown using MCF-7 and MDA-MB435 
human breast cancer cells in immuno-deficient mice (Skobe et al., 2001; Karpanen 
et al., 2001; Mattila et al., 2002). However in contrast to the animal studies, 
Williams et al. (2003) were unable to detect dividing lymph vessels in primary 
human breast carcinoma and found few if any intra-tumoural lymphatic vessels. 
Dissemination was hypothesised to occur as the cancerous cells invade and 
destroy existing lymphatic vessels and the recombinant VEGF-C used in the 
animal studies was expressed at much higher concentrations than would 
normally occur.
Involvement of VEGF-D was elucidated by Stacker et al. (2001) who used 
293EBNA cells expressing VEGF or VEGF-D for subcuaneous injection into SCID 
mice. They found that VEGF-293 and VEGF-D-293 cells developed into highly 
vascularised tumours whereas the control 293 cells did not produce such large, 
vascularised tumours. Oedema was also noted in VEGF-293 tumours, which was 
not observed in VEGF-D-293 tumours. Moreover the growth of VEGF-D-293
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tumours was found to be inhibited by intraperitoneal injections of a mAb specific 
for the bioactive region of VEGF-D, which blocks binding of VEGF-D to both 
VEGFR-2 and VEGFR-3. The VEGF-D-293 tumours alone were found to contain 
LYVE-l-positive lymphatic vessels within the tumour mass as well as in the 
outer connective tissue capsule region surrounding the tumour and by use of dye 
injection experiments, these vessels were found to be functional. A massive 
tumour infiltrate within the lymph nodes was also reported in such animals. 
Together, these studies demonstrated the lymphangiogenic and angiogenic effect 
of VEGF-D through VEGFR-3 and VEGFR-2 respectively, as well as showing that 
VEGF-D-induced lymphangiogenesis can promote metastatic spread of tumour 
cells through the lymphatic network.
A study by Leu et al. (2000) had investigated functional lymphatics within a 
murine sarcoma and found that although lymphangiogenic factors VEGF-C and 
VEGFR-3 were present, functional lymphatic vessels did not form within the 
tumour, possibly because they collapsed due to solid stress exerted by the 
growing malignancy. However this study did not measure the expression of 
VEGF-C and VEGF-D which have been proteolytically processed into active 
forms. Thus the ability of a tumour to induce lymphangiogenesis of functional 
lymphatic vessels through which it can disseminate most likely depends upon 
which VEGF family members it is expressing and processing, as well as the 
interstitial pressure of the tumour.
The role of VEGF-D was also assessed by Niki et al. (2000), who found that the 
expression of VEGF-D was inversely correlated with metastatic spread of lung 
adenocarcinoma to lymph nodes. However this study was based on analysis of 
RNA from clinical samples by PCR which cannot take into account the extent of 
VEGF-D proteolytic processing into an active form which can bind VEGFR-2 and 
VEGFR-3 with high affinity. Nevertheless the possibility of more growth factors
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in addition to the VEGF family cannot be ruled out. A later study by Dadras et 
al. (2003) showed that intra- and peri-tumoural lymphangiogenesis in primary 
human cutaneous melanomas occurs and can be correlated with metastasis. 
However, although expression of VEGF-C was detected more frequently in 
tumour cells of metastatic melanomas than non-metastatic melanomas, these 
differences were not statistically significant (P > 0.05) and the authors suggest 
that lymphatic vessel growth might be stimulated by other growth factors which 
are as yet unknown. One possible candidate could be basic fibroblast growth 
factor (bFGF), which was found to be associated with the presence of peri- 
tumoral lymphatics in cutaneous melanoma (Straume et al., 2003).
Despite the controversy that remains regarding the functional significance of 
tumour-stimulated de novo growth of lymphatic vessels in clinical cases of cancer, 
the lymphatics are widely recognised as an important potential conduit for 
disseminating tumour cells from certain tumours. Once the molecular 
mechanisms of lymphangiogenesis are better elucidated this may serve as a 
potential therapeutic target to reduce metastasis of primary tumours.
1.4.2 Lymphatics as an entry for pathogens
Metastasising cancer cells are not the only entities which seek to hijack the 
lymphatics for purposes which are not in the animal's best interest. The 
pathogen Yersinia Pestis, a facultative anaerobic intracellular Gram-negative 
coccobacillus is a prime example, an organism known to be responsible for the 
deaths of nearly 200 million people through the infectious disease termed plague 
or Black Death (reviewed by Velendzas et al., 2004). This disease was responsible 
for at least three pandemics and multiple epidemics. It was during the last 
pandemic (starting in around 1855 in China) that Alexandre Yersin isolated the 
plague bacillus and developed an antiserum to combat the disease.
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The organism can be transmitted from an animal host to a human via the bite of a 
vector. More than 200 different species can serve as hosts, frequently rodents but 
also cats, dogs, deer, rabbits, camels and sheep. The vector is usually the rat flea, 
Xenopsylla cheopis but the human flea Pulex irritans as well as ticks and lice can 
also serve as carriers (Velendzas et al., 2004). The bacillus proliferates in the 
flea's oesophagus, preventing food from entering the stomach. The flea will try 
to overcome starvation by fervently attempting to feed more often on its host or 
an unfortunate human and as it tries to swallow, the distended bacillus-packed 
oesophagus recoils and deposits the bacillus into the victims' skin. It may then 
enter the lymphatics either alone or engulfed by an antigen presenting cell and 
traffick to a nearby draining lymph node. As the bacillus proliferates it induces 
inflammation and produces the characteristic bubo, a necrotic and haemorrhagic 
lymph node (figure 1.10). The bacteria may also be ingested by macrophages, in 
which they will proliferate. From there the bacilli may spread through efferent 
lymph to the thoracic duct, gaining entry into the vasculature and then 
potentially every organ, causing septicaemia and haemorrhage throughout the 
body. Direct inhalation of the bacillus results in pneumonic plague whilst 
delivery of the bacillus to the vasculature and bypassing the lymphatics results in 
septicaemic plague. However as bubonic plague has a longer incubation time of 
2-6 days (as opposed to pneumonic plague which has a trypical mortality rate of 
100% within 24h if left untreated), the potential for infecting more individuals 
and carriers is much higher. Yersinia Pestis is still very much endemic 
throughout most of the world and between 1967 and 1993, the World Health 
Organisation reported an annual average of 1666 cases of plague.
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Figure 1.10 Swollen lymph nodes in a patient infected with Yersinia Pestis, resulting in the 
characteristic buboes.
1.4.3 Lymphoedema
Clinical oedema results when either the volume of interstitial fluid exceeds the 
drainage capacity of the lymphatics or the lymphatic vessels become blocked, 
causing interstitial fluid to accumulate (Berne et al., 1998). Such tissue fluid 
imbalance may be hereditary and is termed primary lymphoedema, 
characterised by hypoplastic or aplastic superficial or subcutaneous lymphatic 
vessels which fail to transport lymphatic fluid into the venous circulation. Non­
inherited secondary lymphoedema occurs when the lymphatic vessels are 
damaged as a result of infection, trauma (from burns or radiation), surgery, 
tissue grafting or transplantation (reviewed by Swartz, 2001). If this arises in the 
lungs it is termed pulmonary oedema whilst such excess fluid in the peripheral 
tissues is known as generalised oedema. Pulmonary oedema is a frequent 
complication of cardiovascular disease, occurring when pulmonary capillary 
hydrostatic pressure exceeds plasma oncotic pressure, resulting in serious
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interference with gaseous exchange due to fluid accumulation within the 
pulmonary interstitium or within the alveoli themselves, which can prove lethal.
Lymphatic filariasis is caused by a parasite known as the filaria round-worm. 
This organism infects the lymph nodes and provokes the growth of connective 
tissue, leading to the blockage of lymph flow from a limb. As fluid accumulates 
and oedema develops, the limb swells and grows to enormous proportions, as 
shown in figure 1.11, (Rischer and Easton, 1995). In such an advanced stage the 
lymphatics have been damaged irreversibly and the disease is frequently termed 
elephantiasis. The parasitic worm is carried by tropical mosquitoes and poses a 
great problem in developing countries. Secondary infection by bacteria through 
"entry lesions" in the skin can provoke acute adenolymphangitis, characterised 
by a worsening of the condition (reviewed by Shenoy, 2002).
Figure 1.11 Elephantiasis in the right leg of a female patient from Ghana. (Photograph from 
www.filariasis.org)
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Myxoedema is a symptom of hypothyroidism and a lower-than normal 
metabolic rate (Berne et al., 1998). It is produced by an accretion of 
mucopolysaccharide in the tissues, which results in an accumulation of fluid. 
This produces the characterisitic puffy features of a patient with hypothyroidism, 
coupled with an enlarged tongue, hoarseness, joint stiffness, effusions of the 
pleural, pericardial and peritoneal spaces; and entrapment of pressure on 
peripheral and cranial nerves. Other unpleasant symptoms include 
constipation, loss of hair, menstrual dysfunction and anaemia. The end stage of 
untreated hypothyroidism is myxoedema coma, an acute medical emergency 
which, since it frequently occurs in older patients with underlying pulmonary 
and vascular disease, has a very high associated mortality (Greenspan and 
Strewler, 1997).
Unfortunately despite the discomfort and danger of lymphoedema, few 
treatments have been developed and even fewer have proved effective (Swartz, 
2001). Oedema resulting from an increase in interstitial osmotic forces due to 
increased permeability of the blood microcirculation has been treated with some 
success by drugs such as Coumarin, of the benzopyrone family. These stimulate 
proteolysis by macrophages, thus reducing oncotic pressure within the 
interstitium. However sustained oedema elicits reorganisation of the 
extracellular matrix by fibroblasts. This precipitates an overall decrease in tissue 
elasticity and may cause protein accumulation which exacerbates the situation.
The advent of gene therapy may herald an era of greater success in treating 
oedema with fewer side effects. Yoon et al. (2003) used naked plasmid DNA 
encoding human VEGF-C on rabbit ear and mouse tail models of secondary 
lymphoedema and found that the increase in lymphangiogenesis that occurred 
lead to a decrease in thickness and volume of lymphoedema, improved 
lymphatic function and attenuation of the fibrofatty changes of the skin which
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occur with prolonged lymphoedema. Thus VEGF-C gene therapy may represent 
a novel therapeutic approach to managing this disabling condition.
The study of the lymphatics was neglected for many years, with much more 
effort concentrated on the blood circulatory system. The lack of markers was 
blamed, which forced investigators to rely solely on observing morphological 
differences between blood and lymphatic vessels. Another factor cited as a 
reason to place less effort on research into the lymphatics was the lack of fatal 
lymphatic diseases, with the exception of cancer (Mortimer, 1997). However the 
lymphatics have far reaching implications in a number of diseases and 
debilitating conditions as described above and these make them very well worth 
while studying. Also with the explosion in the number of specific lymphatic and 
blood endothelial cell markers there is no longer an excuse.
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1.5 The Migration of Leukocytes Throughout the 
Vasculature and Lymphatic Systems: in Sickness
and in Health.
Although the lymphatic and blood vascular systems are structurally distinct 
(figure 1.12), they are functionally interconnected and act in concert to maintain 
homeostasis within the tissues, cell nutrition and removal of metabolic by­
products. The two systems also provide transport routes for leukocytes and are 
thus essential in the systemic effects of both innate and acquired immunity. 
Leukocytes travel through the blood vasculature to peripheral tissues and to the 
lymph nodes. The lymphatics are responsible for the trafficking of leukocytes 
from the tissues to the lymph nodes.
Figure 1.12 The discrete networks of blood vasculature and the lymphatics within peripheral 
tissue. Whole mount staining of mouse ear tissue of blood capillaries (red, stained with rat anti­
mouse CD31) and lymphatic vessels (green, rabbit anti-mouse LYVE-1). Image captured at a 
magnification of x100.
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Both innate and specific immunity are mediated and regulated by cytokines, 
which regulate the growth and differentiation of leukocyte subsets as well as 
activate and regulate inflammatory cells. Two of the key pro-inflammatory 
cytokines are the tumour necrosis factors TNFa and TNFp, whose effects on 
lymphatic endothelium have been extensively studied during the course of this 
PhD.
1.5.1 The TNF superfamily
Evidence to suggest that a tumour necrotizing molecule existed arose from the 
observation that cancer patients occasionally showed spontaneous regression of 
their tumours following bacterial infections. Subsequent research indicated that 
endogenous mediators synthesised in response to bacterial products were likely 
to be responsible for this effect. In 1975 it was demonstrated that a bacterially- 
induced circulating factor had strong anti-tumour activity against tumours 
implanted in the skin of mice (Carswell et al., 1975) and was named tumour 
necrosis factor (TNF or TNFa). This was the first member of a superfamily of 
related ligands to be identified, all of which are involved in immune regulation 
and inflammation, acting through TNF receptors which also constitute a 
superfamily. This introduction will only mention TNFa and TNFp, the 
proinflammatory cytokines of interest in this thesis. However to date the 
superfamily consists of a total of 17 known members
1.5.1.1 TNFa
TNFa is a non-glycosylated protein which exists in either a soluble (157aa) or 
membrane-bound (233aa) form (Pennica et al., 1984; Wang et al., 1985; Shirai et 
al., 1985). When in membrane-bound form, TNFa has a molecular weight of 26 
kDa and consists of a 29 residue cytoplasmic domain, a 28 residue 
transmembrane region and a 176 residue extracellular domain. This is present as 
a type II transmembrane protein on the cell surface and is believed to associate as
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a homotrimer. The soluble protein is created by proteolytic cleavage within the 
membrane proximal extracellular domain mediated by the 85 kDa 
metalloproteinase TNF-alpha converting enzyme (TACE), (Black et al., 1997), 
generating a 157 residue product (Wang et al., 1985; Moss et al., 1997) which 
circulates as a homotrimer under normal physiological conditions (Smith et al., 
1987). Both forms of TNFa are biologically active, although Decoster et al. (1995) 
have shown (through mutation of the standard TNF cleavage site and generation 
of a membrane-bound, uncleavable mutant) that soluble TNF is more potent in 
cytotoxic assays.
The mouse orthologue of TNFa shares 79% sequence identity with human TNFa, 
although mouse TNFa consists of a longer 235-residue polypeptide with a 
potential N-glycosylation sequence (Asn-Ser-Ser) at amino acids 7-9 (Pennica et 
al., 1985; Fransen et al., 1985). However, the two molecules are cross-reactive and 
have been shown to bind each other's receptors.
TNFa is expressed by a wide range of cells including macrophages, CD4+ and 
CD8+ T cells (Ware et al., 1992), adipocytes (Kern et al., 1995), keratinocytes 
(Lisby et al., 1995), mammary and colon epithelium (Varela and Varela, 1996), 
osteoblasts (Modrowski et al., 1995), mast cells (Bissonnette et al., 1995), dendritic 
cells (Zhou and Tedder, 1995), pancreatic beta-cells (Yamada et al., 1993), 
astrocytes (Lee et al., 1993), neurons (Tchelingerian et al., 1996), monocytes 
(Frankenberger et al., 1996) and steroid-secreting cells within the adrenal zona 
reticularis (Gonzalez-Hemandez et al., 1996).
1.5.1.2 TNFP
TNFp (lymphotoxin-a, LT-a) is another cytotoxic protein with similar 
biochemical characteristics and biological activities to TNFa, with which it shares 
28% amino acid homology (Gray et al., 1984; Pennica et al., 1984; Li et al., 1987).
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Cells known to express TNFp include NEC cells, T cells and B cells (Ware et al., 
1992).
TNFp is glycosylated, with a molecular weight of 25 kDa and like TNFa, 
circulates as a non-covalent linked homotrimer (Eck et al., 1992; Hochman et al., 
1995). TNFp does not have a transmembrane form but it can be membrane- 
associated due to its binding to membrane-anchored lymphotoxin-p (LTp), with 
which it readily forms a trimeric complex, in either 2:1 in favour of LT-p (the 
major form) or a 1:2 ratio, the minor form (Browning et al., 1993; Hochman et al., 
1995).
1.5.2 Receptors
TNF receptor superfamily members (TNFRSF) are all type I transmembrane 
glycoproteins but may exist in both membrane-bound and soluble forms (Baker 
and Reddy, 1998). Both TNFRI (also known as p55) and TNFRII (p75) are 
capable of binding TNFa and TNFp. TNFRI is a 55 kDa transmembrane 
glycoprotein comprised of 455 amino acid residues and is expressed by virtually 
all nucleated mammalian cells (Loetscher et al., 1990; Schall et al., 1990; Gray et 
al., 1990). Mouse and human TNFRI molecules share 64% sequence identity, 
with 70% homology in the extracellular domain and have been shown to bind 
human and mouse TNFa with equal affinity (Barrett et al., 1991). Soluble TNFa 
binds TNFRI with a Kd of 20-60 pM whilst TNFp displays a slightly lower 
affinity, with a Kd of 650 pM (Marsters et al., 1992).
The cytoplasmic region contains an 80 amino acid residue "death domain" that 
can trigger an apoptotic pathway (Tartaglia et al., 1993). Binding of TNF to 
TNFRI leads to the recruitment of several proteins such as TRADD (TNFR- 
associated death domain protein) to the death domain. Other proteins such as 
RIP (receptor interacting protein) and TRAF2 (TNFR-associated factor 2) may
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then also bind to TRADD, resulting in a signal cascade of kinases which leads to 
the activation of the transcription factors NFkB and API. Multiple genes may 
then be up-regulated and apoptosis is suppressed (reviewed by Baker and 
Reddy, 1996). However if an alternative protein, FADD (Fas-associated death 
domain protein) is recruited to TRADD, a caspase cascade is initiated, resulting 
in apoptosis.
TNFRII is also widely expressed but binds TNFa with a much lower affinity (Kd: 
300 pM) than TNFRI does. Since systemic TNFa levels are usually approximately 
100 pM, this would suggest that TNFRI is the more physiologically-relevant 
receptor and mediates most TNFa activity.
The effects of TNFa and TNFp are critical for local inflammatory responses. For 
example, a neutralising anti-TNFa antibody was found to reduce joint swelling 
and leukocyte infiltration into joint fluid in antigen induced arthritis in rabbits 
(Lewthwaite et al., 1995). Administration of this antibody also led to a decrease 
in the expression of aMp2 integrin on cells in the joint fluid. The generation and 
characterisation of TNFa-/- mice also revealed a vital role for TNFa in the 
containment and resolution of infection (Marino et al., 1997). The effects of TNFa 
on vascular endothelium are described in detail in section 1.5.3 of this 
introduction, whilst the effects on lymphatic endothelium are explored in 
chapters 4,5 and 6 of this thesis.
1.5.3 Leukocyte influx into tissues
The extravasation of leukocytes from the vascular lumen into the tissues is 
dependent upon a series of sequential molecular interactions between these cells 
and the endothelium. Recruitment of leukocytes to non-inflamed peripheral 
tissue is required without inflammatory stimulus as macrophages and dendritic 
cells (DCs) must be present constitutively. These cells originate from the bone
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marrow and circulate as monocyte precursors in the blood, from which they 
must be recruited. One of the chemotactic molecules constitutively expressed 
and implicated in acting on these circulating monocytes is BRAK (breast and 
kidney expressed chemokine, CXCL14), (Kurth et al., 2001). However the roles 
of this chemokine or other chemoattractants have not been examined in the 
context of non-inflammatory recruitment of monocytes to tissues (reviewed by 
Imhof and Aurrand-Lions, 2004).
Populations of DCs in the lungs have rapid turnover rates, requiring de novo 
constitutive migration of precursor cells to constantly replace those which have 
emigrated to the thoracic lymph nodes (Vermaelen et al., 2001). Schneeberger et 
al. (2000) used this observation to try to elucidate the molecular mechanisms 
involved in constitutive migration. They found that mice deficient in ICAM-1, E- 
selectin or P-selectin or both did not exhibit a reduction of DCs in the lungs. 
However animals deficient in the expression of CD18 (02 integrin) showed a 
marked decrease in the number of DCs in the lungs. CD18 is known to interact 
with ICAM-1 but clearly interactions with other ligands appear to be occurring, 
such as ICAM-2. Immature DCs express high levels of DC-SIGN, the human DC 
adhesion receptor (CD209) and Geijtenbeek et al. (2000a) were able to 
demonstrate that this receptor interacts with ICAM-2, constitutively expressed 
on vascular endothelium. They found that these interactions mediated DC 
rolling and transendothelial migration from the vasculature into the peripheral 
tissues, both inflamed and normal. The researchers postulate that such 
interactions could also be important in the exit of DCs from tissues into the 
lymphatics.
Recruitment of leukocytes to tissues during inflammation has attracted much 
more interest from researchers and is therefore better characterised. Upon 
inflammation, proinflammatory cytokines such as TNFa, stimulate vascular
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endothelial cell production of prostaglandins and nitric oxide, potent 
vasodilators which increase local blood flow to optimise delivery of leukocytes to 
the site of inflammation (Baumann and Gauldie, 1994). The activated 
endothelium also exhibits increased expression of certain adhesion-mediating 
cell surface proteins and thus the circulating leukocytes passing through the 
post-capillary and collecting venules of inflamed tissue experience an increase in 
the residence time on the venular surface (figure 1.13). The first visible display of 
this in vivo is the slow rolling or sliding of leukocytes along the endothelium. A 
well-characterised mediator of this is E-selectin, an llOkD glycoprotein also 
known as CD62E or ELAM-1 (endothelial leukocyte adhesion molecule-1). E- 
selectin is exclusively expressed on endothelium and can bind complex sialylated 
carbohydrate groups related to the Lewis-X or Lewis-A family found on various 
surface proteins of granulocytes, monocytes and certain memory T-cells 
(reviewed by von Andrian and Mackay, 2000). It is also responsible for the initial 
attachment of neutrophils (Bevilacqua et al, 1989) and eosinophils (Weller et al,
1991). This tethering is reversible and may be followed by either the release of 
the leukocyte and its return to circulation or by a firmer interaction.
E-selectin is the first adhesion molecule to be up-regulated on vascular 
endothelium, typically 1 to 2 h following the onset of antigen challenge. 
Vascular cell adhesion molecule-1, VCAM-1 is subsequently up-regulated by 
pro-inflammatory cytokines through NFkB (Neish et al., 1992), and binds to the 
VLA-4 (a4pi) integrin on leukocytes, marking the beginning of a phase of firmer 
attachment of the leukocyte to the endothelium (Staunton et al., 1988; Springer,
1990). A second firm interaction is mediated by intercellular adhesion molecule- 
1, ICAM-1 and its integrin ligand LFA-1, also known as CDlla/CD18 or aLp2, 
(Rothlein et al., 1986). ICAM-1 is constitutively expressed on endothelium but 
expression increases upon NFKB-mediated activation by pro-inflammatory 
cytokines (Springer, 1990). ICAM-1 and VCAM-1 play reciprocal roles in the
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binding of resting T cells to resting endothelium and to endothelium activated by 
proinflammatory cytokines respectively (Oppenheimer-Marks et al., 1991). 
ICAM-1 mediates a firm adhesion with the leukocyte through either LFA-1 
(Makgoba et al., 1988) or Mac-1 (CDllb/CD18, aM02) and this interaction also 
plays a role in the transmigration of leukocytes across the blood vessel into the 
tissue. In the absence of LFA-1, T cells retain the ability to bind to endothelium, 
most likely due to interactions between other receptor-ligand pairs such as VLA- 
4 and VCAM-1, although migration is substantially reduced (Kavanaugh et al., 
1991; Greenwood et al., 1995). Endothelial cells constitutively express ICAM-2, a 
second ligand for LFA-1 (Staunton et al., 1989) which is down-regulated in 
response to TNFa. McLaughlin et al. (1999) identified the TNFa response 
elements within the human ICAM-2 promoter and found that binding sites for 
NFkB and Ets family members were involved in basal promoter activity but that 
TNFa-induced down-regulation of ICAM-2 in endothelial cells was mediated by 
the Ets family member Erg. In the mouse, ICAM-1 and ICAM-2 were shown by 
Lehmann et al. (2003) to have redundant roles in lymphocyte recirculation 
through lymph nodes. However ICAM-1 alone was shown to be involved in T 
cell migration into inflamed skin and in trapping within the lung. Thus it 
appears that ICAM-2 does not have a role in inflammation but rather is 
constitutively expressed in normal tissue for lymphocyte recirculation.
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endothelium
leukocyte
Figure 1.13 Molecular interactions in adhesion of a leukocyte to vascular endothelium. The four 
phases of adhesion are indicated in capital letters at the top of the diagram, with the predominant 
interactions of adhesion molecules indicated by arrows. Tethering is facilitated by leukocyte receptors 
that occur at high density on the tips of microvillous surface protrusions. The selectins are the principal 
molecules involved in this, interacting with sulphated sialyl-Lewis-X-like sugars. Integrins reduce the 
velocity of leukocyte rolling. Rolling leukocytes respond to chemoattractants on endothelial cells via 
seven transmembrane domain receptors (7TMR) and are thus activated. p2 integrins and cu integrins 
are activated and may bind members of the endothelial Ig superfamily to bring about leukocyte arrest 
prior to transmigration. These molecules include intercellular adhesion molecule 1 and 2 (ICAM-1 and 
ICAM-2), vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin-cell adhesion molecule 
type 1 (MAdCAM-1). VCAM-1 is not constitutively expressed by endothelium but rather is involved in 
homing of leukocytes to inflamed tissue throughout the body. MAdCAM-1 is required for homing of 
leukocytes to gut and associated lymphoid tissue only. Adapted from von Andrian and Mackay, 2000.
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The role of CD44 in rolling and adherence of leukocytes to vascular endothelium 
has become increasingly appreciated over the last few years. Activation of T cells 
through the T cell receptor induces activation of CD44 and adhesion 
(DeGrendele et al., 1997a, 1997b; Lesley et al., 1994) and facilitates the 
extravasation of activated T cells into an inflamed peritoneal site (DeGrendele et 
al., 1997b). CD44 expression by circulating T cells has also been shown to 
correlate with autoimmune disease in human (Estess et al., 1998) and in murine 
models (Brocke et al., 1999). Peripheral blood monocytes constitutively express 
CD44 but do not bind HA unless stimulated with LPS (Levesque and Haynes, 
1996; Levesque and Haynes, 1997). The interactions between CD44 and HA have 
been shown to be very important in the rolling phase of the leukocyte along the 
endothelium. Gee et al. (2003) suggested that LPS-induced CD44-mediated HA 
binding in primary monocytes might be regulated by endogenously produced 
TNFa and IL-10 via the induction of sialidase activity.
HA is by no means the only molecule that CD44 can interact with and a recent 
study by Nandi et al. (2004) provided data to show that CD44 also plays a role in 
cell arrest via interaction with VLA-4. Both mouse and human T cell 
extravasation is initiated by the activated form of CD44 associating with VLA-4 
in a manner dependent upon the cytoplasmic tail of CD44. In the absence of this 
domain CD44-HA mediated rolling can still occur but the adhesion of VLA-4 to 
its ligand, VCAM-1 is prevented.
Leukocyte movements are tightly regulated by chemokines, structurally related 
chemotactic cytokines which are subclassed according to the relative position of 
conserved cysteine residues. The most numerous CC subfamily have the first 
two cysteines adjacent, whereas the CXC chemokines have the first two cysteines 
separated by one amino acid. CX3C chemokines are characterised by the first 
two cysteine residues being separated by three intervening amino acids and C
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chemokines lack the first and third cysteine residues. Chemokines bind seven- 
transmembrane-domain receptors which are coupled to heterotrimeric G 
proteins (reviewed by Thelen, 2001). Activated endothelium and leukocytes 
already within the tissue secrete chemokines such as RANTES (regulated upon 
activation, normal T-cell expressed and secreted, CCL5), IL-8 (CXCL8) and MCP- 
1 (monocyte chemotactic protein-1, CCL2). Gerszten et al. (1999) demonstrated 
that when IL-8 and MCP-1 were applied to HUVEC monolayers expressing E- 
selectin, the arrest of rolling monocytes was enhanced. MIP-ip (Macrophage 
inflammatory protein-1 p, CCL3/4), IL-8 and RANTES have been shown to bind 
to transmembrane heparan sulphate proteoglycans on the luminal surface of 
vascular endothelial cells and be presented to leukocytes. Tanaka et al. (1993) 
found that MIPip induced both chemotaxis and adhesion of T cells to vascular 
endothelium. They established that it is present on lymph node endothelium 
and when immobilized by binding to proteoglycan, could also induce binding of 
T cells to VCAM-1. Spillmann et al. (1998) studied the interaction between a 
heparan sulphate chain and IL-8 dimer and found that a minimal sequence of 18- 
20 monosaccharide units were necessary to span the two saccharide-binding sites 
on the dimer. Halden et al. (2004) later demonstrated that IL-8 can bind 
syndecan-2 on HUVEC, which is up-regulated following TNFa stimulation. 
However they also found that binding could occur between IL-8 and a non­
glycosylated form of syndecan-2, albeit with a higher Kd value and thus 
concluded that protein-protein interactions could contribute to chemokine- 
proteoglycan interactions. Interaction of RANTES with the glycosaminoglycan 
chains of CD44 was demonstrated by Roscic-Mrkic et al. (2003). They found that 
such binding induced the formation of a signalling complex composed of CD44, 
src kinases and adapter molecules, which led to the activation of the p44/42 
mitogen-activated protein kinase (MAPK) pathway
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When chemokines bind to these proteoglycans, the binding site for chemokine 
receptors remains exposed (reviewed by Proudfoot et al., 2000), permitting the 
chemokine to interact with its seven transmembrane spanning G-protein-coupled 
receptor expressed on a rolling leukocyte which passes over the endothelium. 
This elicits a rapid integrin-activation signal, dependent upon the individual 
chemokines and receptor (reviewed by Thelen et al., 2001), which permits the 
leukocyte to attach more firmly to the endothelium via integrin-VCAM-1 or -  
ICAM-1 interactions.
Upon activation by contact with the endothelium, leukocytes undergo 
cytoskeletal rearrangement to permit a morphological change from spherical to 
flattened, allowing a greater surface area of contact with the endothelium 
(reviewed by Imhof and Aurrand-Lions, 2004). Vascular endothelial cells also 
undergo a change in shape and basement remodelling to aid extravasation of 
leukocytes whilst still maintaining vascular integrity. In vitro studies have 
shown that considerable leukocyte trafficking can occur without an increase in 
the permeability of the endothelial cell monolayer or a decrease in electrical 
resistance, (reviewed by Muller, 2003).
1.5.3.1 Paracellular transmigration
A leukocyte poised to take the classical paracellular route across endothelium 
must breach the large array of endothelial junctions, which are responsible for 
maintaining the integrity of the endothelium and regulating vascular 
permeability. To date, three types of endothelial junction have been described: 
tight junctions, adherens junctions and gap junctions (reviewed by Imhof and 
Aurrand-Lions, 2004). These junctions resemble those found in epithelium but 
have a less ordered spacial organisation, which reflects the need for frequent 
remodelling to permit leukocyte trafficking.
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Tight junctions are the most apical of the three, containing occludin, claudins 
and junctional adhesion molecules (JAMs). Occludin is a 65-kDa protein with 
four transmembrane domains and a hypothesised topology of two extracellular 
loops with a short cytoplasmic N-terminus and a long cytoplasmic C-terminus 
(reviewed by Luscinskas et al., 2002). The C-terminal tail can associate with 
several cytoplasmic components including zona occludens (ZO)-l, -2 and -3, 
which in turn link to the actin cytoskeleton (figure 1.14). However, the role of 
this protein at these junctions remains unknown.
Claudins constitute a large family of proteins, which contain a similar membrane 
topology to occludin and associate with ZO-1, -2 and -3 but share no amino acid 
sequence homology with occludin (Furuse et al., 1998). Heterogeneous claudin 
species form tight junctional strands and the combinations and ratios of 
abundance of each claudin species is believed to define the permeability of the 
junction to macromolecules (Furuse et al., 2001). However the roles of claudins 
in leukocyte transmigration are still under investigation (reviewed by Luscinskas 
et al., 2002). A study by Poritz et al. (2004) suggested that the TNFa-induced 
redistribution of claudin-1 and ZO-1 away from the tight junctions of endothelial 
cells that they observed in vitro could explain the increased intestinal 
permeability associated with the chronic intestinal inflammation which occurs in 
patients with irritable bowel disease. Thus these proteins may be involved in 
regulating the permeability of the endothelium.
JAM family members include JAM-A, JAM-B and JAM-C and belong to the 
immunoglobulin superfamily. JAM-A, the first to be cloned, has two 
extracellular Ig domains, which are capable of both homophilic interactions and 
heterophilic interactions with LFA-1. JAM-A is also capable of interactions with 
several proteins including occludin and ZO-1 through its cytoplasmic tail 
(reviewed by Imhof and Aurrand-Lions, 2004). Through the use of a monoclonal
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antibody with blocking activity, Del Maschio et al. (1999) demonstrated that 
JAM-A aided monocyte and neutrophil recruitment and transmigration at sites 
of injury. Stimulation of endothelial cells with inflammatory cytokines was 
found to induce the redistribution of JAM-A from intercellular junctions to the 
luminal surface of the cells, resulting in reduced transendothelial migration of 
leukocytes under static conditions but no change under flow (Shaw et al., 2001). 
JAM-B and JAM-C have also been shown to interact with ZO-1 and all three 
JAMS are believed to be involved in the regulation of tight junction formation 
and cell polarity through recruitment of both ZO-1 and the cell polarity protein 
PAR-3 (Ebnet et al., 2003). In addition, JAM-B and JAM-C act as receptors for 
integrins: JAM-B binds a4pi whilst JAM-C binds aMp2 and aXp2. JAM-B and 
JAM-C may also interact with each other (reviewed by Imhof and Aurrand- 
Lions, 2004). JAM-B is implicated in facilitating and controlling the 
transmigration of leukocytes across HE Vs, discussed in section 1.5.4 of this 
chapter (Johnson-Leger et al., 2002). Thus the JAMs appear to be involved in 
both the structural maintenance of cell-cell junctions and integrin-mediated 
transmigration.
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Figure 1.14 Schematic representation of a tight junction. Homophilic interactions occur 
between occludin molecules on adjacent cells. Occludin has a short N-terminal and an extended C 
terminal, which interacts with zona occludens molecules ZO-1, ZO-2 and ZO-3. All three JAM 
molecules may also interact with either occludin or ZO-1, as well as the cell polarity protein PAR-3.
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Adherens junctions are cell membrane contacts formed by cadherins, a large 
family of transmembrane adhesion molecules which act in a homophilic way to 
connect epithelial or endothelial cells (reviewed by Yagi and Takeichi, 2000). VE- 
cadherin (also known as cadherin-5) is found on blood vascular endothelial cells 
and possesses the same organisation typical of other cadherins, consisting of an 
extracellular domain comprising five repeat motifs (Luscinskas et al., 2002). The 
extracellular domain is responsible for homophilic interactions while the 
cytoplasmic tail provides a linkage to the actin cytoskeleton via a- and p-catenins, 
plakoglobin and pl20 and contributes to stable adhesion (figure 1.15). The role 
of VE-cadherin as a gate keeper which must be pushed aside by transmigrating 
cells is also widely accepted (reviewed by Muller, 2003). Thus this molecule does 
not directly participate in the process of leukocyte transmigration but rather 
contributes to the maintenance of the vascular integrity (Imhof and Aurrand- 
Lions, 2004).
The other adhesion molecules found at adherens junctions, CD31 and CD99, play 
much more active roles in transmigration. CD31 (described in detail in section
1.3.5 of this chapter) is actively recruited to sites of monocyte transendothelial 
migration. Studies where CD31 interactions have been prevented using a 
blocking mAb have shown an approximately 90% reduction in transmigration, 
both in vivo and in vitro, identifying CD31 as a playing a key role in the process. 
The important role played by CD99 in transmigration was demonstrated by 
Schenkel et al. (2002). They showed that this heavily O-glycosylated 32 kDa type 
I transmembrane protein was not only expressed on leukocytes as was 
previously believed but was also found on endothelium, particularly at 
intercellular junctions. Furthermore it is able to form homophilic interactions 
with CD99 molecules on leukocytes and diapedesis of monocytes could be 
blocked by over 90% in the presence of a CD99 blocking antibody. However,
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CD99 is believed to regulate a step in transmigration which is distinct from that 
controlled by CD31 (Imhof and Aurrand-Lions, 2004).
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Figure 1.15 Schematic representation of the principal protein interactions at a cadherin- 
based adherens junction. Homophilic interactions occur between extracellular domains of 
cadherin on adjacent cells, whilst the intracellular domain of cadherin interacts with catenins and 
may be linked to the actin cytoskeleton through vinculin. Additional proteins such as p120 stabilise 
these interactions.
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Gap junctions are clusters of hydrophilic transmembrane channels which permit 
the direct exchange of ions and small molecules (Beyer, 1993). Each channel is 
composed of six polypeptide subunits, connexins, arranged around a central 
pore (figure 1.16). Connexins 37, 40 and 43 are constitutively expressed by 
vascular endothelium and primarily at cell-cell contacts. The gap junctional 
coupling between leukocytes and the endothelium may have a role in 
modulating transendothelial migration, although this remains controversial 
(Imhof and Aurrand-Lions, 2004).
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Figure 1.16 Schematic diagram of a gap junction between two adjacent cells. This 
transmembrane channel is composed of six connexin polypeptides arranged around a central pore 
(A). Each connexin has four transmembrane domains and intracellular N- and C-termini (B).
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The change in morphology of the endothelium also permits some leakage of 
macromolecules such as fibronectin and fibrin, the insoluble cleavage product of 
fibrinogen (Abbas, 1997), which form a scaffolding to facilitate leukocyte 
migration and retention within the tissue.
1.5.3.2 Transcellular transmigration
In addition to the paracellular migration of leukocytes squeezing between 
adjacent endothelial cells, another pathway for transmigration is also believed to 
occur, termed transcellular migration. Ultrastructural studies carried out in the 
1960s suggested that leukocytes could pass through the body of an endothelial 
cell (Marchesi and Gowans, 1964). This finding was supported by the work of 
Feng et al. (1998) who demonstrated that neutrophils stimulated with a 
chemotactic peptide could emigrate from inflamed venules primarily by a 
transcytotic pathway. In this study, serial electron microscopic sectioning 
showed clearly that the course taken by the transmigrating neutrophil did not 
involve endothelial cell-cell junctions. More recent work has sought to address 
the molecular interactions that permit and control this form of transmigration.
The preliminary stages of junctional-independent migration are suggested in a 
paper by Barreiro et al. (2002), who found that the endothelial adhesion molecule 
VCAM-1 localised to microvilli and microspikes at the apical surface of TNFa- 
activated human umbilical vascular endothelial cells (figure 1.17). The 
cytoplasmic tail of VCAM-1 was shown to bind the active N-terminal domain of 
the actin cytoskeleton linker proteins ezrin and moesin in vitro, which were also 
shown to colocalise within the microvilli-like projections. Additionally, they 
demonstrated that ICAM-1 colocalised with ezrin and clustered around 
lymphocytes throughout adhesion and transmigration, whereas VCAM-1 
clusters were only observed during adhesion and had disappeared once 
transmigration had occurred. The authors observed VCAM-l-ezrin docking
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structures which were raised above the endothelial surface to form a cup-like 
structure. The formation of this was found to be associated with the relocation of 
cytoskeletal components such as the actin bundling protein a-actinin, the focal 
adhesion protein vinculin and the actin-nucleating protein VASP. 
Phosphoinositides and the Rho/pl60 ROCK pathway (which participate in the 
activation of ERM proteins) were identified as being involved in the generation 
and maintenance of the anchoring structure.
ICAM-1
VCAM-1
Figure 1.17 Formation of the endothelial docking structure for adhered lymphocytes.
Differential interference contrast image of the lymphocyte is shown in the grey-scale panel, with the 
endothelial ICAM-1 (green) and VCAM-1 (red) forming around it. The VCAM-1-positive projections 
from the endothelial cell are shown in the lower panel. (Bar represents 3.5pm). Taken from 
Barreiro et al., 2002.
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The role that these microvilli-like projections and cup-like structures could play 
in transcytosis was suggested by Carman et al. (2003). As in the paper by 
Barreiro et al. (2002), they also observed the cup-like structures and found that 
the projections which encircled the leukocyte were ICAM-l-enriched and 
extended up the sides of the leukocytes and clustered the leukocyte integrin 
LFA-1 into linear tracks (figure 1.18). Such projections were found to form 
independently of VCAM-l-VLA-4 interactions; however disruptions of the 
projections with various cytoskeletal inhibitors did not affect firm adhesion and 
the authors suggest that such structures are more important in transendothelial 
migration. They followed up this hypothesis with a subsequent study (Carman 
and Springer, 2004), in which they provide direct evidence for transcellular 
diapedesis. By monitoring transmigration of chemokines-activated monocytes, 
neutrophils and lymphocytes through human umbilical vein endothelial cells, 
they found that transcellular migration (occurring away from cell-cell junctions) 
accounts for 7 ± 1%, 5 ± 2% and 11 ± 4% respectively of total migration events, i.e. 
a minority. However, the authors also mentioned that this could be an 
underestimation as events occurring near cell-cell junctions were hard to judge 
and therefore denoted as paracellular. Thus the transmigratory cup appears to 
provide directional guidance to leukocytes to permit their extravasation and such 
transcytosis accounts for a least some transmigrational events. The extent to 
which these occur remains to be accurately determined as the speed of 
transcellular migration in comparison to paracellular migration is unknown. If 
one mechanism occurs much more rapidly than the other, its contribution to 
transmigration could be underestimated when observing what are effectively 
snap-shots of events following fixation. The mechanisms by which the 
endothelium "decides" which route for migration it wishes to offer a leukocyte 
remain to be elucidated. However it is currently accepted that the transcytotic 
pathway of extravasation is probably not the main route taken by leukocytes 
(reviewed by Imhof and Aurrand-Lions, 2004).
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Figure 1.18 ICAM-1-enriched microvilli-like membrane projections formed by a CHO cell 
encircling a leukocyte (Scale bar, 5 pm.) Taken from Carman et al., 2003.
1.5.4 Recirculation of T cells to the lymph nodes
The homing of naive T cells from the blood to the stroma of peripheral lymph 
nodes involves different adhesion molecules and occurs across high endothelial 
venules, HEVs (Anderson and Anderson, 1976; Anderson et al., 1976). HEVs are 
modified post-capillary venules which are lined with plump endothelial cells, 
thus giving the venules their name due to their appearance in transverse 
sections. Intravital microscopy revealed that the HEV endothelium has greater 
adhesiveness for circulating lymphocytes and a collision with the vessel wall will 
result in a loose attachment which may last several seconds. A similar collision 
occurring with normal vessel walls of the microcirculation would cause the 
lymphocyte to immediately rebound or adhere very briefly before being swept 
on by the force of the blood flow (Johnson-Leger et al., 2000). The low affinity 
attachment with the HEV permits a proportion of T cells to spread out into 
mobile forms and extravasate into the stroma of the lymph node, perchance to 
encounter their specific antigen.
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Adherence of lymphocytes to HEVs is mediated by homing receptors termed 
addressins. These are responsible for directing the lymphocytes to their ligands 
on specific and anatomically distinct sites. L-selectin (CD62L) is considered the 
most important homing receptor on naive T cells. This 90-100 kD, variably 
glycosylated carbohydrate-binding protein is abundant on naive T cells but has 
low expression on memory cells. Its ligands include sulphated 
glycosaminoglycans on GlyCAM-1, a secreted proteoglycan on HEVs; CD34 on 
endothelial cells; and mucosal addressin cell adhesion molecule-1 (MadCAM-1) 
on endothelial cells in the gut. L-selectin mediates rapid low-affinity attachment 
tethering between the leukocyte and endothelium. The integrins mediating the 
firmer attachment of the lymphocytes and subsequent transmigration are less 
well characterised. However JAM-B, expressed on HEVs in human tonsil and a 
subset of human leukocytes is predicted to play a role in this. Johnson-Leger et 
al. (2002) have demonstrated that in the mouse, leukocytes migrate in much 
greater numbers across monolayers of endothelioma cells transfected with JAM- 
B. Moreover in a human model, the researchers found that either an anti-JAM-B 
antibody or soluble JAM-B were sufficient to block the transmigration of primary 
human peripheral blood leukocytes across HUVECs expressing endogenous 
JAM-B.
Monocytes do not adhere to HEVs in lymph nodes that drain non-inflamed 
tissues but adherence becomes possible after an inflammatory challenge (Imhof 
and Aurrand-Lions, 2004). Chemokines such as CCL3 and CXCL8 can be 
transported to the draining lymph nodes, where they are captured on HEVs, 
subcapsular sinuses and reticular fibres (Gretz et al., 2000). Inflammatory 
chemokines such as CXCL9 are also transported to lymph nodes from their site 
of production within inflamed tissue and contribute to the recruitment of 
monocytes.
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Once the naive T cell is within the lymph node and activated by binding of 
specific antigen, the cell up-regulates adhesion molecules such as LFA-1 
(CDllaCD18), VLA-4 (a4pl integrin), VLA-5 (a5pl integrin), VLA-6 (a6pl 
integrin) and CD44.
1.5.5 Leukocyte trafficking through afferent lymphatics
Generation of a primary immune response is dependent upon the delivery of 
antigen to lymphoid organs, either via the blood, lymph or mobile antigen- 
presenting cells (Zinkemagel, 1996). Dendritic cells (DC) are bone marrow- 
derived accessory cells present in the interstitium of most organs, including the 
dermis of the skin. They will phagocytose microorganisms, dead cells and 
cellular debris prior to migration across the lymphatic endothelium and through 
afferent lymphatic vessels to the T-cell rich paracortical area of a regional lymph 
node (figure 1.19). Although other cell types such as macrophages or activated 
parenchymal cells may drive the activation and proliferation of memory T cells, 
DCs alone are capable of stimulating the expansion of naive T cells and thereby 
initiating primary immune responses (Randolph, 2001). They are abundant in T 
cell rich areas of lymph nodes and the spleen and found in immature form 
circulating in the blood as well as scattered throughout the epidermis of the skin, 
where they are termed Langerhans cells (LC). LC contain the Birbeck granule, a 
cytoplasmic organelle whose function remains to be determined but enables LC 
to be distinguished from dermal DC by electron microscopy (Abbas et al, 1997; 
Weinlich et al, 1997). LC also express the chemokine receptor CCR6, which 
through interactions with macrophage inflammatory protein 3a (MIP3a) may 
promote their migration to normal skin (von Andrian and Mackay, 2000). DC 
endocytose protein antigen, which then undergoes proteolytic processing in 
either the endosome or lysosome. The peptides are loaded on to an MHC class II 
molecule within an exocytic vesicle from the Golgi and transported to the cell 
surface for presentation as MHC class II-peptide complexes. DC display high
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levels of expression of MHC class I I  molecules and thus may be distinguished 
from monocytes which exhibit lower levels of expression (Weinlich et al, 1997). 
DC also have distinct morphology, with long, thin cytoplamic processes and a 
lobulated and excentrically localised nucleus.
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Figure 1.19 The lymphatics as a conduit for leukocytes. Cells such as DCs from the 
interstitium transmigrate across the lymphatic endothelium to gain access to the lymphatic 
capillaries and afferent lymphatic vessels before reaching the lymph node. They then home to the 
T-cell rich paracortical areas and thus an immune response to antigen may be elicited.
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DC migrate and home to the T cell areas of lymphoid organs from afferent 
lymphatic vessels that drain peripheral tissues (Austyn, 1989). Upon reaching a 
lymph node, DCs down-modulate receptors for inflammatory chemokines and 
up-regulate receptors for lymphoid chemokines to aid migration to the T-cell 
area of the node (von Andrian and Mackay, 2000). Naive T cells collect in the 
paracortical region of lymph nodes and the spleen, having migrated directly 
from the vasculature. The murine contact hypersensitivity (CHS) model has 
been used extensively to study the migration of DC from the skin in response to 
antigenic challenge. In this model, a skin sensitising agent is applied to an area 
of mouse skin and is captured by LC or dermal DC, which migrate to lymph 
nodes in an IL-1 and TNFa-dependent manner (Cumberbatch et al., 2002) and 
elicit an IL-l-dependent hapten-specific T cell activation (Nakae et al., 2002). 
Once the mouse has been sensitised and memory T cells are resident throughout 
the body, a challenge by cutaneous application of the same antigen, typically to 
the ear, results in local inflammation and oedema. Nakae et al. (2002) used IL- 
la /  p■/-, TNFa-/_and IFNy/- mice to dissect out the roles of these cytokines in the 
development of CHS. They found that whilst IL-1 plays a crucial role in antigen- 
specific T cell activation through CD40L and 0X40 induction on T cells, TNFa is 
key in the elicitation phase. This confirmed the findings of early work by 
McHale et al. (1999) who demonstrated that neutralising antibodies against 
TNFa, IL-1 a and IL-lp were no more effective at inhibiting the increase in ear 
thickness and accompanying up-regulation of adhesion molecules than 
antibodies against TNFa alone. TNFa is produced by keratinocytes and LC 
within the skin, as well as mast cells. However production by CD4+ T cells was 
not found to be directly involved (Nakae et al., 2002). TNFa stimulates the up- 
regulation of ICAM-1, MCP-1, MIP-la and MIP-lp, leading to the ear swelling 
which characterises the elicitation phase.
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Exogenous administration of proinflammatory factors IL-lp, TNFa or 
lipopolysaccharide (LPS) promotes the loss of DCs from the periphery within 12h 
(reviewed by Randolph, 2001) and such migration is known to involve a cohort 
of chemokines and adhesion molecules. Epidermal LCs have been used in the 
majority of studies to elucidate the factors involved in DC migration. For such 
cells to be initially mobilised, their migratory capacity must be triggered by one 
or more factors, all converging to produce NFkB activation. In addition to the 
proinflammatory cytokines IL-lp and TNFa, microbial factors and exogenous 
DNA activate Toll-like receptors, TLRs (O'Neill, 2004). Stimulation with necrotic 
cells following tissue injury and with CD40L, typically expressed on activated T 
cells can also trigger maturation. Such stimulated LCs then downregulate E- 
cadherin, thus permitting their detachment from neighbouring keratinocytes, 
coupled with up-regulation of adhesion molecules such as a6pl and CD44, 
induction of matrix metalloproteinase-9 and de novo expression of the 
chemokines receptor CCR7, which is believed to be essential in permitting DC 
entry into lymphatic vessels (reviewed by Randolph, 2001) as a lack of migration 
was observed in mice deficient for CCR7 (Forster et al., 1999) and mice deficient 
in both ELC (CCL19) and SLC (CCL21), the chemotactic ligands for CCR7 (Gunn 
et al., 1999; Luther et al., 2000). However CCR7 is also necessary for naive T cells 
to enter the lymph node and such mice therefore do not have normal lymph 
nodes. Thus initially it was considered possible that defective DC migration is 
secondary to these genetic abnormalities. However further evidence to show 
that CCR7 was indeed a key regulator was provided by Ohi et al. (2004), who 
demonstrated that the absence of this chemokine receptor in mice prevented DC 
migration into dermal lymphatics under both inflammatory conditions and 
during constitutive trafficking. Martin-Fontecha et al. (2003) analysed factors 
affecting migration of dendritic cells to the draining lymph nodes in mice and 
demonstrated that subcutaneous injection of inflammatory cytokines increased 
DC migration. They claimed that this was due to an increase in SLC expression,
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as detected by in situ hybridisation and antibodies. The role of ELC in mediating 
cysteinyl leukotriene (cysLT)-induced chemotaxis of DCs has been demonstrated 
more convincingly (Robbiani et al., 2000). cys-LTs are mediators of immediate 
hypersensitivity reactions and induce DC migration through the lipid transporter 
multi-drug resistance protein 1 (MDR-1). The researchers were able to show 
such migration occurs specifically to ELC and that accumulation of DCs in the 
lymph nodes was blocked using anti-ELC antibodies. However although the 
paper identifies a role for ELC in DC migration from the epidermis in vivo, 
expression of ELC by lymphatic endothelial cells in the periphery remains to be 
addressed.
Other possible candidates for DC migration are L-selectin and mannose receptor. 
Irjala et al. (2001) demonstrated binding of L-selectin on leukocytes to mannose 
receptor on sinusoidal endothelial cells and suggested that as mannose receptor 
is also expressed on afferent lymphatic vessels, this interaction may additionally 
play a role in leukocyte exit from non-lymphoid tissues. Further studies to 
investigate such binding using dermal lymphatic endothelial cells could assess 
this putative role in leukocyte trafficking into the lymphatics.
The involvement of the chemotactic protein osteopontin (OPN) in DC migration 
and its interaction with CD44 and avP3 integrin is described in Weiss et al, 2001. 
OPN was found to be up-regulated in skin and lymph nodes in the sensitization 
phase of CHS and it induced chemotactic DC migration in microchamber assays. 
The researchers also generated DC from bone marrow culture and detected 
expression of two OPN receptors, CD44 and avp3 integrin by flow cytometry. 
mAbs against these two adhesion molecules known to block OPN binding were 
used to show that DC migration was dependent upon CD44 and avp3 integrin 
interactions with OPN.
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Weiss et al (2001) did not demonstrate whether OPN was secreted by 
microvascular blood endothelial cells or lymphatic endothelium. However, 
strongly class II positive cells in cords within dermal sheets have been observed 
by many investigators and Weinlich et al show that these vessels are ICAM-1 
negative. The ICAM-1 positive structures had "the typical morphology of blood 
vessels [and] did not contain DC". In the same publication an 
immunohistochemical analysis of molecules on DC was carried out on migrating 
cells in organ culture. The authors found that expression of the CTLA-4 receptor, 
CD86 was induced, as was increased surface expression of MHC class II.
Lymphatic vessels are also responsible for trafficking other leukocytes in 
addition to DCs. Mancardi et al (2003) demonstrated that mouse lymphatic 
endothelial cells derived from experimentally induced lymphangiomas could 
induce cell migration of neutrophils, lymphocytes and monocyte/macrophages. 
Moreover they detected message of CXC, CC and C chemokines KC, IP10, Mig-1, 
BCL, MIP-2, SLC, RANTES, MCP-1, CIO and Lptn. Expression of the CC 
chemokine receptor D6 by lymphatic endothelium was detected by Nibbs et al. 
(2001), which could influence chemokine-driven trafficking of leukocytes 
through the lymphatics.
In recent years extensive work has been undertaken by Gwendalyn Randolph 
and co-workers into monocyte-derived dendritic cells. They found that the 
culture of blood mononuclear cells in the presence of HUVEC grown on 
extracellular matrix resulted in the differentiation of these cells into DCs within 2 
days, particularly after phagocytosing particles in subendothelial collagen 
(Randolph et al., 1998). These DCs then migrated across the endothelium in an 
ablumenal-to-lumenal direction, as would occur across lymphatic endothelium, 
termed reverse transmigration. Monocytes which differentiated into 
macrophages remained in the sub-endothelial matrix. The authors conclude that
86
Chapter 1 General Introduction 1.5 Leukocyte Migration
this would suggest that the endothelium itself is responsible for initiating 
monocyte differentiation but full differentiation is dependent upon additional 
stimulus, such as the uptake of potential antigen. A later study revealed that 
such monocyte-derived DCs use CCR8 in addition to CCR7 to migrate from the 
tissues to the lymphatic vessels (Qu et al., 2004).
Much less is known about the constitutive migration of leukocytes to lymph 
nodes in the absence of inflammatory stimuli. Huang et al. (2000) demonstrated 
that DCs are capable of transporting apoptotic cells to lymph nodes in the 
absence of external stimuli and Scheinecker et al (2002) provided evidence that 
constitutive presentation of self antigen at the draining lymph node was 
mediated by DCs under non-inflammatory conditions. Also as described above, 
Vermaelen et al. (2001) have demonstrated that pulmonary derived DCs 
constitutively migrate to the lymph nodes. The adhesive mechanisms and 
chemokines involved in these processes, from both uninflamed and inflamed 
tissue are in the early stages of being understood, although a role for JAM-A has 
recently been characterised. Cera et al. (2004) detected JAM-A on the surface of 
DCs and found that DCs from Jam-A-l- mice exhibited an increase in random 
migration and transmigration across lymphatic endothelial cells. Such mice also 
showed increased localisation to lymph nodes of skin DCs and an enhanced 
reaction to contact hypersensitivity. The study supported earlier work which 
found that JAM-A on endothelial cells enhances transmigration, as they reported 
a decrease in lymph node homing in endothelium-restricted Jam-A deficiency. 
Thus it would appear that endothelial JAM-A has a positive role in promoting 
cell extravasation whilst DC JAM-A plays a role in limiting cell motility. 
Although the migration of DC through the lymphatics to the lymph nodes is 
becoming better understood, the mechanism whereby DC enter the lymphatics 
remains to be elucidated.
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1.6 Aims of this thesis
Since the identification of LYVE-1 in 1999 by Banerji et al. as a novel member of 
the Link protein superfamily, the majority of investigators from other 
laboratories have sought to use it as a highly specific marker for lymphatic 
endothelium. However, the functions and mechanisms by which expression of 
this protein is regulated have remained unknown and this PhD has sought to 
characterise them.
• Monoclonal antibodies against mouse LYVE-1 were generated and 
characterised, as described in chapter 3, to permit investigations into 
mouse tissue and complement studies carried out using the human 
monoclonal antibodies already raised by Dr. Remko Prevo.
• Factors regulating LYVE-1 expression were investigated extensively, 
described in chapter 4, to define limitations that this lymphatic marker 
may have as well as to shed light on the roles it may play under 
physiological and pathological conditions.
• The potent effects of proinflammatory cytokines on LYVE-1 expression 
identified in chapter 4 were further pursued in chapter 5, to examine other 
molecular changes in inflamed lymphatic endothelium. The expression of 
adhesion molecules on lymphatic endothelium was of particular interest, 
because in contrast to the well-characterised protein expression profile of 
inflamed blood vascular endothelium, no similar studies had been 
undertaken for lymphatic endothelium.
• Studies into the alteration in expression profile were also pursued in 
chapter 6 through the use of in vivo models of inflammation and the 
physiological relevance with respect to the trafficking of antigen 
presenting cells was explored.
88
CHAPTER 2
Methods & Materials
2.1 General Reagents............................................................................ 90
2.2 Antibodies........................................................................................95
2.3 Bacterial Culture............................................................................. 98
2.4 Molecular Biology Methods........................................................ 101
2.5 Tissue Culture............................................................................... 117
2.6 Protein Biochemical Methods......................................................125
2.7 Generation of Polyclonal Antisera..............................................128
2.8 Generation of mAbs Against Mouse LYVE-1...........................129
2.9 Immunohistochemistry & Immunofluorescence Ab Stainingl33
2.10 Animal Procedures..................................................................... 138
89
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2.1 General Reagents
2.1.1 Chemicals
BAY 11-7082 was purchased from Chemicon (Harrow, UK) and a stock 
solution of 20 mM made up in DMSO, storing in aliquots at -20°C.
EDTA: 0.5 M stock was made with ethylenediaminetetraacetate dihydrate 
(di-sodium salt) in water and adjusted to pH 8.0 with NaOH.
Ilomastat (GM6001), matrix metalloproteinase inhibitor was purchased from 
Chemicon.
OPD (O-Phenylenediamine) substrate and buffer tablets were from SIGMA 
(Poole, UK).
PBS: 1 tablet of PBS (Phosphate buffered saline, Dulbecco A; from Oxoid Ltd, 
England) was dissolved per 100 ml H20.
PMA (phorbol 12-myristate 13-acetate) was purchased from Calbiochem 
(Merke Biosciences Ltd, Nottingham, UK). A 200 pg/m l stock was prepared 
in DMSO and stored at -20°C.
Saponin (from Quillaja bark) was from SIGMA.
SSC: A 20 x stock solution contained 3 M NaCl, 0.3 M Sodium citrate (pH 7.0). 
Tris-HCl buffer: 2 M stock was made from Tris base (Tris-
hydroxymethylamino methane) in water and adjusted to pH 8.0 with HC1.
All other chemicals were purchased from either SIGMA (Poole, UK) or BDH 
(Leicester, UK), unless otherwise stated.
2.1.2 Molecular biology reagents
2.1.2.1 General reagents
Actinomycin D (SIGMA) dissolved in methanol at 5m g/m l and stored at -  
20°C in the dark.
Agarose was purchased from Invitrogen (Paisley, UK).
Bio 101 GeneClean II kit was from Q-BIOgene-ALEXIS (Nottingham, UK). 
Gene Pulser Cuvettes, 0.2cm were purchased from BioRad (Hercules, USA).
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Hybond-N+ and Hybond-C+ transfer membranes were purchased from 
Amersham Pharmacia Biotech (Amersham, UK).
Mixed Bed Resin, Analytical grade was from BioRad.
Pyrococcus furiosus (Pfu) polymerase was from Stratagene (Amsterdam 
Zudoost, The Netherlands) and was used with the buffer provided.
QIAEXII gel extraction kit was purchased from Qiagen (Crawley, UK). 
RNeasy Mini Kit was purchased from Qiagen.
SequaGel sequencing system was purchased from National Diagnostics 
(Hessle, UK).
TE buffer was prepared, consisting of 10 mM Tris pH 8.0,1 mM EDTA, both 
purchased from SIGMA.
2.1.2.2 Nucleic acids
lkb and lOObp DNA Ladders were purchased from New England Biolabs 
(Hertfordshire, UK) and diluted in glycerol-bromophenol blue loading buffer 
to 50ng/ml.
0X174-HfleIII digest was purchased from New England Biolabs.
Biotin-11-CTP was purchased from Perkin Elmer (Wellesley, USA).
Biotin-16-UTP was purchased from Roche (Lewes, UK).
dNTPs were purchased from Bioline (London, UK) as 100 mM stocks. A 50x
(12.5 mM for each dNTP) stock was made in sterile water and stored at -20°C.
RNA Ladder was purchased from New England Biolabs.
tRNA (from brewer's yeast was purchased from Roche.
2.1.23 Enzymes
AMV Reverse Transcriptase, 21U/pl was purchase from Cambio (Cambridge, 
UK)
DNA Polymerase I, Large (Klenow) Fragment was purchased from New  
England Biolabs.
Pyrococcus furiosus (Pfu) polymerase was from Stratagene and was used 
with the buffer provided.
Restriction enzymes were purchased from New England Biolabs or Roche and 
used with the recommended buffers according to manufacturers' instructions. 
RNAsin was purchased from Promega (Southampton, UK).
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T4 ligase and buffer was from New England Biolabs.
T4 Polynucleotide Kinase was from New England Biolabs.
TaqPlus® Precision PCR System was purchased from Stratagene.
Thermus aquaticus (Taq) polymerase (BioTaq) was purchased from Bioline 
(London, UK) and used with the buffers provided.
2.1.2.4 Radiolabelled reagents
[a32P]dCTP (-3000 Ci/mmole) and [y32P]ATP (7000 Ci/mmole) were both 
purchased from Amersham Pharmacia Biotech.
2.1.3 Cell culture reagents
2.1.3 1 Media
The following reagents were purchased from Gibco (Paisley, UK):- 
DMEM (Dulbecco modified Eagle medium),
FCS (Foetal Calf Serum), which was heat inactivated prior to use (20 min 
55°C),
G418 (Geneticin), from which a 125 m g/m l stock solution was prepared in 
RPMI (Roswell Park Memorial Institute) medium (also from Gibco), adjusted 
to neutral pH with NaOH, filter sterilised and stored at 4°C, and 
Trypsin EDTA.
The following reagents were purchased from SIGMA:-
Gentamycin sulphate, from which a 50 m g/m l stock solution was prepared in 
RPMI and used at a working concentration of 50 pg/ml,
Gelatin 2% (w /v) solution, type B, used at a working concentration of 0.1% 
(w /v) in PBS,
L-Glutamine, of which a stock solution of 200 mM was prepared, stored at - 
20°C and used at a working concentration of 2 mM.
Penicillin and Streptomycin, from which stock solutions of penicillin at 100 
U/m l) and streptomycin at 5 m g/m l were prepared, stored at -20°C and used 
at working concentrations of 1 U /m l and 50 jig/ml respectively.
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Accutase was purchased from PAA Laboratories (Yeovil, UK) and stored in 
aliquots at -20°C.
Cytokines and growth factors were purchased from R&D Systems (Oxford) 
and reconstituted according to the manufacturers recommendations prior to 
storage at -20°C.
EGM-2 MV BulletKit media was purchased from Cambrex Bioscience 
(Walkersville, USA), consisting of EBM-2 (Endothelial basal medium) and 
supplemented with the supplied SingleQuots (Hydrocortisone, EGF, FBS, 
VEGF, FGF-B, R3-IGF, ascorbic acid and gentamycin/amphotericin-B) prior 
to use.
Type I collagen (rat tail) was purchased from BD (San Diego, USA)
UltraCHO medium was purchased from Bio Whittaker
2.1.32 Transfection reagents
HEPES (used for calcium phosphate transfections) was from SIGMA.
HUVEC Nucleofector™ kit (solutions, cuvette and electroporator were from 
Amaxa Biosystems.
LIPOFECTIN® reagent and serum-free OptiMEM were both purchased from 
Life Technologies (Roskilde, Denmark).
2.1.3.3 Reagents fo r  magnetic cell sorting o f cells (MACS)
Cell strainers, 70pm mesh were purchased from BD Falcon, (Bedford, USA). 
MACS columns, (sizes LS and MS), metal stand, pre-separation filters (30pm 
mesh) and goat anti-rat MACS beads were purchased from Miltenyi Biotec 
GmbH (Bisley, UK).
2.1.3A Tissue culture ware
Tissue culture flasks and multiwell dishes were from Nunc (Roskilde, 
Denmark).
Tissue culture dishes (14 cm) and 8-chamber slides were from BD Falcon 
(Bedford, USA).
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2.1.4 Reagents for the generation of monoclonal antibodies
FBS (Foetal Bovine Serum), Australian origin, was purchased from GIBCO 
and batch-tested prior to ordering, to ensure that an individual batch was 
suitable for supporting hybridoma growth.
HAT (Hypoxanthine, lOmM, Aminopterin, 0.4pM, Thymidine, 16.5pM, L 
Glycine, 3pM, Sodium pyruvate, ImM) lOOx concentration solution was 
prepared in water and filter-sterilised, storing in aliquots at 4°C.
GKN isotonic buffer was prepared from sodium chloride, 137 mM; potassium 
chloride, 5.37 mM; Na2H P04,10 mM; NaH 2P04.H20,5 mM and glucose, 11 
mM, dissolved in water and filter sterilised.
HT, (Hypoxanthine, lOmM, 0.4pM, Thymidine, 16.5pM, L Glycine, 3pM, 
Sodium pyruvate, ImM) lOOx concentration solution prepared in water and 
filter-sterilised, storing in aliquots at 4°C.
Polyethylene Glycol (PEG) 1500 was from Roche.
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2.2 Antibodies
Antibodies directed against murine and human cell surface receptors, 
intracellular proteins and chemokines are listed in tables 2.1 and 2.2 below, 
along with their specificity, host, isotype and source.
2.2.1 Primary anti-mouse antibodies
Specificity Antibody Host Clone Source
CD31 MEC13-3 Rat IgG BD Pharmingen
CD44 IM7 Rat IgG BD Pharmingen
ICAM-1 - Goat Polyclonal R&D Systems
ICAM-1 cbl 1331 Rat IgG Cymbus Biotechnology
JE/MCP-1 - Goat Polyclonal R and D Systems
LYVE-1 Bl/10 Rat IgGl See chapter 3
LYVE-1 C l/8 Rat IgG2a See chapter 3
LYVE-1 - Rabbit Polyclonal Prevo et al., 2001
Macrophage 
mannose receptor
F4/80 Rat IgG2b Prof. S. Gordon
MIP-3a - Goat Polyclonal R and D Systems
Podoplanin 8.1.1 Hamster IgG DSHB, Iowa
Podoplanin Viennese Nanni Rabbit Polyclonal Prof. D. Keijaschki
Prox-1* - Rabbit Polyclonal RDI
RANTES - Goat Polyclonal R and D Systems
SLC - Goat Polyclonal R and D Systems
VCAM-1 429
(MVCAM.A)
Rat IgG2a BDPharmingen
VE-Cadherin 11D4.1 Rat IgG BDPharmingen
Table 2.1 Primary anti-mouse antibodies.
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2.2.2 Primary anti-human antibodies
2.2 Antibodies
Specificity Antibody Host Clone Source
a3 Integrin 1A3 Mouse IgGl CR-UK
oc4 Integrin 7.2 Mouse IgGl CR-UK
oc6 Integrin MP4F10 Mouse IgG2b CR-UK
a9pi Integrin Y9A2 Mouse IgGl Serotec
avP3 Integrin 23C6 Mouse IgGl CR-UK
cxMpi Integrin 24 Mouse IgGl CR-UK
cxMpi Integrin TS2/4.1.1 Mouse IgGl CR-UK
pl Integrin P5D2 Mouse IgGl CR-UK
PI Integrin TS2/16 Mouse IgG2a CR-UK
Cytochrome C - Mouse Dr. R. Thome
CD31 JC70A Mouse IgGl DakoCytomation
CD34 581 Mouse IgGl BD Pharmingen
CD44 El/2.8 Mouse IgGl CR-UK
CD44 25.32 Mouse IgGl CR-UK
CD63 H5B6 Mouse IgGl Developmental studies 
hybridoma bank
E-Selectin BHG-E4 Mouse IgGl R&D Systems
E-Selectin 62E Mouse IgGl CR-UK
EEA1 14 Mouse IgGl BD Pharmingen
ICAM-1 15.2 Mouse IgGl Serotec
ICAM-1 PIW16 Mouse IgGl CR-UK
ICAM-2 B-Tl Mouse IgGl Serotec
ICAM-3 ICAM3.1 Mouse IgGl CR-UK
ICAM-3 ICAM3.2 Mouse IgGl CR-UK
JAM-1 3b8 Mouse IgGl Prof. C. Buckley
LYVE-1 8C Mouse IgGl Dr. R. Prevo
LYVE-1 6A Mouse IgGl Dr. R. Prevo
LYVE-1 3A Mouse IgGl Dr. R. Prevo
LYVE-1 - Rabbit Polyclonal Baneiji et al. 1999
PDI - Mouse IgGl Dr. R. Thome
Podoplanin Viennese Susi Rabbit Polyclonal Prof. D. Kerjaschki
Podoplanin D2-40 Mouse IgGl Signet
Prox-1* - Rabbit Polyclonal RDI
Sialoadherin HSn 7D2 Mouse IgGl CR-UK
TIE-2 4g8 Mouse IgGl CR-UK
VCAM-1 MCA 907 Mouse IgG CR-UK
VCAM-1 51-10C9 Mouse IgGl BD Pharmingen
VE-CAD CAD-5 Mouse IgG Prof. C. Buckley
Table 2.2 Primary anti-human antibodies. (*The rabbit anti-Prox1 antisera was raised 
against human but cross-reacts with mouse)
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2.2.3 Secondary antibodies and conjugates
Specificity Conjugate Host Source Notes1
Goat IgG Alexa568 Donkey Molecular
Probes
red fluorescent (578/603)
Hamster
I*G
Alexa568 Goat Molecular
Probes
red fluorescent (578/603)
Human IgG HRP Goat Pierce used for ELISA
Mouse IgG Alexa488 Goat Molecular
Probes
green fluorescent 
(495/519)
Mouse IgG Alexa568 Goat Molecular
Probes
red fluorescent (578/603)
Mouse IgG Alexa594 Goat Molecular
Probes
red fluorescent (590/617)
Mouse IgG HRP Goat Pierce used for ELISA
Mouse IgG HRP Goat DAKO
(K4006)
part of Envision system 
for IHC
Rabbit IgG Alexa488 Goat Molecular
Probes
green fluorescent 
(495/519)
Rabbit IgG Alexa568 Goat Molecular
Probes
red fluorescent (578/603)
Rabbit IgG Alexa594 Goat Molecular
Probes
red fluorescent (590/617)
Rabbit IgG HRP Goat Pierce used for ELISA and 
Westerns
Rabbit IgG HRP Goat DAKO
(K4010)
part of Envision system 
for IHC
Rat IgG Alexa488 Goat Molecular
Probes
green fluorescent 
(495/519)
Rat IgG Alexa568 Goat Molecular
Probes
red fluorescent (578/603)
Rat IgG Alexa488 Donkey Molecular
Probes
green fluorescent 
(495/519)
Table 2.3 Secondary antibodies and conjugates.
1) The numbers in brackets refer to wavelengths for fluorescent absorption and fluorescence 
emission maxima (nm) for fluorescent conjugates (adapted from Molecular Probes Inc).
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2.3 Bacterial Culture
2.3.1 Bacterial media
Agar plates were made by adding Bacto-agar (BD) to freshly dissolved LB 
medium (see below) to a final concentration of 1.6% (w /v) and autoclaving. 
Appropriate antibiotics were added after the solution had cooled down to 
approximately 50°C and the solution poured into 9 cm petri dishes. Plates 
were dried at room temperature and stored at 4°C for up to 1 month.
Ampicillin (D[-]-a-aminobenzylpenicillin) was purchased from SIGMA. A 
stock of 100 m g/m l was made in water and stored in aliquots at -20°C. A 
concentration of 100 pg/m l was used for agar plates and liquid medium. 
When ampicillin was used together with tetracycline, a concentration of 25 
pg/m l was used.
LB (Luria broth) medium was made by dissolving 10 g Tryptone (BD), 5 g 
Yeast extract (BD) and 5 g NaCl in 1 litre water and autoclaving.
SOB medium was made by dissolving 2 g Tryptone, 0.5 g yeast extract, 200 pi 
5 M NaCl in 100 ml of water and autoclaving. 1/100 volumes of sterile 1 M 
MgC12 and 1/100 volume of sterile 1 M KC1 were then added.
SOC medium was made by adding 1/50 volume of 1 M filter-sterilised 
glucose to autoclaved SOB medium.
Terrific broth (Modified) was purchased as a dried media from SIGMA and 
prepared according to the manufacturer's instructions.
Tetracycline (Hydrochloride) was purchased from SIGMA and a 7.5 m g/m l 
stock was made in 50% (v/v) aqueous ethanol. Tetracycline was used at 7.5 
pg/m l together with 25 pg/m l ampicillin in agar plates and liquid culture.
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2.3.2 Bacterial strains
The following E.coli strains were used:
DH5a, used for transformation with pRcCMV vector and luciferase vectors 
(see section 2.4.1), which confer resistance to ampicillin.
MC1061/p3, used for transformation with pCDM7Ig vector, which confers 
resistance to ampicillin and tetracycline.
2.3.3 Preparation of glycerol stocks
A single colony was picked from an agar plate and used to inoculate a liquid 
culture of LB supplemented with the appropriate antibiotics and grown 
overnight with shaking at 37°C. The following day 700 pi of the culture was 
supplemented with 300 pi glycerol and stored at -80°C.
2.3.4 Preparation of calcium competent DH5a or MC1061/p3
Bacteria were streaked out on an agar plate and grown overnight at 37°C. A 
single colony was then used to inoculate 5ml LB and grown overnight at 37°C 
with agitation. This was subsequently used to inoculate 500ml LB, which was 
grown at 37°C with agitation until in mid-log phase (OD600nm between 0.4 
and 0.6). The flask was chilled on ice for 15-30 min and then centrifuged at 
5000 RPM at 4°C in a Heraeus Megafuge 2.0R in autoclaved tubes. Cells were 
resuspended in 100ml chilled washing buffer (30 mM Potassium acetate, 50 
mM MnCh, 100 mM KC1, lOmM CaCh, 15 % Glycerol) and incubated on ice 
for 15 min. Cells were centrifuged again at 3000 RPM at 4°C and then 
resuspended in 20ml chilled storage buffer (10 mM MOPS pH 7.0, 75 mM 
CaCh, 10 mM KC1, 15 % glycerol) prior to dividing into 200 pi aliquots and 
snap freezing in a dry-ice ethanol bath. Vials were stored at -80°C.
2.3.5 Transformation of calcium competent E.coli
50 pi of calcium competent E. coli were used for each transformation. Plasmid 
DNA was added on ice (typically 1 pg of DNA of intact plasmid or 5 pi of 
ligation mix) and incubated on ice for 30 min. Bacteria were heat-shocked at 
42°C for 90 sec and then allowed to recover for 1 min on ice. Preheated SOB
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(4 x vol) was added and cells were incubated for lh  at 37°C with agitation. 50 
pi to 200 pi of culture was spread on agar plates supplemented with the 
appropriate antibiotics. MC1060/p3 transformed with the pCDM7Ig plasmid 
were grown on agar plates supplemented with 25 pg/m l ampicillin and 7.5 
pg/m l tetracycline. DH5a transformed with either pRcCMV or a luciferase 
plasmid were grown on agar plates supplemented with 100 pg/m l ampicillin.
2.3.6 Preparation of electrocompetent E. coli
An agar plate was streaked with the desired bacterial strain and grown 
overnight at 37°C. A single colony was picked and used to inoculate 10 ml 
LB, growing overnight at 37°C with agitation. This pre-culture was 
subsequently used to inoculate 1 litre of LB and grown at 37°C with agitation 
until OD600nm was between 0.5 and 0.8. The flask was chilled on ice for 15-30 
min and cells then centrifuged for 15 min at 4200 RPM in a JS 4.2 rotor at 4°C. 
The pelleted cells were resuspended in 500 ml of ice-cold water and 
centrifuged again. Cells were resuspended in 20 ml.
2.3.7 Electroporation of E.coli
40 pi electrocompetent E.coli were used for each transformation. Plasmid 
DNA (typically 0.5 pg of intact plasmid or 1 pi of ligation mix) was added to 
the cells on ice and left for 1 min. The mixture of cells and DNA was 
transferred to a 0.2 cm chilled cuvette and placed in the pulse chamber of a 
Bio-Rad electroporation apparatus. One pulse was given at the following 
settings: 25 pF, 200 Q, 2.5 kV. 1 ml of SOC medium was then added to the 
cuvette and the suspension was transferred to a 15 ml round-bottomed Falcon 
tube. The cells were incubated in the 37°C shaker for one hour. 
Approximately half of the culture (concentrated to 100 pi by centrifugation) 
was spread out on agar plates with appropriate antibiotics and grown 
overnight at 37°C.
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2.4 Molecular Biology Methods
2.4.1 RNA
All reagents used were maintained in RNase-free conditions
2.4.1.1 Extraction o f to ta l cellular RNA from tissues
(The method used was adapted from Chomczynski and Sacchi, 1987, Anal. 
Biochem. 162,156-159)
Buffers and solutions 
DEPC-treated water
DEPC, 0.1% (v/v) in distilled deionized water was incubated at 37°C 
overnight to drive off the DEPC and then autoclaved.
Denaturing solution 
Guanidine thiocyanate, 4 M 
Sodium citrate, 25 mM
Mercaptoethanol, 0.1 M, added just before use.
Procedure
Tissue was homogenised in denaturing solution, 1 ml per lOOmg of tissue, 
using either a small (2 ml) Dounce homogeniser or a EUROTURRAX® T 25 
motorised dispersion device, depending on the scale of the RNA preparation. 
Sodium acetate, pH 4.0,2M, 0.1 ml per 1 ml solubilised tissue was added, then 
acid-equilibrated phenol chloroform (5:1), 1.2ml per 1 ml, shaking vigorously 
and then chilling on ice for 15 minutes. Samples were centrifuged at lOOOOg 
for 20 min at 4°C. The upper aqueous layer containing the RNA was 
transferred to new tubes and an equal volume of isopropanol added. 
Samples were placed at -20°C for 1 h and the precipitates collected by 
centrifuging as before. The pellets were redissolved in 0.3 ml denaturing 
solution and precipitated as before by addition of an equal volume of 
isopropanol at -20°C for 1 h. RNA pellets were recovered by centrifugation, 
washing in 75% (v/v) ethanol before vacuum-drying the RNA in a Speed Vac
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(Savant) and dissolving in DEPC-treated water by heating to 70°C. RNA was 
stored at -80°C
2.4.1.2 Extraction o f to ta l cellular RNA from cells
Adherent cells were lifted using trypsin-EDTA and washed with PBS. All 
supernatant was aspirated off and the cell pellet resuspended in RLT lysis 
buffer from the RNeasy kit (Qiagen), 600 p i /<5 x 106 cells according to the 
manufacturer's instructions. Briefly, cells were lysed by vortexing and an 
equal volume of 70 % ethanol was added. The sample was then applied to an 
RNeasy column which was subsequently washed with buffers RW1 and RPE 
respectively before eluting the RNA in nuclease-free water.
2.4.13 Electrophoresis of RNA through agarose-formalehyde gels 
Buffers and solutions
Running Buffer, made up as a lOx concentrate stock and diluted to lx  in 
DEPC-treated water.
0.2 M MOPS
0.05 M Sodium Acetate
5 mM EDTA, pH 8.0
Sample buffer
30% formamide, deionized on mixed bed resin in order that pH > 4 
0.67 x concentrate MOPS
4% formaldehyde, deionized on mixed bed resin in order that pH < 7 
33.3% glycerol
0.3 m g/m l bromophenol blue
in DEPC-treated water, stored in aliquots at -20°C
Procedure
A 1% (w /v) agarose gel was made by dissolving agarose in lx  running buffer, 
heating to allow the agarose to dissolve and then cooling to 50°C before 
adding deionized formaldehyde to a final concentration of 2% (v /v ) and 
pouring into the gel tray. The gel was pre-run at 5V/cm for approximately 5 
min before the samples were loaded, with a magnetic stirrer within the tank 
to permit running buffer to circulate. Typically 10-15 pg of sample was
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vacuum dried and resuspended in 20 pi sample buffer supplemented with 
ethidium bromide at a final concentration of 10 pg/m l. Samples were boiled 
for 2 min then cooled on ice prior to loading. An RNA ladder (New England 
Biolabs) was included in a parallel lane to serve as a size standard and 
prepared according to the manufacturers' recommendations. Electrophoresis 
was carried out at a constant voltage of 4-5V/cm. RNA was visualized by 
placing the gel on a UV transilluminator and photographed.
2.4.14 Northern blotting: Neutral transfer by capillary transfer by  upward  
f lo w
Following agarose-formaldehyde electrophoresis, the gel was rinsed in DEPC- 
treated water and then soaked for 20 min in 5 gel volumes of 0.5 M NaOH. 
The gel was transferred to 10 gel volumes of 20x concentrated SSC for a 
further 40 min. Meanwhile, Hybond N+ membrane (Amersham) was 
immersed in lOx SCC. The gel was inverted and placed on Whatman 3MM 
paper, with wicks trailing in to lOx SSC and Saran wrap around to prevent 
short-circuiting. The top right hand comer of the gel was trimmed to aid 
subsequent orientation and the membrane laid on top with the corresponding 
comer trimmed. 3 pieces of Whatman 3MM paper were laid on top to the 
membrane and a pile of tissue paper placed above, with a flat plate on top of 
the stack and a 500g weight to weigh it down. Upward transfer of RNA was 
allowed to occur for 4 h. The membrane was washed briefly in 6x SSC prior 
to Northern hybridisation.
2.4.1.5 Preparation o f 32P-labelled DNA probes
DNA probes comprising either full length LYVE-1 or an approximately 600bp 
fi-actin fragment were amplified from human dermal lymphatic endothelial 
cells (HDLEC) by the primers ActinFwd (AGGCATCCTCACCCTGAAGTAC) 
and ActinRev (TTGCCAATGGTGATGACCTGGC). Probes were then 
radiolabelled by random oligonucleotide priming and Klenow polymerase 
(High Prime DNA Labeling Kit, Roche) whereby a complementary DNA  
strand is synthesised with the modified deoxyribonucleoside-triphosphate 
[a32P] dCTP (Redivue, Amersham) incorporated. Briefly, approximately 30 
ng DNA probe, either from a digested vector or a PCR product, was
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denatured by boiling for 10 min then chilled rapidly in an ice-ethanol bath. 
dGTP, dATP, dTTP and High Prime reaction mixture were added plus 5 pi 
(1.85 MBq) of [a-32P] dCTP prior to incubation at 37°C for 10 min. The 
reaction was stopped by addition of 2 pi 0.2 M EDTA pH 8. The probe was 
separated from un-incorporated nucleotides on a Sephadex G-25, NAP-5 
column (Amersham Pharmacia Biotech) and eluted in 1 ml TE. The eluted 
probe was mixed with 100 pg sheared salmon testis DNA (SIGMA) and 
denatured for 5 min at 100°C prior to hybridisation.
2.4.1.6 Northern Hybridisation
The membrane containing the RNA from neutral transfer was placed in 
ExpressHyb hybridisation solution (Clontech) at 65 °C, rotating slowly in a 
Hybaid hybridisation oven for 1 h prior to addition of the [a-32P] labelled 
probe. Hybridisation was carried out overnight at 65°C. The following day, 
blots were first rinsed and washed at low stringency (2x SSC, 0.05% (w /v) 
SDS, 2 x 15 min at room temperature) and then washed at high stringency (0.1 
x SSC, 0.1% SDS, 2 x 20 min at 50°C) prior to autoradiography for 1 day to one 
week, as appropriate.
For re-probing, blots were stripped in 0.1% SDS at 100°C, then rinsed in 2x 
SSC and re-probed with another cDNA probe.
2.4.1.7 Generation of f ir s t strand synthesis products
First strand synthesis from total RNA was carried out by oligo-dT priming. 3- 
5pg total RNA was heated for 10 min with oligo-dTi2-i8 primers (Collaborative 
Research), prior to the addition on ice of 0.5pM dNTPs, 0.1M Tris-HCl, pH8.3, 
20 U RNasin and lU /p l AMV reverse transcriptase in a total volume of 50 pi. 
The reaction mixture was incubated for 90 min at 42°C.
2.4.1.8 Affymetrix array analysis
Preparation of double-stranded cDNA and in vitro transcription 
The first approach for preparing biotinylated complementary RNA (cRNA) 
from total RNA isolated from cultured cells used the MessageAmp™ aRNA 
kit from Ambion (detailed below). cRNA was prepared for duplicate analysis
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of HDLEC (described in chapter 5 of this thesis). However, the quality of 
RNA yielded by this kit was highly variable and thus this method was 
replaced by supplying total RNA to the Paterson Institute for Cancer 
Research, Manchester, where complementary RNA was prepared by an 
alternative method whereby phenol-chloroform extraction was used to 
recover nucleic acids from solution, rather than columns supplied in the 
Ambion kit.
The MessageAmp™ aRNA kit supplied all enzymes, buffers, filter cartridges 
and other reagents for the preparation of biotinylated complementary RNA. 
5 jig of total RNA prepared by RNeasy purification from human LEC cultured
in either the presence or absence of human recombinant TNFa, lOng/ml for
72 h was used for each amplification reaction. RNA and T7 Oligo (dT) primer 
were heated together to 70°C for 10 min in a thermal cycler prior to first 
strand synthesis by reverse transcriptase, to synthesise cDNA with a T7 
promoter sequence by incubation in a hybridisation oven at 42°C for 2 h. 
Second strand cDNA synthesis was then carried out by DNA polymerase at 
16°C for 2 h in a thermal cycler. The cDNA was purified using a filter 
cartridge, to remove RNA, primers, enzymes and salts before in vitro 
transcription.
To make biotin labelled cRNA, 7.5 jil of 10 mM biotin-ll-CTP (Perkin Elmer) 
and biotin-16-UTP (Roche) were included in the T7 RNA-polymerase- 
catalysed reaction, carried out for 13 h at 37°C in a hybridisation oven. The 
cRNA was purified using a filter cartridge and eluted in nuclease-free water. 
cRNA was concentrated by vacuum centrifugation and the concentration 
estimated in a UV spectrophotometer at 260 nm. The typical yield was 
between 100 and 200 jig from the initial 5 pg total RNA. 2-3 jig were subjected 
to agarose gel electrophoresis, to ensure that the amplified cRNA was visible 
as a smear from lOObp to 2Kb, with a brighter region between 500bp and 1Kb.
Fragmentation of complementary RNA
25 jig of cRNA was fragmented in a total volume of 50 pi with 10 pi 5x 
fragmentation buffer (200 mM Tris-acetate, pH 8.1, 500 mM KOAc. 150 mM 
MgOAc, filter sterilised) by heating to 94°C in a thermal cycler for 35 min.
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The sample was then chilled on ice and stored at -80°C. Biotin-labelled cRNA 
was also prepared from HDLEC RNA by Dr. Yvonne Hey at the Paterson 
Institute for Cancer Research.
Affymetrix GeneChip analysis of human transcripts
Biotin-labelled human cRNA target was hybridised to the probe set on the 
GeneChip® Human Genome U133 Plus 2.0 array at the CR-UK microarray 
facility at the Paterson Institute for Cancer Research, Manchester. Triplicate 
sets of data were generated and normalisation of data was performed in 
Bioconductor and RMA by Dr. Stephen Taylor, Bioinformatics, WIMM.
Micro array analysis of complementary RNA derived from mouse 
Mouse LEC were cultured for 12h in either EGM-2 medium alone or 
supplemented with mouse recombinant TNFa (R and D Systems), lOOng/ml. 
RNA and biotin-labelled cRNA were prepared at the Paterson Institute for 
Cancer Research, as from the HDLEC, and applied to the GeneChip® Mouse 
Expression Set 430 array. Due to limited availability of this primary cell line, 
only one set of data could be obtained.
2.4.2 DNA
2.4.2.1 Plasmids
pCDM7Ig used for expression of soluble Ig fusion proteins was kindly 
provided by Dr. Alejandro Aruffo, Bristol-Myers Squibb, Seattle, WA. 
pRcCMV used for eukaryotic expression was from InVitrogen. 
pGL3-Basic, a luciferase construct was obtained originally from Promega and 
kindly donated by Dr. John Moore, Cancer Research UK, Weatherall Institute 
of Molecular Medicine.
pGL3-Enhancer, a luciferase construct containing SV40 enhancer elements, 
was purchased from Promega.
2A.2.2 Constructs
LYVE-1: Full-length human LYVE-1 cDNA cloned into pRcCMV is described 
in Banerji et al., (1999).
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LYVE-1 Fc: The N-terminal leader and extracellular domain of human LYVE- 
1 (Met 1 -  Gly 232) and mouse LYVE-1 (Met 1 -  Gly 228) cloned into the 
pCDM7Ig vector as a fusion with the Fc domain of human IgGl is described 
in Banerji et al., (1999) and Prevo et al., (2001) respectively.
Podoplanin Fc. Full length podoplanin was cloned into pCDM7Ig, as 
described in appendix II.
pBR-pactin-Luc, containing a chicken p-actin promoter and luciferase reporter 
gene on a pBR backbone was a kind gift from Dr. Katya Simon, MRC Human 
Immunology Unit, Weatherall Institute of Molecular Medicine. 
pGL3-Basic and pGL3-Enhancer constructs containing either lengths of 
upstream human LYVE-1 sequence or the chicken p-actin promoter from pBR- 
Pactin-Luc were generated in this thesis (appendix I).
2.4.23 Agarose gel electrophoresis 
Buffers
TBE (Tris-borate) EDTA buffer: 0.09 M Tris-borate, 0.002 M EDTA, pH 8.0 
(stored at room temperature).
Loading buffer (6 x): 2.5 m g/m l bromophenol blue, 30% v /v  glycerol
(stored at room temperature).
Ethidium bromide: A 10 m g/m l stock solution was made in H2O.
Procedure
Agarose gels (0.9 - 1.2% w /v ) were made in TBE buffer supplemented with 
0.5 pg/m l ethidium bromide. DNA samples were mixed with 1 /6  vol of 
loading buffer and run under constant voltage (80 V to 110 V). Gels were 
visualised under UV illumination.
2.4.2 A Digestion of DNA w ith  restriction endonucleases
Typically 1 pg of plasmid or purified PCR product was digested with 10 -  20 
units of the appropriate restriction enzyme supplemented with the 
appropriate buffer and BSA (lOOpg/ml) in a total volume of 50pl and 
incubated for at least 2.5 h at 37°C. Digests were loaded onto agarose gels for 
subsequent purification. Digests of PCR products were purified directly using 
GeneClean (see below).
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2.4.2.5 Purification o f DNA Fragments from  Agarose Gels
DNA fragments were separated on agarose gels and bands were excised 
under brief UV illumination. DNA was then purified using the Bio 101 
GeneClean II kit (Q-BIOgene) according to manufacturers' instructions. 
Briefly, 4.5 vol of 6 M Nal and 0.5 vol of TBE modifier was added to the gel 
fragment and heated at 55°C for 5 min to melt the gel. 10 pi of GLASSMILK® 
silica suspension was added and incubated for 1 min. The GLASSMILK® was 
washed three times with salt solution in 50% ethanol (NEW WASH) and 
DNA eluted in 20 pi H2O in two successive steps, pooling eluants and 
centrifuging to remove any GLASSMILK carried over.
2.42.6 Ligation o f digested DNA fragments
Ligations were carried out in a final volume of 10 pi containing approximately 
0.2 pg of linearised plasmid, 50 ng of the appropriate purified insert and 200 
U of T4 DNA ligase in lx  ligase buffer. Samples were incubated overnight at 
15°C.
2.4.2.7 PCR (Polymerase Chain Reaction)
PCR was performed using either a Perkin Elmer Cetus DNA thermal cycler or 
a Hybaid PCR Express. Taq polymerase was used for large-scale screening of 
bacterial colonies or cDNA whilst Pfu polymerase or Taq Plus polymerase 
were used for amplification of DNA for protein expression. All solutions 
were prepared from freshly distilled de-ionised water. Primers were ordered 
from Invitrogen and their melting temperatures (Tm) were calculated 
according to their GC content: each A or T = 2°C, each G or C = 4°C. 
Annealing temperatures for PCR were set at 5°C below the calculated Tm.
2.42.8 Amplification w ith  Taq Polymerase
Reactions were carried out in a total volume of 50pl in water with:
5 pi 10 x NH4 buffer (supplied with Taq)
0.25 mM dNTP 
1 mM MgCh
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0.2 ]liM forward primer 
0.2 ]liM reverse primer 
0.5 pi Taq (2.5 U)
O.lpg of plasmid DNA (or 1 pi of cDNA), added last
25-30 cycles were carried out, each consisting of 1 min denaturing at 94°C, 1 
min annealing at Tm-5°C and extension at 72°C for 1 min/kb target DNA
2A.2.9 Am plification w ith  Pfu Polymerase
Reactions were carried out in a total volume of 50pl in water with:
5 pi lOx Pfu buffer (lx = lOmM Tris pH 8.3,50mM KC1,2.5mM MgCh)
1 mM dNTP (0.25 mM of each dNTP)
0.2 pM forward primer 
0.2 pM reverse primer 
0.5 pi Pfu (2.5 U)
0.5 pg of plasmid DNA (or 1-2 pi of cDNA)
25 cycles were carried out, each consisting of 1 min denaturing at 94°C, 5 min 
annealing at Tm-5°C and extension at 68°C for 10 min
2.4.2.10 Amplification Using TaqPlus® Precision PCR System
This enzyme mixture (purchased from Stratagene) combines the proof­
reading ability of Pfu with the faster polymerizing rate of Taq and was used to 
amplify longer DNA targets and generate higher yields of product for 
cloning. PCR was carried out according to the manufacturers instructions. 
Briefly, reactions were carried out in a total volume of lOOpl in water, with 
TaqPlus® Precision 10 x buffer, 0.8 mM dNTP (0.2 mM of each dNTP), 
2.5ng/pi of each primer, TaqPlus® Precision polymerase mixture, 5 U and 250 
ng DNA template. The cycling parameters used were denaturing at 94°C for 1 
min, followed by annealing at Tm-5°C for 1 min, then extension at 72°C for 1 
min/kb target DNA.
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2.4.2.11 Small-scale Preparation o f Plasm id DNA (miniprep)
Plasmid DNA was prepared from overnight cultures grown in LB. Cultures 
were harvested by centrifuging at 472 g for 5 min in a Heraeus Megafuge 2.0. 
Plasmid DNA was extracted using the QIAprep Spin miniprep kit (Qiagen) 
according to the manufacturers' instructions. The integrity of the DNA was 
examined by agarose gel electrophoresis.
2.4.2.12 Large-scale Preparation o f Plasm id DNA (maxiprep)
Solutions for maxiprep:
Resuspension buffer 
25 mM Tris pH 8.0 
10 mM EDTA
Lysis buffer 
200 mM NaOH 
1 % (w /v) SDS
Neutralisation buffer 
3 M Potassium acetate 
13.5% (v/v) Acetic acid
Procedure
A preculture was prepared using a single colony of the transformed bacteria 
of interest to inoculate 10 ml of LB supplemented with the appropriate 
antibiotics and grown overnight at 37°C with agitation. This was 
subsequently used to inoculate 1 litre of TB, again supplemented with 
antibiotics, which was agitated overnight at 37°C. The following day cells 
were pelleted by centrifugation at 2500 g for 15 min in 500 ml Heraeus 
Sepratech bottles in a bench-top centrifuge (Heraeus megafuge 2.0R). Cells 
were resuspended in 20 ml resuspension buffer and then lysed by adding 40 
ml lysis buffer. Lysis was allowed to proceed for 5 min before the addition of 
20 ml of ice-cold neutralisation buffer. The suspension was incubated on ice 
for 5 min prior to centrifugation at 2500 g for 20 min at 4°C. The supernatant 
was filtered and DNA precipitated by addition of 0.6x vol of isopropanol. The 
suspension was centrifuged at 2500 g for 20 min at 4°C and the DNA pellet
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was washed in 75% ethanol and centrifuged as before. The pellet was air- 
dried, resuspended in 4-5 ml TE and 1.2 g /m l CsCl was added and warmed 
to 37°C to aid dissolving. Ethidium bromide was added at a final 
concentration of 0.8 mg/ml. This mixture was centrifuged at 2,500 g for 15 
min at room temperature. The supernatant was transferred to thick-wall 
polycarbonate tubes (Beckman) and centrifuged in a TLA-100.3 rotor in a 
Beckman TL-100 ultracentrifuge at 270,000 g at 20°C overnight. The following 
day, the plasmid bands were extracted from the caesium gradient with a 
plOOO pipette and the ethidium bromide removed by repeated extraction with 
an equal volume of CsCl saturated isopropanol. The DNA was precipitated 
by addition of lOx vol of 50% (v/v) isopropanol and centrifuged at 3000 g for 
15 min at 4°C. The pellet was washed in 75% ethanol, centrifuged as before 
and allowed to dry before finally dissolving in 1000 -  1500 pi of TE buffer. A 
typical yield was usually between 2-6 mg plasmid DNA/litre of bacterial 
culture.
2.4.2.13 Southern Blotting: A lkali Transfer hy Upward Capillary Transfer
Following agarose-TBE gel electrophoresis and rinsing briefly in water, the 
gel was soaked in denaturation solution (NaOH 0.5 M and NaCl 1.5M) for 30 
min with gentle agitation. Upward capillary transfer onto Hybond N+ was 
set up as for Northern blotting but using denaturation solution instead of SSC 
and allowing to transfer overnight. The membrane was then washed in 5x 
SSC.
2.4.2.14 Southern Hybridisation
The membrane containing the DNA from transfer was placed at 42°C in a 
hybridisation oven in hybridisation solution:
Formamide, (de-ionised) 50 % (v/v)
SSC, 5x
Na2HP04, 0.05 M 
SDS, 0.5 % (w /v)
Denhardt's reagent, 5x
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Denhardt's reagent was made up as a 50x stock solution from Ficoll 400, 
polyvinylpyrrolidone and bovine serum albumin fraction V, all at 1 % (w /v) 
in water, filtered and stored in aliquots at -20°C
The membrane was incubated for 2h before the addition of denatured DNA 
probe (prepared as described earlier in "Preparation of 32P-labelled DNA 
probes) and salmon testis DNA. Hybridisation was carried out overnight at 
42°C. The following day the membrane was washed, as for Northern 
hybridisation and then submitted to autoradiography for 15 min 48h as 
appropriate.
2.4.2.15 Primer Extension Analysis
All reagents were prepared using DEPC-treated H2O
Preparation of the Oligonucleotide Primers
Oligonucleotide primers were designed which were 90 oligonucleotides in 
length and would hybridise to target sequences located between 100 and 350 
nucleotides downstream of the suspected 5' terminus of the mRNA. Primers 
had a GC content of approximately 50% and had a G or C residue at the 3' 
terminus. Five primers were used, designed to hybridise between 40 and 60 
residues apart from each other in order that products would differ in size by 
an amount equivalent to the distance between the two primers and confirm 
results obtained from each primer.
Oligonucleotide primers were phosphorylated in a reaction containing: 
Distilled deionized water 6.5j l i 1
10X kinase buffer 1.5pl
oligonucleotide primer (5-7 pmoles or 60ng) l.Opl
T7 polynucleotide kinase (~ 10 units) l.Opl
[<y32p]ATP (7000 Ci/mmole),(from Amersham) 2.0pl
Reactions were incubated at 37°C for lh  and then quenched by addition of 150 
pi TE, pH 7.6. 25ng of carrier RNA (brewer's yeast tRNA) was added and 
nucleic acid was prepitated by addition of 0.1 x vol 3 M sodium acetate, pH
5.2 and 2.5 x vols 100 % ethanol and storage for at least lh  at -80 °C. The 
precipitated oligonucleotide was collected by centrifugation at 20,800 g for 15
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min at 4°C. The radioactive supernatant was discarded and the pellet washed 
in 70 % ethanol prior to centrifuging again. The supernatant was discarded 
and the pellet air-dried and then dissolved in 500 pi TE. 2 pi of radiolabeled 
oligonucleotide primer was placed in 10ml scintillation fluid in a liquid 
scintillation counter. The specific activity of the radiolabeled primer was 
calculated to ensure that it ~2 x 106 cpm/pmole of primer.
Hybridization and Extension of the Oligonucleotide Primer 
104 to 105 cpm (20-40 fmoles) of the DNA primer was added to 0.5-150pg of 
the RNA to be analyzed and 0.1 volume of 3M sodium acetate (pH 5.2) and
2.5 volumes of ethanol were added. The solution was stored for lh  at -80°C 
prior to recovery of nucleic acid by centrifugation at 20800 for 10 minutes at 
4°C. The pellet was washed in 70% ethanol and centrifuged again. Following 
removal of ethanol, the pellet was air-dried and then resuspended in 8pl of TE 
(pH 7.6). Samples were re-dissolved by repeated pipetting, prior to adding 
2.2pl of 1.25 M KC1 and gently vortexing, then centrifuging for 2 seconds. The 
oligonucleotide/RNA mixture was placed in a heat block at 95 -  100°C for 5 
min, followed by another heat block set to 60°C to allow annealing. The 
sample was incubated for 2h.
Meanwhile, a 300 pi aliquot of primer extension mix (20mM Tris-Cl (pH 8.4), 
lOmM MgCh, 1.6mM dNTP solution containing all four dNTPs and 50pg/ml 
actinomycin-D) was thawed on ice and supplemented with 3pl of 1M DTT 
and reverse transcriptase to a concentration of 2 units/pl. 0.1 unit/pl of 
RNasin was added, gently mixing by inverting the tube several times and 
then stored on ice.
The sample was removed from the water bath, centrifuged for 2 sec and then 
48 pi of supplemented primer extension mix was added before mixing gently 
again and centrifuging for 2 seconds. The sample was incubated for 1.5h at 
42°C to allow the primer extension reaction to proceed.
The reaction was quenched by addition of 200pl of TE (pH 7.6). Nucleic acids 
were precipitated by the addition of 50pl of 10M ammonium acetate and 
700pl of ethanol. The sample was mixed well by vortexing and then
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incubated for at least lh  at -80°C. The nucleic acid was pelleted by 
centrifugation at 20800 g for 10 min, then washed with 70% ethanol and 
centrifuged again, removing the supernatant.
Preparation of size markers
Two DNA ladders were radiolabelled and electrophoresed in parallel to 
primer extension products, to measure the size of the products.
pGEM4-MspI
The first ladder was prepared from pGEM-4, originally from Promega and 
kindly donated by Dr. Simon Brackenridge, MRC Human Immunology Unit, 
Weatherall Institute of Molecular Medicine. This plasmid was digested with 
Mspl to yield 18 fragments sized from lbp to 242bp, in addition to three larger 
fragments of 404, 424 and 501bp. Following digestion of 20jig in lOOpl, the 
reaction was quenched at 65°C for 20 min prior to the addition of DNA  
polymerase I, large (Klenow) fragment, 1 pi and [a32P]dCTP (-3000 
Ci/mmole) to a 20pl aliquot. As only one dNTP was present, the 3'—>5' 
exonuclease activity of the enzyme degraded the double-stranded DNA from 
3'OH until a base was exposed that was complementary to the dNTP present. 
Thus [a32P]dCTP was incorporated into the 3' overhangs of fragments. The 
reaction was incubated for 30 minutes at 37°C before the addition of 100pl TE. 
DNA was precipitated by adding 12pl sodium acetate and 300pl ethanol, 
washed in 70% ethanol and resuspended in 10pl formamide loading buffer: 
80% deionized formamide 
lOmM EDTA (pH8.0) 
lm g/m l xylene cyanol F 
lm g/m l bromophenol blue).
Approximately half of this was loaded onto the polyacrylamide gel.
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0X174-HaeIII
This ladder was purchased from New England Biolabs and radiolabelled in
the following reaction mixture:
Distilled, deionised water 15.5pl
Polymerase buffer (supplied with the enzyme) 2.0pl
DNA (lpg/pi) 0.5pl
(Klenow) DNA polymerase I l.Opl
[a32P]dCTP (-3000 Ci/mmole) l.Opl
The reaction was incubated for 30 minutes at 37°C and the DNA recovered as 
with pGEM4-MspI ladder and loaded onto the gel in parallel with primer 
extension product to be analysed.
Analysis of the Primer Extension Products
The nucleic acid precipitate from a primer extension reaction was dissolved 
in I O j l i I  formamide loading buffer (see above). The sample was re-dissolved 
by repeated pipetting and then heated for 8 minutes at 95°C before chilling 
rapidly on ice and analysing immediately by electrophoresis through a 
denaturing polyacrylamide gel.
Once the tracking dyes had migrated an appropriate distance through the gel, 
the gel was removed and transferred to a piece of Whatman 3MM filter paper 
for drying on a heat-assisted vacuum-driven gel dryer for 1 - 1.5h at 80°C. An 
image of the gel was established using autoradiography.
2.4.2.16 Preparation of genomic DNA 
Buffers and solutions 
Lysis buffer
20% (w /v) sucrose 27.5 ml
1M Tris-HCl, pH 7.4 0.5 ml
IMMgCh 0.25 ml
Triton X-100 0.5 ml
Water 21.25
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SET buffer
lM N aC l
0.5M EDTA, pH 8.0 
1M Tris-HCl, pH 7.4
7.5 ml 
0.5 ml
2.5 ml
39.5 mlWater
Other reagents
Proteinase K was purchased from Boehringer Mannheim and a stock 
solution of 10 m g/m l was prepared in SET buffer. This was then stored in 
aliquots at -20°C.
Tris-HCl-saturated phenol (pH 8.0)
Phenol-chloroform, 1:1 
4M sodium acetate, pH 5.0 
SDS, 10% (w /v)
Tris-HCl, 10 mM (pH 8.0)
Procedure
Approximately 1 x 107 cells were centrifuged at 2000 RPM for 5 minutes and 
resuspended in 5 ml lysis buffer, prior to incubation on ice for 5 minutes to 
release the nuclei. Cells were then centrifuged at 3000 RPM for 20 minutes at 
4°C and the nuclei resuspended in 5 ml SET buffer. Proteinase K was added 
to a final concentration of 200 (ig/ml, as well as 500pl SDS. The suspension 
was gently mixed and incubated at 37°C overnight.
The following day, phenol extraction of genomic DNA was performed, with 
addition of an equal volume of phenol. An equal volume of phenol- 
chloroform was then added to the aqueous layer and a final extraction was 
performed with diethylether. DNA was precipitated by addition of 0.1 x 
volume sodium acetate and 2.5 x volume 100% ethanol and harvested by 
centrifugation at 4000 RPM to obtain a pellet. The DNA pellet was rinsed in 
70% ethanol and air-dried briefly, then dissolved in 10 mM Tris-HCl.
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2.5 Tissue Culture
2.5.1 Cell lines and transfectants
2.5.1.1 Transformed cell lines
293T cells: The transformed human primary embryonic kidney fibroblast cell 
line 293T was obtained from the Cancer Research UK cell bank.
Human LYVE-1 293T: stable transfectants of full-length human LYVE-1 in 
293T were made by Dr. Suneale Banerji, MRC Human Immunology Unit, 
Oxford.
Mouse LYVE-1 293T: stable transfectants of full-length mouse LYVE-1 in 
293T were made by Dr. Remko Prevo and Branwen Hide, MRC Human 
Immunology Unit, Oxford.
Y3 rat myeloma cells were kindly donated by Dr. Michael Puklavec, Dunn 
School of Pathology, University of Oxford
NS-1 mouse myeloma cells were kindly donated by Jackie Cordell at the 
Nuffield Department of Clinical Laboratory Sciences, University of Oxford, 
UK.
RAW 264.7 mouse monocyte-macrophage cells were kindly donated by Dr. 
Sigrid Heinsbroek, Dunn School of Pathology, University of Oxford.
2.5.12 Primary cell lines
HMVEC, primary human microvascular endothelial cells were purchased 
from Cambrex Bio Science as a cryopreserved stock
HDMEC, primary human dermal microvascular endothelial cells were 
purchased from PromoCell, Heidelberg, as a cryopreserved stock 
HDMEC-derived immuno-selected primary lymphatic endothelial cells (LEC) 
were kindly donated by Dr. Ernst Kriehuber
HUVEC, human umbilical vein endothelial cells were purchased from Totem 
Biologicals
Primary mouse dermal LEC, lymphatic endothelial cells were prepared as 
described in section 2.5.8 of this chapter.
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2.5.2 Culture conditions
All mammalian cells were grown at 37°C in humidified incubators with 5% 
CO2.
293T, RAW 264.7, Y3 and NS-1 cells were grown in RPMI1640 supplemented 
with 10% FCS (heat inactivated at 55°C for 20 min), 2 mM L-glutamine, IU /m l 
penicillin and 50 pg/m l streptomycin, hereafter referred as RPMI 10% FCS. 
Stable LYVE-1 transfected 293T cells were grown in identical medium 
supplemented with 1.25 m g/m l G418.
Calcium phosphate transfections (see section 2.5.13.1) were carried out in 
DMEM medium with similar supplements (DMEM 10% FCS).
Hybridomas were grown in RPMI 1640 supplemented with 20% myeloma 
tested FBS, L-glutamine penicillin, streptomycin and 1 x HT, as described in 
section 2.1.4.
Endothelial cells were cultured in EGM-2 MV supplemented with the 
supplied SingleQuots (Hydrocortisone, EGF, FBS, VEGF, FGF-B, R3-IGF, 
ascorbic acid and gentamycin/amphotericin-B) prior to use. Primary human 
endothelial cells were cultured on gelatin-coated plasticware whilst mouse 
LEC were cultured on collagen-coated plasticware.
2.5.3 Collagen-coating of tissue culture dishes for mouse LEC
Type I collagen was dissolved in 20 mM acetic acid at 0.1 m g/m l and filter- 
sterilized. Sufficient solution was added to the culture dish or flask to cover 
the bottom and incubated at room temperature for lh. The solution was then 
removed and the culture dish washed twice with PBS before being left for 
another hour to allow the dish to dry.
2.5.4 Gelatin-coating of tissue culture dishes for human endothelial cells
Sufficient gelatin, 0.1% in PBS was applied to the culture dish or flask to cover 
the bottom and incubated at 37°C for 2h before removing the gelatin solution 
for reuse and storing the tissue culture ware at 4°C until required
118
Chapter 2 Methods and Materials 2.5 Tissue Culture
2.5.5 Passaging of cells 
2.5.5.1293T and R A W 264.7
Adherent cells were grown to confluence, washed with PBS and incubated in 
pre-warmed Trypsin/EDTA for 5 min at 37°C. Lifted cells were resuspended 
in 3-5 x the original volume of culture medium by gentle pipetting and 
divided over fresh culture dishes.
2.5.5.2NS-1 andY3
Fresh medium was added to cells which had grown to a high density in 
suspension and the cells were redistributed between new flasks, typically 
splitting 1:20. When cells were split for the final time before carrying out a 
fusion with splenocytes, NS-1 and Y3 were split more severely, typically 1:40.
2.5.5.3 Endothelial cells
Commercially available endothelial cells were cultured in EGM-2 MV 
according to the manufacturer's instructions. Other endothelial cells were 
cultured in the same manner. Human endothelial cell lines were cultured in 
gelatin-coated flasks whilst mouse endothelial cells were grown on collagen- 
coated flasks
2.5.6 Frozen storage of cells
Subconfluent cultures were detached in Trypsin/EDTA and 1 x vol of fresh 
medium added. Cells were centrifuged for 4 min at 1300 RPM in a bench top 
centrifuge. The pellet was then resuspended in freezing medium (90% FCS, 
10% DMSO) and transferred to cryo-vials (1 ml per vial) for storage at -80°C 
or transferred to liquid nitrogen after 1-2 days at -80°C.
2.5.7 Recovery of frozen cells
The cryo-vial was warmed rapidly to 37°C and thawed cells were 
immediately transferred to culture medium. Endothelial cells were placed in 
flasks at a minimum density of 10000 cells/cm2 and cultured overnight before 
applying fresh pre-warmed medium. All other cell types were suspended in
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medium and centrifuged for 4 min at 1300 RPM before resuspending in fresh 
culture medium and transferring to a culture dish or flask.
2.5.8 Preparation of mouse LEC from skin
LECs were isolated from a litter of mouse pups, 3 and 4 days post partum. 
Between 8 and 12 pups were used for each preparation. Limbs and tail were 
discarded and the skin from the torso and head were removed, placing on ice 
in PBS supplemented with 5x penicillin-streptomycin for 30 min then 
transferring to Dispase (Gibco), 2 m g/m l in PBS, incubating dermis-side 
down overnight at 4°C
The following day, skin was rinsed in PBS and the epidermis removed. The 
dermal sheets were digested further with collagenase A, 2mg/ml; ovine 
testicular hyaluronidase, 0.2 mg/ml; DNase I, 50 pg/ml; and elastase, 50 
pg/m l in 10 ml PBS, adding 20 ml more PBS before transferring to 37°C for 30 
min incubation with agitation. The digest was then passed through a 70 pm 
filter, adding RPMI-10% FCS before centrifuging at 1700 RPM for 10 min. The 
pellet was resuspended in 20 ml RPMI-10% FCS prior to centrifuging again at 
1500 RPM for 5 min. Cells were plated out in large (T225) gelatin-coated 
flasks for 4 h to allow adherence of endothelial cells, then washed with PBS 
before adding EGM-2, incubating overnight.
For selection of LEC, cells were first detached by incubation with accutase, 
prewarmed to 37°C. Cells were washed in MACS buffer (0.5 % BSA, 2 mM 
EDTA in PBS, maintained on ice throughout the procedure), centrifuging at 
1500 RPM for 5 min and then resuspending in 10 ml MACS buffer and passed 
through a pre-wetted Miltenyi 30 pm filter, washing the filter with an extra 3 
ml MACS buffer. Cells were centrifuged again and resuspended in 2 ml 
MACS buffer. Rat anti-mouse LYVE-1 monoclonal antibody, C l/8  (see 
chapter 3) was added to a final concentration of 5 pg/m l and the cells 
incubated at 5°C for 20 min on a rotating wheel. Cells were washed twice in 
10 ml MACS buffer, then resuspended in 240 pi MACS buffer and 60 pi anti­
rat MACS beads, incubating for 15 min at 5°C on a rotating wheel. Cells were 
then washed with MACS buffer, 5 ml and following centrifugation were
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resuspended in 2 ml MACS buffer. Cells were passed through a pre-wetted 
Miltenyi 30 pm filter, washing with a further 1 ml MACS buffer. A Miltenyi 
LS MACS column with another 30 pm filter on a magnetic stand were pre- 
equibrated with 3 ml MACS buffer and the cells loaded onto the column 
through the filter. 1 ml of MACS buffer was added to the column and 
allowed to drain through, followed by a further 2 ml. The filter was 
discarded and 2 x 3ml buffer was run through the column. Cells bound to the 
column were eluted by removing the column from the magnetic stand, 
adding 5 ml MACS buffer and forcing it through using the plunger. Cells 
were pelleted by centrifugation at 1500 RPM for 5 min then resuspended in 2 
ml buffer before passing though a second LS column as before but with no 
filters. Cells were collected by centrifugation and resuspended in 12 ml EGM- 
2, plating out in a medium-sized (T75) gelatin-coated flask.
The following day a second round of selection was carried out. Cells were 
lifted using accutase and following centrifugation and washing in 5 ml MACS 
buffer were resuspended in 1 ml MACS buffer. Cells were incubated and 
washed as before with rat anti-mouse LYVE-1, and MACS buffer then 
resuspended in 80 pi MACS buffer and 20 pi MACS beads. Following 
incubation as with the first selection, cells were washed in 5 ml MACS buffer 
and resuspended in 1 ml. A Miltenyi MS MACS column and 30 pm filter on a 
magnetic stand were pre-equilibrated with 1 ml buffer before application of 
the cell suspension. The column and filter were washed with 0.5 ml buffer; 
the filter was then discarded and the column washed a further 2 x 0.5 ml. 
Cells were eluted by removing the column from the magnetic stand, applying 
2 ml of buffer and forcing it through the column using the plunger. Cells 
were pelleted by centrifugation and resuspended in 1 ml buffer for passage 
through a second MS column as before, then plated out in 5 ml EGM-2 in a 
collagen-coated small (T25) flask for expansion.
2.5.9 Derivation of primary HDLEC from HDMEC
Human dermal microvascular endothelial cells (HDMEC) were purchased 
from PromoCell, Heidelberg, Germany and cultured as described in sections
2.5.2 and 2.5.5.3 of this chapter, in medium (T75) flasks. At each passage, cells
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were lifted with Accutase and half of the population were replated in a fresh 
flask whilst the other half were stained for expression of LYVE-1 (using the 
mAb 8C), podoplanin (with rabbit anti-sera) and CD34 (BD Pharmingen) and 
assayed by flow cytometry. The percentage of cells expressing the BEC 
marker CD34 was found to decrease with passaging whilst the number of 
cells expressing the LEC markers LYVE-1 and podoplanin increased, 
suggesting that the LEC outgrew the BEC. Thus at passage 12 and beyond, 
these cells were termed HDLEC.
2.5.10 Trypan blue dye exclusion assay
The viability of cultured cells was assessed by measuring the capacity to 
exclude trypan blue dye. Adherent cells were lifted with PBS-5mM EDTA, 
centrifuged at 1300 RPM for 4 min and resuspended in equal volumes of PBS 
and commercially prepared trypan blue dye solution (SIGMA). Following 10 
min incubation at room temperature, cells were counted by haemocytometer 
and the number of cells excluding dye and thus appearing white expressed as 
a percentage of the total number of cells. Dead cells are unable to exclude the 
dye and therefore appear blue. A minimum of three cell counts were carried 
out per sample and the mean percentage viability expressed ± standard error.
2.5.11 MTT proliferation assay
The proliferation of cultured cells was measured by MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay, 
originally described by Mosmann (1983). This assay measures the ability of 
mitochondrial enzymes to reduce the yellow MTT tetrazolium salt into blue 
crystals of MTT formaza. A stock solution of MTT (SIGMA) was prepared by 
dissolving 7.5 m g/m l in PBS pH 7.5 and filtering through a 0.22 pm filter 
(Gerlier and TTiomasset, 1986). Cells were cultured in a monolayer in 24-well 
dishes (1.77cm2 per well) and to 200 pi medium, 40 pi MTT solution was 
applied per well. Following 1 h incubation at 37°C/5 % CO2 in a humidified 
incubator, supernatant was removed and 200 pi of 0.04 M HC1 in isopropanol 
was added to each well to dissolve the dark crystals of MTT formazan formed 
within cells. Cell debris was removed by centrifuging for 4 min at 1300 RPM.
122
Chapter 2 Methods and Materials 2.5 Tissue Culture
Supernatants were transferred to a 96-well plate for quantitation in a 
microplate reader (BioRad) at 590 nm.
2.5.12 Tube-formation assay
24-well culture dishes were coated with Matrigel (BD), 0.5ml/well on ice and 
gels were allowed to solidify at 37°C for lh. Cultured adherent HDLEC were 
lifted by trypsin-EDTA, seeded into Matrigel-coated wells at approximately 
15000 cells/cm2 and incubated for 24h at 37°C/5% CO2 in a humidified 
atmosphere. Images were then captured using a Zeiss Axioskop microscope.
2.5.13 Transfection methods
2.5.13 1 Transient transfection of293T cells by calcium phosphate 
precipitation
293T cells were grown in DMEM (10% FCS) until approximately 70% 
confluent. The transfection mixture was prepared by combining plasmid 
DNA (20 p.g for a 14-cm dish or 5-10 jig for a 6-well dish) with 250 mM CaCh, 
1 ml or 125 pi respectively. The same volume of HEPES buffer pH 6.95 (280 
mM NaCl, 50 mM HEPES, 1.5 mM Na2HPC>4) was then added drop by drop 
while vortexing. The mixture was incubated for 10 min on ice before adding 
to culture medium. Cells were incubated for 5-6 h at 37°C and the medium 
then changed to RPMI (10% FCS). Serum-free medium (UltraCHO) was used 
in place of RPMI 10% FCS when cells were transfected for production of 
soluble Fc fusion proteins, to avoid contamination of the fusion protein with 
bovine Ig.
2.5.13.2 Electroporation ofHUVEC
FIUVEC were passaged two days before transfection and cultured to 
approximately 90% confluency. The medium was removed and cells were 
washed with PBS prior to lifting using trypsin-EDTA. Fresh medium was 
applied to neutralise the trypsin and the cells were counted. 1 x 106 cells were 
used per nucleofection sample, centrifuging at 200 g for 10 minutes. The cell 
pellet was resuspended in HUVEC Nucleofector™ Solution (Amaxa
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Biosystems), to which 5pg DNA (in up to 5pi distilled, deionised water) was 
added. The sample was then transferred to a cuvette (Amaxa Biosystems) 
and placed in the cuvette holder in the electroporator (also from Amaxa 
Biosystems), The sample was electroporated on programme U-01, before re­
plating cells in pre-warmed medium within a gelatin-coated well of a six-well 
dish. Gene expression was assayed after 24h.
2.5.13.3 Lipofectin transfection o f RAW  264.7
2 x 105 RAW 264.7 were seeded into a well of a six-well dish and cultured for 
approximately 24h until 60% confluent. The following solutions were 
prepared:
Solution A: 100 pi serum-free OptiMEM (Life Technologies)
2 pg DNA
Solution B: 5 pi LIPOFECTIN® reagent (Life Technologies)
100 pi serum-free OptiMEM 
Solutions A and B were combined and incubated at room temperature for 12 
minutes. Meanwhile, cells were lifted with trypsin-EDTA, neutralised with 
medium and then washed with 2 ml OptiMEM per well. 0.8 ml OptiMEM 
was added to the combined solutions, yielding a total volume of 1 ml which 
was used to resuspend the cell pellet. Cells were re-plated into 6-well dish 
wells and after 24h medium was replaced with normal growth medium 
(RPMI-10% FCS). Gene expression was assayed after a further 48h.
2.5.14 Expression and purification of soluble Fc fusion proteins
The fusion protein constructs (mouse LYVE-1 Fc, human LYVE-1 Fc and 
podoplanin Fc) were transfected into 293T cells by calcium phosphate 
precipitation. Transfected cells were grown in serum free UltraCHO for 3 
days. Culture supernatants (300-400 ml) were harvested and the pH adjusted 
to pH 8 using 2M Tris pH 8.0 and passaged twice through protein A- 
Sepharose columns (1 ml), which were then washed with PBS and eluted with 
0.1 M Glycine pH 2.5. Samples of effluent (0.5 ml) were neutralised by 
addition of 1/20 volume of 2 M Tris pH 8.0.
124
Chapter 2 Methods and Materials 2.6 Protein Biochemical Methods
2.6 Protein Biochemical Methods
2.6.1 Measurement of protein concentration
Protein concentration was estimated by measuring the OD 280 nm using a UV 
spectrophotometer. An OD of 1.0 was assumed to be equivalent to 1 m g/m l 
protein.
2.6.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Gels were cast and rim in a Hoefer gel caster and electrophoresis apparatus. 
The composition of a 10% gel, loading buffer and electrophoresis buffer is 
listed below. Typically 1 pg of sample protein was dissolved in 5-10 pi of SDS- 
PAGE loading buffer and boiled for 5 min. Gels were run at a constant 
current of 20 mA. Pre-stained molecular weight markers were purchased 
from Bio-Rad.
Buffers and solutions
10% resolving gel (5 ml)
2.3 ml H20
1.3 ml 1.5 M Tris-HCl pH 8.8
1.3 ml 40% Acrylamide 
50 pi 10% (w /v) SDS
50 pi 10% (w /v) ammonium persulphate 
10 pi TEMED
5% stacking gel (2 ml)
1.4 ml H20
250 pi 1 Tris-HCl pH 6.8 
250 pi 40 % Acrylamide 
20 pi 10% SDS
20 pi 10% ammonium persulphate 
5 pi TEMED
(0.125 M) 
(5 %)
(0.1 %) 
(0.1 %) 
(0.03 %)
(0.39 M) 
(10.4 %) 
(0.1 %) 
(0.1 %)
(0.02% v /v )
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2 x Loading buffer
0.1 M Tris-HCl pH 8.0, 4% (w /v) SDS, 50 % (v/v) glycerol, 2 m g/m l 
bromophenolblue, + /-  0.36 M P-mercapto-ethanol.
Electrophoresis buffer
25 mM Tris, 250 mM glycine pH 8.3,0.1% SDS.
2.6.3 Coomassie blue staining of protein gels
Gels were incubated in Coomassie blue stain solution (see below) for 30 min 
at room temperature and destained overnight. Gels were then dried for lh  at
10% acetic acid
2.6.4 Western blotting
Following SDS-PAGE, gels were transferred to nitrocellulose membranes 
(Hybond C Extra; Amersham Life Sciences) using a semi-dry blotting 
apparatus (Hoefer). Three layers of Whatmann 3MM paper and the 
nitrocellulose membrane were soaked in blotting buffer (20% methanol, 20 
mM Tris base, 150 mM glycine, 0.1% SDS). The membrane was laid on top of 
the Whatmann paper, with the gel and three additional Whatmann papers 
placed on top of the membrane. The gel was then transferred at constant 
current (1 h at 1.2 A or overnight at 0.2 A). After transfer, the membrane was 
washed in H2O.
Membranes were blocked in incubation buffer (PBS, 0.2% (v/v) Tween, 5% 
(w /v) dried milk powder) for at least lh  and subsequently incubated with the 
primary antibody for lh  (see specific sections for details). After washing 4 
times over a 30 min period in washing buffer, (PBS, 0.2% (v/v) Tween), 
membranes were incubated with HRP-conjugated secondary antibody (1 h), 
washed as before and developed using chemiluminescent detection 
(Supersignal chemiluminescent substrate, Pierce).
80°C.
Coomassie stain solution
2.5 m g/m l coomassie blue 
50% methanol
Destain solution 
50% methanol 
10% acetic acid
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2.6.5 Enzyme-linked immunosorbant assay to quantitate chemokine 
concentrations
All ELISA kits for the quantitation of chemokines in cell culture supernatant 
were purchased from R and D systems and the manufacturer's instructions 
strictly adhered to. Briefly, appropriately diluted supernatant was applied in 
triplicate to pre-coated ELISA wells, alongside a negative control of medium 
alone and chemokines standards, applied in duplicate. Bound chemokine 
was detected using a secondary HRP-conjugated antibody and OPG, for 
measurement in a BioRad microplate reader at 490nm. Chemokine 
concentrations were calculated from a standard concentration curve and 4PL 
logistic plot.
2.6.6 Estimation of shed LYVE-1 in culture supernatant
HDLEC were passaged 48h prior to the experiment, to allow surface 
expression of LYVE-1 to have fully recovered from trypsin-EDTA-mediated 
loss. Cells were washed three times in PBS and once in unsupplemented 
endothelial cell basal medium EBM-2. Cells were then cultured for 24h in
triplicate wells of either EBM-2 alone, or supplemented with TNFa or TNFp.
96-well MaxiSorp™ (Nunc) ELISA plates were coated for 16h at room 
temperature with affinity-purified rabbit anti-human LYVE-1, 0.25 fig/well. 
Plates were rinsed and supernatant was applied. Dilutions of human LYVE-1 
fusion protein (0-80 ng/m l) were applied in triplicate to permit quantitation 
of shed LYVE-1 in supernatants. Also, as a positive control, supernatant from 
PMA-stimulated 293T-human LYVE-1 tranfectants (20ng/ml PMA for 4h) 
was applied in triplicate. Following a lh  incubation, plates were washed and 
incubated with mouse anti-human LYVE-1 mAb for lh  before a secondary 
incubation of goat anti-mouse IgG (Pierce), 1:4000. Detection was performed 
using O-phenylenediamine substrate (OPD) substrate (Sigma) and the 
absorbance measured by Bio-Rad microplate reader at 490nm. 
Concentrations of shed LYVE-1 were calculated from the standard curve 
using a 4PL logistics plot.
127
Chapter 2 Methods and Materials 2.7 Generation of Polyclonal Antisera
2.7 Generation of Polyclonal Antisera
The general procedure for the generation of polyclonal antibodies is described 
below, whereas the production and purification of each immunogen is 
described in section 2.5.4.
2.7.1 Immunisation
For each individual antigen, two New Zealand White rabbits were 
immunised by staff at the Biomedical Services Unit of the John Radcliffe 
Hospital Oxford. Pre-immune bleeds (5 ml) were collected prior to the first 
injection. Rabbits were immunised with 100 pg of antigen suspended 1:1 
(v/v) in complete Freund's adjuvant in a total volume of approximately 0.5 
ml per rabbit. Two consecutive boosts were carried out at 4 weekly intervals 
with antigen mixed (1:1 v /v ) in incomplete Freund's adjuvant. Test bleeds (5 
ml) were carried out one week after each booster injection. Rabbits were bled 
out approximately one week after the last test bleed.
Blood collected in Falcon tubes was allowed to clot over night at 4°C. The 
following day, the samples were centrifuged at 2300 g for 10 min and the 
serum transferred to Eppendorf vials for another centrifugation step at 20,800 
g for 5 min. Serum was then stored in aliquots at -20°C or at 4°C with 0.05 % 
azide as a preserving agent.
2.7.2 Assessment of antibody reactivity by ELISA
The specificity of antisera for the immunising antigen was tested by ELISA 
using immobilised antigen. ELISAs were performed in 96-well plates (Nunc 
Maxisorp) at room temperature. Plates were coated by overnight incubation 
with antigen and an irrelevant Fc fusion protein control as a negative control 
(to assess whether reactivity was against the required antigen as opposed to 
the human IgGl Fc domain) dissolved in coating buffer (15 mM Na2C03, 34 
mM NaHCCb pH 9.3; 50 pi/well). The following day, wells were washed 
three times with PBS then once with washing buffer (PBS, 0.05% v /v  Tween 
20) before a final wash with PBS alone. Non-specific binding was blocked 
using blocking buffer (PBS, 1% w /v  BSA. 0.05% Tween 20), 200pl per well, 
incubating for 2 h. Wells were washed as before then incubated with serial
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dilutions of antiserum and preimmune serum in washing buffer, 50|li1 per well 
for 1 h. The plate was washed as before prior to detection of bound antibody 
using an HRP-conjugated secondary antibody, raised in goat against the 
primary species (1:4000), 50pl per well for 1 h. Wells were washed again prior 
to detection using lOOpl per well O-phenylenediamine substrate (OPD). The 
reaction was quenched by addition of 2.5 M H2SO4 (lOOpl per well) after 
approximately 20 min and absorbance at 490nm measured in a BioRad 
microplate reader.
2.8 Generation of Monoclonal Antibodies Against
Mouse LYVE-1
2.8.1 Testing of sera for myeloma culture
Test batches of foetal bovine serum (Australian origin) for myeloma culture 
were ordered from GIBCO in order to establish which serum was most 
efficient in supporting myeloma and hybridoma growth, permitting the 
growth of a colony from a single cell.
Mouse myeloma NS-1 and rat myeloma Y3 cells were diluted in RPMI 
supplemented with 10% test-serum and Glutamine/Penicillin/Streptomycin 
to theoretical densities of 1 cell/well and 5 cells/well of 96 well plate, lOOpl 
per well. The FBS was deemed suitable if 100 % of wells at a density of 5 
cells/well and over 90 % of wells at a density of 1 cell/well supported 
colonies after 12 days in culture. Sera from batches 3135881S and 3597502S 
were found to support myeloma growth at these cell densities and therefore 
used during the course of this thesis. Aliquots of sera were stored at -20°C 
until required. Medium supplemented with sera was stored at 4°C and any 
remaining after one week was discarded.
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2.8.2 Immunisation
The antigen used for immunisation was a soluble fusion protein of mouse 
LYVE-1 and the Fc domain of human IgGi Female DA strain rats were 
immunised with purified LYVE-1 Fc fusion protein (100 jig) in complete 
Freund's adjuvant followed by two boosts in incomplete Freund's adjuvant. 
Test bleeds were taken by tail bleed one week after the booster injections and 
tested in ELISA as described below. A final boost without adjuvant in PBS 
alone was given three days before the sacrifice of the animal, to prepare the 
spleen for fusion.
2.8.3 Testing the titre of antisera
The reactivity of the antiserum with immunising antigen was tested by ELISA 
as described in detail in section 2.7.2. Briefly, plates were coated with 5 
jig /m l LYVE-1 Fc or podoplanin-Fc as a negative control and were incubated 
with preimmune serum and serum from the immunized animals, followed by 
HRP-conjugated goat anti-rat IgG. (1:4000) and O-phenylenediamine (OPD) 
substrate.
2.8.4 Hybridoma fusions
One immunised animal was sacrificed by carbon dioxide and the spleen 
removed. Splenocytes were carefully drawn out using curved forceps and 
resuspended in GKN isotonic buffer (NaCl, 137 mM; KC1,5.37 mM; Na2HP04, 
10 mM; NaH2P04.H20, 5 mM, Glucose, 11 mM in water, filter sterilised) and 
passed through a cell strainer. Half of the splenocytes from a rat were used 
per fusion; the remainder were cryo-preserved in freezing solution, as 
described above. Splenocytes for the fusion were centrifuged at 100 g for 5 
min in a Heraeus Labofuge 400 centrifuge and then counted (approximately 
1.2 x 108). Cultures of the myeloma fusion partner (either NS-1 or Y3) which 
had been split 1:40 three days earlier were centrifuged twice in the same 
manner following a cell count, aspirating off the supernatant and 
resuspending the cells in GKN buffer between each centrifugation step. 
Typically 7 x 107 myeloma cells were used so that the ratio of spleen cells to 
myeloma cells was 1:2 in favour of splenocytes whilst using about 10 % more
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myeloma cells than necessary (1.2:2.0) to compensate for losses incurred in the 
centifugation and aspiration steps. The splenocytes and NS-1 suspensions 
were combined and the mixture was incubated at 37 °C for 5 min before 
centrifuging (5 min at 100 g). The cell pellet was loosened by gentle tapping 
and 1 ml of pre-warmed Polyethylene Glycol (PEG) was added slowly for 1 
min while stirring the cells with a pipette and then continuing stirring for a 
further minute. During this procedure the cells were kept warm by holding 
the tube in a beaker of water heated to 37°C. Subsequently, 1 ml of GKN 
buffer was added drop by drop over a period of 1 min, followed by another 1 
ml GKN buffer for 1 min. Then 8 ml GKN buffer was added at a rate of 1 
drop per sec, stirring after each minute. The cell suspension was topped up to 
50 ml with GKN buffer and centrifuged at 50g for 5 min without braking. 
Cells were resuspended in RPMI supplemented with 20 % FBS and 
Pen/Strep. 1 ml of cell suspension was added to each well of a 24-well dish in 
a total of 4 dishes. Cells were grown for 4 h before the addition of 1 m l/w ell 
of 2x HAT in RPMI supplemented with 20 % FBS and Pen/Strep. 
Hybridomas were grown for two weeks before screening for positive clones.
2.8.5 Screening of hybridomas for production of antibodies against LYVE-1
Two different procedures were used to screen hybridoma supernatants for the 
presence of anti-LYVE-1 mAbs.
2.8.5.1293T-mouse LYVE-1 transfectant assay
293T-Mouse LYVE-1 transient transfectants fixed on cytospin slides were 
used, prepared as described in section 2.9.2. Non-specific binding to cells was 
blocked by incubating with 10 % goat serum in PBS for 10 min. Supernatant 
from wells containing hybriomas was applied to each slide and incubated at 
room temperature for 30 min. In parallel one slide was incubated with rat 
IgG, 10 pg/m l in PBS-5% FCS as a negative control and another slide with rat 
anti-mouse LYVE-1 antiserum as a positive control, diluted 1:50 in PBS-5 % 
FCS. Slides were washed in PBS prior to application of the secondary 
antibody, goat anti-rat Alexa 488,10 pg/m l in PBS-5 % FCS, for 30 min. Slides 
were washed in PBS and then fixed in formaldehyde, 2 % in PBS and covered 
with Vectashield with DAPI and a coverslip.
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2.8.52 ELISA
The reactivity of the hybridoma supernatant against mouse LYVE-1 Fc fusion 
protein was tested by ELISA, in a similar manner to that in which reactivity of 
polyclonal antisera was assessed (section 2.7.2). Plates were coated with 5 
pg/m l LYVE-1 Fc and incubated with undiluted hybrioma supernatant. A 
negative control of supernatant from a well with no hybridoma growing in it 
was included, as was a positive control of the rat serum, diluted 1:50 in RPMI- 
20 % FBS medium. Wells were then incubated with an HRP-conjugated goat 
anti-rat IgG. (1:4000) and O-phenylenediamine (OPD). Substrate absorbance 
at 490nm was measured in a BioRad microplate reader.
2.8.6 Re-cloning hybridomas
To ensure that a hybridoma was monoclonal, cells were diluted in 
supplemented medium to theoretical densities of 1 cell/well and 5 cells/well 
in 96-well plates, lOOpl per well. Cells were cultured for one week prior to re­
screening of supernatant for presence of LYVE-1 mAbs using both of the 
assays described above. Positive colonies were then re-cloned again in the 
same manner.
2.8.7 Ig subtyping of LYVE-1 monoclonal antibodies.
The subtype of the LYVE-1 mAbs was determined by ELISA using a 
commercial rat-hybridoma subtyping assay (BD Pharmingen), according to 
manufacturers' instructions. Briefly, ELISA plates were coated with mouse 
anti-rat subtype specific Ig, then incubated with hybridoma supernatant 
followed by HRP-conjugated mouse anti-rat antibodies and detected using O- 
phenylenediamine substrate (OPD).
2.8.8. Culture of hybridomas and purification of antibody
Hybridomas were cultured in RPMI-1640 supplemented with 20% FBS, lx  HT 
(see section 2.1.4), Penicillin/streptomycin and L-Glutamine in tissue culture 
flasks. For large-scale production of monoclonal antibodies, hybridoma 
supernatants were passed through 2 ml columns of protein G Sepharose. The 
columns were washed with PBS and bound mAb eluted with 0.1 M Glycine
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pH 2.0 (500 pi fractions). Eluted fractions were neutralised with 100 pi 2 M 
Tris pH 8.0 and the purified antibody subsequently buffer exchanged into 
PBS by dialysis or by means of microcon concentrator tubes (Millipore) by 
Alastair Waugh, MRC Human Immunology Unit, WIMM. Antibody 
preparations were stored in aliquots at -80°C (long term) or 4°C (short term).
2.9 Immunohistochemistry and 
Immunofluorescence Antibody Staining
2.9.1 Source of tissue sections
2.9.1.1 Frozen human skin sections
Frozen sections of human squamous cell carcinoma were kindly donated by 
Graham Ogg, Weatherall Institute of Molecular Medicine, University of 
Oxford, UK.
2.9.12 Paraffin-embedded mouse tissues
Tissues from C57B1/6 mice were kindly donated by Dr. Ian Dransfield, MRC 
Centre for Inflammation Research, University of Edinburgh, UK. Mouse 
tissues were fixed in PBS 4% paraformaldehyde. Tissues were embedded in 
paraffin wax and cut on silanized glass microscope slides, both manipulations 
being performed by Simon Bidolph, Department of Paediatric Pathology, 
John Radcliffe Hospital, Oxford.
2.9.1.3 Mouse frozen tissue sections
For frozen sections, tissues from Balb/c mice were snap-frozen on dry ice, cut 
into 8 pm sections using a cryotome and air-dried overnight before wrapping 
in aluminium foil for storage at -20°C.
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2.9.2 Preparation of cytospin slides
Adherent cells were lifted with PBS- 5 mM EDTA, centrifuged at 1300 RPM 
for 4 min and then resuspended in PBS. Non-adherent cells were simply 
centrifuged and resuspended in PBS. Approximately 7 x 105 cells/ml 
suspension was placed on ice and three drops were applied to a cytospin 
bucket and centrifuged at 550 RPM for 5 min to transfer cells on to a 
Superfrost slide. Cells were fixed in acetone for 10 min and slides were stored 
wrapped in aluminium foil at -  80°C.
2.9.3 De-waxing and antigen retrieval of paraffin-embedded sections
Prior to staining, sections were dewaxed and rehydrated by successive 
incubation in Citroclear® (2x6  min), 100 % Ethanol (2 x 5  min), 50 % aqueous 
Ethanol (5 min) and water (5 min). Slides were then subjected to antigen 
retrieval by microwave treatment (95-100°C, 10 min) in DAKO Target 
Retrieval Solution pH 6.0. A glass staining jar was filled with sufficient 
quantity of buffer (approx. 400 ml) covered with SaranWrap and heated to 95- 
100°C in a microwave (4 min 750 W). The de-waxed slides were placed in 
buffer, briefly brought back to the boil by heating for 1 min at 750 W and then 
heated at 80 W for another 9 min. Slides were then transferred to PBS (at room 
temperature).
2.9.4 Single immunoperoxidase staining
Slides of paraffin-embedded sections of mouse tissues were de-waxed, 
rehydrated and subjected to antigen retrieval as described above. Slides were 
then washed in PBS and blocked in PBS 20% goat serum for at least 5 min. 
Endogenous peroxidase activity was blocked by a 5 min pre-incubation in a 
peroxidase quenching agent (DAKO, contains 0.03% H2O2) prior to incubation 
with the primary antibody, rat anti-mouse LYVE-1 monoclonal antibody in 
PBS 5% FCS for 30-45 min at room temperature. Controls included staining 
with rat IgG isotype control. After washing with PBS, slides were incubated 
with HRP-conjugated goat anti-rat Ig (DAKO Envision kit) for 30-35 min. 
After another wash step, slides were developed with diaminobenzidine 
(DAB; Envision kit) and counterstained with hematoxylin. Finally, slides
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were mounted in Aquamount®, viewed under a Zeiss microscope and 
photographed using a ProgRes camera and software.
2.9.5 Flow cytometry
Adherent cells, either endothelial cells or 293T, were lifted in either PBS-5 mM 
EDTA by gentle pipetting following a 15-min incubation at 37°C or by 
Accutase, following a 5-min incubation at 37°C. Cells were transferred to 96 
(U-shaped) well plates (« 2 x 105 cells/well). The cells were pelleted by 
centrifugation of the plate (380 g for 3 min), resuspended in FACS buffer 
(PBS, 5% FCS, 0.1% azide), 100 pi/well, and centrifuged again. Cell pellets 
were then resuspended in FACS buffer, 100 pl/w ell containing the 
appropriate primary antibody at 10 pg/m l and incubated for 30 min at 5°C 
with gentle shaking. Controls included staining with an isotype-matched 
antibody. Cells were centrifuged as before and washed by resuspension in 
200 pi FACS buffer and centrifuged again. After centrifugation, cells were 
resuspended in 100 pi FACS buffer containing the secondary antibody, an 
AlexaFluor 488 conjugate at 1:200 and incubated for 30 min at 5°C with gentle 
shaking in the dark. After a final wash in 200 pi FACS buffer, cells were 
resuspended in 200 pi FACS fix (2% v /v  formaldehyde in PBS) and 
transferred to FACS tubes. Samples were stored at 4°C until required and 
then analysed by flow cytometry using a Becton-Dickinson FacScan, 
FACscalibur.
2.9.6 Immunofluorescence staining of cells
For detection of cell surface proteins, adherent cells were grown in 24-well 
dishes or 8 well chamber slides and stained in situ. Wells were washed with 
PBS and then incubated with goat serum, 10 % in PBS for 10 min. Cells were 
incubated in FACS buffer (PBS, 5% FCS, 0.1% azide) containing the primary 
antibodies at 10 pg/m l and incubated for 30 min at room temperature. 
Controls included staining with an isotype matched antibody or pre-immune 
serum. Cells were subsequently washed with PBS and incubated with FACS 
buffer containing the secondary antibodies, AlexaFluor conjugates at a 
concentration at 1:200, for 30 min at room temperature in the dark. After a 
final wash, cells were fixed in 2% formaldehyde for 10 min. After removal of
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the formaldehyde solution, cell were washed with PBS and then a drop of 
fluorescent mounting medium with DAPI (Vectashield®) was added and the 
cell layer was covered with a cover slip. When chamber slides were used, the 
plastic chamber walls were lifted from the slides by soaking in 80% methanol 
for 10 min. Slides were subsequently covered with fluorescence mounting 
medium and a cover slip. Cells were then viewed under a Zeiss Axioskop 
microscope equipped with epifluorescence illumination.
2.9.7 Staining of intracellular antigens
For detection of intracellular antigens, adherent cells were first permeabilised 
as follows. Cells were fixed by incubation in freshly prepared 4% (w /v) 
paraformaldehyde in PBS for at least 10 min at room temperature. Cells were 
then washed with PBS and incubated in permeabilisation buffer (PBS, 0.2 % 
saponin, 1% BSA, 10 % goat serum) for 20 min at room temperature. Cells 
were stained as normal, except that incubations with the primary and 
secondary antibodies were carried out for 45 min and all antibody incubations 
were performed in permeabilisation buffer.
For tracking TNFa-mediated LYVE-1 internalisation, cells in chamber slides 
were pre-incubated for 2h at 37°C with rabbit anti-human LYVE-1, lOpg/ml 
and TNFa, lOng/ml. Cells were then permeabilised as detailed above and 
stained using the appropriate markers for subcellular compartments.
To stain nuclei for Prox-1, cells were fixed by incubation in freshly prepared 
4% (w /v) paraformaldehyde in PBS for 20 min at room temperature, washed 
with PBS, permeabilised by incubation in 0.5% (v/v) Triton X100 in PBS for 5 
min at room temperature and then washed in PBS again. Following a 5 min 
incubation in blocking buffer (4% (w /v) BSA and 5% goat serum in PBS) at 
room temperature, cells were incubated in the same buffer overnight at 4°C 
with rabbit anti-prox-1. The following day, cells were washed with PBS and 
incubated for 30 min in the presence of the secondary antibody (1:200) goat 
anti-rabbit AlexaFluor®594 in blocking buffer. Cells were washed in PBS and 
then fixed in 2% (v/v) formaldehyde in PBS for 10 min. After removal of the
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formaldehyde solution, cell were washed with PBS and then a drop of 
fluorescent mounting medium with DAPI (Vectashield®) was added and the 
cell layer was covered with a cover slip. Cells were viewed under a Zeiss 
Axioskop microscope.
2.9.8 Whole mount staining of mouse ears
The ventral and dorsal surfaces of the ear were gently peeled apart to reveal 
the dermis and then laid dermal-side down in wells of a 24-well dish and 
fixed in 1 m l/w ell paraformaldehyde, 4 % (w /v) in PBS, pH 7.5, overnight at 
5°C with gentle agitation. The following day, ears were washed in 0.3 % 
Triton X-100 in PBS for approximately 5 h at 5°C with gentle agitation, 
changing the buffer every hour after an initial brief wash. Tissue was washed 
briefly in blocking buffer (3 % skimmed milk powder in 0.3 % Triton X-100 in 
PBS) and then incubated for 2 h at room temperature in blocking buffer. The 
primary antibodies were then applied at 10 pg/m l in blocking buffer, 500 
pl/w ell and tissue was incubated overnight at 5°C with gentle agitation. The 
following day, tissue was washed as before for about 5 h prior to a 2h 
incubation at room temperature in the dark in blocking buffer with secondary 
antibodies (1:200) conjugated with the appropriate AlexaFluor dye. Tissue 
was then washed as before and placed dermis side up on a Superfrost 
microscope slide, lowering on to a coverslip with Vectashield® and sealing 
using nail polish. Slides were stored at 4°C in the dark until viewed by 
confocal microscopy.
2.9.9 Confocal microscopy
Confocal microscopy was performed using a Bio-Rad Radiance 2000 laser 
scanning confocal microscope equipped with argon and green helium/neon  
lasers and analysed using LaserSharp2000 software. Cells were stained as for 
normal immunofluorescence microscopy and images taken in sequential 
scanning mode whereby each fluorophore is excited and analysed separately 
to prevent bleed-through of different fluorophores. Whole mount sections 
were visualised by XY scanning in LaserSharp2000 to create multiple layers, 
which were subsequently projected into one image.
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2.10 Animal Procedures
2.101 Animals
All animals were maintained in the Biomedical Services Facility at the John 
Radcliffe Hospital, Headington, Oxford. The strains used were Balb/c mice, 
DA rats and New Zealand white rabbits.
2.10.2 Mouse ear explants
Male mice aged 8 weeks and older were euthanised by rising concentration of 
CO2. Ears were then removed, incubated in 5X penicillin-streptomycin on ice 
for 30 min, split into dorsal and ventral halves and each floated split-side 
(dermis) down in RPMI 1640-10% FCS, penicillin-streptomycin and 
glutamine. Explants were cultured in a humidified atmosphere at 37°C in 5%
CO2, in either the presence or absence of recombinant murine TNFa,
100ng/ml.
2.10.3 Elicitation of oxazolone-induced contact hypersensitivity in mice
Balb/c male mice aged 8-10 weeks were sensitised by topical application of 
3% (w /v) oxazolone (4-ethoxymethlene-2 phenyl-2-oxazoline-5-one,
purchased from Sigma) in 95% ethanol to the shaved abdomen, 50pl per 
mouse. The following day a further 100pl of 2.5% (w /v) oxazolone was 
applied to each mouse. Five days later the outside of the left ears were 
challenged by topical application of 0.5% (w /v) oxazolone solution, 50 pi per 
ear, whilst the right ears were treated with vehicle alone.
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3.1 Introduction
In 1975 Kohler and Milstein succeeded in maintaining an antibody-secreting cell 
in culture, exploiting the properties of transformed myeloma cells to confer 
immortalisation on primary spleen cells by somatic cell hybridisation or cell 
fusion. Thus hybrid clones or "hybridomas" were generated from individual B 
lymphocytes from a mouse immunised with a specific antigen, with each 
hybridoma producing a single monoclonal antibody against the predefined 
antigen.
Since the early 1970s the quest for isolating a homogeneous population of 
antibodies by creation of a hybridoma cell line sought to address three important 
technical difficulties. Firstly, an appropriate fusion partner was necessary. 
Myelomas (B-cell tumours) can be induced by intraperitoneal injection of mineral 
oil and once isolated may be immortalised to continue dividing in vitro. These 
cells may also be selected to yield a line which does not produce functional 
antibodies, as the transformation process that gives rise to these tumours results 
in cells secreting antibodies of unknown specificities, which could lead to the 
production of a hybridoma secreting more than one type of antibody. Secondly, 
the conditions for a successful fusion had to be determined. Initially SV40 was 
used to trigger fusion of the plasma membranes between two adjacent cells but 
this method has given way to the use of polyethylene glycol (Pontecorvo 1975). 
Thirdly, hybrid cells must be selected from a background of unfused cells. 
Spleen cells from the immunised animal are easily eliminated as they are not 
immortalised and cannot survive for more than one or two weeks in culture. 
However the myeloma cells will continue to divide, whether or not they have 
fused and due to their smaller karyon will rapidly out-compete the hybrid cells, 
which are in the minority. To achieve effective killing of unfused myeloma cells
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these cells are selected to have a mutation in one of the enzymes of the salvage 
pathway of purine nucleotide biosynthesis (Littlefield 1964). If aminopterin, a 
folic acid antagonist that inhibits purine and pyrimidine nucleotide biosynthesis 
is added to the medium, de novo synthesis is blocked and these cells will die 
(figure 3.1). Such selected myeloma cells can only be rescued if they have 
successfully fused with a wild type spleen cell. The hybrid must then use the 
salvage pathway, which relies upon hypoxanthine and thymidine, supplied in 
the medium.
Monoclonal antibodies have three main advantages over polyclonal antibodies 
derived from the sera of immunised animals: they exhibit a single binding 
specificity, are biochemically homogeneous and are potentially in endless 
supply. Whilst immunisations of multiple animals are required to generate 
polyclonal antibodies, an established hybridoma cell line can go on producing 
antibodies against a specific epitope of the antigen for the lifetime of that cell 
line.
Previous studies into the expression of LYVE-1 in human have used both 
polyclonal antibodies raised in rabbit and monoclonal antibodies raised in mice. 
Antisera to mouse LYVE-1 have been raised in rabbits (Prevo et al, 2001) to 
demonstrate that mouse LYVE-1 antigen is an endocytic receptor for hyaluronan 
in 293T transfectants and a marker for lymphatic endothelium. However, a more 
extensive study into the physiological role of LYVE-1 in vivo and under various 
pathological conditions would benefit from the use of monoclonal antibodies to 
eliminate the possibility of cross-reactivity with apparently unrelated antigens, 
which can occur because polyclonal antiserum represents complex mixtures of 
antibodies of different specificities. One of the aims of this chapter was to 
generate a monoclonal antibody which could be used in tissue staining to detect 
changes in the expression of LYVE-1 during inflammation, as well as to permit
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the isolation of murine primary dermal lymphatic endothelial cells from murine 
dermis. Such a reagent would prove invaluable to other studies detailed in this 
thesis and also for subsequent research.
In addition, another important requirement was to generate mAbs that could be 
used to investigate LYVE-1 function. Some antibodies block ligand binding, as 
was found to be the case with 3A, one of the human LYVE-1 mAbs generated by 
Dr. Remko Prevo in the same laboratory. The 3A mAb was found to block 
binding of HA and has been a valuable reagent for defining LYVE-1 function in 
transfected cells. Similiarly, in the case of CD44, numerous antibodies including 
BRIC 235, KM 81 and KM 201 have been shown to block HA-binding and these 
have proved invaluable in elucidating CD44 function (Lesley et al. 1993; Zheng et 
al., 1995). Additionally, Sherman et al. (1998) used an antibody to block the 
interaction of CD44 with FGF and thus demonstrated the role of CD44 in growth 
factor presentation and promoting limb outgrowth during development. 
Alternatively a mAb may induce ligand binding, as was found to be the case for 
IRAWB 14, dramatically inducing HA binding by some CD44+ cell lines that did 
not constitutively bind HA (Lesley et al., 1992). Other mAbs may induce 
shedding of antigen, for example IM7.8.1 on CD44 (Zheng et al., 1995). An anti­
mouse LYVE-1 function-blocking antibody could prove very useful in 
elucidating the role of LYVE-1 as an HA-binding protein under various 
physiological conditions and (in the case of a shedding-inducing antibody) the 
significance of membrane bound or soluble LYVE-1.
This chapter describes the generation of two mAbs against mouse LYVE-1 and a 
series of assays in which the various properties of these antibodies were 
explored.
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De novo pathway Salvage pathway
Phosphoribosyl pyrophosphate
Thymidine Hypoxanthine
Uridylate
HGPRT ITK
Aminopterin
Nucleotides
Figure 3.1 Selection of hybridomas through defects in nucleotide biosynthesis. Both the 
myeloma cells and splenocytes can synthesize purine nucleotides and thymidylate de novo from 
phosphoribosyl pyrophosphate and uridylate respectively in several steps. One of these steps 
involves the transfer of a methyl or formyl group from activated tetrahydrofolate. Aminopterin 
blocks the reactivation of tetrahydrofolate and thus inhibits the de novo pathway. Cells must then 
use the salvage pathway in which thymidylate is synthesized from thymidine using thymidine 
kinase (TK) and purine is synthesized from exogenously supplied hypoxanthine using the enzyme 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Myeloma cells are defective in TK 
through selection in bromodeoxyuridine, which is metabolized by TK to form a toxic product. 
Similarly they are defective in HGPRT through selection in thioguanine or azaguanine, analogues 
of normal metabolites that function as substrates for HGPRT but give rise to non-functional purines. 
Thus such cells cannot grow in hypoxanthine-aminopterin-thymidine (HAT) medium unless 
“rescued” by their splenocyte fusion partner that possesses TK and HGPRT.
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3.2 Results
3.2.1 Immunisation of rats and testing of antisera
Prior to the start of this PhD, a 694-bp LYVE-1 fragment encoding the cleavable 
NH2 terminal leader and extracellular domain of mouse LYVE-1 was amplified 
from mouse stomach cDNA and cloned into the IgFc vector pCDM7Ig (Prevo et 
al., 2001). This yielded a construct encoding amino acid residues 1-228 of the 
LYVE-1 sequence, fused at the COOH terminus with the 234-residue hinge, CH2 
and CH3 region of human IgGi (figure 3.2). This construct had proved 
immunogenic in rabbits and polyclonal antisera against LYVE-1 had been 
successfully raised. Hence it was used here in the immunisation of rats to 
generate monoclonal antibodies against mouse LYVE-1. The fusion protein was 
produced by transfecting the construct into human 293T cells using calcium 
phosphate and then purifying the secreted protein from the supernatant by 
protein A-Sepharose chromatography. 2 rats were immunised with the purified 
protein.
Antibody responses of the rats were monitored by ELISA. A microtitre plate was 
coated with either LYVE-1 Fc or podoplanin Fc, an irrelevant fusion protein 
generated by cloning cDNA encoding the extracellular domain of podoplanin 
into the same construct (see appendix II), to assess the proportion of immune 
response which had been raised against the Fc domain of the immunogen. 
Serum prepared from animals following immunisation and also from the same 
animals before the immunisation schedule had commenced (as preimmune 
controls), were applied to the microtitre plate. Bound antibody was detected by 
peroxidase-conjugated goat anti-rat IgG and O-phenylenediamine (OPD) 
substrate and quantitated by spectrophotometry at 490 nm. As shown in figure 
3.3, the antiserum from both rats showed specific reactivity to LYVE-1.
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Figure 3.2 Schematic representation of the LYVE-1 Fc construct used for mAb production.
Panel A shows the amino acid sequence for mouse LYVE-1. The N terminal leader and C-terminal 
transmembrane anchor are underlined and residues within the HA-binding Link module are shown 
in red. Amino acid residues 1-228 of the LYVE-1 sequence encoding the cleavable NH2 terminal 
leader peptide and the extracellular domain are highlighted in yellow. Panel B shows the fusion 
protein resulting from cloning this 228-residue sequence into pCDM7 Ig. LYVE-1 sequence was 
fused at the COOH terminus with the 234-residue hinge, CH2 and CH3 region of human IgGi, 
producing a soluble product when transfected into 293T fibroblasts.
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In the case of rat 2, binding of the immune sera remained maximal even at a 
dilution of 1:10000, whereas binding of the pre-immune sera was negligible 
beyond 1:5000. Immune serum from rat 1 exhibited a much lower titre, apparent 
only at dilutions less than 1:2000. Hence rat 2 was chosen for hybridoma 
generation.
Reciprocal Dilution
Rati preimmune on LYVE-1 
Rat2 preimmune on LYVE-1 
Rati immune on LYVE-1 
Rat2 immune on LYVE-1 
Rati preimmune on podoplanin 
Rat2 preimmune on podoplanin 
Rati immune on podoplanin 
Rat2 immune on podoplanin
Figure 3.3 Test bleed of mouse LYVE-1 Fc immunised rats. Sera from both rats, from either the 
preimmune test bleed (negative controls) or from the test bleed taken a week after the final 
immunisation, were serially diluted and applied to a microtitre plate precoated with either LYVE-1 - 
Fc or podoplanin-Fc at 5 pg/ml. Bound antibody was detected with HRP-conjugated goat anti-rat 
antibody and OPD substrate, measuring the absorption at 490nm. Values are the mean ± 
standard deviation for triplicate wells.
146
Chapter 3 Generation of mAbs Against Mouse LYVE-1 3.2 Results
3.2.2 Generation and screening of hybridomas
Two potential fusion partners for rat splenocytes were available, the mouse 
myeloma cell line NS-1 and the rat myeloma cell line Y3 (kindly provided by Dr. 
Mike Puklavec, Sir William Dunn School of Pathology, Oxford). To select the 
optimal fusion partner, mock fusions were carried out, using splenocytes from a 
naive rat and either NS-1 or Y3. Cells from each fusion were plated out in four 
24-well dishes and after 12 days the number of hybridomas was counted. From 
the NS-1 fusion, multiple hybridomas were visible in some wells, with 91% of 
wells containing a least one colony. In contrast only 9% of wells from the Y3 
fusion contained hybridoma colonies. Therefore NS-1 was shown to be the 
optimal fusion partner with the respect to the number of successful fusion events 
and resulting colonies. However, as NS-1 are derived from murine myeloma, the 
fusion is cross species and whilst such a hybridoma is establishing a stable 
karyotype, a loss of chromosomes can occur which may result in the inability to 
secrete antibodies. Indeed before committing to a fusion the splenocytes from rat 
2 with higher serum titre against LYVE-1, a fusion between splenocytes from rat 
1 was performed with NS-1. 96% of wells in four 24-well plates contained one or 
more hybridomas and supernatants from the wells were assayed by ELISA in a 
microtitre plate coated with LYVE-1 Fc fusion protein. However no secretion of 
antibodies (either against LYVE-1 or the Fc portion) was detected (data not 
shown). Therefore Y3 were used as the fusion partner for rat 2 splenocytes for 
despite yielding a lower number of successful fusion events, this myeloma line 
was derived from the same species.
A final booster injection was administered to the rat three days before sacrifice. 
Half of the splenocytes were fused with Y3 cells as described in Methods and 
Materials; the remaining half were cryopreserved and then used for a second 
fusion at a later date. Cells from each fusion were plated out in four 24-well
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plates and cultured for two weeks. From each fusion, seven wells from a total of 
96 contained hybridomas. Supernatant was screened by immunofluorescence 
against human 293T fibroblasts transiently transfected with mouse LYVE-1. 
Cytospin slides of these cells were prepared and hybridoma supernatant was 
applied. Bound antibody was detected using the AlexaFluor® 488 goat anti-rat 
IgG, staining nuclei with DAPI to aid visualisation by fluorescence microscopy. 
This method had the advantage that hybridomas secreting antibodies against the 
Fc domain would not give a positive result in this assay. Figure 3.4 shows the 
staining of LYVE-1 transfectants by supernatant from an antibody-secreting 
hybridoma and also by the positive control of rat polyclonal antiserum, whilst a 
non-secreting hybridoma (the negative control) showed no staining.
An ELISA was also carried out, coating a microtitre plate with LYVE-1 Fc and 
applying the hybridoma supernatants. Bound antibody was detected by 
peroxidase-conjugated goat anti-rat IgG and O-phenylenediamine (OPD) 
substrate and quantitated by spectrophotometry at 490 nm. The comparative 
absorption values are shown in figure 3.5.
Two hybridomas from the first fusion and one hybridoma from the second 
showed reactivity against LYVE-1. Samples of these were cryopreserved; 
however unfortunately one of the hybridomas (A4) from the first fusion stopped 
growing, most probably due to chromosome instability and was abandoned. The 
remaining two hybridomas, B l/10 and C l/8  were cloned twice by limiting 
dilution and expanded. These were isotyped by ELISA and found to be IgGl 
kappa and IgG2a kappa respectively (data not shown). Both hybridomas were 
grown in large scale culture and the antibodies purified from conditioned media 
by protein G-Sepharose chromatography.
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Figure 3.4 Screening hybridomas for binding to 293T-LYVE-1 transfectants by 
immunofluorescence microscopy. Positive transfectants were identified by supernatant from an 
anti-mouse LYVE-1 secreting hybridoma and goat anti-rat AlexaFluor 488 (upper panel) or by rat 
anti-mouse LYVE-1 polyclonal serum (positive control, middle panel). However, supernatant from 
a negative hybridoma failed to stain any cells (lower panel). Nuclei were stained with DAPI (blue).
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Figure 3.5 Screening hybridomas by ELISA. The supernatants from the anti-LYVE-1 secreting 
hybridomas B1/10 and C1/8 were applied to a microtitre plate precoated with LYVE-1 Fc fusion 
protein, alongside supernatant from the A4 hybridoma which had ceased to secrete antibody and 
B2, a hybridoma which had tested negative in the transfectant assay. The positive control included 
in this assay was the rat serum from the final bleed out, diluted 1:50 in PBS-0.05% Tween20. The 
negative control was supernatant taken from a well where no hybridoma was growing. Values are 
the mean absorbances at 490nm, ± standard deviation for triplicate wells.
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3.2.3 Assessing the LYVE-1 mAbs for immunoperoxidase staining of paraffin 
sections
The main purpose of generating mAbs against mouse LYVE-1 was to obtain a 
marker for detecting lymphatics in tissue sections which would avoid 
background non-specific binding artefacts associated with polyclonal antisera 
and permit greater flexibility when carrying out double-staining. The ability to 
survey LYVE-1 expression on lymphatics on paraffin sections would be 
particularly useful as embedding formalin-fixed sections in paraffin has been 
used extensively to preserve tissue structure even when stored for long periods 
of time at room temperature. Although some antigens have proved sensitive to 
the fixation procedure, human LYVE-1 proved to be still readily detected by both 
polyclonal sera and monoclonal antibodies and consequently it was predicted 
that the antibodies generated against mouse LYVE-1 would prove as effective.
To assess the reactivity of the mAbs against paraffin-fixed antigen, paraffin 
sections of mouse intestine and stomach were de-waxed and rehydrated, then 
heated treated with DAKO target retrieval solution pH 6.0. After treatment 
slides were stained with either Bl/10, C l/8  or rat IgG isotype-matched control, 
followed by HRP-conjugated rabbit anti-rat Ig and DAB substrate to detect 
bound antibody. General tissue structure was stained using hematoxylin. As 
shown in figure 3.6 both B l/10 and C l/8  showed strong staining of vessels with 
collapsed lumens, the classic morphology of lymphatic vessels.
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Figure 3.6 Specificity of mAbs B1/10 and C1/8 for immunohistochemical staining of LYVE-1 
in paraffin sections. Mouse intestine and stomach tissue sections were dewaxed, rehydrated and 
retrieved prior to staining using either B1/10 (panels A, B and C), C1/8 (panels D and E) or an 
irrelevant rat IgG isotype control (panel F). Sections of intestine are shown in panels A, B and D; 
stomach sections are shown in panels C, E and F. Images were captured at either 200X 
magnification (panels A, D and E) or 400X (panels B, C and F).
152
Chapter 3 Generation of mAbs Against Mouse LYVE-1 3.2 Results
3.2.4 Immunofluorescence staining using the newly generated mAbs
The ability of the mAbs to specifically stain lymphatic endothelium was 
confirmed by double staining with the lymphatic endothelium marker 
podoplanin. Frozen sections of 8pm thickness were prepared from mouse ear 
and stained with C l/8  and the hamster anti-mouse podoplanin monoclonal 
antibody 8.1.1. The AlexaFluor conjugates of goat anti-rat 488 and goat anti­
hamster 568 were used to detect bound primary antibodies and revealed 
complete colocalisation of the C l/8  antigen with podoplanin (figure 3.7, panels 
A-C). Staining with the hamster anti-podoplanin antibody required fixation in 
paraformaldehyde (PFA) and therefore to investigate whether or not C l/8  was 
as effective on frozen tissue that had not been fixed, double staining with rabbit 
antisera against podoplanin was also performed (figure 3.7, panels D-F). Again 
clear colocalisation of C l/8  antigen with podoplanin was visible and C l/8  was 
shown to be of use on unfixed tissue.
3.2.5 The use of Cl/8 for whole-mount staining of tissue lymphatics
In recent years the staining of whole mount sections of intact tissue has been 
used increasingly as a powerful way to visualise in three dimensions complete 
vessel structures. However this technique relies on fixing the tissue in 
paraformaldehyde (PFA), which is known to destroy some epitopes and render 
the monoclonal antibodies that recognise them completely useless. If one of 
these antibodies proved able to recognise tissue fixed in this manner, this would 
permit LYVE-1 expression to be surveyed on a greater number of vessels than is 
permitted by frozen sections and with different combinations of other antibodies. 
For example the rabbit antisera against podoplanin has proved a much more 
reliable antibody than the hamster mAb 8.1.1 and thus for double staining a 
LYVE-1 antibody other than that of rabbit antiserum is required.
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Figure 3.7 The use of C1/8 in immunofluorescence staining of frozen sections. Panels A-C: 
Frozen sections of mouse ear were fixed for 20 min at 4°C in PFA, blocked in 4% BSA and 5% 
goat serum, then stained using C1/8,10pg/ml and the hamster anti-podoplanin mAb 8.1.1,1:1000, 
detecting with the AlexaFluor® goat conjugates 488 (green) and 568 (red) respectively. Slides 
were then incubated in 10mM Tris-HCL for 10 min, before mounting in DAPI-Vectashield. Images 
were captured at 400X. C1/8 staining is shown in the top panel, 8.1.1 in the middle and a merge in 
the lower panel. Panels D-F: Frozen sections were stained using C1/8 and the rabbit antiserum 
against podoplanin, 1:800, detecting using the AlexaFluor® goat conjugates 488 (green) and 594 
(red) respectively. Nuclei were stained with DAPI (blue) and images were captured by confocal 
microscopy at 600X.
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As C l /8 had consistently shown greater binding to LYVE-1 on ELISA than 
Bl/10 and was shown to work on PFA-fixed frozen sections (figure 3.7), whole 
mount staining using this mAh was attempted first as it was deemed more likely 
to be successful. Mouse ears were removed and immediately transferred to PFA, 
as described in detail in chapter 2. Tissue was permeabilised with PBS-0.3% 
Triton X-100 and C l/8  was applied at lOpg/ml in a blocking buffer of PBS-0.3% 
Triton X-100 with 3% skimmed milk powder. An AlexaFluor goat anti-rat 488 
conjugate was used as the secondary detecting antibody and following mounting 
the tissue was viewed both with an inverted fluorescence microscope to capture 
images in one plane of focus only and subsequently with a confocal microscope, 
capturing multiple planes of focus to build up a three-dimensional image. C l/8  
proved highly suitable for use in this technique, yielding strong staining of 
lymphatic vessels with very low background (figure 3.8, panel A). The staining 
pattern of C l/8  was identical to that obtained with rabbit anti-mouse LYVE-1 
polyclonal antibody (figure 3.8 panel B), where the polyclonal antibody was used 
in double staining with a rat anti-mouse CD31 mAb and no LYVE-1 staining was 
visible on highly CD31-positive blood capillaries. (CD31 is expressed at higher 
levels by blood endothelial cells than lymphatic endothelium, (Hirakawa et al., 
2003)). Thus it was shown that C l/8  is a suitable antibody for specifically 
staining LYVE-1 on lymphatic endothelium within whole mount ear sections. 
Further whole mount staining revealed that unlike most other antibodies tested, 
C l/8  was not sensitive to the length of fixation and still yielded clear staining in 
tissue fixed for as little as 3h to as long as 14 days. Hence double-staining with 
goat anti-ICAM-1 (which required a short fixation incubation of 3h, figure 3.8 
panel C) was possible, as was staining with rabbit podoplanin antiserum (panel 
D), which required much longer fixation of at least 48h.
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Figure 3.8 The specificity of C1/8 in whole-mount tissue staining. Mouse ear was fixed in 
PFA, permeabilised with Triton X-100 and stained with either C1/8 alone (panel A) or rabbit anti- 
LYVE-1 polyclonal antibody and anti-CD31 mAb (panel B), in combination with the AlexaFluor® 
conjugates 488 and 568. The LYVE-1-positive lymphatic vessels are shown in green whilst the 
CD31-positive blood vasculature is shown in red. Panel C shows tissue fixed for only 3h and 
stained with C1/8 (green) and goat anti-ICAM-1 (red) following inflammation induced by a delayed 
hypersensitivity reaction (detailed in chapter 6). Tissue in panel D was fixed for over 48h prior to 
staining with C1/8 (green) and podoplanin antisera (red). All images were captured by confocal 
microscopy at a magnification of 100X.
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Whole mount staining of mouse ear tissue to detect LYVE-1 using C l / 8 on SLC 
(Secondary lymphoid chemokine, 6Ckine or CCL21)-positive lymphatic vessels 
again reveals the specificity of C l/8 , staining the individual lymphatic 
endothelial cells at cell-cell junctions whilst SLC appears to hold either an 
intracellular location or is membrane bound (figure 3.9).
Figure 3.9 The specificity of C1/8 for SLC-positive lymphatic endothelium in whole mount 
tissue staining of mouse ear. Tissue was stained using goat anti-SLC (red) antisera and C1/8 
(green), with the AlexaFluoi® conjugates donkey anti-goat 568 and donkey anti-rat 488 
respectively. Images were captured by confocal microscopy at 100X magnification (panel A) and 
600X magnification (panel B), where an individual vessel can be seen.
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3.2.6 Characterisation of the epitopes for LYVE-1 mAbs Bl/10 and Cl/8
In addition to the requirement for mAbs for use as markers for detecting 
lymphatics, it was of interest to carry out preliminary epitope mapping and 
functional assays. Mouse and human LYVE-1 share approximately 74% amino 
acid sequence homology and consequently it was possible that the mAbs 
generated here against the murine protein would cross-react with the human 
orthologue. An ELISA was used to test this, coating a microtitre plate with either 
human or mouse LYVE-1 Fc fusion proteins, then applying either B l/10 or C l/8  
and detecting bound antibody using HRP-conjugated goat anti-rat antibody and
O-phenylenediamine (OPD), quantitating by spectrophotometry at 490 nm. As 
shown in figure 3.10, both mAbs bound to mouse LYVE-1 in a concentration- 
dependent manner, attaining saturation binding at concentrations of 2.5 jig/ml 
and higher. However neither antibody bound to wells coated with human 
LYVE-1 even when tested at high concentrations (10pg/ml) and hence it was 
concluded that both were specific for the mouse and neither was reactive with 
the Fc portion. The maximum level of binding by C l/8  was consistently higher 
that that of Bl/10, suggesting that these two mAbs recognise different epitopes. 
Also binding by C l/8  was approximately two-fold that of Bl/10. There are 
several possible explanations for this. The first possibility is that the C l /8 
epitope may be present as two copies per molecule and may include a post- 
translational modification with a repetitive structure. A second possible 
explanation may be that Bl/10 recognises an epitope that represents a post- 
translational modification present only on a proportion of LYVE-1 molecules. A 
third alternative is that the Bl/10 epitope may be masked on a proportion of 
LYVE-1 molecules, either due to self-association with other LYVE-1 molecules or 
glycosylation. The possibility that the epitopes consist solely of glycan chains is 
unlikely as no cross-reactivity with human LYVE-1 was observed.
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Figure 3.10 Titration of C1/8 and B1/10 and LYVE-1 species specificity. Affinity purified 
antibody was applied in triplicate at a series of concentrations to microtitre plates coated with either 
immobilised mouse or human LYVE-1 Fc fusion protein. Whilst both mAbs showed binding to the 
mouse protein, binding to human fusion protein was at background levels.
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3.2.7 Determining the effect of the degree of LYVE-1 sialation on mAb binding
To explore the possibility that a post-translational modification was part of either 
Bl/10 or C l/8  epitopes, the effect of desialation was explored. Experiments 
carried out by a fellow DPhil student in the same laboratory (Tom Nightingale) 
demonstrated that these N-glycans are sialated and that HA binding by LYVE-1 
is tightly controlled by the degree of sialation. The effect of sialation on the 
ability of the mAbs to recognise and bind LYVE-1 was therefore investigated 
using an ELISA.
a  2-3, 6, 8-neuraminidase from Vibrio cholerae cleaves a2—>3 and cx2—>6 linkages 
to Gal, GlcNAc and GalNAc residues. LYVE-1 is sialated at the N-glycosylation 
sites and possibly also on O-glycans but a more heavily sialated protein, fetuin 
was used as a positive control to ensure that the enzyme was effective, as 
observed by a decrease in the molecular weight (figure 3.11, panel A). Desialated 
LYVE-1 was used to coat a microtitre plate, alongside LYVE-1 which had been 
incubated in the same conditions but without neuraminidase (mock digestion) 
and LYVE-1 which was completely untreated (to ensure that the conditions of 
neuraminidase treatment alone were not sufficient to alter binding). B l/10 and 
C l/8  were applied to the plate and bound antibody was detected using HRP- 
conjugated goat anti-rat antibody and O-phenylenediamine (OPD), quantitating 
by spectrophotometry at 490 nm. Figure 3.11, panel B shows that binding of 
Bl/10 decreased by approximately 37%. This suggests that a sialated glycan 
may lie close to or affect the conformation of the Bl/10 epitope. This is not the 
case for C l/8 , which showed little reduction in binding upon treatment with 
neuraminidase.
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Figure 3.11 The effect of sialic acid removal on LYVE-1 mAb binding. Purified LYVE-1 Fc was 
treated with neuraminidase in parallel to fetuin, a heavily sialated protein. Proteins were 
electrophoresed on a 10% polyacrylamide gel (panel A), showing de-sialated fetuin (lane 1), 
untreated fetuin (lane 2), de-sialated LYVE-1 (lane 4), untreated LYVE-1 (lane 5).and molecular 
weight markers in lanes 3 and 6, with bands of sizes 116, 80 and 51.8 kDa. A microtitre plate was 
precoated with LYVE-1 Fc which was either untreated, mock-treated, or had been incubated with 
neuraminidase. mAbs were applied at 10pg/ml to triplicate wells and bound antibody was 
measured as mean absorption following detection with an HRP conjugate and substrate, ± 
standard error (panel B).
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3.2.8 Preliminary epitope mapping using mouse/human LYVE-1 chimeras
The regions of the extracellular domain containing the B l/10 and C l/8  epitopes 
were further delineated using two mouse/human chimaeric LYVE-1 constructs, 
to establish whether the epitopes lay within the Link module and therefore may 
affect ligand binding. The chimaeras were kindly donated by a fellow DPhil 
student in the laboratory (Branwen Hide) and the compositions are illustrated in 
the schematic in the upper panel of figure 3.12. All transfectants were lifted with 
PBS-5mM EDTA prior to staining in triplicate with either of the mAbs and the 
AlexaFluor®488 conjugate. Both mAbs were found to recognise full length 
mouse LYVE-1 and chimaera C but not chimaera A. Therefore both epitopes are 
likely to lie in the region between residues 55 and 111.
3.2.9 Functional assays
3.2.9.1 Testing the ability of the mAbs to induce shedding o f LYVE-1
The induction of shedding of antigen by certain antibodies has been well- 
documented, for example the shedding of CD44 by the mAb IM-7.8.1 (Zheng et 
al., 1995). Therefore it was of interest to determine whether or not either of the 
mAbs generated here could induce shedding of LYVE-1 from the cell surface in 
transfectants. 293T were transiently transfected with mouse LYVE-1 in pRcCMV 
and incubated for 24h at 37°C in the presence of either Bl/10, C l/8  or rat IgG 
control, all in triplicate. Cells were then stained with rabbit anti-mouse LYVE-1 
and AlexaFluor® 488-conjugated goat anti-rabbit to measure LYVE-1 surface 
expression by flow cytometry (figure 3.13). A decrease in LYVE-1 surface 
expression was observed after incubation with both Bl/10 and C l/8  to 66% and 
74% of that on cells incubated with the irrelevant isotype-matched control. 
However this could be due to suppression of polyclonal antibody binding to 
epitopes already occupied by mAbs rather than shedding of the antigen. 
Alternatively shedding may have occurred and to a more dramatic extent at an
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earlier time point than that at which the experiment was carried out and by 24h 
expression had begun to recover. Antibody-induced shedding may also be 
temperature dependent and future experiments could explore whether or not 
this is the case. Also the loss of surface expression may be either due to 
internalisation or shedding and an ELISA or Western blot could be performed to 
detect shed LYVE-1 in the supernatant.
3.2.10 Determining ability of the mAbs to block HA binding
Certain antibodies have well-characterised abilities to block the binding of their 
antigen to its ligand and have thus proved invaluable reagents in functional 
studies, as outlined in the introduction to this chapter. To assess adhesion 
blockade of Bl/10 and C l/8 , 293T were transiently transfected with mouse 
LYVE-1 in pRcCMV and then incubated for 30 min in triplicate with either 
Bl/10, C l/8  or rat IgG isotype-matched control at either 4°C or 37°C. FITC-HA 
was added and all cells were incubated at 4°C for 30 min to prevent endocytosis 
of HA. HA binding was assessed by flow cytometry, using untransfected cells 
incubated with FITC-HA as a control to demonstrate that no LYVE-1- 
independent or non-specific binding was occurring. Figure 3.14 shows that at 
37°C Bl/10 reduced HA binding by almost 70%, although such HA blocking did 
not occur at 4°C. This temperature dependence suggests that LYVE-1 was either 
internalised or shed at 37°C and the decrease in surface expression was 
responsible for a reduction in HA binding. It would be interesting to explore this 
possibility further, as outlined in the section above.
HA binding by mouse LYVE-1 in plate binding assays was found to only occur 
on very recently prepared protein (less than 12h following purification). 
However this approach could be used to assess the effect of the mAbs on ligand 
binding without the variables of internalisation or shedding.
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Figure 3.12 Epitope mapping of mAbs using mouse/human LYVE-1 chimaeras in transfected 
293T cells. Panel A shows the LYVE-1 constructs used in 293T stable transfectants generated by 
Branwen Hide. Mouse sequence is shown in blue, with human sequence in red. The precise aa 
junctional regions are indicated. Lower panels show FACS histograms of 293T transfectants. 
Untransfected cells are shown in panel B. Panel C shows FACS of full length mouse LYVE-1 
transfectants whilst chimera A and chimera C transfectants are shown in panels D and E 
respectively. Cells were stained with either C1/8 (blue), B1/10 (black), rabbit polyclonal anti-LYVE- 
1 (red) or an isotype-matched antibody (black dotted line) and AlexaFluortB)488.
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Figure 3.13 Testing for mAb-induced shedding of LYVE-1. Mouse LYVE-1 transfectants were 
incubated for 24h with antibodies at 50 jug/ml, either B1/10, C1/8 or an irrelevant isotype-matched 
antibody, IgG in triplicate. Cells were stained with rabbit anti-LYVE-1 and AlexaFluor 488 goat anti­
rabbit in triplicate for each condition and LYVE-1 expression was measured by flow cytometry, ± 
standard error.
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Figure 3.14 Assaying HA blocking ability of the LYVE-1 mAbs. The amount of FITC-HA bound 
to LYVE-1 transfectants after 30 min incubation at 4°C following pre-incubations with antibody at 
either 37°C or 4°C for 30 min was measured by flow cytometry, to quantitate the mean 
fluorescence of triplicate samples, ± standard error.
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3.3 Discussion
This chapter has described the characterisation of two rat monoclonal antibodies 
generated against a fusion protein of mouse LYVE-1 and the Fc portion of human 
IgG. The two hybridomas were cloned and termed Bl/10 and C l/8 . Both mAbs 
were found to specifically bind mouse LYVE-1 and proved suitable antibodies 
for use in immunoperoxidase staining of paraffin-fixed sections as well as for 
immunofluorescence on cells and frozen sections, both fixed in PFA and unfixed. 
C l/8  was found to act as a specific marker for the detection of lymphatics in 
whole mounted mouse ear and was used extensively for this application (chapter 
6), as it exhibited strong, specific binding which was not sensitive to the length of 
fixation. Thus C l /8 proved an invaluable reagent throughout this PhD, in the 
study of LYVE-1 expression, its variation both in vitro and in vivo and elucidating 
its possible functions. It also allowed greater flexibility in the choice of a second 
antibody when double staining. This was especially important as the most 
reliable podoplanin antibody was raised in rabbit and hence LYVE-l-podoplanin 
double staining could not be carried out if only polyclonal antisera against 
LYVE-1 existed. Another important application of these monoclonal antibodies 
was the positive selection of lymphatic endothelial cells when preparing a pure 
population from mouse dermal sheets (described in chapter 6). C l/8  yielded a 
purer population of LYVE-l-positive lymphatic endothelial cells (LEC) than 
either Bl/10 or the rabbit polyclonal antibody (Dr. Steven Clasper, unpublished 
observation).
Both Bl/10 and C l/8  were found to specifically recognise mouse LYVE-1 protein 
on both transfected cells and immobilised in plate-binding assays. No binding 
was observed to either immobilised human LYVE-lFc in a plate-binding assay or 
to human LYVE-1 stable transfectants when measured by flow cytometry. This
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demonstrated that the mAbs were not recognising the Fc portion of the protein 
or a novel epitope formed between the Fc domain and LYVE-1 and were specific 
for mouse LYVE-1, with no cross-reactivity towards the human orthologue. 
Partial epitope mapping using mouse-human LYVE-1 chimaeras showed that the 
epitopes of both Bl/10 and C l/8  lie within the Link domain, between residues 
55 and 111. As the maximum level of binding by C l/8  in microtitre plate assays 
was consistently higher that that of B l/10 by approximately two-fold, it is highly 
likely that these two mAbs recognise different epitopes. The C l/8  epitope may 
be present as two copies per molecule and may include a post-translational 
modification with a repetitive structure. Alternatively, the B l/10 epitope may 
represent a post-translational modification that is present only on a proportion of 
LYVE-1 molecules. Another possibility is that the Bl/10 epitope is masked on a 
proportion of LYVE-1 molecules, either due to self-association with other LYVE-1 
molecules or glycosylation. However, it is unlikely that the epitopes consist 
solely of glycan chains as no cross-reactivity with human LYVE-1 was observed. 
Mouse LYVE-1 contains sites for N-glycosylation at residues N52 and N129, i.e. 
adjacent to the 56-amino acid residue region to which the epitopes of B l/10 and 
C l/8  have been mapped. De-sialation of LYVE-1 resulted in a decrease in the 
binding of B l/10 by approximately 37%, which suggests that a sialated glycan 
may lie close to or affect the conformation of the Bl/10 epitope. This is not the 
case for C l/8 , which showed little reduction in binding upon treatment with 
neuraminidase.
Preliminary experiments into functional properties of the mAbs showed that 
Bl/10 may induce loss of LYVE-1 expression from the surface of transfectants at 
37°C. Thus the decrease observed in HA binding by these cells following 
incubation with Bl/10 may be secondary to the reduction in LYVE-1 surface 
expression. However further experiments are required to assess the mechanism 
by which this occurs and to what extent over a time course.
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4.1 Introduction
4.1.1 Blood and lymphatic endothelial cells
The blood and lymphatic microvascular systems constitute discrete networks 
which perform very different but complementary functions. Whilst the blood 
vessels deliver dissolved proteins, fluids and cells to the interstitium, the 
lymphatics are responsible for draining excess fluid and returning protein to the 
circulation, thus maintaining homeostasis within the tissues. The two systems 
take on contrasting roles in antigen presentation too. Antigen presenting cells 
from the tissues travel to the lymph node via the lymphatics to be brought into 
contact with T-lymphocytes which have entered the lymph node via high 
endothelial venules (HEV) from the circulation. Although the morphology of 
isolated blood endothelial cells (BEC) does not permit them to be distinguished 
from isolated lymphatic endothelial cells (LEC), (Kriehuber et al., 2001), it would 
be fair to assume that their very different physiological roles would demand that 
they have distinct molecular phenotypic differences.
The first rigorous isolation and characterisation of dermal LEC and BEC was 
carried out by Kriehuber et al. (2001). These researchers isolated podoplanin- 
positive LEC and podoplanin-negative BEC from a dermal cell suspension 
obtained from adult patients undergoing breast reduction or abdominoplasty 
and sorted by flow cytometry. They showed that LEC and BEC constitute stable 
endothelial cell lineages which are specialized to carry out their diverse 
functions. Whilst both types of EC express VE-cadherin, CD31, vWF and secrete 
MIP-3P, LEC alone expressed LYVE-1, prox-1, podoplanin, VEGFR-3 and SLC. 
Also when the two EC types were plated in Matrigel™, they were found to 
assemble tubules in a strictly homotypic manner. In a more recent study, 
Hirakawa et al. (2003) showed that BEC and LEC are phenotypically distinct by
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RNA array analysis, which permitted a much wider range of genes to be 
surveyed than studies with antibodies could allow. Transcription profiling 
studies revealed that BEC exhibit higher expression of several extracellular 
matrix and adhesion molecules in comparison to LEC, including versican, 
collagens, laminin, N-cadherin and CD34, as well as growth factor receptors 
endoglin and VEGFR-1. They also reported that LYVE-1 and prox-1 were not 
detected in BEC, as discussed previously in the general introduction. This 
present chapter details the investigations carried out into variations in LYVE-1 
expression in cultured cells, shown by extensive phenotyping to be LEC.
4.1.2 Possible regulation of LYVE-1 expression in LEC
Previous examination of both mouse and human tissue by immunofluorescence 
microscopy revealed that even in apparently normal tissue, the expression of 
LYVE-1 varies much more dramatically than that of other lymphatic markers 
(unpublished observation). Such variation was also observed when primary 
human LEC were cultured in vitro. Both immunofluorescence microscopy and 
flow cytometry showed the differences in LYVE-1 expression between batches of 
cells in culture, even though no variation in the rate of proliferation or expression 
of other proteins was apparent. Throughout this PhD, primary endothelial cells 
were cultured in commercial Endothelial Growth Medium, EGM-2 purchased 
from Clonetics which was supplied as basal media requiring the addition of 
various supplements shortly before use. In addition to FBS, these included the 
recombinant growth factors acidic FGF, EGF and IGF; hydrocortisone; and 
ascorbic acid. LYVE-1 expression appeared particularly sensitive to the age of 
media: cells expressed higher levels of LYVE-1 when cultured in freshly 
supplemented medium, suggesting that LYVE-1 expression is influenced at least 
in part by the concentration and activity of a labile factor. Experiments carried 
out in this chapter sought to address the effects on LYVE-1 expression of such 
molecules, in particular growth factors and cytokines to which lymphatic
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endothelium may be exposed in tissues. This was also driven by the knowledge 
that such factors are known to regulate expression of CD44, the closest 
homologue of LYVE-1. For example over-expression of EGF on tumour cells was 
found to be associated with in vivo tumour aggression due to increased 
proliferation, enhanced cell attachment and migration into the extracellular 
matrix (Zhang et al., 1996). EGF was found to induce CD44 expression both at 
the protein and mRNA levels in 3T3 mouse fibroblasts and enhanced cell 
attachment to HA. In a subsequent publication (1997), Zhang et al. identified a 
novel EGF-responsive element, ERE in the CD44 promoter, to which an EGF- 
inducible nuclear protein binds. Clearly as growth factors can affect CD44 
expression in such a specific manner, it was of interest to study the effects of EGF 
and other growth factors on lymphatic endothelium and expression of LYVE-1.
Experiments described in this chapter also sought to determine the effects of pro- 
inflammatory cytokines and chemokines on LYVE-1 expression. It is already 
widely accepted that inflammatory cytokines alter the expression of a variety of 
proteins in blood vascular endothelium, to enhance extravasation of leukocytes 
from the circulation (detailed in the general introduction). Thus it was 
considered likely that such a change in expression may also be induced in 
lymphatic endothelium, in response to the requirement for increased reverse 
migration of antigen presenting cells into the lymphatic vessels. It was of great 
interest to determine whether LYVE-1 was one such molecule that experienced a 
change in expression, in view of its possible involvement in facilitating leukocyte 
adhesion via HA-interactions (Jackson, 2004). In this respect it is noteworthy that 
other groups have demonstrated that CD44 on leukocytes was affected by pro- 
inflammatory agents. For example, expression of CD44 on monocytes was found 
to be elevated in inflamed tissue (Haynes et al., 1991) and the induction of CD44 
on endothelial cells by IL-la was demonstrated by Fitzgerald and O'Neill (1999). 
The functional role of CD44 in adhesion of leukocytes to inflamed vascular
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endothelium is described in the general introduction to this thesis. As LYVE-1 is 
restricted to the lymphatic endothelium, experiments described in this chapter 
sought to determine whether its expression is up- or down-regulated during 
inflammation, signalling a role in regulating leukocyte adhesion or migration. 
Previous work in the Jackson laboratory (Tom Nightingale, DPhil thesis, 
University of Oxford, 2004) had shown that LYVE-1 is constitutively expressed in 
lymphatic endothelium in a sialated, non-binding form, thus suggesting that 
control of endogenous neuraminidase activity might regulate LYVE-1 function in 
vivo. Activation of such a LYVE-1-HA interaction might, for example, stimulate 
rearrangement of the endothelial cell cytoskeleton, to aid transmigration of APCs 
across the lymphatic endothelium. An interaction between CD44 on APCs and 
LYVE-1-bound HA could also occur. Alternatively LYVE-1 may play a role in 
sequestering smaller fragments of HA for degradation, to resolve acute 
inflammation. Thus the effect of pro-inflammatory mediators on LYVE-1 
expression and HA binding could provide evidence for a physiological role for 
this lymphatic endothelium-restricted receptor.
Many human cancers are associated with pre-existing chronic inflammatory 
conditions (Schacter et al., 2002). A common feature of solid tumours is hypoxia, 
which is known to have radical effects on blood vessel endothelial cells, 
stimulating angiogenesis through the up-regulation of VEGF family receptors 
and ligands. It was therefore of interest to determine whether hypoxia might 
influence lymphatic endothelium in some way, initially focusing on LYVE-1 
expression. If LYVE-1 did indeed possess a hypoxia responsive element, 
sensitivity to oxygen tension could explain variations observed in LYVE-1 
expression in vivo. A dramatic change in expression could be of prognostic use, 
as has proved the case for carbonic anhydrase 9 (CA9), which is up-regulated by 
hypoxia in a number of cancers (Wykoff et al., 2000; Koukourakis et al., 2001; 
Olive et al., 2001).
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Another agent which could affect LYVE-1 expression on LEC in vitro is the 
diacylglycerol analogue phorbol 12-myristate 13 acetate (PMA), a potent 
activator of mitogen activated kinases (MAPKs) through protein kinase C (PKC). 
Among the many proteins regulated by these intracellular molecular signals are 
matrix metalloproteinases, MMPs, which are capable of degrading extracellular 
matrix and play critical roles in endothelial cell migration (Park et al., 2003). 
Research carried out in the Jackson laboratory (S. Clasper and D. G. Jackson, 
unpublished; Tom Nightingale, DPhil thesis, University of Oxford, 2004) had 
found that PMA stimulated MMP-dependent shedding of LYVE-1 by 293T 
human fibroblast transfectants. In this chapter, further experiments were carried 
out to investigate whether this finding was borne out in human LEC which 
express endogenous LYVE-1, in order to assess whether regulation of LYVE-1 
expression involves the MAPK pathway.
4.1.3 Aims
The experiments described in this chapter sought to determine factors and 
conditions responsible for regulating LYVE-1 expression in primary human LEC.
• A panel of growth factors, cytokines and chemokines, were used to 
stimulate LEC prior to quantitation of LYVE-1 expression.
• Extensive characterisation of the effect of TNFa on LYVE-1 expression and 
the mechanism of regulation were carried out
• The response of lymphatic endothelium to hypoxia was investigated in a 
preliminary study.
• Stimulation of LEC by PMA was carried out to determine the effect on 
LYVE-1 surface expression and the mechanism of regulation.
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4.2 Results
4.2.1 Derivation of human lymphatic endothelial cells (LEC)
The study of LYVE-1 expression in response to various factors and conditions 
depended upon the availability of cultured primary lymphatic endothelial cells 
which endogenously expressed LYVE-1. Such cells had to be well adapted to 
culture and grow over a number of passages to allow for expansion of the 
population whilst retaining their molecular characteristics. Isolation of primary 
LEC from tissue was not possible due to the lack of availability of human tissue. 
Therefore primary LEC were obtained from commercially available human 
dermal microvascular endothelial cells (HDMEC), which contained both LEC 
and BEC. Such microvascular endothelial cells were purchased from two 
sources: PromoCell, Heidelberg and Clonetics, Cambrex Bioscience Inc, 
Walkersville, USA.
4.2.1.1 Human dermal endothelial cells from Clonetics, USA
HDMEC supplied by Clonetics had been isolated from dermal tissue from a 47 
year old male and at early passages contained a mixed population of both LYVE-
1-positive LEC and CD34-positive BEC in approximately equal numbers, as 
shown in figure 4.1 A. However by passage 5 the number of LYVE-1 positive 
cells had diminished to approximately 10% (figure 4.1) and by passage 9 had 
entered senescence and ceased to proliferate. Attempts to derive a population of 
pure LEC through selection with mouse anti-human LYVE-1 mAb and anti­
mouse magnetic cell sorting (MACS) beads failed to yield cells which would 
proliferate sufficiently to expand the population. Thus the unselected cells were 
used in preliminary experiments into regulation of LYVE-1 expression by growth 
factors, cytokines and chemokines. As BEC are LYVE-1 negative, the
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contribution of such cells to total LYVE-1 expression was considered only 
important if one of the growth factors or cytokines induced a change in the 
transcriptional profile of BEC to resemble that of LEC and thus an indirect 
increase in LYVE-1 expression. However the advent of cells from PromoCell, 
Germany superseded the use of these cells.
4.2.1.2 Human dermal microvascular endothelial cells from PromoCell, Germany
HDMEC purchased from PromoCell had been derived from a 7 year old male 
donor and initially consisted of a mixed population of both LYVE-l-positive LEC 
and CD34-positive BEC. However unlike the HDMEC from Clonetics, these cells 
were found to proliferate beyond 20 passages. To investigate the expression of 
LEC markers LYVE-1 and podoplanin and the BEC marker CD34 with passaging, 
cells were continuously cultured and at each passage were lifted with PBS-5mM 
EDTA. Half of the population were re-plated for continued growth whilst the 
other half were stained with mouse anti-LYVE-1, mouse anti-CD34, rabbit anti- 
podoplanin or irrelevant isotype-matched controls and the appropriate 
AlexaFluor® 488 conjugated secondary antibody. Expression of each of these 
proteins at each passage was then assayed by flow cytometry (figure 4.2). The 
percentage of cells expressing the BEC marker CD34 was found to decrease with 
passaging whilst the number of cells expressing the LEC markers LYVE-1 and 
podoplanin increased, suggesting that the LEC outgrew the BEC. Hence all 
experiments were carried out on the same batch of PromoCell HDMEC, which 
were used at passage 12 or above.
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Figure 4.1 Mixed phenotype of commercial HDMEC (Clonetics). Early passage (typically 
passage 2-3) cells consisted of discrete islands of BEC (expressing CD34, red) and LEC (LYVE-1 - 
positive). Panels A, B and C show a BEC-enriched region whilst panels D, E and F a LEC- 
enriched area. At later passage (passage 5 and after), expression of both LYVE-1 (panel G and 
FACS histogram) and CD34 (data not shown) had decreased markedly and cells ceased to 
proliferate.
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Figure 4.2 Derivation of a pure population of LEC by outgrowth from a mixed population of 
commercial HDMEC. PromoCell HDMEC were cultured continuously and at each passage a 
sample was stained in triplicate with either the anti-LYVE-1 mAh 8C, anti-CD34 or rabbit polyclonal 
anti-podoplanin. The appropriate AlexaFluor® 488 conjugated goat antibody was used for 
secondary detection and the percentage of positive cells (± standard error) assayed by flow 
cytometry. Staining using irrelevant isotype matched controls was also carried out at each 
passage.
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4.2.1.3 Characterisation ofPromoCell HDLEC
Immunofluorescence microscopy of the putative HDLECs showed that virtually 
all cells expressed the pan-endothelial cell marker CD31, podoplanin and the 
transcription factor prox-1 (seen within the nucleus, colocalising with DAPI, 
figure 4.3). In cells of passage 12 and above, over 99% of the population were 
podoplanin-positive, as shown by flow cytometry (figure 4.3, lower right panel) 
and no CD34 expression was observed (upper right panel). Due to their 
predominantly LEC phenotype these HDMEC-derived cells are hereafter termed 
human dermal lymphatic endothelial cells, HDLEC and prior to the availability 
of freshly immuno-isolated primary LEC for experimental work, served as a 
convenient cell line to study the regulation of LYVE-1 expression. 
Comprehensive analyses of adhesion molecule expression by HDLEC and of 
their changes in gene expression in response to inflammation are presented later 
in this thesis (chapter 5). Studies on primary LYVE-1 immuno-isolated murine 
LEC which became possible later during this thesis are also described in chapter 
5.
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Figure 4.3 Characterisation of HDMEC-derived LEC (HDLEC). Immunofluorescence 
microscopy to show that the majority of cells express CD31, podoplanin and prox-1, whilst no cells 
express CD34. Cells were stained with either mouse anti-CD31, rabbit anti-podoplanin, mouse 
anti-prox-1 or mouse anti-CD34. The appropriate AlexaFluor® 568 goat secondary conjugates 
were used for detection and nuclei were counterstained using DAPI (left and upper right panels). 
Podoplanin expression was quantitated by flow cytometry, staining cells with the same polyclonal 
antibody and goat anti-rabbit AlexaFluor® 488 conjugate to demonstrate that over 99% of 
PromoCell HDLEC are podoplanin positive, (lower right panel). Microscopy images were captured 
at 200X magnification.
FL1-H
Podoplanin expression
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4.2.2 Changes in LYVE-1 surface expression in response to culture conditions
The effects of a panel of recombinant human cytokines, chemokines and growth 
factors on LYVE-1 expression were studied quantitatively using flow cytometry 
following incubation with individual factors for 72h of culture (figure 4.4). The 
inflammatory cytokine IL-6 induced an increase in LYVE-1 expression in the 
cells, as did Angiopoietin-2 and VEGF-C. A more marginal increase in 
expression was induced by the growth factors FGFacidic, G-CSF and GM-CSF, 
the cytokine IFNy and chemokines MIP-3a and MIP-3p. However the most 
striking result obtained from this experiment was the abrogation of LYVE-1 
surface expression following treatment with TNFa and TNFp (figure 4.4).
The effects of cytokines and growth factors was next assessed on LEC present 
within commercial HDMEC obtained from Clonetics, USA. Although BEC are 
present in these populations, LYVE-1 expression has never been observed on 
such CD34-positive cells. However like the PromoCell HDLEC, these cells 
exhibited a similar loss of LYVE-1 following exposure to TNF (figure 4.5). 
Additionally a similar study on the effects of cytokines, chemokines and growth 
factors was also carried out on immunoselected primary human dermal LEC. 
These cells became available later in these studies and only in very limited 
quantities. They comprised a population isolated by immunoselection with 
podoplanin and were kindly donated by Dr. Ernst Kriehuber (laboratory of Prof. 
Donscho Kerjaschki, Vienna, Austria), the phenotype of which is described in 
detail in Kriehuber et al. (2001). TNF was found to precipitate the same loss of 
LYVE-1 from the cell surface (figure 4.6). Hence it can be concluded that down- 
regulation of LYVE-1 is likely to be an authentic response of LEC and the 
HDLEC derived from the initially mixed population of HDMEC have preserved 
the phenotype of primary LEC.
181
Chapter 4 Expression of LYVE-1 in lymphatic endothelial cells 4.2 Results
?  7 0
<u
1  6 0
*33
a 50
2 40
>  3 0
ocn vo oo m
i i i i  , _
( N  0 0  ( J
S  ^  r£
O
a,
£>
T N F a
LYVL- 1 expression (fluorescence) LYVE-1 expression (fluorescence)
Figure 4.4A Effects of cytokines, chemokines and growth factors on LYVE-1 expression in 
primary HDLEC. Cells were cultured for 72h in the presence of one of the growth factors, 
chemokines or cytokines, then lifted with PBS-5mM EDTA and stained for LYVE-1 using the mAb 
8C and AlexaFluoKg)488 goat anti-mouse. Cells were stained in triplicate alongside an isotype- 
matched control for quantitation by flow cytometry. Data shown are the mean percentage of LYVE- 
1-positive cells, ± standard error (panel A). Flow cytometry histograms to show the loss of LYVE-1 
from PromoCell HDLEC following exposure to TNFa, 10Ong/ml and TNFp, 100ng/ml are shown in 
panels B and C respectively, where the black lines represent untreated (control) cells, red 
represents TNF-treated and grey the isotype-matched controls.
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Figure 4.5 Effect of cytokines, chemokines and growth factors on LYVE-1 expression in LEC 
present within unselected commercial HDMEC (Clonetics). Cells were cultured following the 
same method as for PromoCell endothelial cells and assayed for surface expression in a similar 
manner but stained in duplicate (due to slower growth and hence fewer cells), with an isotype- 
matched control for each condition. Data shown are the mean percentage LYVE-1-positive cells, ± 
standard error.
183
Chapter 4 Expression of LYVE-1 in lymphatic endothelial cells 4.2 Results
60
Growth factor, cytokine or chemokine
Figure 4.6 Effect of cytokines, chemokines and growth factors on LYVE-1 expression in 
immunoselected primary dermal human LEC. Primary LEC immuno-isolated for podoplanin 
expression (Kriehuber et al., 2001, see methods section for further details) were cultured following 
the same method as for PromoCell and Clonetics endothelial cells and assayed for surface 
expression in a similar manner in duplicate, with an isotype-matched control for each condition. As 
non-specific staining was higher on these cells than the other endothelial cells (typically 7% as 
opposed to less than 1%), the percentage of positive cells stained by the isotype-matched antibody 
for each condition were subtracted from the mean percentage of LYVE-1 positive cells. The 
corrected percentages of LYVE-1-positive cells are plotted ± standard error.
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4.2.3 Effects of TNF on primary HDLEC
In view of the dramatic down-regulation of LYVE-1 in HDLEC induced by both 
TNFa and TNFp, it was decided to characterise the response more fully in terms 
of the effects of these pro-inflammatory cytokines on HDLEC physiology and the 
fate of LYVE-1 upon down-regulation. HDLEC derived from PromoCell 
HDMEC were used for such experiments as they exhibited higher expression of 
LYVE-1 than the immunoselected LEC over a larger number of passages and had 
a shorter doubling time.
4.2.3.1 Effect on morphology
Following stimulation of primary HDLEC with TNFa or TNFp, a striking change 
in morphology of the cells was observed, from rounded cobble-stone-like to 
elongated. Images were captured by phase contrast microscopy (figure 4.7). 
Such a change is indicative of cytoskeletal rearrangement induced by this pro- 
inflammatory cytokine and demonstrates that HDLEC undergo a much more 
dramatic change than simply a loss of LYVE-1 surface expression. However no 
increased propensity of cells to lose adhesion was observed.
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Figure 4.7 Effect of TNFa on the morphology of cultured primary HDLEC. Cells were cultured 
for 48h in either medium alone or supplemented with TNFa, 10ng/ml. Images were captured by 
phase contrast microscopy at 100x magnification. A similar elongated morphology was observed 
in cells following stimulation with TNFp (data not shown).
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4.23.2 Viability and proliferation
One possible explanation for the loss of surface expression of LYVE-1 by TNF- 
treated HDLEC might have been the induction of apoptosis or a loss of viability. 
TNFa was first isolated due to its ability to induce regression of tumours and is 
known to induce apoptosis in some transformed cell lines (detailed in the 
introduction to chapter 5). To assess a potential cytotoxic effect on HDLEC, a 
trypan blue dye-exclusion assay was performed. The results (table 4.1) showed 
that cells treated with TNFa or TNFp excluded dye as effectively as untreated 
cells (table 4.1) and thus showed that TNF-treatment did not cause a reduction in 
viability in these cells. Viability was further confirmed by the continued 
expression of the lymphatic endothelium surface protein podoplanin (figure 4.8). 
Moreover, TNFa did not cause a significant reduction in the rate of proliferation 
of these cells when detected by the MTT dye-reduction assay (figure 4.9), as 
might have been expected if the cytokine were affecting cell integrity.
% Viable 
cells
Standard
error
Control 87.77 5.12
TNFa 87.51 2.37
TNFp 92.98 0.68
Table 4.1 Viability of TNF-stimulated HDLEC. A trypan blue dye exclusion assay was performed 
on cells cultured for 48h in the presence of either TNFa (100ng/ml), TNFp (100ng/ml), or in 
medium alone and then lifted with PBS-5mM EDTA (as for analysis by flow cytometry) and 
incubated on ice for 30min. Data represent cells counted from five replicates.
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Figure 4.8 Loss of surface LYVE-1 in TNFa treated HDLEC, as assessed  by 
immunofluorescence microscopy. Cells were cultured for 48h with or without TNFa, (100ng/ml), 
and then double-stained using the mAb 8C and rabbit anti-podoplanin serum, with AlexaFluor® 
conjugates 488 (green) and 594 (red) respectively. Fluorescence is shown both as the LYVE-1 
and podoplanin channels alone and as both channels merged. Double positive cells appear 
yellow.
188
Chapter 4 Expression of LYVE-1 in lymphatic endothelial cells 4.2 Results
0.7
0.6
£ ACc 0 . 5inONm
CQ
g  0 . 4  
a
I  0 . 3  £
| o . 2
C t r l
0 6 12 1 8 2 4 3 0 3 6 4 2 4 8
Time (h)
Figure 4.9 Effect of TNFa on the rate of HDLEC proliferation in vitro. Cells were cultured with 
or without TNFa and MTT was applied at several time points to triplicate wells for 1 h incubation. 
The absorbance of the cell lysate was measured at 490nm and the mean absorbance plotted at 
each time point ± standard error.
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4.2.3.3 Effect of TNFa on tube formation by HDLEC in Matrigel™
To address the possibility that TNFa might affect the ability of HDLEC to form 
tubules, cells were plated out on Matrigel™, a solubilized basement membrane 
preparation isolated from Engelbreth-Holm-Swarm (EHS) mouse sarcoma which 
is rich in extracellular matrix proteins. HDLEC were plated out on Matrigel™ in 
either the presence or absence of TNFa. After 24h cells had formed extensive 
tubules and images were captured from phase contrast microscopy. 
Representative fields of view are shown in figure 4.10. However no difference in 
overall tubule density or individual tubule branching was observed between 
untreated and TNFa-stimulated. This correlates with the proliferation assay and 
thus these experiments show that TNFa does not have a significant effect on 
lymphangiogenesis or HDLEC proliferation.
4.2.3.4 Time course
A time course to follow the effect of TNFa on surface expression of LYVE-1 was 
carried out, measuring the percentage of LYVE-l-positive cells by flow cytometry 
at 0, 6, 12, 24, 48 and 72h following exposure to the cytokine (figure 4.11). A 
reduction in expression was apparent within the first 6h of treatment, during 
which time the level (measured as percentage of LYVE-1 positive cells) decreased 
by over 50% of the initial value; however, total abrogation of surface expression 
was only complete after 48h.
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Figure 4.10 Effect of TNFa on HDLEC tubule formation in  vitro. Cells were plated out at a 
density of 15000/cm2 on 0.5cm-thick Matrigel™ either in EGM-2 alone or supplemented with TNFa, 
10ng/ml. After 24h, images were captured at 50x and 200x by phase contrast microscopy.
191
Chapter 4 Expression of LYVE-1 in lymphatic endothelial cells 4.2 Results
cn
a>>.J
cCB
70
5 0
4 0
3 0
20
10
0
120 2 4 3 6 4 8 6 0 7 2
Time (h)
0) u 
S3Vu§5
 ^ no H
.2 ^  55 >H
i da>
7 0
6 0
5 0
4 0
3 0
20
10
0
0 2 412 3 6 4 8 6 0 7 2
Time (h)
Figure 4.11 Time course of TNFa-induced LYVE-1 down-regulation in primary HDLEC. Cells 
were cultured for between 0 and 72h in quadruplicate in the presence of TNFa, then lifted and 
stained with the anti-LYVE-1 mAb 8C and goat anti-mouse AlexaFluor®488 for analysis by flow 
cytometry. The mean percentage of LYVE-1 positive cells (upper graph) and mean fluorescence 
intensity (lower graph) are plotted at each time point, ± standard error.
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4.23.5 Concentration dependence
Soluble TNFa binds TNFRI with a Kd of 20-60 pM whilst TNFp displays a slightly 
lower affinity, with a Kd of 650 pM (Marsters et al., 1992). Initial experiments 
carried out in this thesis used a concentration of TNF of lOOng/ml 
(approximately 6nM and 100 x Kd). Therefore LEC were treated with lower 
concentrations of the cytokine and LYVE-1 expression assayed by flow 
cytometry, to investigate whether the effect was as pronounced at concentrations 
closer to the Kd of TNF are used. Surface expression was measured by flow 
cytometry after 48h following exposure of cells to TNFa in the range of 0.1 to 
lOOng/ml (6pM-6nM) of TNF. As shown in figure 4.12, concentrations of TNFa 
at or just above the Kd value (5ng/ml; 160pM) were sufficient to result in total 
loss of surface expression of LYVE-1, whilst even the lowest concentration of 
O.lng/ml (lOx fold below the Kd value) still induced approximately 50% loss.
4.2.3.6 Recovery
The next question posed was whether the effect of TNFa on LYVE-1 expression 
was reversible upon removal of the cytokine. To investigate the phenomenon, 
HDLEC were cultured for 48h in either the presence or absence of TNFa followed 
by withdrawal and replacement of the medium with cytokine-free EGM-2 and 
measurement of LYVE-1 surface expression by flow cytometry. The results 
(figure 4.13) showed that the effects of TNFa were fully reversible with full 
recovery of LYVE-1 within 48h.
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Figure 4.12 Concentration dependence of TNFa. Cells were cultured for 48h in triplicate in the 
presence of TNFa at concentrations between 0 and 10 ng/ml, then lifted and stained with the anti- 
LYVE-1 mAb 8C and goat anti-mouse AlexaFluoKg)488 for analysis by flow cytometry. Data are 
plotted as the mean percentage of positive cells (upper graph) and mean fluorescence intensity 
(lower graph) ± standard error.
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Figure 4.13 Reversibility of TNF-induced down-regulation of LYVE-1 in cultured HDLEC.
Cells were cultured for 48h in the presence of TNFa, 10 ng/ml, then washed twice with PBS and 
once with fresh EGM-2 medium before continued culture in media with no additions of cytokine. At 
12h, 24h, 48h and 72h after the change of medium, cells from triplicate wells were lifted and 
stained with the anti-LYVE-1 mAb 8C and goat anti-mouse AlexaFluor®488 for analysis by flow 
cytometry. The graph shows the mean percentage of LYVE-1 positive cells, ± standard error at 
each time point.
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4.2.4 The fate of LYVE-1 following exposure to TNF
4.2.4.1 Effects of TNFa stimulation on LYVE-1 protein
TNFa-induced down-modulation of LYVE-1 could be mediated by either 
shedding or internalisation of the receptor. The following experiments were 
designed to determine which of these two mechanisms was involved.
During the course of this thesis, studies carried out by a fellow DPhil. student 
Tom Nightingale on 293T stable transfectants had shown that phorbol 12- 
myristate 13 acetate (PMA), an analogue of diacylclycerol that signals via protein 
kinase-C (PKC) induced shedding of LYVE-1 from the cell surface. To 
investigate whether such shedding also occurred following stimulation with 
TNFa or TNFp, cells were cultured for 24h in the presence or absence of these 
cytokines and the loss of cell surface LYVE-1 assessed by immunofluorescence 
microscopy (figure 4.8). In addition, the supernatants were removed and 
assayed for shed LYVE-1 using a quantitative enzyme-linked immunosorbent 
assay (ELISA) calibrated with purified soluble LYVE-1 Fc and detected with the 
LYVE-1 mAb 8C. Culture media from LYVE-1 transfected 293T cells which shed 
receptor in response to PMA were used as a positive control. The results 
revealed that untreated HDLEC shed low but appreciable levels of LYVE-1 into 
the culture media, (approximately lOng/ml). Surprisingly however, shedding 
was suppressed following TNFa treatment (figure 4.14).
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Figure 4.14 Shedding of LYVE-1 by cultured primary HDLEC in response to TNF. HDLEC 
were cultured for 24h in the presence of either TNFa, TNFp or with no additions. The 
supernatants were then applied to a microtitre plate, precoated with rabbit anti-human LYVE-1. 
The ELISA was calibrated with purified soluble LYVE-1 Fc fusion protein and supernatants from 
293T human LYVE-1 transfectants stimulated for 4h with PMA, (20ng/ml) were used as a positive 
control. Bound protein was detected using the LYVE-1 mAb 8C and an HRP-conjugated goat 
antibody with OPG and the mean concentration of LYVE-1 ± standard error was calculated.
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It should be noted however that although no shed LYVE-1 could be detected in 
the supernatant following TNFa stimulation, the mechanism of shedding may 
have destroyed epitopes which could be recognised by the mAb employed in the 
above ELISA. PMA-induced shedding of LYVE-1 by transfectants had 
previously been shown to be mediated by matrix metalloproteinases (MMPs) 
and hence could be inhibited by the broad spectrum MMP inhibitor Ilomastat. 
To investigate whether the same mechanism was responsible for TNFa-induced 
loss of surface expression, cells were treated for lh  with Ilomastat prior to 
incubation for 24h in either EGM-2 alone or with TNFa. Surface expression of 
LYVE-1 was then assayed by flow cytometry. Ilomastat was found to have no 
effect on loss of cell surface LYVE-1 following stimulation with TNFa (figure 
4.15) and thus it was concluded that TNFa-induced LYVE-1 down-regulation 
was not mediated by MMPs.
These data suggested that LYVE-1 was being internalised rather than shed. To 
investigate this latter possibility, confocal microscopy was used. HDLEC were 
cultured for 3h, 6h, 12h, 24h and 48h in the presence or absence of TNFa then 
either permeabilised with saponin or left intact prior to staining for LYVE-1 and 
podoplanin. The results confirmed initial co-localisation of LYVE-1 with 
podoplanin at the cell surface (figure 4.16). However as early as 3h after TNFa 
addition, only podoplanin remained in this location and LYVE-1 was completely 
lost. Permeabilisation of the cells revealed that LYVE-1 was present 
intracellularly, consistent with TNF-induced internalisation. By 48h the 
intracellular LYVE-1 had also disappeared, indicative of degradation.
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Figure 4.15 Effect of Ilomastat on TNF-induced loss of surface LYVE-1 by cultured primary 
HDLEC. Cells were cultured in triplicate for 1h in the presence of Ilomastat, (25 pM) prior to the 
addition of TNFa, 10 ng/ml and incubation for 24h. Cells were then lifted and stained in triplicate 
with the LYVE-1 mAb 8C and goat anti-mouse AlexaFluor®488 for analysis by FACS. The mean 
percentage of LYVE-1 positive cells was calculated for each condition ± standard error.
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Figure 4.16 Analysis of TNFa-induced LYVE-1 internalisation by confocal microscopy
(following page). HDLEC were stimulated with TNFa, (10ng/ml) and at each time point cells were 
either permeabilised with saponin or left intact. LYVE-1 was detected using 8C and goat anti­
mouse AlexaFluor®488 (shown in green) whilst podoplanin was detected using rabbit antisera and 
goat anti-rabbit AlexaFluor(R)594 (red). Bars represent 10pm.
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To identify the intracellular compartment with which LYVE-1 was associated, a 
series of markers were employed. These included CD63, an integral membrane 
protein with four transmembrane regions and the putative lysosomal targeting 
signal Gly-Tyr in its short cytoplasmic tail, found in lysosomes and late 
endosomes (Metzelaar et al, 1991) and early endosome antigen 1 (EEA-1), a 
hydrophilic peripheral membrane protein believed to be required for vesicular 
transport of proteins (Mu et al, 1995). Other markers were protein disulphide 
isomerase (PDI), a highly active and abundant protein chaperone found on the 
endoplasmic reticulum (Narindrasorasak et al, 2003), TGN46, a glycoprotein 
implicated in the recruitment of cytosolic factors and vesicle formation on the 
trans-Golgi network (Prescott et al, 1997; Hickinson et al, 1997) and cytochrome c, 
the mitochondrial marker. Following 3h of TNF stimulation, LYVE-1 was found 
to colocalise less with PDI and TGN46, suggesting a decrease in de novo synthesis 
(figure 4.17). To study newly internalised LYVE-1, cells were incubated with 
rabbit anti-human LYVE-1 in either the presence or absence of TNFa, then 
permeabilised and stained for either CD63 or with EEA-1. After 3h of TNFa 
stimulation, cells showed colocalisation of LYVE-1 with both the lysosomal and 
early endosomal markers. However, more cells showed a greater abundance of 
LYVE-1 within the lysosomal compartment at this time point. As expected no 
colocalisation of LYVE-1 was observed with cytochrome c, the mitochondrial 
marker. Thus it was concluded that TNFa stimulation induces internalisation of 
LYVE-1 and degradation within lysosomes, concomitant with a rapid decrease in 
de novo synthesis.
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Figure 4.17 Intracellular localisation of LYVE-1 in primary HDLEC following TNFa 
stimulation. To study location of intracellular LYVE-1, cells were cultured for 3h either with or 
without TNFa then permeabilised with saponin and stained with rabbit anti-human LYVE-1 (green) 
and for intracellular vesicle markers PDI or TGN46 in red, with secondary antibodies goat anti­
rabbit AlexaFluor®488 and anti-mouse AlexaFluor®568 respectively. To study location of 
internalised LYVE-1, cells were incubated for 3h with rabbit anti-LYVE-1 (green) +/- TNFa, then 
permeabilised and stained with either anti-CD63, anti-EEA-1 or anti-cytochrome c (red), with 
secondary antibodies goat anti-rabbit AlexaFluoKD488 and anti-mouse AlexaFluoK§)568 
respectively. Images were captured at magnification: 600X.
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4.2.42 Effects of TNFa stimulation on LYVE-1 mRNA levels
The preceding sections describe how exposure to TNF led to internalisation and 
degradation of cell surface LYVE-1 by HDLEC. Confocal microscopy had 
revealed a decrease in LYVE-1 localised to the endoplasmic reticulum and Golgi 
apparatus, suggesting a decrease in synthesis. It was next determined whether 
the putative inhibition by TNFa of de novo synthesis of LYVE-1 was manifest at 
the level of transcription or translation.
HDLEC were cultured for 72h in either medium alone or with TNFa (10 ng/ml). 
Total RNA was prepared and subjected to agarose-formaldehyde gel 
electrophoresis, then transferred onto charged membrane and probed with [a- 
32P] labelled LYVE-1 for Northern hybridisation. Figure 4.18 shows that although 
the 1.8kb LYVE-1 mRNA was clearly observed in untreated cells, no message 
was detected after TNFa treatment, despite equal loading of RNA, as shown by 
the p-actin controls.
To investigate the rate of LYVE-1 mRNA loss, total RNA was isolated from 
FIDLEC cultured for 12, 24, 48 or 72h in the presence or absence of TNFa. 
Reverse transciptase-PCR was then carried out on this RNA using either LYVE-1 
or p-actin primers for 10-30 cycles. Products were run on an agarose gel and then 
transferred to nylon membrane for Southern blotting using LYVE-1 or p-actin 
radiolabelled probes (figure 4.19). This revealed that loss of LYVE-1 mRNA was 
already complete by 12h of TNF treatment, consistent with the findings from 
confocal microscopy which revealed a loss of LYVE-1 surface expression and 
detection of less nascent protein in association with the biosynthetic machinery 
of the endoplasmic reticulum and Golgi after only 3h (see figure 4.17). Similarly, 
surface LYVE-1 protein was internalised within 3h and had undergone 
substantial degradation by 12h. Thus the down-regulation of both LYVE-1 
mRNA and protein occur concurrently.
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Figure 4.18 Effect of TNFa on LYVE-1 mRNA in primary HDLEC. A Northern blot of total RNA 
isolated from HDLEC cultured for 72h +/- TNFa, (10ng/ml) was probed with either LYVE-1 or p- 
actin 32P-labelled cDNAs, followed by autoradiography. An RNA ladder was electrophoresed in 
parallel and size markers in bases are indicated on the left.
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Figure 4.19 Effect of TNFa on LYVE-1 mRNA levels in primary HDLEC, assessed  by semi- 
quantitative PCR. First strand cDNA prepared from primary HDLEC cultured for varying time 
periods (12-72h) with or without TNFa were subjected to RT-PCR using LYVE-1 primers 269F and 
764R or (3-actin primers from 10-30 cycles prior to electrophoresis, transfer to nitrocellulose and 
hybridisation to LYVE-1 or p-actin probes (see methods, chapter 2). Samples in which the cDNA 
was omitted (C) were included as negative controls.
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4.2.5 Investigating possible involvement of NFkB in TNFa-induced down- 
regulation of LYVE-1
TNF is one of many inducers of NFkB, the inducible eukaryotic transcription 
factor (Bowie and O'Neill, 1999). Other activators of NFkB include viral and 
bacterial products, T- and B-cell mitogens, agents of cellular stress such as 
endoplasmic reticulum protein overload, UV light, oxidizing agents, cigarette 
smoke and asbestos fibres, to mention only a few on an ever expanding list. 
Within unstimulated cells NFkB exists in the cytoplasm in an inactive form, 
comprising the transcriptionally active dimer bound to an inhibitor protein, IkB. 
Although NFkB can be composed of a variety of different subunits, the majority 
of work has focused on the p50/p65 dimer and its association with hd3a (Bowie 
and O'Neill, 1999). Upon stimulation, hcBa is rapidly phosphorylated on two 
serine residues, thus targeting the inhibitor protein for ubiquitination and 
degradation by proteasome. The NFkB dimer is then released and can 
translocate to the nucleus to activate target genes by binding to kB elements 
within their promoters. NFkB may act as either an inducer or repressor of 
transcription. To explore the possibility that LYVE-1 down modulation was via 
an NFKB-dependent pathway, preliminary experiments into the effect of 
inhibitors were carried out.
Among many different inhibitors of NFkB, the compound BAY 11-7082 which 
blocks the phosphorylation of hcB-a was shown to inhibit NFKB-mediated 
induction of ICAM-1, VCAM-1 and E-Selectin in HUVEC (Pierce et al., 1999). 
Therefore BAY 11-7082 was used in preliminiary experiments to investigate the 
involvement of NFkB in TNFa-induced down-regulation of LYVE-1. To establish 
the optimal concentration of BAY 11-7082, the effects were first tested by cell 
viability. Primary HDLEC were treated for 24h and then their viability assessed
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by a trypan blue dye-exclusion assay in which dead cells were distinguished by 
their failure to exclude dye and distinct morphology (figure 4.20). BAY 11-7082 
was found to be very toxic to HDLEC at concentrations of 5pM and above, which 
were used in the paper by Pierce et al. (1999). A titration of BAY 11-7082 
concentration and dye exclusion assay was also performed on 293T cells. These 
cells also failed to exclude dye and lost adherence at concentrations of BAY-11- 
7082 of 10 pM and higher (data not shown). Therefore a concentration of 2 jaM of 
BAY 11-7082 was used for subsequent experiments. Cells were pre-incubated 
with BAY 11-7082 for lh  before the addition of TNFa. 24h later cells were lifted 
and stained for LYVE-1 expression for quantitation by flow cytometry (figure 
4.21). Although TNF-induced loss of LYVE-1 was not prevented by 
preincubation with BAY 11-7082, the inhibitor reduced the loss of LYVE-1 by 
TNFa and TNFp by 21% and 25% respectively.
While these results provided suggestive evidence to support the hypothesis that 
TNF-induced loss of LYVE-1 was mediated by NFkB, this could not be 
demonstrated conclusively by this experiment due to the toxicity of BAY 11-7082. 
An alternative, less toxic inhibitor of NFkB was therefore employed, 
prostaglandin A l, PGA1 (Rossi et al., 2000). Cells were treated with PGA1 prior 
to stimulation with TNFa and after 5h, LYVE-1 surface expression was measured 
by flow cytometry. It was found that PGA1 itself caused loss of surface 
expression (figure 4.22).
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Figure 4.20 Effect of BAY 11-7082 on HDLEC viability. Cells were cultured for 24h in EGM-2 
medium supplemented with BAY 11-7082, 0 -  20 pM. Supernatants were then removed and 
trypan blue applied. After 10 minutes the percentage of live cells was assayed in triplicate at each 
concentration of BAY 11-7082 ± standard error (upper graph). Untreated cells (panel A) excluded 
dye whilst cells treated with 10 pM or higher concentrations of BAY 11-7082 failed to exclude dye 
(panel B). Immunofluorescence staining with rabbit anti-podoplanin and goat anti-rabbit 
AlexaFluor® 594 with nuclei counterstained with DAPI revealed that unlike the untreated cells 
(panel C), cells which had been exposed to BAY 11-7082 became largely de-nucleated and 
permeable to antibody (panel D). Magnification: X100.
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Figure 4.21 Effects of BAY 11-7082 on TNF-induced shedding of LYVE-1 in HDLEC. Cells 
were incubated for 1h with BAY 11-7082, 2 pM prior to addition of either TNFa, (10 ng/ml) or 
TNF{3, (100 ng/ml). Cells were incubated for 24h, then lifted and stained with the LYVE-1 mAb 8C 
and goat anti-mouse AlexaFluor®488 for quantitation of LYVE-1 surface expression by flow 
cytometry. The bar chart shows the mean percentage of LYVE-1 positive cells ± standard error for 
cells under each condition.
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Figure 4.22 Effect of PGA1 on surface expression of LYVE-1 in HDLEC. Cells were 
preincubated with PGA1, 100pM for 1h prior to the addition of TNFa. Following a 5h incubation, 
cells were lifted and stained with 8C and goat anti-mouse AlexaFluor®488 to measure LYVE-1 
expression by flow cytometry, ± standard error.
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4.2.6 Possible effects of LYVE-1 down-regulation on HA binding
In view of the finding that inflammatory mediators down-regulate LYVE-1 in 
primary HDLEC, it was interesting to consider the possible physiological 
consequences. As described in the general introduction to this thesis (chapter 1), 
LYVE-1 expressed on primary HDLEC does not constitutively bind HA. 
Therefore subsequent experiments focused on whether LYVE-1 becomes 
functionally activated during TNFa-induced internalisation, leading to uptake 
and/or degradation of its ligand, HA.
4.2.6.1 Effects of TNFa on HA binding by LYVE-1 in HDLEC
To test this hypothesis, confocal microscopy was used to detect HA colocalisation 
with internalised LYVE-1 2h following stimulation with TNFa, as at this time 
LYVE-1 had been internalised but not degraded. As HDLEC also express CD44 
(chapter 5) which might interfere with interpretation of the results, cells were 
pre-incubated with the mAb BRIC235 which blocks HA binding by CD44 (Lesley 
et al., 1993). Following a 40-minute incubation with BRIC235 and rabbit anti­
human LYVE-1, biotinylated high molecular weight HA, > 1 MDa (prepared by 
Dr. David Mahoney, Department of Biochemistry, Oxford) and TNFa were 
added. Cells were permeabilised with saponin after 2h and HA and LYVE-1 
detected with the conjugates streptavidin-AlexaFluor®568 and AlexaFluor®488 
respectively (figure 4.23).
Internalised HA was detected in both untreated and TNFa-stimulated HDLEC. 
However, following 2h incubation in the presence of TNFa, a marginal increase 
in the amount of intracellular HA was observed, a proportion of which appeared 
to colocalise with the newly internalised LYVE-1 (figure 4.23).
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Figure 4.23 Effect of TNFa on HA internalisation by primary HDLEC. Cells were pre-incubated 
with rabbit anti-LYVE-1 and BRIC235 prior to the addition of either biotinylated HA alone (-175 
jug/ml) or with TNFa (10ng/ml). Following a 2h incubation, cells were fixed with PFA and 
permeabilised with saponin. Bound rabbit anti-LYVE-1 was detected by goat anti-rabbit 
AlexaFluor®488 (green) and biotinylated HA by streptavidin-conjugated AlexaFluor®568 (red).
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42.6.2 Effects of TNFa on HA binding by LYVE-1 in primary mouse dermal LEC
The previous experiment indicated that HDLEC internalise HA and that the 
extent of uptake was marginally increased in response to TNFa, perhaps via 
LYVE-1. To further investigate this, primary mouse dermal LEC were used 
(described more fully in chapter 5). These cells were fresh isolates at a much 
earlier passage than HDLEC and consequently did not express CD44. Resting 
and TNFa-treated mouse LEC were assayed for their capacity to internalise 
fluorescent high molecular weight (> lMDa) HA using both flow cytometry 
(figure 4.24) and confocal microscopy (figure 4.25).
Figure 4.24 shows that a small but significant number of cells (5.4%) either bound 
or internalised fluorescent HA and this number increased (11.6%) following 
stimulation for 2h with TNFa. To assess whether this fluorescence represented 
internalised HA, confocal microscopy was used and revealed that fluorescent 
HA was internalised by LYVE-1-positive mouse LEC, both in the resting state 
and following TNFa stimulation (figure 4.25). As with the human cells, some 
colocalisation between LYVE-1 and HA was visible, although no dramatic 
increase in intracellular HA was apparent following incubation with TNFa. In 
summary, the internalisation of HA by LYVE-l-positive primary mouse dermal 
LEC has been shown and future experiments to address the mechanism of this 
and possible involvement by LYVE-1 and TNFa-induced activation could seek to 
explore this phenomenon more fully.
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Figure 4.24 Binding of fluorescent HA by primary mouse dermal LEC. Cells were cultured in 
the presence of fluorescent HA, (lOpg/ml), prior to lifting with PBS-5mM EDTA and assaying either 
bound or internalised HA by flow cytometry. Resting cells are shown in black and TNFa- 
stimulated (10ng/ml) cells in blue. 5.4% of resting cells bound fluorescent HA whereas 11.6% of 
cells bound HA following 2h of stimulation with TNFa.
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Control TNFa
Figure 4.25 immunofluorescence microscopy to demonstrate that fluorescent-HA is 
internalised by primary dermal mouse LEC. Cells were pre-incubated with fluorescent-HA and 
the anti-LYVE-1 mAb C1/8 prior to culturing in either the presence or absence of mouse 
recombinant TNFa, 10Ong/ml. Cells were then fixed with PFA, permeabilised with saponin and 
LYVE-1 was detected using AlexaFluor®568 (red) goat anti-rat secondary antibody. 
Representative images were captured at a magnification of X 600. Bar = 72pm.
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4.2.7 Effect of IL-6 on LYVE-1 expression on HDLEC
Earlier experiments had shown a marginal increase of LYVE-1 expression on 
HDLEC following exposure to IL-6. LYVE-1 surface expression was found to 
increase on both PromoCell HDLEC (figure 4.4) and Clonetics HMVEC (figure 
4.5). To assess the possible significance, this was characterised further using 
PromoCell HDLEC.
4.2.7.1 Concentration dependence
HDLEC were cultured for 48h in varying concentrations of IL-6, from 0-20 
ng/ml. Cells were then lifted and stained for LYVE-1 expression for quantitation 
by flow cytometry. Figure 4.26A shows the IL-6 concentration-dependent 
increase in the number of LYVE-1 positive cells, with the maximal increase 
occurring at 10-20 ng/ml. The FACS histograms are displayed in figure 4.26B 
and show the marginal increase in both the number of LYVE-1 positive cells and 
the amount of protein expressed.
4.2.72 Time-course
The effect of IL-6, 20ng/ml, on surface expression was quantitated using flow 
cytometry after 0, 6, 12, 24, 48 and 72h of exposure. Figure 4.27 shows that 
LYVE-1 surface expression steadily increased up to 72h after exposure. These 
results further strengthen the evidence that IL-6 induces or otherwise stabilises 
LYVE-1 expression in HDLEC. Although not pursued further in this present 
thesis, the potential significance or these findings are discussed later in the 
chapter (section 4.3).
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Figure 4.26 Effect of IL-6 on LYVE-1 surface expression in HDLEC. A. Cells were cultured in 
the presence of recombinant human IL-6 at concentrations between 0 and 20 ng/ml for 48h in 
triplicate. Cells were then lifted and stained with 8C and goat anti-mouse AlexaFluor®488. LYVE- 
1 expression as represented by mean fluorescence was assayed by flow cytometry and the mean 
of triplicate samples is expressed ± standard error. B. Flow cytometry plots of LYVE-1 expression. 
Untreated cells are represented by a green line; cells treated with IL-6, 20 ng/ml are shown in blue. 
Staining using isotype-matched control antibody is shown in black.
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Figure 4.27 Time course of effect of IL-6 on LYVE-1 expression on HDLEC. Cells were treated 
with IL-6, 20 ng/ml, in triplicate for between 6 and 72h; some cells were left untreated. Cells were 
then lifted and stained with 8C and goat anti-mouse AlexaFluoKD488. LYVE-1 expression as 
represented by mean fluorescence was assayed by flow cytometry and the mean of triplicate 
samples is expressed ± standard error.
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4.2.8 Effect of hypoxia on HDLEC
Hypoxia is known to have a dramatic effect on protein expression and cell 
biology in blood vascular endothelial cells. To determine whether hypoxia might 
influence HDLEC in some manner, preliminary experiments sought to address 
the effect of hypoxia on LYVE-1 expression. HDLEC were cultured for 14h in 
either normoxic conditions or hypoxic conditions (0.1% oxygen). Cells were 
lifted and stained for LYVE-1, podoplanin or carbonic anhydrase-9, CA9 (an 
indicator of hypoxic shock on endothelial cells) and surveyed by flow cytometry 
(figure 4.28). CA9 was induced following hypoxic shock as expected. 
Interestingly, the levels of LYVE-1 expression were decreased by 40% under 
hypoxic conditions, whereas the levels of podoplanin (included as a control) 
remained unchanged.
4.2.9 Effect of PMA on LYVE-1 expression.
In addition to the pro-inflammatory down-regulation of LYVE-1 expression on 
HDLEC, LYVE-1 expression might also be altered through a different signal 
cascade, the MAPK pathway, by the diacylglycerol analogue PMA (detailed in 
the introduction to this chapter). It was of interest to determine whether the 
phenomenon of PMA-induced MMP-dependent shedding of LYVE-1 by 293T 
human fibroblast transfectants (S. Clasper and D. G. Jackson, unpublished; Tom 
Nightingale, DPhil thesis, University of Oxford, 2004) also occurred in human 
LEC which expressed endogenous LYVE-1 and whether it was via the same 
mechanism.
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Figure 4.28 Effect of hypoxia on LYVE-1 expression in primary HDLEC. Cells were cultured 
for 14h either under normal conditions, i.e. 20% 02,5% CO2 at 37°C in a humidified incubator, or at 
0.1% O2, 5% CO2 at 37°C in a humidified incubator. Cells were then lifted and stained in triplicate 
using either mouse anti-CA9, rabbit anti-podoplanin or 8C and the appropriate goat 
AlexaFluor®488 conjugate for quantitation by flow cytometry. Normoxic expression is shown in 
green, hypoxic in blue and isotype-matched controls in black. Representative histograms for each 
are shown in the upper panel. The percentage positive cells were calculated from the gates 
indicated by a black horizontal line on the histograms, discounting cells stained by the isotype 
control antibodies. The mean percentage of positive cells for each protein ± standard error is 
plotted in the lower panel.
LYVE-1 expression 
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4.2.9.1 The effect of PMA on LYVE-1 shedding in HDLEC
To investigate the whether or not any shedding of LYVE-1 occurred upon 
stimulation of PKC, HDLEC were treated with PMA for 4h prior to the removal 
of supernatant. The presence of shed LYVE-1 in the supernatant was assayed by 
an ELISA calibrated by soluble LYVE-1 Fc. Supernatant samples were applied in 
triplicate to a microtitre plate pre-coated with rabbit anti-human LYVE-1. Bound 
antigen was detected by the mouse anti-human LYVE-1 mAb 8C and goat anti­
mouse HRP-conjugate with OPG substrate. As shown in figure 4.29, LYVE-1 
was shed upon stimulation with PMA and soluble LYVE-1 was detected in 
medium. Less shed LYVE-1 was detected in the supernatant from HDLEC than 
from 293T transfectants largely because 293T grow to greater densities and the 
transfectants expressed elevated levels of LYVE-1 in comparison to those 
endogenously expressed in HDLEC.
4.2.9.2 Involvement of matrix metalloproteases
The previous experiment had shown that PMA stimulated shedding of LYVE-1 
from HDLEC as had been found originally on 293T transfectants. Therefore it 
was deemed likely that shedding was occurring through a very similar process, 
namely by matrix metalloproteinases. To test this hypothesis, HDLEC were 
preincubated for 2h with the MMP inhibitor Ilomastat and then incubated with 
PMA, prior to lifting and staining for LYVE-1, for quantitation by flow cytometry 
(figure 4.30). The results revealed that Ilomastat blocked shedding by 47%. 
Hence it was concluded that PMA-stimulated shedding is mediated by MMPs 
and is distinct from the mechanism that down-regulates LYVE-1 surface 
expression in response to TNFa.
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Figure 4.29 Effect of PMA on LYVE-1 shedding. HDLEC and 293T human LYVE-1 transfectants 
were cultured in triplicate for 4 h in either the presence or absence of PMA, 20ng/ml; supernatants 
were harvested and applied to a microtitre plate which was precoated with rabbit anti-human 
LYVE-1. Bound protein was detected using 8C and an HRP-conjugated goat antibody with OPG 
substrate. Protein was quantitated using soluble LYVE-1 Fc at known dilutions and the values are 
expressed ± standard error.
222
Chapter 4 Expression of LYVE-1 in lymphatic endothelial cells 4.2 Results
3 5  - i
I f  3 0
sa>S
5
S  2 5
s
s
S 20
s0
•35 15cnSbax
Z  101m >>< 5  -
C o n t r o l  P M A  D o m a s t a t  I l o m a s t a t  +
P M A
Figure 4.30 Effect of Ilomastat on PMA-induced shedding of LYVE-1 from HDLEC. Cells were 
preincubated with Ilomastat, 25 pM, for 2 h prior to the addition of PMA, 20ng/ml. Following a 4h 
incubation, cells were lifted and stained in triplicate with 8C and goat anti-mouse AlexaFluoKE)488 
to measure LYVE-1 surface expression by flow cytometry. The mean fluorescence of cells from 
each condition was plotted ± standard error.
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4.3 Discussion
4.3.1 Preliminary phenotyping of HDLEC
The primary aim of this chapter was to determine factors which regulated 
expression of LYVE-1 on primary human dermal lymphatic endothelial cells, 
(HDLEC) in culture. The cells upon which the majority of these studies were 
carried out were derived from commercial human dermal microvascular 
endothelial cells (HDMEC) that contained a mixture of both lymphatic (LEC) and 
blood vascular endothelial cells (BEC). These cells gave rise to a predominantly 
LEC phenotype with continuous culture and thus at later passages of 12 and 
above, virtually all cells expressed the LEC markers podoplanin, prox-1, the pan- 
endothelial cell marker CD31 and retained expression of LYVE-1. A loss of 
LYVE-1 expression was observed in other primary endothelial cell lines at higher 
passage numbers.
The outgrowth of BEC by LEC described in this thesis is similar to that reported 
by Nisato et al. (2004), in a manuscript published during the later stages of this 
PhD. These researchers also investigated the phenotype of commercially 
available HDMEC and demonstrated outgrowth by LEC, resulting in a pure LEC 
population at later passages, defined by expression of podoplanin. However, in 
contrast to the finding described in this thesis, Nisato et al. reported optimal 
yields of LEC from HDMEC purchased from Clonetics rather than PromoCell. 
The likely explanation for the differences in results is batch to batch variation 
between commercial HDMEC preparations in terms of initial LEC/BEC ratios 
and that LEC can in fact be isolated from either source.
The molecular basis to explain the phenomenon of outgrowth by one cell 
population over another was very recently partially elucidated by Groger et al.,
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2004. They demonstrated that podoplanin-selected LEC constitutively express 
IL-3, a broadly acting cytokine which regulates haematopoietic cell 
differentiation. The endogenous supply of cytokine was found to be responsible 
for maintaining a LEC phenotype in culture and regulated both expression of 
prox-1 and podoplanin. BEC were not found to express IL-3 but addition of IL-3 
to the medium induced transdifferentiation of BEC into LEC. Thus the LEC are 
not truly outgrowing the BEC but secreting IL-3 to induce a predominantly LEC 
phenotype.
The paper by Groger et al., 2004 raises the question of how phenotypically 
similar BEC-derived LEC are to LEC which have undergone no such 
transdifferentiation. However, data obtained from experiments using PromoCell 
HDLEC showing the down-regulation of LYVE-1 by TNFa has been confirmed 
by two other human cell lines: HDMEC from Clonetics and LEC isolated by 
immunoselection with podoplanin from Dr. Ernst Kriehuber (detailed in this 
chapter), as well as in mouse primary LEC and in a murine model (described in 
chapter 5). Therefore the PromoCell HDLEC have been shown to be suitable for 
use in the in vitro characterisation of factors affecting the variability of LYVE-1 
expression on human LEC.
4.3.2 Factors affecting variability of LYVE-1 expression in cultured cells
Although PromoCell HDLEC retained expression of podoplanin and prox-1 at 
consistent levels beyond passage 12, LYVE-1 expression was found to be highly 
variable, with between 55% and 80% of cells LYVE-1 positive. This reflected the 
observation of variable LYVE-1 expression in tissues and suggests that LYVE-1 
on cultured cells may be regulated by labile factors within the medium which are 
also present in vivo. To address this observation of variability, LYVE-1 
expression on PromoCell HDLEC was measured by flow cytometry following 
culture in media supplemented with a panel of recombinant human growth
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factors, cytokines and chemokines. These were selected on the basis that they 
may come into contact with lymphatic endothelium in vivo, both under normal 
physiological conditions and also in inflammation, as the response of lymphatic 
endothelium to inflammatory stimuli had not previously been characterised. 
The growth factors FGF acidic, VEGF-C and angiopoietin-2 promoted a marginal 
increase in LYVE-1 expression, typically from 57% to 70%. However most 
strikingly, the inflammatory cytokines TNFa and TNFp precipitated a loss of 
LYVE-1 surface expression, to less than 1% and 2% respectively of the starting 
level. This result was confirmed by similar studies detailed in this chapter, 
which were carried out using HDMEC from Clonetics and LEC isolated by 
immunoselection with podoplanin from Dr. Ernst Kriehuber: both cell lines 
experienced a total loss of LYVE-1 upon stimulation with TNFa, which was 
quantitated by flow cytometry. Such a dramatic effect demanded follow-up 
experiments to characterise it fully.
4.3.3 Characterisation of TNFa-induced down-regulation of LYVE-1
Neither TNFa nor TNFp induced an apoptotic, necrotic or autophagic response 
in HDLEC. Cell viability was confirmed by the ability to exclude dye and by 
sustained expression of the lymphatic endothelial cell surface glycoprotein 
podoplanin. Moreover the rate of proliferation was unaffected and cells showed 
no greater or lesser propensity to form tubules in Matrigel™ when exposed to 
TNFa. Thus TNFa did not appear to induce lymphangiogenesis in acute 
stimulation (up to 72h) of LEC. Chronic inflammation in tissues is known to 
induce both angiogenesis and lymphangiogenesis (Fogt et al., 2004; Kaiserling et 
al., 2003; Baluk et al., 2005) and therefore stimulation of LEC by the pro- 
inflammatory cytokine TNFa might have been expected to increase proliferation 
and tubule formation. However, it is likely that other factors such as VEGF-C 
release by infiltrating macrophages induce lymphangiogenesis during chronic 
inflammation. Equally, it is not clear whether chronically inflamed lymphatics
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shown the same down-regulation of LYVE-1 as in acute inflammation. Clearly 
those issues warrant further investigation in future studies.
TNFa was found to induce a very striking change in the morphology of HDLEC, 
with confluent cultures assuming an elongated shape very distinct from the more 
rounded cobble-stone appearance of untreated cells. Other studies have shown 
that vascular endothelial cells in inflamed tissue also undergo a change in shape 
and basement membrane remodelling to aid extravasation of leukocytes but 
maintain vascular integrity, with no increase in the permeability of the 
endothelial cell monolayer or decrease in electrical resistance, (reviewed by 
Muller, 2003). The change in morphology of HDLEC suggested that the cells 
were undergoing major rearrangements in the cytoskeleton and it is tempting to 
speculate that these might facilitate leukocyte reverse transmigration in a similar 
manner to the forward transmigration seen in vascular endothelium, a 
phenomenon investigated further in chapters 5 and 6.
The dependence of down-regulation of LYVE-1 on TNFa concentration was 
demonstrated by titration: a maximal effect was attained by 5 ng/m l TNFa, 
although the loss of 50% of LYVE-1 surface expression occurred at less than 0.1 
ng/ml. Although normal plasma concentrations of TNFa are much lower than 
this, typically 5.6 pg/m l (Zinman et al. 1999), this cytokine can reach much 
higher concentrations within the tissues in disease. For example, a study by 
Calabresi et al. (2003) measured ischemia-induced cardiac TNFa in rats as 80 
pg/m g protein, as opposed to the normal cardiac TNFa concentration of 50 
pg/m g protein.
The effect of TNFa was also found to be completely reversible, thus supporting 
earlier findings that the cytokine was not inducing cell death. Cells were 
stimulated with TNFa for 48h before thorough washing and application of fresh
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medium. Expression recovered to the level measured in untreated cells by 48h, 
with a rapid increase in LYVE-1 surface expression measured by flow cytometry 
between 12 and 24h after replacement with fresh medium. Hence this would 
suggest that in vivo, LYVE-1 expression recovered once TNF was down-regulated 
and the acute phase of inflammation was over. Experiments carried out in this 
chapter may also implicate IL-6 in this recovery of expression.
IL-6 induced a marginal increase in LYVE-1 expression on HDLEC from 
PromoCell (from 57% to 73% of cells) and HDMEC from Clonetics (from 9% to 
16%). This increase in expression was found to be dependent upon the 
concentration of the cytokine, with maximal effects observed at 10-20ng/ml at 
48h. This increase was shown in both the percentage of LYVE-1 positive cells 
and the mean and median fluorescence but was not nearly as striking as the 
TNF-induced loss of expression. However, the effect of IL-6 on increasing LYVE- 
1 expression on HDLEC may play an important role in inflammation. Other 
studies have shown that a variety of peptide factors including IL-1 and TNFa 
enhance IL-6 production in fibroblasts (reviewed by Akira and Kishimoto, 1992). 
However, IL-6 suppresses LPS-induced IL-1 and TNFa production. Hence the 
concentrations of these cytokines fall in the later stages of acute inflammation, 
whilst the concentration of IL-6 rises. Therefore IL-6 may play a role in 
stimulating the recovery of LYVE-1 surface expression. IL-6 may also serve as an 
autocrine or paracrine factor for LEC differentiation, in a similar manner to IL-3 
(Groger et al., 2004). Future experiments will seek to investigate this further.
4.3.4 The mechanism for TNFa-mediated LYVE-1 down-regulation
The loss of LYVE-1 surface expression following TNFa stimulation was found to 
be due to internalisation and degradation rather than through MMP-mediated 
shedding. Untreated HDLEC were shown by ELISA to shed low levels of LYVE- 
1 constitutively; however no soluble LYVE-1 was detected in the supernatant
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following stimulation with either TNFa or TNFp and even constitutive shedding 
was abolished. Furthermore, the loss of LYVE-1 could not be prevented by 
incubation with the MMP inhibitor, Ilomastat. This contrasts with the 
mechanism of PMA-induced loss of LYVE-1 surface expression. Previous work 
in the Jackson laboratory had shown that PMA stimulated PKC and induced 
MMP-dependent shedding of LYVE-1 in 293T human fibroblast transfectants 
through MAPK signal transduction (S. Clasper and D. G. Jackson, unpublished; 
Tom Nightingale, DPhil thesis, University of Oxford, 2004). Experiments 
detailed in this chapter demonstrated that MMP-mediated shedding also 
occurred in primary HDLEC, which endogenously express LYVE-1. Thus TNFa- 
induced down-regulation is via a very different mechanism to that of PMA- 
mediated shedding and LYVE-1 expression is regulated by multiple signal 
cascades. It will be very interesting to explore the pathway involved in IL-6- 
mediated up-regulation of LYVE-1 in future experiments, as well as the 
mechanism whereby LYVE-1 is partially down-regulated in hypoxia, discussed 
later in this thesis section.
The internalisation of LYVE-1 was followed using confocal microscopy. In 
untreated cells LYVE-1 colocalised with podoplanin and was almost entirely 
restricted to the surface. After 3h of stimulation with TNFa, LYVE-1 appeared to 
be intracellular and colocalised with EEA-1, an early endosome marker and 
CD63, a lysosomal marker. More colocalisation of LYVE-1 with CD63 than EAA- 
1 was observed at this time point, suggesting a rapid internalisation and incipient 
degradation within 3h. By 48h no LYVE-1 was detected but podoplanin 
expression was retained at the cell surface. These results imply that the down- 
modulation of LYVE-1 by TNFa occurs by internalisation and transport through 
the endosomal pathway, most likely culminating in degradation within a 
lysosome (figure 4.31).
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Figure 4.31 Intracellular localisation of LYVE-1 in a resting lymphatic endothelial cell (right) 
and following TNFa stimulation (left). In an unstimulated cell, de novo synthesis of LYVE-1 is 
carried out at the endoplasmic reticulum and the protein undergoes post-translational modifications 
within the Golgi, prior to vesicular transport to the plasma membrane and expression at the cell 
surface. Following TNFa stimulation, this synthesis stops and cell surface LYVE-1 is internalised 
and transported via endosomes to a lysosome, where it is degraded.
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After stimulation with TNFa, there was a reduction in the amount of LYVE-1 
associated with the endoplasmic reticulum and the trans-Golgi network, 
suggesting a decrease in de novo synthesis. A Northern blot of total RNA isolated 
from LEC cultured for 72h either in the presence or absence of TNFa revealed 
that the major 1.8kb LYVE-1 mRNA species was only detected in RNA from 
untreated cells. Semi-quantitative PCR was used to analyse mRNA levels at 
earlier time points and revealed that the loss of LYVE-1 mRNA had occurred 
within 12h. Clearly the internalisation and degradation of LYVE-1 was coupled 
with transcriptional down-regulation, either at the level of mRNA synthesis or 
turnover. A time course to follow the loss of LYVE-1 from the cell surface 
revealed that more than half of this protein was lost within 6h and by 48h no 
LYVE-1 remained. Thus the abundance of LYVE-1 mRNA is reduced concurrent 
with the internalisation and degradation of LYVE-1. Colocalisation studies using 
the ER and Golgi markers would suggest that the down-regulation of message 
has occurred by 3h following stimulation.
4.3.5 Putative down-modulation of LYVE-1 via NFkB
Preliminary experiments to investigate the involvement of the transcription 
factor NFkB in TNF-induced down-regulation of LYVE-1 found that pre­
incubation with the NFkB inhibitor BAY 11-7082 reduced TNFa- and TNFp- 
induced loss of LYVE-1 surface expression by 21% and 25% respectively. This 
provided strong evidence that TNF down-modulated LYVE-1 through NFkB, 
although further experiments using gel shift assays will be required to prove the 
involvement of this transcription factor. The NFkB pathway is known to initiate 
a new transcription profile in a cell in response to pro-inflammatory stimulation. 
Therefore the involvement of this transcription factor following TNF stimulation 
of HDLEC would suggest a change in expression of other proteins in addition to 
LYVE-1. The nature of these changes is detailed in the next chapter of this thesis.
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The apparent cytotoxicity of BAY 11-7082 to both HDLEC and 293T was not 
found in HUVEC by Pierce et al., 1997, in the paper where the effects of BAY 11- 
7082 were originally characterised. These researchers claim that BAY 11-7082 
had no effect on the rate of proliferation of HUVEC when used at concentrations 
which in this PhD were found to be cytotoxic to HDLEC and 293T. The 
resistance of HUVEC to cytotoxicity is surprising and it would be interesting to 
carry out a trypan blue exclusion assay on such cells treated with BAY 11-7082, to 
validate the results of the proliferation assay carried out in the original study.
In several of the experiments detailed in this chapter, TNFa appeared to have a 
more dramatic effect of LYVE-1 expression than TNFp. An example of this is 
shown in the experiment involving BAY 11-7082, where following 24h of 
stimulation, TNFa had precipitated a 76% loss of LYVE-1 expression whereas 
TNFp had only induced a 55% loss. This finding is corroborated by numerous 
studies, including that carried out by Desch et al (1990) who found that the 
adhesion of neutrophils to HUVEC was more pronounce when the endothelial 
cells were stimulated with TNFa rather than TNFp. The recombinant proteins 
were both expressed in mammalian systems to allow the appropriate post- 
translational modifications and both were equipotent on a molar basis in 
producing cytotoxicity in L929 fibroblast cells. The researchers concluded that 
the difference in pro-inflammatory activity was due to primary sequence 
differences.
4.3.6 Does TNFa activate LYVE-1 to bind HA?
The physiological consequences of the TNFa-mediated internalisation and 
degradation of LYVE-1 were explored in some preliminary experiments to 
address the intriguing possibility that TNFa transiently activates HA binding 
and uptake. As discussed in chapter 1 of this thesis, LYVE-1 expressed on LEC 
does not bind HA. However, TNFa may activate LYVE-1 to precipitate binding
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and transient uptake of HA in the primary stages of inflammation. LYVE-1 has 
previously been shown to promote binding and internalisation of HA through 
receptor-mediated endocytosis in 293T transfectants (Prevo et al., 2001). As it has 
been shown in this chapter that LYVE-1 is degraded following TNFa-induced 
internalisation, TNFa-stimulated cells were examined by confocal microscopy 
after 2h, before degradation had occurred. Internalisation of HA by both 
primary human dermal LEC and primary mouse dermal LEC was shown and 
some colocalisation of HA with LYVE-1 was visible, particularly in the case of 
the human cells. However this colocalisation may be due to intracellular 
transport to the same subcellular compartment, namely the lysosomes. Uptake 
of fluorescent HA was also quantitated by FACS, which showed that a small but 
significant (approximately 5%) portion of mouse LEC were either binding or had 
internalised HA. This increased to over 11% following stimulation with TNFa, 
although expression of CD44 was also up-regulated on some cells, which may be 
responsible for some or all of the increased binding. Also, although LEC appear 
capable of internalising HA, the mechanism by which this occurs and the 
involvement, if any, of LYVE-1 remains to be determined. Future experiments 
will employ the human LYVE-1 blocking antibody 3A, to investigate whether 
incubation with these antibodies reduces HA uptake. Also it would be 
interesting to incubate HA with primary LEC isolated from the LYVE-1-/- knock­
out mouse, to determine by microscopy whether they are capable of 
internalisation of HA. This would test whether a LYVE-1 dependent mechanism 
is responsible, or either a LYVE-1 independent mechanism or a second 
compensatory mechanism is employed.
A role for LYVE-1 in the transport of HA across lymphatic endothelium has 
previously been suggested, as HA is transported from the tissues to the regional 
lymph node through lymphatic vessels and LYVE-1 was shown to mediate HA- 
intemalisation in LYVE-1 293T transfectants (Prevo et al., 2001). As LYVE-1 is
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expressed on both the luminal and abluminal faces of the lymphatic 
endothelium, it was suggested that this lymphatic-specific receptor for HA may 
act as a shuttle for transcytosis of the ligand, binding it at the abluminal face and 
releasing it into the lumen of the vessel. Uptake from the abluminal face, 
particularly in response to inflammation may be to remove low molecular weight 
fragments of HA from the interstitium to aid clearance of potentially pro- 
inflammatory signals and precipitate the resolution of acute inflammation. 
Cultured cells have their basal surface in contact with the substrate and therefore 
uptake may be more pronounced if the cells are cultured in Matrigel and 
permitted to form tubules prior to the addition of HA.
4.3.7 Investigating the response of LYVE-1 expression to hypoxia
Hypoxia is a common feature in solid tumours and is associated with aggressive 
growth, metastasis and poor response to treatment (Hockel et al., 1996; Brizel et 
al., 1996). Moreover, many human cancers are associated with pre-existing 
chronic infectious or inflammatory conditions (Schacter et al., 2002). Given that 
the data reported in this chapter has consistently shown that LYVE-1 is down- 
regulated by the pro-inflammatory cytokines TNFa and TNFp, it was of also of 
interest to examine LYVE-1 expression under hypoxic conditions. Preliminary 
studies to address this on HDLEC found that following culture for 14h under 
hypoxic conditions, a marginal decrease in LYVE-1 expression was measured, 
whilst no change in the amount of surface expression of podoplanin was 
observed. Therefore expression of LYVE-1 by HDLEC was shown to be sensitive 
to oxygen tension and future experiments will address the mechanism by which 
this occurs and whether down-regulation is more pronounced at other time 
points. LYVE-1 does not appear to possess a hypoxic response element, as if this 
were the case a more dramatic change in expression such as that seen in the 
positive control, carbonic anhydrase 9 (CA-9),would have occurred. A possible 
mechanism by which LYVE-1 is down-regulated could be via IL-la, which has
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been shown to be induced in vascular endothelium following hypoxia and up- 
regulated the adhesion molecules E-selectin and ICAM-1 upon reoxygenation, 
thus potentially altering endothelium-leukocyte adherence. Therefore it would 
be interesting to measure LYVE-1 expression in HDLEC undergoing 
reoxygenation following hypoxic shock. Studies described in chapter 5 and 6 of 
this thesis found that the adhesion molecules VCAM-1, ICAM-1 and E-selectin 
are up-regulated on lymphatic endothelium following stimulation with TNFa 
and it would also be interesting to examine the expression of these receptors on 
lymphatic endothelium following hypoxic shock.
4.3.8 Conclusion
Experiments detailed in this chapter have identified LYVE-1 as a tightly 
regulated cell surface protein on HDLEC cultured in vitro, with a putative role in 
the acute phase of inflammatory events within the lymphatics. The 
internalisation of LYVE-1 following TNFa stimulation may serve as a mechanism 
by which LYVE-1 is activated to bind HA and thus HA uptake by lymphatic 
endothelium is accomplished under pro-inflammatory conditions. Alternatively 
LYVE-1 may serve another function in addition to that of an HA receptor and 
require down-regulation in order for the inflammatory reaction of lymphatic 
endothelium to proceed. The role of LYVE-1 in inflammation was further 
explored in the experiments described in chapter 5.
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Introduction
The dramatic and specific down-regulation of LYVE-1 expression by TNFa and 
TNFp described in the previous chapter illustrates the potent effects that such 
pro-inflammatory cytokines may have on lymphatic endothelium. In this 
chapter these effects are explored further, assessing the effects of TNFa on the 
expression of other proteins relevant to cell adhesion and migration in the 
lymphatics.
5.1.1 Inflammation-induced changes in gene expression on blood vascular 
endothelium
Recruitment of leukocytes such as macrophages and dendritic cells (DCs) from 
the blood to tissues occurs in the absence of inflammation, as detailed in the 
general introduction to this thesis in chapter 1. However in the presence of pro- 
inflammatory stimuli, the vascular endothelium becomes activated to recruit an 
increased number of leukocytes from the blood, which extravasate into the 
tissues to the site of inflammation.
The response of blood vascular endothelial cells to pro-inflammatory mediators 
such as TNFa, particularly with respect to the adhesion molecules induced, has 
been extensively characterised and is detailed in chapter 1 of this thesis. Blood 
vascular endothelium is known to up-regulate the adhesion molecules E-selectin, 
which binds to complex sialylated carbohydrate groups related to the Lewis-X or 
Lewis-A family on a variety of leukocytes (reviewed by Albelda et al., 1994); 
vascular cell adhesion molecule-1 (VCAM-1), binding the integrin ligand VLA-4 
(a4pi), (Staunton et al., 1988; Springer, 1990); and intercellular adhesion 
molecule-1 (ICAM-1), binding to its integrin ligand LFA-1 (aLp2), (Rothlein et al.,
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1986). However no comprehensive study has been carried out, to date, to 
examine the expression of these adhesion molecules on lymphatic endothelium.
The increased chemokine secretion by blood vascular endothelium in response to 
pro-inflammatory stimuli has also been extensively documented, for example 
RANTES (regulated upon activation, normal T-cell expressed and secreted, 
CCL5), IL-8 (interleukin-8, CXCL8) and MCP-1 (monocyte chemotactic protein-1, 
CCL2), which may enhance the arrest of rolling monocytes on HUVEC (Gerszten 
et al., 1999). Also, in addition to enhanced adhesion of T-cells, secretion of MIP- 
ip (macrophage inflammatory protein-1 p, CCL3/4) by vascular endothelium was 
found to induce chemotaxis and further recruit circulating leukocytes from the 
blood (Tanaka et al., 1993).
To aid the extravasation of leukocytes from the blood, vascular endothelial cells 
undergo a change in shape but without compromising vascular integrity 
(reviewed by Muller, 2003). These endothelial cells also undergo extensive 
remodelling of cell-cell junction to control leukocyte diapedesis. For example the 
transmembrane immunoglobulin superfamily member CD31 is redistributed 
from the intercellular junctions, perhaps as a means of regulating the 
transmigration of leukocytes (Romer et al., 1995). Furthermore anti-CD31 
antibodies have been shown to block transmigration (Muller et al., 1993), as have 
antibodies against CD99, a transmembrane glycoprotein also found at 
endothelial cell-cell junctions (Schenkel et al., 2002).
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5.1.2 Aims
The active role played by blood vascular endothelium in recruiting increased 
number of leukocytes to inflamed tissue has been shown extensively in previous 
studies. However the mechanisms whereby these newly recruited cells, (such as 
those which have differentiated from monocytes into professional antigen 
presenting cells), leave the tissue via lymphatic capillaries to travel to the lymph 
nodes remain to be characterised. Data from the previous chapter of this thesis 
had indicated that lymphatic endothelial cells respond to the pro-inflammatory 
TNFa with a marked change in morphology, indicative of cytoskeletal 
rearrangement, as well as a dramatic down-modulation of LYVE-1, the lymphatic 
endothelial specific HA receptor. Experiments detailed in this chapter examined 
the inflammation-induced change in expression of molecules in primary 
lymphatic endothelial cells in vitro, which may be involved in reverse- 
transmigration of leukocytes across lymphatic endothelium from inflamed tissue.
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Results
5.2.1 Effect of proinflammatory cytokines and chemokines on expression of 
leukocyte adhesion molecules in primary HDLEC
The previous chapter describes the derivation of a pure population of LEC from 
a mixed population of human dermal microvascular cells purchased from 
PromoCell. These cells proved to be well adapted to culture and retained 
expression of the lymphatic markers LYVE-1, podoplanin and prox-1. It was also 
found that when stimulated with TNFa and TNFp, LYVE-1 was dramatically 
down-regulated. However, there is comparatively little known about the 
identities of other cell surface receptors or adhesion molecules expressed by 
lymphatic endothelial cells, or how their levels might be affected by 
inflammatory mediators.
To initiate such a study, the expression of key leukocyte adhesion molecules 
ICAM-1 and VCAM-1 on resting and cytokine-treated primary HDLEC in 
culture was investigated. The expression of these receptors is known to be 
regulated by inflammatory cytokines in blood vascular endothelium and it was 
of interest to examine whether their expression was similarly regulated on 
primary HDLEC.
HDLEC were cultured for 24h in either unsupplemented medium or in the 
presence of one of the following cytokines or chemokines: IL-la, IL-2, IL-6, IL-8, 
TNFa, TNFp, IFNy, MIP-3a or LPS. Cells were then assayed by flow cytometry 
for the expression of VCAM-1 and ICAM-1 (figures 5.1 and 5.2).
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Figure 5.1 Effects of inflammatory cytokines on VCAM-1 and ICAM-1 expression in cultured primary 
HDLEC. Cells were cultured for 24h with individual cytokines or LPS as indicated (see methods), then lifted 
with PBS-5mM EDTA and stained using either mouse anti-VCAM-1 (BD Pharmingen, mAb: 51-10C9, upper 
graph) or anti-ICAM-1 (Serotec, lower graph) or a mouse lgG1 isotype-matched control, with 
AlexaFluor®488 goat anti-mouse conjugate to permit detection by flow cytometry. Samples were cultured 
and stained in triplicate, with an isotype-matched control for each cytokine/chemokine which exhibited a 
mean fluorescence <1.0. Data plotted represent the mean fluorescence, ± standard error.
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Figure 5.2 Representative FACS histogram plots to show up-regulation of VCAM-1 and ICAM-1 
on HDLEC following stimulation under pro-inflammatory conditions. Expression on untreated 
cells is shown in black, cytokine/chemokine-treated cells in blue and the isotype-matched control as a 
dotted black line.
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Virtually no VCAM-1 was detected on untreated cells but following stimulation 
with TNFa and TNFp, expression was induced 19 fold and 13 fold respectively. 
In contrast, low to intermediate levels of ICAM-1 were detected even on 
unstimulated cells. However treatment with TNFa or TNFp resulted in a 14 fold 
and 6 fold up-regulation of ICAM-1 expression, which also increased in response 
to IL-la, IFNy and LPS, albeit to a lesser extent (3-4 fold). No such effects on 
expression of either molecule were observed in response to IL-2, IL-6 or the 
inflammatory chemokines IL-8 and MIP-3a (CCL20). As TNFa was the most 
potent inducer of both VCAM-1 and ICAM-1 expression, as well as inducing the 
down-modulation of LYVE-1 characterised in chapter 4, all subsequent 
experiments involved this pro-inflammatory cytokine.
5.2.2 Kinetics of adhesion molecule up-regulation in primary HDLEC
To establish the kinetics of adhesion molecule expression induction in primary 
HDLEC by TNFa, surface expression of VCAM-1 and ICAM-1 was assessed by 
flow cytometry between 0 and 48h following TNFa stimulation. Expression of E- 
selectin was also measured, as this molecule is known to be involved in the 
preliminary attachment of leukocytes to inflamed vascular endothelium prior to 
VCAM-1- and ICAM-l-mediated interactions.
Results (figure 5.3) show that E-selectin had undergone a considerable (6-7 fold) 
induction by 6-12h but was much more transient than either ICAM-1 (reaching 
maximal expression at 12h) or VCAM-1 (peaking at around 24h), both of which 
are more sustained. The gradual increase in the expression of adhesion 
molecules following exposure TNFa suggests new protein synthesis rather than 
translocation of existing protein to the cell surface. This response of de novo 
synthesis supports the array analysis data indicating a new expression program 
in lymphatic endothelium induced by inflammation.
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Figure 5.3 Time course to follow the up-regulation of VCAM-1, ICAM-1 and E-Selectin on primary 
HDLEC. Samples of HDLEC were cultured in triplicate for between 0 and 48h in TNFa (10ng/ml)- 
supplemented medium, then lifted with PBS-5mM EDTA and stained with either anti-VCAM-1 (mAb: 51- 
10C9), anti-ICAM-1 (mAb: PIW16), anti-E-selectin (BIIG-E4) or an isotype-matched control. Goat anti­
mouse AlexaFluor 488 was used to detect bound antibody for quantitation of protein by flow cytometry. 
Irrelevant isotype-matched controls were included at each time point, with mean fluorescence <1.0. 
Data shown represent mean fluorescence, ± standard error.
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5.2.3 Effects of TNFa on other key leukocyte adhesion molecules
Given the dramatic response to TNFa of ICAM-1 and VCAM-1 expression on 
HDLEC, it was of interest to establish whether other adhesion molecules 
involved in leukocyte adhesion and transmigration were also expressed on 
HDLEC and whether their expression level was altered by cytokine treatment. 
To achieve this, HDLEC were screened with a large panel of mAbs to a variety of 
proteins including the Ig superfamily receptors ICAM-2 and ICAM-3, the 
integrins a3, a4, a6 and pi, as well as the junctional adhesion molecule JAM-1 
(table 5.1). For some adhesion molecules, more than one antibody was used, to 
ensure that an antibody suitable for use in flow cytometry was employed. 
Representative FACS histogram profiles are shown in figure 5.4. A summary of 
proteins detected and the antibodies used is shown in table 5.1.
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Figure 5.4 Effect of TNFa on expression of adhesion molecules in primary HDLEC. Cells 
were cultured in triplicate in either medium alone (black line) or in the presence of TNFa, 10ng/ml 
(blue line) for 48h prior to lifting with PBS-5mM EDTA and staining with the antibodies as indicated 
in the figure (see also table 5.1). Irrelevant isotype-matched antibodies were included as controls 
(dotted lines). AlexaFluor®488 conjugates were used for detection and representative histograms 
are shown (MFI = mean fluorescence intensity). Where more than one antibody was used, the 
hybridoma name is shown in brackets. Cells stained using D2/40 were fixed in formaldehyde prior 
to staining, as detailed in the methods. As positive controls for the efficacy of stimulation by TNFa, 
some cells were also stained for LYVE-1 using 8C , as well as VCAM-1 and ICAM-1. (Histograms 
continued on following page)
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Adhesion
molecule
Antibody
name
Expression level in primary 
HDLEC (mean fluorescence)
Control +TNFa
Xfold
change
a3 Integrin 1A3 238.41 218.74 -0.92
a4 Integrin 7.2 28.76 36.86 + 1.28
a6 Integrin MP4F10 33.51 38.32 +1.14
a9pi Integrin Y9A2 3.36 2.51 -1.34
aVp3 Integrin 23C6 57.13 71.69 + 1.24
aMp2 Integrin 24 3.54 3.08 -1.15
aMP2 Integrin TS2/4.1.1 4.41 2.98 -1.48
CD44 El/2.8 683.64 1083.92 + 1.59
E-Selectin BHG-E4 2.94 4.51 + 1.53
ICAM-1 PIW16 35.8 561.34 15.68
ICAM-2 B-Tl 371.86 150.62 -2.47
ICAM-3 ICAM3.2 2.41 2.07 -
JAM-1 3b8 62.09 69.38 + 1.12
LYVE-1 8C 29.88 2.97 - 10.01
Podoplanin polyclonal 135.65 141.73 + 1.04
Podoplanin D2-40 36.09 38.8 + 1.08
Sialoadherin HSn 7D2 8.43 7.24 -1.16
pi Integrin P5D2 2.57 2.78 _
pi Integrin TS2/16 4.01 2.81 -1.43
Tie-2 4g8 5.18 5.82 + 1.12
VCAM-1 MCA 907 1.94 10.4 + 5.36
VCAM-1 51-10C9 2.58 14.75 + 5.72
VE-Cadherin CAD-5 104.3 119.77 + 1.15
Table 5.1 Quantitative analysis of adhesion molecule expression in primary HDLEC. Values 
of mean fluorescence obtained by flow cytometry from the histogram plots shown in figure 5.4. 
Isotype-matched antibodies gave values of mean fluorescence of 2.0 or less.
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Results from these experiments show that in addition to the marked up- 
regulation of the leukocyte adhesion molecules VCAM-1 and ICAM-1, E-selectin 
(involved in leukocyte tethering in vascular endothelium) was also up-regulated 
1.5 fold. The data also show that ICAM-2, an alternative receptor to ICAM-1 for 
the integrin LFA-1 (aLp2), is expressed. ICAM-2 is implicated in constitutive 
trafficking across blood vascular endothelium. Intriguingly ICAM-2 is down- 
modulated (2.5 fold) following stimulation with TNFa, as has been reported on 
vascular endothelium (McLaughlin et al., 1998). No ICAM-3 expression was 
detected in primary HDLEC, confirming an earlier study by Doussis- 
Anagnostopoulou et al. (1993), which found that ICAM-3 expression rarely 
occurs on endothelium but may be induced by an unidentified cytokine- 
mediated mechanism in lymphoid neoplasms. The experiment detailed in this 
thesis has shown that TNFa is not involved in the in vitro induction of ICAM-3 in 
primary lymphatic endothelial cells.
Expression of the integrins a3, a4, a6 and aVp3 was also detected, particularly a3 
integrin, which exhibited very high levels of expression, typically 10 fold high 
than those of other integrins. The known ligands of a3 integrin include 
fibronectin, laminin and collagens, whilst a4 integrin interacts with fibronectin, 
a6 integrin with laminin and aVp3 with vitronectin, fibrinogen, von Willebrande 
factor, thrombospondin, fibronectin, osteopontin and collagen (Lodish et al., 
1995). Thus these integrins connect cells with the extracellular matrix. Curiously 
only very low levels of pi integrin were detected, suggesting that the antibodies 
used do not detect the particular splice variants of pi integrin expressed by 
primary HDLEC. Alternatively the a integrins detected may form heterodimers 
with integrins other than pi in primary HDLEC, for example a6p4 and a4p7. 
Integrin a4 (with pi or p7) may also play a role in leukocyte adhesion through 
interactions with VCAM-1. However no significant change in expression 
occurred following stimulation with TNFa.
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High expression of the junctional molecules JAM-1 (also known as JAM-A) and 
vascular endothelial-cadherin (VE-cadherin, or cadherin-5) were detected in 
primary HDLEC. JAM-1 and VE-cadherin are known to be associated with tight 
junctions and adherens junctions respectively. However no significant change in 
the level of surface expression was detected. Low levels of expression of the 
angiopoietin receptor Tie-2 were detected on primary HDLEC, confirming an 
earlier study by Kriehuber et al. (2001), in which Tie-2 was detected by both 
Northern and Western analyses in primary LEC and BEC. Similarly low levels of 
sialoadhesin (siglec-1), a sialic acid-binding immunoglobulin-like lectin were also 
detected and underwent no significant change in response to TNFa.
5.2.4 Gene array analysis
To assess the effects of TNFa on LEC gene expression more comprehensively, a 
gene array analysis of LEC cultured in either the presence or absence of TNFa 
was carried out. Thus virtually the entire human genome could be surveyed for 
genes responsive to TNFa. Clearly changes in expression of other adhesion 
molecules were of particular interest and this approach was not limited by 
availability and expense of antibodies, as such analysis at the protein level would 
be. Also the array analysis allows read-out for other molecules relevant to 
inflammation, such as chemokines, cytokines and matrix metalloproteinases, that 
would be difficult to survey in large numbers by antibodies.
LEC were cultured for 72h in either the presence or absence of TNFa. Total RNA 
was prepared by RNeasy (Qiagen), figure 5.5A and double-stranded DNA 
synthesized using the Ambion aRNA kit. The same kit was used to perform in 
vitro transcription to amplify the number of original transcripts and obtain 
biotin-labelled complementary RNA (figure 5.5B), which was subsequently
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fragmented by metal-induced hydrolysis to obtain suitably sized RNA 
oligonucleotides (figure 5.5C) for application to the array.
Hybridisation to the Affymetrix® gene-chip (GeneChip® Human Genome U133 
Plus 2.0) was performed by the CR-UK microarray facility at the Paterson 
Institute for Cancer Research. The probe sets represented on the array were 
derived from sequences selected from GenBank®, dbEST and RefSeq. This single 
array provided comprehensive coverage of the transcribed human genome and 
permitted the analysis of the expression level of over 47,000 transcripts and 
variants, including 38,500 well-characterised human genes.
Each GeneChip® probe array consisted of many probe cells, each containing 
millions of copies of oligonucleotide probes. The biotinylated, fragmented target 
RNA was applied to the probe array in a hybridization cocktail containing 
blocking agents BSA and herring sperm DNA, along with probe array controls. 
The controls consisted of known amounts of biotinylated prokaryotic genes and 
permitted assessment of the performance of hybridisation, washing and labelling 
procedures. Following a 16h incubation, the probe array underwent automated 
washing with non-stringent and then stringent wash buffers on a Fluidics station 
operated by Affymetrix® Microarray Suite software. Targets were labelled using 
streptavidin phycoerythrin (SAPE) and washed, all on the Fluidics station with 
Microarray Suite. The probe array was then scanned using a laser. The amount 
of light emitted at 570nm is proportional to the bound target and the software 
defined the probe cells whilst measuring the intensity of each. Data was 
normalised and scaled according to the intensity of signals from the house­
keeping genes GAPDH, p-actin and ISGF-3 (STAT1), which show consistent 
levels of expression over a diverse set of tissues.
Duplicate sets of complementary RNAs (cRNA) were prepared and the quality of 
each probe cRNA was assessed by comparing the ratio of 5' to 3' ends: ratios
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greater than 1.0 indicate degradation of probe RNA. Researchers at the Paterson 
Institute found that the quality of RNA yielded by the Ambion kit was highly 
variable and thus this method was replaced by preparation of complementary 
RNA at the Institute from total RNA supplied. Thus, RNA was prepared as 
before from HDLEC cultured either in EGM-2 alone or supplemented with TNFa 
and cRNA was synthesized at the Patterson Institute. Triplicate sets of data were 
obtained and are summarized in table 5.2.
Analysis of the data confirmed findings obtained from earlier FACS analyses 
which had shown induction of VCAM-1, ICAM-1 and E-selectin expression. The 
abundance of these transcripts increased 4-177 fold following stimulation with 
TNFa. Similarly down-regulation of LYVE-1 was also borne out in this 
experiment, confirming the Northern blot analysis and semi-quantitative reverse- 
transcriptase PCR experiment described in chapter 4. Interestingly, the array 
analysis also showed that LYVE-1 underwent the most dramatic down- 
regulation of all the transcripts surveyed on this array. No significant change 
was observed in integrins oc3, a4, a5, a9 or (31 transcripts, although these were 
detected in both untreated and TNFa-treated cells. aV integrin transcript was 
found to be induced almost 3 fold, although only a 1.2 fold increase in expression 
was detected by FACS.
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Figure 5.5 Preparation of RNA for hybridisation to the Affymetrix® gene-chip. RNA from HDLEC 
cultured for 72h in either the presence or absence of TNFa was prepared (RNeasy, Qiagen), panel A. 
Synthesis of double-stranded cDNA and in vitro transcription was performed using the Ambion aRNA 
kit, to obtain biotin-labelled complementary RNA (panel B), which was fragmented to obtain RNA 
oligonucleotides (panel C) for application to the array. Approximately 3 pg of RNA at each step was 
subjected to electrophoresis on a 1% agarose-TBE gel in 70% formamide buffer. DNA ladders were 
electrophoresed on the same gels and the size (kb) of bands are indicated.
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Genes up-regulated
Adhesion Molecules Fold change
VCAM-1 177.17
ICAM-1 16.99
Claudin-1 5.30
E-Selectin 4.03
Integrin aV 2.72
Claudin-14 2.34
Desmoplakin 1.91
Chemokines, Growth 
Factors and Cytokines
MCP-1 (CCL2) 131.03
GCP-2 (CXCL6) 48.84
ENA-78 (CXCL5) 44.58
RANTES (CCL5) 44.46
MIP3a (CCL20) 28.91
IL-8 (CXCL8) 21.87
I-TAC (CXCL11) 11.79
Fractalkine (CX3CLI) 10.55
IL-la 9.05
GM-CSF (CSF-2) 7.72
IP-10 (CXCL10) 5.64
IL-15 4.80
VEGF-C 4.37
TNFS6 3.88
IL-ip 3.26
M-CSF (CSF-1) 3.21
TNFS13 3.19
TNFS4 2.15
TNFS18 2.15
CXCL16 2.13
FGF-5 2.05
Extracellular Matrix 
Molecules
Fold change
Reelin 2.77
Syndecan-4 1.82
Matrix Fold change
Metalloproteases
MMP10 5.65
MMP19 2.93
ADAM8 2.16
MMP9 2.13
ADAM9 1.43
ADAM17 1.42
Receptors
CD69 5.18
TNFRS4 4.67
C-type lectin-like 3.21
receptor-1
IL-7R 3.16
Miscellaneous
Diubiquitin 122.36
TRAF-1 10.46
TNFAIP3 10.41
NFkB2 5.23
NFkB3 3.49
TNFAIP2 3.46
TNFAIP1 2.58
TANK 2.22
TNFAIP6 2.13
NFkBI 2.09
Podoplanin 1.42
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Genes down-regulated
Adhesion Molecules Fold change
LYVE-1 94.65
Endomucin-2 18.32
Multimerin 18.12
Integrin 05 2.31
ICAM-2 2.23
Integrin a8 1.04
CD31 1.98
Integrin 04 1.83
Integrin ocE 1.67
Plakoglobin 1.63
Connexin-37 1.58
Integrin alO 1.48
Integrin a6 1.44
Chemokines and 
Growth Factors
HCC-1 (CCL14) 2.73
FGF basic 1.56
FGF acidic 1.49
Extracellular Matrix 
Molecules
Fold change
Semaphorin sem2 4.58
Syndecan-2 3.07
Versican 2.16
Tens in 1.97
Glypican 1.95
Matrix
Metalloproteases
ADAMTS-1 4.06
MEIH1 3.24
MMP16 1.78
Receptors
CXCR4 (Fusin) 6.61
Endoglin 1.90
Flt4 1.63
IL1R1 0.68
Mannose receptor, C 
type 1
1.44
Miscellaneous
Prox-1 5.28
vWf 3.51
Table 5.2 Representative data from Affymetrix® array analysis in HDLEC. Cells were cultured 
in triplicate +/- TNFa, 10ng/ml for 72h. Total RNA was prepared from each sample and 
complementary, biotinylated RNA synthesised at the Patterson Institute, for application to the gene- 
chip. Data was normalised and mean values of expression for each transcript calculated from the 
triplicate samples. Fold changes in expression induced by TNFa are shown for each transcript.
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The dramatic up-regulation of transcripts encoding the leukocyte inflammatory 
chemokines MCP-1, RANTES and MIP-3a suggested lymphatic endothelial cells 
may play a role in promoting migration of leukocytes during inflammation. 
Kriehuber et al. (2001) had detected TNFa-stimulated induction of MIP-3a and 
MCP-1 in LEC at the protein level. However, data from the microarrays in this 
current thesis indicate that a wide range of other chemokines were also induced 
(2-50x fold) including the CXC chemokines GCP-2, ENA-78, IL-8, I-TAC, IP-10 
and CXCL16, as well as the CX3C chemokine fractalkine and the 
monocyte/macrophage chemoattractant CSF-1. No significant changes in 
transcript levels were seen for SLC, the main constitutive chemokine thought to 
regulate trafficking of CCR7-positive dendritic cells to the lymph nodes through 
afferent lymphatics (and also implicated in recruitment of naive T cells across 
HEVs). In addition to chemokines, the matrix metalloproteinases MMP9 
(gelatinase B), MMP10 (stromelysin-2), MMP19 and the enzyme ADAM8 were 
significantly induced (2-5 fold) by TNFa. These molecules are associated with 
many diverse functions including leukocyte trafficking and regulation of 
chemokine activity. Numerous TNF receptor associated proteins such as TNF 
receptor-associated factor-1 (TRAF-1) and TNF associated proteins-1, -2 and -3 
(TNFAIP-1, -2 and -3), involved in signal transduction are also up-regulated, 
which have never been characterised in lymphatic endothelium before to date. 
NFkB transcripts also increased.
In addition to LYVE-1, other genes downregulated by TNFa included the 
secretory granule protein multimerin, the L-selectin ligand endomucin, the type I 
mannose receptor and p5 integrin. Transcripts of the adherens junction 
components plakoglobin and CD31 also decreased in abundance, as did the gap 
junction molecule connexin-37, suggestive of a loosening of cell-cell junctions 
prior to leukocyte transmigration. Intriguingly the transcription factor Prox-1 
underwent down-regulation by over 5 fold. This result was unexpected as this
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protein has never been implicated in inflammation but rather is more commonly 
associated with establishing a lymphatic endothelial lineage, triggering 
embryonic lymph bud development and lymphatic endothelial cell 
differentiation.
Data from this array analysis demonstrate that lymphatic endothelial cells 
respond to the pro-inflammatory cytokine TNFa with major changes in the 
expression of genes associated with leukocyte adhesion and trafficking. In this 
way lymphatic endothelium possesses an inflammation-induced expression 
program similar to that seen in the blood vasculature.
5.2.5 Kinetics of induction of chemokine synthesis in primary HDLEC
The Affymetrix array analysis had demonstrated that synthesis of chemokines 
transcripts such as those for MCP-1, RANTES and MIP-3a increase dramatically 
following stimulation with TNF. To determine whether these chemokines were 
expressed at the protein level and secreted, ELISAs were carried out to detect 
presence of chemokines in the supernatant of HDLEC after stimulation with 
TNFa for 6h to 48h as a time course. Another group of cells was left untreated, to 
assay for chemokine production in unstimulated cells. A negative control of 
tissue culture medium (EGM-2) alone was used, to ensure that there was no 
cross-reactivity between the antibodies used to detect the chemokines and 
components in the medium. Time courses for each chemokine are shown in 
figure 5.6.
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Figure 5.6 Time course of chemokine production by primary HDLEC treated with TNFa.
Supernatant from cells cultured in TNFa, 10ng/ml was assayed in triplicate by ELISA for MIP3a 
(first graph), RANTES (second graph) and MCP-1 (third graph), (R and D systems) according to 
the manufacturer’s instructions. Data shown are mean concentrations calculated from chemokine 
standard concentration curves, ± standard error.
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The results show that untreated HDLEC secrete very low levels of RANTES and 
MIP-3a (64 pg/m l and 12 pg/m l respectively) and no MCP-1. TNFa induced 
secretion of all three chemokines (up to 4-14 ng/m l by 72h) and secretion was 
found to be maximal between 6 and 48h. Thus the fold increases in transcript 
levels shown by the array analysis were confirmed at the protein level, where 
TNEa was shown to induce physiological concentrations of these pro- 
inflammatory chemokines.
5.2.6 Effects of TNFa on mouse LEC
The previous sections of this chapter have described the dramatic effects of TNFa 
on primary cultured human LEC derived from commercial HDMEC. Although 
these cells have many if not all the phenotypic characteristics of authentic tissue 
LEC, it was nevertheless important to confirm the findings with freshly isolated, 
early passage LEC from a different source.
5.2.6.1 Isolation of mouse LEC
Primary mouse LEC were isolated from neonatal dermal skin, according to a 
protocol established by Dr. Steven Clasper in the same laboratory (Clasper and 
Jackson, unpublished). In this procedure, which used 3-4 day post-partum mice, 
the skins were removed and incubated overnight in dispase to separate the 
epidermis from the dermal sheets. The dermal sheets were disrupted by a 
cocktail of enzymes (collagenase, hyaluronidase, elastase and DNase I) and 
passed through a 70 pm filter to remove cell clumps from the suspension, prior to 
plating out on gelatine-coated flasks. Endothelial cells adhered more rapidly 
than other dermal cells such as fibroblasts, which form the majority and have a 
more rapid doubling time in culture. Therefore approximately four hours after 
plating, flasks were vigorously tapped to remove and discard non-adherent or 
weakly attached cells, prior to culture of remaining cells overnight, thus avoiding 
immediate overgrowth of LEC by fibroblasts. The following day, lymphatic
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endothelial cells were clearly visible as small "islands" of cobble-stoned 
morphology, between other cells, predomainantly fibroblasts. Cells were lifted 
with a commercial protease preparation, accutase, which unlike trypsin does not 
proteolytically cleave LYVE-1 and is more efficient than EDTA at breaking cell 
contacts with the substratum. LYVE-l-positive LEC were then isolated by 
magnetic bead immuno-selection using the LYVE-1 mAb, C l/8  (generated as 
described in chapter 3). The resulting cells displayed abundant expression of 
LYVE-1 and Prox-1 (figure 5.7). Detection of the other lymphatic markers 
podoplanin (with the mAb 8.1.1) and VEGFR3 (with polyclonal goat antiserum) 
was also performed but these antibodies proved unsuitable for use in 
immunofluorescence microscopy.
5.2.6.1 Effects of TNFa on mouse LEC morphology
To investigate whether the TNFa-induced change in morphology of the primary 
HDLEC (chapter 4) was also precipitated by mouse recombinant TNFa on 
primary mouse LEC, cells were cultured for 24h in either EGM-2 medium alone 
or in media supplemented with mouse recombinant TNFa. Mouse LEC were 
then visualised by phase contrast microscopy. The results (figure 5.8) showed 
that in response to TNFa, the mouse LEC were found to elongate in a very 
similar manner to that of the human LEC, described in chapter 4. TNFa appears 
to induce cytoskeletal rearrangement of the primary mouse LEC, indicating that 
these cells are responsive to this pro-inflammatory cytokine.
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Figure 5.7 Characterisation of primary mouse dermal LEC by immunofluorescence 
microscopy. Immuno-isolated cells were stained with rat anti-mouse LYVE-1 and rabbit anti-prox- 
1, detecting with the appropriate AlexaFluor® conjugates, 488 and 568 respectively and 
counterstaining with the blue nuclei stain DAPI. Cells express both LYVE-1 (green) and prox-1 
(red, but colocalising with DAPI in the nuclei and thus appearing pink).
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Figure 5.8 Phase contrast microscopy of mouse LEC to show the TNFa-induced change in 
morphology. Untreated cells exhibit a cobble-stone-like morphology (upper panel) which 
contrasts with the elongation observed following 24h of stimulation with TNFa, (100ng/ml), shown 
in the lower panel. Images were captured at 100X magnification.
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5.2.6.3 Effect of TNFa on LYVE-1 expression
To determine whether expression of LYVE-1 in primary mouse LEC is affected 
by TNFa in a similar manner to as in HDLEC, early passage (passage four) cells 
were stimulated with TNFa for 12, 24 and 48h, then assayed for LYVE-1 
expression by flow cytometry. The results (figure 5.9) showed that LYVE-1 
surface expression decreased over a period of 48h. However, unlike their human 
counterparts, mouse LEC showed only a 55% loss of LYVE-1 surface expression, 
rather than complete loss of the receptor. Maximal loss of LYVE-1 was observed 
at 12h, after which time expression recovered, even when the cells were 
maintained in the presence of TNFa throughout the experiment. To address the 
possibility that mouse TNFa is more labile at 37°C, the experiment was repeated 
using human TNFa, as TNFRI from both species binds human and mouse TNFa 
with equal affinity (Barrett et al., 1991). However TNFa from both species was 
found to precipitate similar decreases in the expression of LYVE-1 (figure 5.10).
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Figure 5.9 Time course of LYVE-1 down-regulation in primary mouse LEC treated with TNFa.
Cells were cultured for Oh, 12h, 24h and 48h in the presence of TNFa, 10Ong/ml then lifted with 
accutase and stained for LYVE-1 using the mAb C1/8 and goat anti-rat AlexaFluor®488 prior to 
analysis by flow cytometry. Values shown are the mean fluorescence of C1/8 staining, with values 
for mean fluorescence of staining by an irrelevant rat IgG control subtracted at each time point.
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Figure 5.10 Comparative effects of human and murine TNFa on LYVE-1 down-regulation in 
primary mouse LEC. Cells were cultured 12h in the presence or absence of either human or 
murine recombinant TNFa (100ng/ml), then lifted with accutase and stained for LYVE-1 using the 
mAb C1/8 and goat anti-rat AlexaFluor®488 prior to analysis by flow cytometry. Untreated cells 
are shown in black, cells treated with TNFa are in blue and those stained with an isotype matched 
control as a dotted black line.
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One possible explanation for the reduced response of these cells is that the 
murine LEC were isolated from post-partum dermis, whereas human LEC were 
isolated from young adult dermis. Delayed up-regulation of blood vascular 
endothelial adhesion molecules due to depressed endogenous TNFa production 
in the lungs of neonatal mice following elicitation of inflammation has been 
reported by Qureshi et al., (2003). However in the present case, exogenous TNFa 
was administered and therefore this cannot be the explanation here. 
Nevertheless, expression of TNF receptors has not been measured on these cells 
and a low expression may account for why these cells are less responsive than 
the HDLEC.
To address this issue, mouse dermal LEC were isolated from adult nude mice 
and tested for their responses to TNFa. Immuno-competent mice could not be 
used for such studies as the depilatory cream employed to remove the fur was 
found to substantially reduce the yield and viability of the isolated cells (S. 
Clasper, unpublished observation). The results (figure 5.11) showed that these 
cells displayed the same degree of response to TNFa as those cells isolated from 
neonates. Although it is possible that LEC from the nude, athymic mice also 
exhibit reduced responsiveness to TNFa, there may be species differences in 
TNFa response of lymphatic endothelial cells. Data from HDLEC derived from 
PromoCell HDMEC have been validated in chapter 4 by identical responses to 
TNFa of both HDMEC from Cambrex and podoplanin-positive immuno-selected 
HDLEC from the laboratory of Prof. Dontscho Kerjaschki. Hence the results 
appear to reveal an inherent difference between human and murine LEC in terms 
of their response to an inflammatory stimulus.
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Figure 5.11 Response to TNFa of primary LEC isolated from adult nude mice. Cells were 
cultured for 48h in either the absence (black line) or presence (blue line) of mouse recombinant 
TNFa, 100ng/ml. Cells were stained for LYVE-1 expression with the mAb C1/8 or an isotype- 
matched control (dotted line) and goat anti-rat AlexaFluoK5)488 prior to analysis by flow cytometry.
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5.2.6 A Effects of TNFa on expression of key leukocyte adhesion molecules
Earlier experiments detailed in this chapter had shown that low levels of ICAM-1 
were expressed on unstimulated HDLEC but following stimulation with pro- 
inflammatory cytokines, expression of both ICAM-1 and VCAM-1 were up- 
regulated. To investigate whether similar up-regulation of leukocyte adhesion 
receptors occurred in primary mouse LEC, cells were cultured for 12h in either 
EGM-1 medium alone or in media supplemented with TNFa, prior to 
immunofluorescence microscopy to detect LYVE-1 with either VCAM-1 or 
ICAM-1 expression (figure 5.12).
Results showed that unstimulated cells expressed virtually no VCAM-1 and low 
levels of ICAM-1, whilst retaining high levels of expression of LYVE-1. However 
following stimulation with TNFa, cells exhibited clear up-regulation of both 
VCAM-1 and ICAM-1. The increased expression of VCAM-1 was also 
quantitated by flow cytometry (figure 5.13).
To study expression of other adhesion molecules, further immunofluorescence 
microscopy was performed using antibodies against the junctional molecules 
CD31 and VE-cadherin. Experiments presented earlier in this chapter had shown 
that both of these molecules were expressed by primary HDLEC but neither 
underwent marked changes in expression following stimulation with TNFa. As 
shown in figure 5.14, expression of both CD31 and VE-cadherin was detected on 
primary mouse LEC. No change in expression was induced by TNFa, despite the 
decrease in LYVE-1 expression which indicated that the cells in the 
representative fields of view were responsive to the cytokine (figure 5.14). Thus 
the early passage mouse LEC confirmed the results obtained with late passage 
HDLEC.
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Figure 5.12 Effect of TNFa on expression of VCAM-1 and ICAM-1 in primary mouse dermal
LEC (following page). Cells were cultured for 12h in either medium alone or supplemented with 
TNFa, (100ng/ml). Cells were then stained with rabbit anti-LYVE-1 (green) and either rat anti- 
VCAM-1 (red) or rat anti-ICAM-1 (red) as indicated, detecting using the appropriate 
AlexaFluor®488 and 568 conjugates and counterstaining nuclei with DAPI. Representative images 
were captured at magnification: x 100.
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Figure 5.13 Quantitation of the increase in VCAM-1 expression in TNFa-stimulated mouse 
LEC. Cells were cultured for 12h in either the presence or absence of recombinant mouse TNFa, 
100ng/ml, then lifted with accutase and stained for VCAM-1, detecting using the AlexaFluor®488 
goat anti-rat conjugate and flow cytometry. Untreated cells are represented by a black line, TNFa- 
stimulated cells in blue and cells stained with an irrelevant isotype matched control shown by the 
dotted line.
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Figure 5.14 Effects of TNFa on expression of CD31 and VE-cadherin in primary mouse 
dermal LEC (following page). Cells were cultured for 12h in either medium alone or supplemented 
with TNFa, (100ng/ml). Cells were then stained with rabbit anti-LYVE-1 (green) and either rat anti- 
CD31 (red) or rat anti-VE-cadherin (red) as indicated, detecting using the appropriate 
AlexaFluor®488 and 568 conjugates and counterstaining nuclei with DAPI. Images were captured 
at 100X.
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To detect whether the primary mouse LEC expressed CD44, as had been found 
in HDLEC, immunofluorescence microscopy was performed on mouse LEC, 
cultured either in the presence or absence of TNFa. All early passage cells were 
CD44-negative but at later passages (six and beyond) a minority of cells were 
found to express CD44 following stimulation with TNFa. This suggested de­
differentiation at higher passage number (figure 5.15).
5.2.6.5 Microarray analysis of resting and TNFa-stimulated mouse LEC
As with primary HDLEC, total RNA was prepared from primary murine LEC 
cultured in either the presence or absence of TNFa and complementary RNA was 
prepared at the Cancer Research UK Patterson Institute, Manchester, where it 
was applied to the GeneChip® Mouse Expression Set 430 array. This two array 
set allows analysis of the expression levels for over 39,000 transcripts and 
variants, including 34,000 confirmed mouse genes and was carried out in a 
similar manner to that of the human gene array analysis. It was imperative to 
use cells which had been cultured for the shortest possible time and therefore 
rather than the triplicate analyses used in the HDLEC samples, this assay was 
carried out using a single set of RNA samples. Data are summarised in table 5.3.
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Control TNFa
Figure 5.15 Evidence for de-differentiation in later-passage primary mouse dermal LEC.
Later passage cells (passage seven) were cultured for 12h in either medium alone or 
supplemented with TNFa, (100ng/ml). Cells were then stained with rabbit anti-LYVE-1 (green) and 
the rat anti-CD44 mAb, IM7 (red). The appropriate AlexaFluor®488 and 568 conjugates were used 
for detection and nuclei were counterstained using DAPI. Images were captured at 100X
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Genes up-regulated
Adhesion molecules Fold change
ICAM-1 8.39
E-Selectin 5.85
VCAM-1 4.81
Integrin a3 2.49
Integrin a5 2.17
Claudin-12 orthologue 2.18
Integrin p3 1.71
Chemokines, 
cytokines and growth 
factors
MCP-3 (CCL1) 20.76
GROp (CXCL2) 9.94
VEGF-C 5.68
IP-10 (CXCL10) 5.30
JE/MCP-1 (CCL2) 4.92
M-CSF (CSF-1) 4.20
RANTES (CCL5) 3.97
MIP3a (CCL20) 3.52
MIP1y (CCL9/10) 2.78
IL-6 2.19
ENA-78 (CXCL5) 2.06
PDGFa 1.97
MIPip (CCL3) 1.95
IGF-7 1.75
I-TAC (CXCL11) 1.62
Extracellular matrix 
molecules
Fibronectin 1.71
Matrix
metalloproteinases
MMP13 39.61
MMP10 13.94
MMP3 12.18
MMP2 2.34
Receptors
EGF receptor 5.25
Miscellaneous
TNFAIP3 2.77
vWf 2.31
TNFRS6 2.21
TRAF-1 2.14
TANK 2.14
NFkB2 2.12
TRAF-3 2.11
TNFAIP1 2.08
Endothelial cell 
specific molecule 1
2.07
Podoplanin 1.25
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Genes down-regulated
Adhesion molecules Fold change
Occludin 7.13
Claudin-5 3.48
Integrin a8 2.76
Multimerin 2.47
Cadherin-5 (VE- 
cadherin)
2.35
Connexin 34 2.20
Integrin a9 1.77
LYVE-1 1.51
Integrin a6 1.37
CD31 1.36
ICAM-2 1.27
Chemokines, 
cytokines and 
growth factors
IGF-2 5.39
IGF-1 3.98
Angiopoietin 3.88
IL-7 2.25
BCA-1 (CXCL13) 1.23
Extracellular matrix 
molecules
Reelin 8.45
Matrix
metalloproteinases 
and inhibitors
ADAMTS5 8.10
Timp-3 4.48
ADAM10 2.40
Receptors
Mannose receptor, C 
type 1
4.39
VEGFR-3 1.83
Miscellaneous
Prox-1 4.39
Table 5.3 Representative data from Affymetrix® microarray analysis in primary mouse 
dermal LEC. Cells were cultured in either the presence or absence of TNFa, (100ng/ml) for 12h. 
Total RNA was prepared and complementary, biotinylated RNA synthesised at the Patterson 
Institute, for application to the gene-chip. Data was normalised and fold changes in expression 
induced by TNFa are shown for each transcript.
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The results show TNFa-induced up-regulation of the transcripts encoding ICAM- 
1 and VCAM-1, as was also seen in the human LEC. However the magnitude of 
changes are more moderate in the mouse primary dermal LEC, with increases of
8.4 fold and 4.8 fold for the respective molecules as opposed to 177 fold and 17 
fold recorded in the human LEC. E-selectin transcript exhibited up-regulation by 
5.9 fold, which is more comparable to that found in the human LEC (4 fold).
Up-regulation of transcripts encoding the chemokines IP-10, RANTES, MIP-3a, 
ENA-78,1-TAC and JE, the mouse orthologue of human MCP-1, were recorded 
in TNFa-stimulated murine LEC as well as in the stimulated human LEC 
described earlier in this chapter. However as with the adhesion molecules 
transcripts the extent of up-regulation of chemokines was not as dramatic as in 
the human LEC. The two species also exhibited some differences in the 
chemokines induced. For example MCP-and GROp were up-regulated in mouse 
LEC alone whereas GCP-2 was only induced in human LEC.
The data also show up-regulation of matrix metalloproteinases in primary mouse 
dermal LEC. Induction of MMP10 (stromelysin-2) was detected in both mouse 
and human LEC following TNFa stimulation, although the identities of other 
MMPs induced differed between the species. Curiously the MMPs detected in 
the murine LEC underwent a more marked up-regulation of transcript 
abundance (up to 39.6 fold) than the human LEC (less than 5.7 fold).
Transcripts of the integrins a4, aV and al were detected but did not change 
significantly upon TNFa stimulation. Interestingly, unlike human LEC, the 
mouse cells showed up-regulation in IL-6 mRNA following TNF stimulation. 
This could account for the recovery of expression of LYVE-1 on these cells 
without the removal of the TNF-supplemented medium, as suggested in chapter 
4. The lack of IL-6 synthesis following TNFa stimulation (Abbas et al., 1997) in
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the human LEC studied may be involved in the failure to re-express LYVE-1. 
Whether this is unique to the human lymphatic endothelial cell line or whether it 
is true in human lymphatic endothelium in general remains to be determined. 
The former hypothesis is more likely correct; otherwise another mechanism 
would have to be responsible for the resolution of the early stages of acute 
inflammation.
As in the data obtained from TNFa-stimulated human LEC, the mouse LEC 
underwent up-regulation of transcript abundance of various TNF receptor 
associated proteins such as TNF receptor-associated factor-1 (TRAF-1) and TNF 
associated proteins-1 and -3 (TNFAIP-1 and -3), as well as NFkB2. However 
again the increase in abundance (2-3 fold) was not as dramatic as that measured 
in the human LEC (2-10 fold).
52.6.6 Effect of TNF on chemokine production by mouse LEC
As with HDLEC, the Affymetrix array analysis on mouse LEC demonstrated that 
synthesis of chemokines such as RANTES (CCL5), MEP3a (CCL20) and JE, the 
mouse homologue of MCP-1 (CCL2) increase dramatically following stimulation 
with TNFa. Chemokine production by mouse LEC was assayed at the protein 
level in a similar manner to the human LEC, using R and D Systems ELISA kits. 
However, only assays for JE and RANTES were available. Mouse LEC were 
stimulated with TNF for 6h to 48h as a time course and as before some cells in 
each case were left untreated, to assay for chemokine production in unstimulated 
cells. A negative control of EGM-2 medium alone was used, to ensure that there 
was no cross-reactivity between the antibodies used to detect the chemokines 
and components in the medium.
Mouse LEC were found to secrete concentrations of JE and RANTES of 100 
ng/m l and 1.6 ng/m l respectively over 72h (figure 5.16). The concentration of JE
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is approximately 10 fold higher than that of the supernatant from stimulated 
HDLEC, whilst the concentration of RANTES is approximately 10 fold less than 
that of the HDLEC. Clearly, direct comparison of these chemokine 
concentrations to those in inflamed tissue in vivo is not possible as the values 
from in vitro experiments are dependent largely on cell density and volume of 
the medium. However, concentrations of the order of ng/m l are detected in 
serum following inflammatory stimuli in animals. For example, after 
intraperitoneal injection of LPS in mice, serum concentrations of MCP-1 of up to 
9 ng/m l were recorded (Marino et al., 1997). Therefore the secretion of these 
pro-inflammatory chemokines in lymphatic endothelial cells could be expected 
to have a significant biological effect in vivo.
The kinetics of chemokine secretion by primary mouse dermal LEC are similar to 
those of the HDLEC. Mouse LEC continue to secrete JE/MCP-1 at a steady rate 
from 6h after stimulation to 72h. RANTES secretion reaches a plateau after 48h 
followed by an apparent decrease, indicating possible uptake and perhaps 
degradation of the chemokine between 48-72h, which may be to prevent a 
prolonged effect.
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Figure 5.16 Time courses of chemokine production by LEC treated with TNFa. Cells were 
cultured in triplicate +/- TNFa, 10Ong/ml for each time point and diluted supernatants applied to 
ELISAs (R and D systems) to detect JE (upper panel) and RANTES (lower panel). Data shown are 
mean concentrations calculated from chemokine standard concentration curves, ± standard error.
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5.3 Discussion
The results in this chapter have presented new evidence that primary LEC 
respond to pro-inflammatory cytokines by adopting a programme of gene 
expression that suggests an active role in co-ordinating leukocyte trafficking. 
Primary HDLEC, initially described in chapter 4, were phenotyped more 
extensively as were primary mouse dermal LEC isolated from neonates, both 
when untreated and following stimulation with TNFa, by flow cytometry, ELISA 
and microarray analysis.
5.3.1 Expression of adhesion molecules on LEC
Cultured HDLEC and freshly immuno-isolated low-passage mouse LEC 
displayed marked up-regulation of key leukocyte-endothelial adhesion 
molecules ICAM-1, VCAM-1 and E-selectin in response to TNFa. In both cases, 
there was a concomitant down-modulation of LYVE-1, described in chapter 4. 
Flow cytometry studies revealed that both E-selectin and VCAM-1 were absent 
from unstimulated LEC but were induced following exposure to TNFa or TNFp. 
ICAM-1 was expressed at low levels on LEC but markedly up-regulated 
following exposure to TNFa, TNFp, IL-la, IFNy and LPS. These data were 
confirmed by microarray analysis, which revealed that up-regulation of these 
adhesion receptors occurs also at the level of mRNA in both the human and 
mouse. Results described in this chapter show that TNFa has a more potent 
inflammatory effect on LEC that TNFp, confirming an earlier study by Desch et 
al., 1990, who found that TNFa was more effective than TNFp in promoting 
adhesion of neutrophils to cytokine-activated HUVEC.
Historically, leukocyte transmigration across blood vascular endothelium has 
been studied much more thoroughly than that across the lymphatics, as outlined
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in detail in the introduction to this thesis. In the case of non-inflamed blood 
vessel endothelium, the multi-step process of transmigration involves initial 
weak interactions between leukocyte selectins and endothelial mucins, followed 
by chemokine-induced firm adhesion between the leukocyte integrins aLp2, 
aMp2, a4p7 and their endothelial ligands ICAM-1, ICAM-2 and MAdCAM-1 
(reviewed by von Andrian and Mackay, 2000). During tissue inflammation, 
cytokines including TNFa, IL-1 and INFy induce peripheral vascular expression 
of VCAM-1, promoting adherence of memory T cells and monocytes bearing the 
VCAM-1 ligand a4pi (Alon et al., 1995; Van Dinther-Janssen et al., 1991). ICAM- 
1 is also up-regulated on endothelium of the blood vasculature and engages with 
leukocyte integrins LFA-1 and Mac-1 both to permit firm adhesion and initiate 
transmigration (Dustin and Springer., 1988). ICAM-1 has also been implicated in 
assisting transmigration of Langerhans cells into afferent lymphatic vessels and 
trafficking to lymph. For example Sligh et al. (1993) demonstrated that ICAM-1 
deficient mice have defective hapten-induced contact hypersensitivity responses 
in the skin. Also Xu et al. (2001) showed that disruption of the ICAM-1 gene 
blocked trafficking of hapten-presenting LC to the lymph node from allergen- 
sensitised skin. However, expression of ICAM-1 by the lymphatics was not 
conclusively demonstrated and it was not known whether it played a role in the 
entry of DCs to afferent lymphatics, migration through the lymphatics or 
transmigration across the lymph node sinus endothelium to enter the lymph 
node paracortex. The data shown in this chapter constitute the first direct 
evidence that ICAM-1 is a significant and highly inducible component of 
lymphatic endothelial cells and supports the earlier research by other groups in 
suggesting a role for ICAM-1 in leukocyte migration in the lymphatics. As both 
the mouse and human LEC used in this chapter are of dermal origin, this would 
suggest that the adhesion molecules are up-regulated in the initial lymphatic 
capillaries and thus may play a role in the initial entry of DCs into the
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lymphatics. Experiments detailed in the following chapter will explore this more 
fully in vivo.
HDLEC were also found to express ICAM-2, which is expressed constitutively in 
blood vascular endothelium (Staunton et al., 1989). Both ICAM-1 and ICAM-2 
are receptors for LFA-1 (CDlla/CD18 or aL02, Makgoba et al., 1988) but ICAM-2 
can also interact with DC-SIGN (CD209), a C-type lectin expressed on DCs. As 
on blood endothelium (McLaughlin et al., 1998), ICAM-2 in primary HDLEC 
underwent a marginal but significant down-regulation in response to TNFa. 
This would suggest that lymphatic endothelial ICAM-2 does not have a role in 
inflammation but rather is constitutively expressed in normal tissue. Blood 
endothelial ICAM-1 and ICAM-2 have been shown by Lehmann et al. (2003) to 
have redundant roles in lymphocyte recirculation through lymph nodes but 
ICAM-1 alone was shown to be involved in T cell migration into inflamed skin. 
Geijtenbeek et al. (2000a) demonstrated that ICAM-2 also interacts with DC- 
SIGN to mediate the extravasation of DC precursors from the blood into the 
tissue. Therefore expression of ICAM-2 on lymphatic endothelium may play a 
role in migration of DCs across the lymphatic endothelium. Alternatively it may 
aid constitutive leukocyte transmigration through the afferent lymphatics. 
Electron microscopy experiments to address whether ICAM-2 is expressed on the 
luminal or abluminal side of endothelium could provide further evidence to 
suggest if ICAM-2 interactions occur with leukocytes entering the lymphatics or 
cells already within the lumen. DC-SIGN can also bind ICAM-3 to enable 
transient high affinity interactions between DCs and T cells to support primary 
immune responses (Geijtenbeek et al., 2000b). Therefore as anticipated no ICAM- 
3 was detected on primary HDLEC.
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5.3.2 Chemokines
The microarray analysis of resting and TNFa-treated LEC not only bore out what 
had been observed at the protein level for the adhesion molecules in terms of 
comparative message abundance but also illustrated the vast range of 
chemokines newly transcribed by LEC.
Stimulation of LEC with TNFa induced the synthesis of chemokines such as 
RANTES, MCP-1, MIP-3a, MCP-3, Fractalkine and IL-8, which act through the 
receptors CCR1 and CCR5; CCR2; CCR6; CCR1, CCR2 and CCR3; CX3CRI; and 
CXCR8 respectively to promote migration of DCs to sites of inflammation and 
recruitment of monocytes and T cells (reviewed by von Andrian and Mackay, 
2000). Neutrophil chemokines such as ENA-78, IL-8 and GROp were also 
induced, acting via the receptors CXCR1 and CXCR2. Expression of RANTES, 
MCP-1 and MIP-3a was confirmed by ELISA, whereby these secreted 
chemokines were detected in culture supernatant. Thus the results described in 
this chapter indicate that the lymphatics have the capacity to actively guide 
migrating cells towards themselves. As blood and lymphatic capillaries are so 
closely apposed within the dermis, it is also possible that these chemokines act in 
a paracrine fashion to recruit more monocytes from the blood after transfer to the 
luminal face of blood vascular endothelium, (Middleton et al., 1997).
Microarray analysis data detailed in this chapter show that the CXC chemokine 
IP-10 transcript was up-regulated in both mouse and human LEC following 
stimulation with TNFa. IP-10 is known to act through CXCR3 to promote the 
migration of effector type I helper T cells (reviewed by von Andrian and Mackay, 
2000). Recently Nakae et al. (2002) found that this chemokine is up-regulated in 
mouse skin in a model of delayed hypersensitivity, through a TNFa-dependent 
pathway. However, the cells producing IP-10 were not identified in that study.
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The data from the gene array analyses performed here in this thesis suggest that 
the lymphatic endothelium is at least partly responsible for the increased 
expression of IP-10 in mouse skin challenged with a sensitising agent. Indeed IP- 
10 is but one of several chemokines up-regulated following TNFa stimulation of 
lymphatic endothelium.
The results described in this chapter also confirm the finding of Mancardi et al, 
2003, in their study on secretion of chemokines from cells derived from 
experimentally induced lymphangioma, where they found high levels of 
JE/MCP-1 and RANTES; the cells they isolated were podoplanin positive and 
were thus deemed mouse LEC. However unlike the present study, that of 
Mancardi et al. did not detect MIP-lp or MIP-ly message. Also the expression of 
CIO, classically found on haematopoietic cells was detected in the 2003 
publication but not by array analysis. These differences in expression may be 
accounted for by the source from which the LEC are derived.
The down-modulation of HCC-1 in TNFa-treated HDLEC was surprising as this 
chemokine is associated with migration of dendritic cells and monocytes in 
inflammation through CCR1. It is possible that HCC1 is up-regulated at an 
earlier time point (less than 72h following TNFa stimulation) than the other 
chemokines. There is a marginal reduction in abundance of BCA-1 mRNA in the 
mouse LEC but this is less surprising than HCC-1 as it is primarily involved in 
migration of B cells (through CXCR5), rather than possible recruitment of antigen 
presenting cells towards lymphatic endothelium for transmigration into the 
lymphatics (von Andrian and Mackay, 2000).
Although the chemokines MCP-1, MIP-3a, RANTES, ENA78, IP10 and CSF-1 are 
induced in both mouse and human LEC, up-regulation of other chemokines was 
restricted to only one of the two species. There is no known mouse homologue
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of IL-8 and therefore the up-regulation of other chemokines such as GROp 
(which is not up-regulated in the human), may play a compensatory role in the 
mouse in the recruitment of neutrophils, in addition to ENA-78. Other species 
differences indicated from the array analysis include the induction of GCP-2 in 
human LEC but not in mouse, and up-regulation of MCP-3 in mouse but not 
human.
5.3.4 Matrix metalloproteinases
The induction of matrix metalloproteinases such as MMP-3, -6, -9, -10 and -19 
was a striking observation from the microarray data. It is tempting to speculate 
that such molecules could potentially facilitate extravasation of monocytes from 
the blood by degrading basement membrane structures on interendothelial tight 
junctions of juxtaposed blood capillaries. It is also possible that they contribute 
to the establishment of chemokine gradients by releasing immobilised 
chemokines from their heparan sulphate proteoglycan binding sites within the 
extracellular matrix (Parks et al., 2004) and, through cleavage of the chemokine, 
activate chemotactic activity. A prime example of this is the neutrophil 
chemokine IL-8, (Van Den Steen et al., 2000), which stimulates the release of 
MMP-9 (gelatinase B) from neutrophils, which was then shown to specifically 
process IL-8 at the amino-terminus, increasing the specific activity and altering 
receptor usage. MMP-9 was later shown to also regulate the other CXC 
chemokines GCP-2 and ENA-78, again at the amino-terminus, inactivating ENA- 
78 (Van den Steen et al., 2003a). MMP-9 was also shown to negatively regulate 
MIG and IP-10 through carboxy-terminal cleavage (Van den Steen et al., 2003b).
The negative regulation of chemokine activity by MMPs is not restricted to 
MMP-9 and ENA78: cleavage of MCP-1, MCP-3 and GCP-2 by MMP-2, -3 or -9 
can also destroy chemotactic activity (McQuibban et al., 2001; McQuibban et al., 
2002; reviewed by Parks et al., 2004). Such modification may even result in these
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chemokines being converted into antagonistic agents. Thus, by modulation of 
chemokine activity, MMPs may be involved in the recruitment of specific 
inflammatory cells into the dermis in response to a particular antigen. The 
establishment of a chemokine gradient and modifications to extracellular matrix 
by MMPs also regulate migration of antigen presenting cells towards the 
lymphatics. Evidence from the microarray data suggests that this carefully 
orchestrated process is regulated at least in part by lymphatic endothelial cells, 
which may instigate both the initiation and resolution of inflammation.
5.3.5 TNF superfamily members
Both the human and mouse microarray data showed that numerous TNF 
receptor associated proteins and NFkB transcripts increased following 
stimulation with TNFa. Intriguingly, the human microarray data also showed 
that TNFa induces expression of the TNF superfamily receptor 0X40 (also 
known as CD134, or by the systematic name TNFRSF4) and its ligand OX40L 
(CD134L or TNFSF4). This receptor is a T cell activation marker with limited 
expression which is believed to promote the survival and perhaps prolong the 
immune response of CD4+ T cells at sites of inflammation (Godfrey et al., 1994). 
Expression of the ligand has been reported on vascular endothelial cells (Imura et 
al., 1996) but the receptor was believed to be restricted to activated CD4+ and 
CD8+ cells. An increase in transcript abundance was also detected for CD137 
(TNFRSF9), another activation-induced glycoprotein which had not been found 
on endothelial cells before. Ligation of this receptor is reported to interrupt T cell 
apoptotic programs associated with activation-induced cell death (Hurtado et al., 
1997). Data from the array analysis could suggest that lymphatic endothelial 
cells are capable of protecting themselves from apoptotic signals during 
inflammation, as well as synthesising ligands to ensure the survival of 
neighbouring T cells. GITR ligand (glucocorticoid-induced TNFR family-related 
ligand, TNFSF18) is another transcript up-regulated in TNFa-treated LEC, which
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has been shown to interrupt apoptosis in T cells when binding to its receptor, 
expressed on normal T lymphocytes from lymphoid tissue (Nocentini et al., 
1997). Interestingly, Fas ligand (TNFSF6) is also transcribed by TNFa-treated 
LEC and this may induce either apoptosis or proliferation of Fas (CD95, 
TNFRSF6) positive cells, depending upon the relative number of expressed Fas 
molecules (Freiberg et al., 1997). While it must be stressed that the consequences 
of these changes in transcription levels remain to be explored in vivo, the data are 
at least suggestive of a role for the lymphatic endothelium in influencing the fate 
of neighbouring leukocytes as well as their own survival.
5.3.6 LYVE-1
The dramatic down-modulation of LYVE-1 in HDLEC first described in chapter 4 
was confirmed again in this chapter in the microarray analyses, where LYVE-1 
mRNA underwent the most dramatic reduction of abundance of all the genes 
surveyed by the human microarray, consisting of over 47 000 transcripts and 
variants. Curiously, mouse LEC did not exhibit the same striking down- 
regulation. Whether the reason for this lies in the developmental stage at which 
the cells were isolated (as discussed earlier in this chapter) or the species from 
which they were derived is unclear, although none of the mouse LEC transcripts 
underwent such dramatic changes as those in the HDLEC.
Another intriguing difference between the mouse and human LEC was the 
recovery of expression of LYVE-1 by mouse LEC that was observed even in the 
presence of TNFa. Experiments described in chapter 4 showed that stimulation 
of HDLEC with IL-6 induced a marginal increase in LYVE-1 surface expression 
and as the microarray analyses carried out in this chapter indicate that IL-6 
mRNA is up-regulated following TNFa stimulation, one could speculate that this 
may be a mechanism whereby the cells recover LYVE-1 expression 
spontaneously. Experiments detailed in this chapter have shown that IL-6
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induces an increase in LYVE-1 surface expression and TNFa is known to up- 
regulate IL-6, which subsequently suppresses TNFa production (Akira and 
Kishimoto, 1992). However why the HDLEC fail to up-regulate IL-6 mRNA in 
response to TNFa and spontaneously recover LYVE-1 expression is unknown.
The down-regulation of LYVE-1 in mouse lymphatic endothelial cells has been 
shown in this chapter and experiments on a mouse model of inflammation in the 
following chapter were devised to ascertain whether this also occurs in vivo. 
These subsequent experiments also sought to address the possible physiological 
role for LYVE-1.
5.3.7 Conclusion
The experiments described in this chapter provide the first direct evidence to 
suggest that lymphatic endothelial cells play an active role in inflammation. 
Much of the data described in this chapter has illustrated that lymphatic vessel 
endothelium behaves in a similar manner to that of blood endothelium during 
inflammation, despite the fact that lymphatic vessels experience reverse 
transmigration, with leukocytes crossing from the abluminal rather than luminal 
surface. Thus these two distinct circulatory systems share parts of the same 
address code for specific vascular targeting.
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6.1 Introduction
6.1.1 The effects of TNF in the skin
The skin, or integumentary system represents the boundary between an 
organism and its environment, and thus it must play a vital role in protecting the 
body from mechanical injury, water loss and the entry of harmful agents. 
Langerhans cells (LC) are dendritic cells found within the basal and suprabasal 
layers of the epidermis. These highly specialised antigen-presenting cells (APCs) 
constitute the first line of immune defence. These cells aggregate to form a 
continuous network and may ingest intruding microbes and other environmental 
components. Such complex antigens are loaded onto MHC class II molecules 
within the cell for presentation at the cell surface to T cells within a regional 
lymph node. Thus LC are responsible for initiating systemic immune responses 
and all migratory events of these cells must be tightly regulated, from the initial 
recruitment of their precursors from the circulation to their mobilisation via the 
lymphatics to regional lymph nodes.
LC are retained within the epidermis by E-cadherin-mediated homophilic 
attachments with keratinocytes (Jakob et al., 1999). Transforming growth factor- 
p (TGF-P) is also believed to play a role in retaining LC by up-regulating E- 
cadherin on these cells and blocking TNFa-induced up-regulation of CCR7, 
which is critical in the migration of LC to the lymphatics (reviewed by Jakob et 
al., 2001).
“The well-characterised murine contact hypersensitivity (CHS) model has been 
used extensively to study the migration of antigen-presenting cells from the skin 
in response to antigenic challenge. In this model (detailed in chapter 1), a skin 
sensitising agent is applied to an area of mouse skin and is captured by LC or
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dermal DC, which migrate to lymph nodes (Cumberbatch et al., 2002) and elicit 
hapten-specific T cell activation (Nakae et al., 2002). Once the mouse has been 
sensitised and memory T cells are resident throughout the body, a challenge by 
cutaneous application of the same antigen, typically to the ear, results in local 
inflammation and oedema. The sensitisation phase of CHS has been extensively 
studied to determine the molecular mechanism whereby LC are mobilised. 
Topical application of skin sensitising agents induces an increase in the 
expression of MHC class II molecules on LC and a decrease in LC density in the 
epidermis (Aiba and Katz, 1990). mRNAs of TNFa and IL-1 are rapidly up- 
regulated within minutes of application (Enk and Katz, 1992) and blocking of 
these pro-inflammatory cytokines with neutralising antibodies can prevent the 
induction of contact hypersensitivity (Cumberbatch and Kimber, 1992). IL-1 and 
TNFa down-regulate E-cadherin mRNA, leading to a reduction in E-cadherin 
surface expression and loss of cellular adhesion between LC and keratinocytes 
(Jakob and Udey, 1998). The maturing LC leave the epidermis and then must 
migrate through the extracellular matrix of the dermis towards the lymphatics.
Proteolytic enzymes such as the matrix metalloproteinases (MMPs) are believed 
to play a role in LC and dendritic cell (DC) migration through the extracellular 
matrix. For example MMP-9 has been detected in LC in situ under conditions 
that induce LC migration and emigration of LC from tissue explants may be 
blocked by MMP inhibitors (reviewed by Jakob et al., 2001). Also chemokines 
and their receptors play critical roles in migration. Expression of chemokine 
receptors on DC and LC alters as these cells mature and migrate. Maturing DCs 
up-regulate receptors for constitutively expressed chemokines such as CCR7, 
which permits chemoattraction towards lymphatic endothelium, which 
expressed the ligand for this receptor, SLC. CCR7 has recently been shown to 
play a vital role in both constitutive DC migration and in increased trafficking 
which occurs in inflammation (Ohl et al., 2004).
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Immature DCs express a number of chemokines receptors such as CCR1, CCR2, 
CCR5 and CXCR1 for the inducible chemokines RANTES (CCL5), MIP-la 
(CCL3), MCP-3 (CCL7) and IL-8 (CXCL8). Upon inflammation and activation of 
DCs, these receptors are down-regulated to permit the cells to leave the 
inflammatory site which has the highest chemokine concentration (von Andrian 
and Mackay). Inflammation also stimulates recruitment of additional monocytes 
from the blood, which differentiate into dendritic cells and contribute to the 
increased trafficking of antigen presenting cells from the dermis to the lymph 
node (Randolph et al., 1998).
Once the DCs have migrated through the extracellular matrix, they must gain 
entry to the lymphatic capillary and traffick through the lymphatics to the 
regional lymph node. However, the roles that the lymphatic endothelium play in 
migration of DCs, both constitutive and in inflammation, have yet to be 
identified. The in vitro studies detailed in chapters 4 and 5 of this thesis 
document a change in transcription and protein profiles in LEC specifically in 
response to pro-inflammatory conditions. One interpretation of this "re­
programming" is that lymphatic endothelium is required to perform vital 
functions in the onset of inflammation, including attracting leukocytes from the 
tissues by the secretion of chemokines, tethering them at the surface through the 
newly expressed adhesion molecules and then allowing transmigration by 
remodeling of cell-cell junctions. To substantiate this hypothesis, experiments 
detailed in this chapter sought to confirm whether or not these changes were also 
observed within intact lymphatic vessels in vivo and are concurrent with the 
massive up-regulation of trafficking which occurs in inflammation.
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6.2 Results
6.2.1 Cultured mouse ear tissue
Experiments detailed in the previous two chapters had shown LYVE-1 down- 
modulation by TNFa in three human primary lymphatic endothelial cell lines 
and two primary mouse cell lines. Similar studies also showed up-regulation of 
ICAM-1 in both mouse and human LEC. To investigate the responsiveness of 
lymphatic endothelium to this pro-inflammatory cytokine within intact tissue, 
mouse ear explants were used and lymphatic endothelium surveyed for LYVE-1 
and ICAM-1 expression by whole mount tissue staining.
Ear explants were cultured in either medium alone (described in chapter 2) or 
supplemented with recombinant mouse TNFa, lOOng/ml. Whole mount tissue 
samples were then prepared, staining for LYVE-1 or ICAM-1.
The images captured of whole mount sections show the branched network of 
blind-ended lymphatic vessels spread throughout the tissue. Strong staining of 
these LYVE-1-positive vessels was observed in tissue cultured in medium alone. 
However a clear reduction in expression of LYVE-1 was observed following 
culturing of explanted tissue in the presence of TNFa. Representative fields of 
view are shown in figure 6.1.
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Figure 6.1 Effect of TNFa on LYVE-1 expression in intact dermal lymphatic vessels. Mouse 
dermal explants were cultured for 24h in either medium alone (panels A and B) or in medium 
supplemented with TNF, 100ng/ml (C and D), prior to whole mount staining using the LYVE-1 mAb 
C1/8 and goat anti-rat AlexaFluor®488. The fluorescence microscope images shown in panels A 
and C were captured at the same exposure and gain settings, as were B and D, at magnification: X 
100 .
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To quantitate the reduction in expression of LYVE-1,10 LYVE-l-stained images 
of control and TNFa-treated tissue were captured and converted to grey scale to 
measure the mean fluorescence of each image by OpenLab software, subtracting 
the background staining from each image captured. The Mann-Whitney 
statistical test was performed on data sets from each pair of ears, to compare the 
difference between the two means. This test was chosen as it makes no 
assumptions that the data is normally distributed, unlike a two-sample t-test. 
The results of analyses show that the majority of pairs demonstrate a statistically 
significant difference at the 0.1% level (figure 6.2). However, it should be noted 
that there was considerable variation between individual ear preparations in the 
expression of LYVE-1, efficiency of staining and responsiveness to TNFa, even 
when manipulations were performed in parallel. In some cases TNFa-treatment 
resulted in a reduction in LYVE-1 expression which was only significant at the 
10% level. In addition, the level of LYVE-1 expression varied between samples of 
untreated tissues and even within different areas of the same ear, as has been 
observed before in both cultured cells and in tissue samples. This variation is 
most probably due to the preparation of ear tissue to expose the dermis, which 
itself acts as a stimulus to induce migration of Langerhans cells from the 
epidermis through up-regulating the production of endogenous pro- 
inflammatory cytokines. Nevertheless, stimulation with TNFa induced a 
significant reduction in LYVE-1 expression on the intact lymphatic vessels within 
cultured mouse ear tissue.
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Figure 6.2 Quantitation of LYVE-1 down-regulation in intact lymphatic vessels. Mouse ear 
tissue was cultured for 24h in either medium alone or in media supplemented with TNFa, 
(100ng/ml), prior to whole mount staining using the LYVE-1 mAb C1/8 and goat anti-rat 
AlexaFluor®488. 10 images were captured of each ear section by fluorescence microscopy and 
the mean fluorescence of each field of view measured by Open Lab software. Representative 
pairs of data are shown on the graph, ± standard error. The Mann-Whitney test was performed to 
assess the statistic significance between each pair of data.
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Parellel whole mount staining of the same dermal explants to detect ICAM-1 
expression showed clear up-regulation of ICAM-1 throughout the tissue 
following TNFa-treatment (figure 6.3). However many of these structures were 
much thinner than lymphatic vessels and likely to represent inflamed blood 
vessel endothelium which characteristically shows an increase in ICAM-1 
expression upon stimulation with TNFa (Springer, 1990). Initial attempts to 
measure ICAM-1 up-regulation on lymphatic endothelium by double-staining 
whole mount tissue with ICAM-1 and the lymphatic marker podoplanin were 
unsuccessful as the antibodies require short (3h) and long (48h) fixation times 
respectively and therefore could not be used in the same staining procedure. 
Also anti-CD34 antibody (to distinguish blood vessels) proved unsuitable for use 
on these tissue sections, probably due to the inability of the antibody to recognise 
paraformalehyde-fixed antigen.
To quantitate ICAM-1 expression in ear tissue cultured in either the presence or 
absence of TNFa, 10 images in grey-scale were captured of each ear section 
stained and the mean fluorescence of each image measured by OpenLab 
software, as had been performed for the quantitation of LYVE-1 expression. The 
results (figure 6.4) show that the mean fluorescence from ICAM-1 staining was 
higher in TNFa-stimulated tissue. However, the large variations in intensity of 
staining in untreated tissue meant that the differences in expression were only 
statistically significant at the 5% level. Also any increase in expression cannot be 
attributed to that on lymphatic endothelium alone.
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Control
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Figure 6.3 Effect of TNFa on ICAM-1 expression in mouse dermal explants. Tissue was 
cultured for 24h in either medium alone or in media supplemented with TNFa, (100ng/ml), prior to 
whole mount staining using the goat anti-ICAM-1 (R and D Systems) and donkey anti-goat 
AlexaFluoKs)568. Images were captured by fluorescence microscope, at magnification: X 100.
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Figure 6.4 Quantitation of ICAM-1 up-regulation in mouse dermis. Mouse ear tissue was 
cultured for 24h in either medium alone or in media supplemented with TNFa, (100ng/ml), prior to 
whole mount staining with goat anti-mouse ICAM-1 and an AlexaFluoKs)568 donkey anti-goat 
conjugate. 10 images were captured of each ear section by fluorescence microscopy and the 
mean fluorescence of each field of view measured by Open Lab software. Representative pairs of 
data are shown on the bar chart, ± standard error. The Mann-Whitney test was performed to 
assess the statistic significance between each pair of data.
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6.2.2 TNFa-mediated contact hypersensitivity in mice
The well-characterised model of oxazolone-induced contact hypersensitivity 
(CHS) was used to study acute inflammation in mice. It held the advantage over 
the use of explant tissue culture of being a more physiological setting for 
inflammation, with endogenously produced pro-inflammatory cytokines 
eliciting the reaction. The model is described in more depth in the introduction 
to this chapter and in chapter 1. The whole animal studies permitted tracking of 
leukocyte migration in relation to any changes in lymphatic vessel receptor 
expression during the elicitation phase, where the sensitised animal is challenged 
with the same antigen.
6.2.2.1 Expression of LYVE-1 following challenge
To assess whether LYVE-1 is down-modulated in TNFa-mediated inflammation 
within mouse dermis, male Balb/c mice were sensitised by application of 
oxazolone to their shaved abdomens. Five days later the left ear of each mouse 
was challenged by painting oxazolone on to the dorsal surface, whilst 95% 
ethanol carrier alone was applied to the right ears as a mock-treated control. The 
mice were sacrificed 24h post-challenge and the increase in ear mass due to 
oedema was used as a parameter for the extent of inflammation (figure 6.5). 
Oxazolone treatment was found to induce a mean gain in mass of mouse ear 
tissue of 2.28 x fold, in comparison to the mass of the contra lateral mock-treated 
ear (± 0.41). Whole-mount tissue sections were prepared of the dorsal and 
ventral aspects. Double-immunofluorescence staining for LYVE-1 and 
podoplanin (figure 6.6) showed that LYVE-1 is indeed down-regulated relative to 
the more stably expressed podoplanin-marker.
302
Chapter 6 Effect of Inflammation on Lymphatic Endothelium In Intact Tissue 6.2 Results
3.5
2.5 -
©
o
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Mouse
Figure 6.5 Increased ear mass elicited by oxazolone in CHS reactions in mice. Oxazolone- 
sensitised male balb/c mice were challenged with the agent on one ear and with ethanol alone to 
the contra-lateral as a mock-treated control. 24h following challenge, mice were sacrificed and 
ears removed and weighed. Ratios of ear masses (oxazolone-treated / mock-treated) of 20 mice 
are shown in the graph above.
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Figure 6.6 Down-modulation of LYVE-1 in mouse dermis following CHS. Ears from a 
sensitised mouse were painted with either ethanol alone (panel A) or with oxazolone in ethanol 
(panel B). 24h following the challenge, whole mount dermal tissue sections were prepared and 
stained for LYVE-1 using C1/8 and polyclonal antibodies to podoplanin. AlexaFluorts) conjugates 
488 (green) and 594 (red) were used respectively. Images were captured at 100X by confocal 
microscopy.
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LYVE-1 expression before and after oxazolone treatment was quantitated using 
the same procedure as for the explant studies. A statistically significant decrease 
in LYVE-1 expression was measured in most ears from mice sacrificed 24h 
following oxazolone challenge (figure 6.7, upper panel). Interestingly, ventral 
aspects of mouse ear tissue showed less significant difference in LYVE-1 
expression and in some cases no difference at all. One possible explanation for 
this is because oxazolone was applied to the dorsal aspect of the ear and thus the 
ventral side would not receive such high levels of stimulation.
Although LYVE-l-negative lymphatic vessels were observed in tissue prepared 
from mice sacrificed 12h post challenge, the difference in expression was not 
statistically significant., (figure 6.7, lower panel).
6.2.2.2 Kinetics of LYVE-1 dozvn-regulation in inflamed dermal tissue
To investigate the kinetics of LYVE-1 down-regulation during the early stages of 
the elicitation phase of oxazolone induced CHS, frozen sections of ears were 
prepared from sensitised mice which had been sacrificed 3h, 6h, 12h, 18h and 24h 
following challenge. As before, the increase in ear mass was used as a parameter 
for the extent of inflammation over this time course (figure 6.8). Double­
immunofluorescence staining for podoplanin and LYVE-1 was performed on 
each tissue section (figure 6.9) and the number of podoplanin-positive vessels 
expressing LYVE-1 recorded (table 6.1). Although lymphatic vessels expressing 
depressed levels of LYVE-1 could be observed, in the mock challenged ear as 
well as at 3h following elicitation, such vessels were rare, accounting for 
approximately less than 5% of podoplanin-positive vessels observed. At 12h 
LYVE-l-negative vessels became more frequently observed, accounting for 71% 
of the vessels examined and by 18h and 24h, only 30% of lymphatic vessels had 
retained LYVE-1 expression.
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Figure 6.7 Quantitation of LYVE-1 expression detected by immunofluorescence microscopy 
of whole mount mouse ear sections. Ears from sensitised mice were painted with either ethanol 
alone or with oxazolone in ethanol and then sacrificed either 12h (lower graph) or 24h (upper 
graph) following the challenge. Whole-mount dermal tissue sections were prepared of the dorsal 
(D) and ventral (V) aspects and stained for LYVE-1 using C1/8 and goat anti-rat AlexaFluoKg)488. 
Fluorescence was quantitated by Open Lab software, capturing 10 images of each ear at x 100 
magnification, both left (L, challenged) and right (R, unchallenged). Exposure and gain settings of 
the camera were unaltered between collecting data of each pair. Background fluorescence was 
subtracted from each image prior to quantitation.
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Figure 6.8 Kinetics of the increase in ear mass elicited by oxazolone in CHS reactions in 
mice. Oxazolone-sensitised male balb/c mice were challenged with the agent on one ear and with 
ethanol alone to the other as a mock-treated control. 3-24h following challenge, mice were 
sacrificed in triplicate at each time point and ears removed and weighed. Ratios of unchallenged 
ear mass to challenged ear mass were calculated and are plotted ± standard error.
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Figure 6.9 Time course to follow the down-modulation of LYVE-1 on mouse ears in the 
elicitation of DCH. Frozen sections of ears from unchallenged mouse ear (control) and from mice 
sacrificed at 6h, 18h and 24h post-oxazolone challenge were stained for LYVE-1 (green) and 
podoplanin (red) with the appropriate AlexaFluor® conjugates. Images were captured at 600X 
magnification by confocal microscopy.
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Time
(h)
Number of 
podoplanin- 
positive 
vessels
Number of 
LYVE-1- 
positive 
vessels
Percentage 
of LYVE-1- 
positive 
vessels (%)
0 24 23 96
3 23 22 96
6 23 22 96
12 24 17 71
18 25 8 32
24 26 8 31
Table 6.1 Quantitation of the percentage of LYVE-1 positive lymphatic vessels in mouse 
dermis following elicitation of inflammation by CHS. The numbers of podoplanin-positive 
vessels visible in 8pm frozen sections were counted and expression of LYVE-1 by these vessels 
was recorded and expressed as a percentage of the number of podoplanin-lymphatic vessels.
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6.2.23 Expression of leukocyte adhesion molecules by dermal lymphatic vessel 
endothelia follow ing oxazolone challenge
To follow the expression of the adhesion molecules VCAM-1 and ICAM-1 in 
DCH, frozen sections prepared at 3h, 6h, 12h, 18h and 24h post-challenge were 
double stained for podoplanin and either VCAM-1 or ICAM-1 (figures 6.10 and 
6.11) and the number of podoplanin-positive vessels expressing these proteins 
recorded (tables 6.2). The results show that expression of neither receptor was 
evident on lymphatic vessels in untreated tissues but 3h following the elicitation 
of inflammation, a minority of vessels (5-10%) was found to be positive for these 
molecules. By 18h, approximately 50% of the lymphatic vessels observed 
expressed these receptors, concurrent with the down-regulation of LYVE-1 
(figure 6.9 and table 6.1). Many of these vessels had adopted an unusual 
morphology: instead of the characteristic collapsed lumen apparent in 
uninflamed tissue, the lumens of many vessels (for example, in figure 6.11 at the 
18h time point) appeared distended. This was most probably due to the 
increased interstitial pressure induced by the oedema associated with the 
elicitation phase of CHS. The increased interstitial pressure stretches the 
collagen and elastin fibres which anchor lymphatic endothelium in the tissues 
and expands the lumen of the vessel, opening intercellular junctions between 
overlapping endothelial cells to allowing passage of fluid and macromolecules 
into the vessel.
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Figure 6.10 Time-course of VCAM-1 expression on mouse dermal lymphatics in the 
elicitation of CHS. Frozen sections of ears from unchallenged mouse ear (control) and from mice 
sacrificed at 6h, 18h and 24h post-oxazolone challenge were stained for VCAM-1 (red) and 
podoplanin (green), with the appropriate AlexaFluor® conjugates. Images were captured at 600X 
magnification by confocal microscopy.
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Figure 6.11 Time course of ICAM-1 expression on mouse dermal lymphatics in the elicitation 
of CHS. Frozen sections of ears from unchallenged mouse ear (control) and from mice sacrificed 
at 6h, 18h and 24h post-oxazolone challenge were stained for ICAM-1 (red) and podoplanin 
(green), with the appropriate AlexaFluoKs) conjugates. Images were captured at 600X 
magnification by confocal microscopy.
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Time
(h)
Number of 
podoplanin- 
positive 
vessels
Number of 
VCAM-1- 
positive 
vessels
Percentage 
of VCAM-1- 
positive 
vessels 
(%)
Number of 
podoplanin- 
positive 
vessels
Number
of
ICAM-1-
positive
vessels
Percentage 
of ICAM-1- 
positive 
vessels 
(%)
0 19 0 0 20 0
3 24 2 8 5
6 31 4 13 6 19
12 24 4 17 24 4 17
18 24 12 50 23 11 48
24 23 12 52 20 14 70
Table 6.2 Quantitation of the percentage of VCAM-1- and ICAM-1-positive lymphatic vessels  
in mouse dermis following elicitation of inflammation by CHS. The numbers of podoplanin- 
positive vessels visible in 8pm frozen sections were counted from 7 fields of view and expression of 
the leukocyte adhesion molecules by these vessels was recorded and expressed as a percentage 
of the number of podoplanin-lymphatic vessels.
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6.2.2 A Effects of inflammation on dermal leukocyte trafficking
The up-regulation of VCAM-1 and ICAM-1 in inflamed lymphatic endothelium, 
coupled with the decreased expression of LYVE-1 is likely to have implications 
for the trafficking of leukocytes such as antigen presenting cells (APCs) en route 
from the dermis to the lymph nodes. To test the hypothesis that APC trafficking 
occurs concurrently with the changes in expression of these receptors, frozen 
sections of mouse ear from the same time points following elicitation of the CHS 
response were again analysed by immunofluorescence, using MHC class II as a 
marker for DCs, monocytes and macrophages. The MHC class II-positive cells 
were closely associated with the lymphatic endothelium, and most likely in the 
process of reverse transmigration. These vessels frequently exhibited a 
distended lumen, suggestive of high interstitial pressure and inflammation as 
described earlier. This apparent reverse transmigration was observed at 18h and 
24h following stimulation, time points at which double-immunofluorescence 
staining detailed in figures 6.10 and 6.11 had shown the up-regulation of VCAM- 
1 and ICAM-1 and down-modulation of LYVE-1 (figure 6.9). Thus it is likely that 
the change in expression of surface molecules is a necessary pre-requisite for the 
increase in DC trafficking which occurs in inflammation. Some transmigration of 
MHC class II positive cells occurred at earlier time points, for example 3h 
following elicitation of inflammation (figure 6.12). These may represent 
constitutive trafficking events as it is known that DC circulate from the dermis to 
the lymph nodes even in the absence of inflammatory stimuli, as described in the 
general introduction (chapter 1), by a mechanism which may not require high 
expression of adhesion molecules such as ICAM-1 and VCAM-1.
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Figure 6.12 Reverse transmigration of MHC class ll-positive APCs into the lymphatics over a 
24h period following elicitation of DCH in mouse ear. Frozen sections were prepared from 
unchallenged tissue (Ctrl) and challenged tissue harvested at 3h, 12h, and 24h post-challenge, 
then stained for podoplanin (green) and MHC class II (red) using the appropriate secondary 
conjugates. Images were captured by confocal microscopy at 600X magnification.
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To gain a three-dimensional perspective of MHC class II-positive cells during 
reverse transmigration, whole mount staining was performed using this marker 
in combination with either LYVE-1 or podoplanin antibodies (figure 6.13). In the 
unstimulated dermis, these APCs appear randomly dispersed between the large 
branched lymphatic vessels and probably constitute immature DCs and LCs 
resident in the tissue (figure 6.13 panel A). Following elicitation of inflammation, 
extensive infiltration of the tissue by inflammatory cells was observed, which can 
be seen surrounding podoplanin-negative dermal capillaries (figure 6.13 panel 
B). These are likely to constitute newly recruited monocytes transmigrating from 
the blood circulation, which subsequently differentiate into DCs and migrate into 
the lymphatics or will remain in the tissue as macrophages (Randolph et al., 
1998). In inflamed dermis, MHC class II-positive cells could be seen surrounding 
podoplanin-positive lymphatic endothelium, probably prior to reverse 
transmigration. The majority of the vessels in contact with these putative APCs 
commonly had a loop-like structure (figure 6.13 panel D), typical of lymphatics 
in association with sweat glands (Prof. Francesco Pezzella, personal 
communication). Such regions of the dermis might be expected to receive higher 
doses of oxazolone, through entry via the sweat gland pore, which could explain 
why more trafficking events occurred across these looped lymphatic capillaries. 
Interestingly, the APCs observed also appeared to associate preferentially with 
LYVE-l-low lymphatic vessels rather than those vessels which retained higher 
expression (figure 6.13 panel C). Whether the down-regulation of LYVE-1 and 
the reverse transmigration of DCs are independent events or whether LYVE-1 
down-regulation is a pre-requisite of DC migration remains to be determined.
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Figure 6.13 Whole mount staining to illustrate the migration of APCs to lymphatic vessels.
Tissue was stained with either rabbit anti-LYVE-1 and rat anti-MHC class II (panels A and C) or 
rabbit anti-podoplanin and rat anti-MHC class II (panels B and D). In naive ear tissue (panel A and 
below), MHC II positive cells appear scattered throughout the tissue. 24h following challenge of 
sensitised tissue with oxazolone, MHCII positive cells are visible lining up alongside podoplanin- 
negative vessels (B) and migrating towards lymphatic vessels expressing LYVE-1 (C) and 
podoplanin (D). Images were captured by confocal microscopy at magnification x 100.
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62.2.5 Effects of inflammation on dermal chemokines expression
The results in chapter 5 showed that the expression and secretion of 
inflammatory leukocyte chemokines including JE, a homologue of human MCP-1 
(CCL2) were strongly up-regulated on TNFa-stimulated primary mouse LEC 
during in vitro culture. To investigate whether this is borne out in inflamed 
tissue, whole-mount tissue sections of oxazolone challenged mouse ear were 
prepared and stained for expression of JE, as well as SLC (CCL21), a chemokine 
reported to be constitutively expressed in lymphatic endothelium (Kriehuber et 
al., 2001), (figure 6.14). In unstimulated dermis, virtually no JE was detected. 
However, 24h following administration of oxazolone to a sensitised mouse, JE 
expression increased dramatically. Curiously, JE was not closely associated with 
lymphatic vessels but scattered throughout the tissue. However, as the sections 
were not double-stained for a lymphatic marker it is possible that some co­
localisation occurs with the lymphatics but is not clearly visible due to the high 
concentration of chemokine secreted from other cells in the tissue. In addition, 
the possibility could not be excluded that the source of JE was indeed the 
inflamed lymphatic endothelium, but that the chemokine was secreted and 
bound to low-affinity sites (such as heparin sulphate proteoglycans) in the 
matrix.
Unlike JE, expression of SLC did not appear to increase in response to oxazolone, 
rather a slight decrease in staining intensity was observed, confirming the 
findings of Kriehuber et al. (2001) from in vitro studies and the results from the 
microarray analyses described in chapter 5 of this thesis. Also SLC appeared 
restricted to the lymphatic endothelium, in contrast to JE. Expression of SLC 
with LYVE-1 on lymphatic endothelium of normal mouse ear tissue is shown in 
figure 6.15. SLC does not co-localise with LYVE-1, which is expressed primarily 
at cell-cell junctions, as has been observed in confluent lymphatic endothelial
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cells in culture (chapter 5). Instead, SLC occupies either an intracellular location 
or is displayed at the surface, bound to heparin sulphate proteoglycan.
Goat polyclonal antisera against RANTES and MCP-1 yielded no staining in 
either normal or inflamed mouse ear tissue (data not shown). This was probably 
due to the failure of these antibodies to recognise formaldehyde-fixed antigen, 
rather than a lack of expression of these chemokines, which are known to be 
expressed by a variety of cell types under inflammatory conditions, including 
keratinocytes and blood vascular endothelium. Therefore further experiments 
would be required to optimize conditions for staining, for example the length of 
paraformaldehyde fixation (which proved to be critical for podoplanin staining 
using the rabbit polyclonal antibody). Immunofluorescence staining of frozen 
sections with chemokines yielded images upon which it was impossible to 
distinguish background staining from expression dispersed throughout the 
tissue. Therefore the key chemoattractants of APCs for lymphatic capillaries 
remain to be identified but the close association of these cells with the lymphatic 
vessels is highly suggestive of reverse transmigration, which is likely to be 
promoted by chemokine secretion from lymphatic endothelial cells, as suggested 
from in vitro studies described in chapter 5.
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Figure 6.12 Whole mount staining of chemokines in inflamed dermis. Paired lateral and 
contra-lateral ears from mice which had either remained unchallenged (panels A and C) or had 
undergone challenge with oxazolone (panels B and D) were stained with either goat anti-JE 
(panels A and B) or goat anti-SLC (panels C and D), detecting with AlexaFluor®568 donkey anti­
goat conjugate. Images were captured by confocal microscopy at X 100.
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Figure 6.13 Expression of SLC by lymphatic endothelium in normal mouse ear. Tissue was 
stained using goat anti-SLC and the LYVE-1 mAb C1/8, detecting using the AlexaFluor® 
conjugates 568 (red) and 488 (green) raised in donkey. Images were captured by confocal 
microscopy at magnification X 600.
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6.3 Discussion
6.3.1 Expression of adhesion receptors in inflammation
The findings in this chapter have confirmed that the down-modulation of LYVE- 
1 which was characterized in vitro in both human and mouse LEC (chapters 4 
and 5) also occurs in intact lymphatic vessels. Mouse dermal explants cultured 
in the presence of TNFa showed a statistically significant lower expression of 
LYVE-1 than tissue cultured in media alone. Moreover, down-regulation of 
LYVE-1 was also observed and quantitated in oxazolone-induced delayed 
contact hypersensitivity, a well-characterised TNFa-mediated model of 
inflammation in the skin. Following 12h of elicitation of inflammation, over 50% 
of lymphatic vessels exhibited a loss of LYVE-1, concurrent with the up- 
regulation of the leukocyte adhesion molecules VCAM-1 and ICAM-1 on 
lymphatic vessels. This confirmed the results described in chapter 5, where 
induction of these receptors by TNFa and TNF0 was detected in cultured 
primary mouse and human LEC. An earlier study by McHale et al. (1999) had 
detected an increase in expression of ICAM-1 and VCAM-1 in endothelium 
during the elicitation phase of contact hypersensitivity in mice, mediated by 
TNFa. However the immunohistochemical studies carried out had not used 
either blood vascular or lymphatic endothelial markers and thus the identity of 
adhesion molecule-positive vessels could not be determined. Other studies had 
presented limited evidence for ICAM-1 and VCAM-1 expression in human and 
ovine lymph node sinuses (Sawa et al., 1999; Young et al., 2000) but these were 
not substantiated by co-localization with lymphatic vessel specific markers. 
Therefore the study described in this chapter is the first to convincingly 
demonstrate expression of VCAM-1 and ICAM-1 in tissue lymphatics and to 
show their up-regulation during inflammation.
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In oxazolone-induced contact hypersensitivity in mice, the up-regulation of 
ICAM-1 and VCAM-1 were concurrent with the down-modulation of LYVE-1 
and the massive increase in the number of APC trafficking events across 
lymphatic endothelium which occurs with the onset of inflammation. 12h 
following elicitation of inflammation, extravasation of newly recruited MHC 
class II-positive cells, most likely monocytes, from blood capillaries were 
observed. These differentiate in the dermis into either macrophages which stay 
resident in the peripheral tissue or DCs, which reverse transmigrate into the 
lymphatics to present their newly acquired antigen within the T cell-rich 
paracortical area of a regional lymph node (Randolph et al., 1998). Data 
presented both in this chapter and in chapter 5 suggest that the lymphatic 
endothelium plays an active role in the regulation of these trafficking events and 
up-regulation of the adhesion receptors ICAM-1 and VCAM-1 may be necessary 
to support the increased number of APC trafficking events of reverse migration 
into afferent lymphatic vessels which occur during inflammation.
6.3.2 The role of chemokines and their receptors in leukocyte trafficking into 
lymphatic endothelium
In recent studies by other workers, constitutive trafficking of DCs was reported 
to occur through a mechanism which involves (among other interactions yet to 
be elucidated) binding of SLC (CCL21) to its receptor CCR7 on the DC surface. 
(Ohl et al., 2004). A role for CCR8 in migration of monocyte-derived DC from 
the dermis to the lymph node under mild inflammatory conditions has also been 
suggested (Qu et al., 2004). However studies of knock-out mice which lack 
several genes encoding CCR7 ligands revealed a reduction in Langerhans cell 
recruitment to the lymph node and thus suggested that CCR8 does not replace a 
need for CCR7 ligands and the two receptors function at different points in a 
common pathway downstream of recruitment into the skin. Qu et al. (2004) also 
showed that CCR8 knock-out mice showed decreased accumulation of
324
Chapter 6 Effect of Inflammation on Lymphatic Endothelium In Intact Tissue 6.3 Discussion
phagocytic DC within the lymph node. They then went on to demonstrate that 
CCL1, the ligand of CCR8, was not expressed in LYVE-l-positive dermal 
lymphatic vessels. This is confirmed by data from the microarray analyses 
(detailed in chapter 5 of this thesis) which found that the transcript for CCL1 
(TCA-3 in mouse, 1-309 in human) was virtually absent in both the mouse and 
human LEC surveyed. However, Qu et al. (2004) detected CCL1 in the 
subcapsule of the lymph node and paracortical vessels that were thought to be 
HEVs and therefore the CCL1/CCR8 interaction may act down-stream of entry 
into the afferent lymphatics, perhaps in regulating entry in the subcapsular sinus 
of the regional lymph node. Whether another ligand for CCR8 is expressed on 
the endothelium of initial lymphatics to mediate reverse transmigration in 
addition to the CCL21/CCR7 interactions or whether CCR8 plays a role in the 
transition between human monocyte subsets and thus indirectly affects 
trafficking across the lymphatic endothelium remains to be determined.
Neither CCR2 nor CX3CRI (mediating inflammatory monocyte recruitment into 
tissue, reviewed by von Andrian and Mackay, 2000) were found to be essential 
for accumulation of Gr-lintermediate monocytic DC precursors in skin or lymph 
nodes under the mildly inflammatory conditions assessed (Qu et al., 2004). 
Whole mount staining shown in this chapter revealed that expression of 
JE/MCP-1 (CCL2), one of the ligands for CCR2, was dramatically induced in 
inflamed mouse dermis. However, although experiments in chapter 5 had 
shown this chemokine is up-regulated by TNFa on both mouse and human 
primary LEC, no clear association with any vessel-like structure could be 
observed in vivo. Instead expression was high throughout the tissue. Thus 
lymphatic endothelium may play a general role in inflammatory cell recruitment 
to the tissues and the chief role of MCP-1 secreted by lymphatic endothelium 
may be in recruiting monocytes from the blood circulation rather than in reverse 
transmigration into the lymphatics, as blood capillaries and initial lymphatics are
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frequently juxtaposed within the dermis. In addition, the chemokines secreted 
by the lymphatic endothelium may exert a more distant effect. An earlier study 
by Palframan et al. (2001) had shown that MCP-1 underwent dramatic induction 
during inflammation in the skin and was transported through the afferent lymph 
to the lymph node cortex from where it was conveyed to the luminal surface of 
HEVs by reticular network fibres, triggering integrin-dependent arrest of rolling 
monocytes and thus enhanced recruitment to the lymph node. The researchers 
concluded that inflamed peripheral tissues could exert "remote control" over the 
composition of leukocyte populations homing to the draining lymph nodes 
through the projection of their local chemokine profile. Results from this chapter 
and chapter 5 suggest that afferent lymphatic endothelial cells may be the source 
of MCP-1 detected by Palframan et al. (2001) and possibly other additional 
chemokines. Thus the lymphatic endothelium may be involved in this one-way 
line of communication and not only influence leukocyte migration and fate in the 
vicinity but also at other more distant locations. It would be of interest to 
investigate whether LEC secrete chemokines into the surrounding extracellular 
matrix and or in the basolateral direction, for transport to the peripheral draining 
lymph node. Transwell™ assays could be employed to test this and determine 
which chemokines are secreted from which surface.
Expression of the constitutive lymphatic vessel chemokine SLC by oxazolone- 
induced inflammation in dermal vessels did not change significantly. Similarly, 
expression of SLC by LEC did not change significantly following stimulation 
with TNFa in the array analysis (chapter 5). Data from the human array revealed 
a very marginal increase (1.1 fold) in expression whereas the mouse transcipt 
showed a very marginal decrease (0.8 fold). This is in agreement with the work 
of Kriehuber et al. (2001), who found that SLC was expressed in an activation- 
independent manner by isolated primary LEC. However Sallusto et al. (1994) 
and Martin-Fontecha et al. (2003) reported an increase in SLC in inflammation
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based on im m unohistochem ical staining of tissue sections. It should  be noted in  
those latter studies that no attempt w as m ade to identify the SLC-positive vessels  
as lym phatic endothelium  using specific markers, w hereas studies by  Kriehuber 
et al. drew  their conclusions from cells w hich had been extensively phenotyped  
as LEC on the basis of their expression of the lymphatic markers LYVE-1, prox-1, 
podoplanin and VEGFR-3.
6.3.3 LYVE-1
The dramatic down-m odulation of LYVE-1 by  LEC has been show n  throughout 
this chapter as w ell as in chapters 4 and 5 of this thesis. This begs the question  
w hy, upon stim ulation w ith  TNF are LEC so keen to rem ove this receptor from  
their surface and from the surrounding m edium ? Observations from  the w hole  
m ount tissue sections of oxazolone-challenged m ouse derm is m ay hold  a clue. 
M any of the sections examined appeared to show  a preference of transm igrating  
MHC class II-positive leukocytes for LYVE-1-low lym phatic vessels, on w hich  
LYVE-1 had been partially or fully down-regulated. Thus it is tem pting to  
speculate that in normal uninflam ed tissue LYVE-1 plays a role in  m aintaining  
lym phatic perm eability and the stabilisation of cell-cell junctions, regulating  
accessibility of the vessel to migrating antigen presenting cells. Clearly som e  
constitutive migration m ust be perm itted but the bulk of DCs are know n to  
remain in the derm is and epidermis, alw ays on guard against an antigen  
challenge and only exiting after inflam m ation-induced maturation. The 
microarray analyses in chapter 5 indicated that certain claudins and occludins, 
know n players in cell-cell junctions w ere also down-regulated. W hole-m ount 
staining of intact lymphatic vessels show n in this chapter, as w ell as 
im m unofluorescence im ages of lymphatic endothelial cells in  culture in  chapter 
5, have show n that LYVE-1 tends to be expressed preferentially at the cell-cell 
junctions. A lso, recent research by Poritz et al (2004) has show n  that TNFa  
disrupts tight junction assembly. Perhaps in  the absence of LYVE-1, the vesse l
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m ay perm it more transmigration betw een endothelial cells and entry into the 
lym phatics, to cope w ith  the increased trafficking of n ew ly  extravasated  
m onocytes. Peripheral blood m onocytes entering the tissues m ust first 
differentiate into DCs before exiting via the lym phatics fo llow ing oxazolone  
challenge and evidence from in vitro and in vivo studies have show n  that this 
process m ay take up to tw o days to com plete (Randolph et al., 1998; Rotta et al., 
2003). Experiments described in this chapter have show n that the onset of loss of 
LYVE-1 does not occur instantaneously follow ing the elicitation o f inflam m ation  
but rather at 12h and later tim e points follow ing challenge, w hich  w ou ld  be m ore 
concurrent w ith  the reverse transmigration of m onocyte-derived DC. To 
establish w hether the down-m odulation of LYVE-1 is a necessary pre-requisite 
for increased leukocyte trafficking, transmigration assays o f m onocyte-derived  
DCs through m onolayers of LEC could be used, rem oving LYVE-1 expression by  
the use of siRNA. Such a m odel could also be used to exam ine the roles of 
adhesion m olecules, by  inducing up-regulation of expression b y  TNFa and using  
blocking antibodies against these receptors to assess their individual 
contributions to trafficking.
If LYVE-1 does indeed play the role of a "gate keeper" in norm al healthy tissue, 
the phenotype of the recently generated LYVE-1 knock-out m ouse w ou ld  be  
expected to show  increased trafficking of antigen-presenting cells to the lym ph  
nodes, even in the absence of pro-inflammatory stim ulus. Recent research by  
Cera et al. (2004) into the functions of the junctional adhesion m olecule JAM-A  
dem onstrated that DCs from Jam -A-im ice exhibit an increase in  random  
migration and transmigration across lym phatic endothelial cells. Such m ice also  
show ed increased localisation of skin DCs to lym ph nodes and an enhanced  
reaction to contact hypersensitivity. Earlier work had found that JAM-A on  
blood vascular endothelial cells enhanced transmigration and therefore it w ou ld  
appear that endothelial JAM-A has a positive role in  prom oting cell
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extravasation. H ow ever JAM-A expressed on DC w as found to p lay a role in  
lim iting cell motility. It w ill be fascinating to discover h ow  the LYVE-1 m ouse  
responds in the delayed hypersensitivity reaction and w hether increased  
trafficking is observed. H ow ever the m echanism  by w hich LYVE-1 could act as 
such a barrier remains purely speculative at this stage. The fact that LYVE-1 is 
abundantly expressed on lym phatic endothelium  in vivo and in  prim ary cultured  
LEC in vitro despite being functionally silent w ith  respect to H A -binding is 
perhaps indicative that LYVE-1 can bind other ligands, either in  LEC them selves 
or in  the surrounding m edium . Such interactions could contribute to the barrier 
function. Another possibility is that LYVE-1 m ay engage in  hom ophilic  
interactions in a similar manner to CD31. U nlike CD31, LYVE-1 does not possess  
Ig dom ains or any similar structures w hich  m ight m ediate such an interaction. 
H ow ever LYVE-1 can form hom o-dim ers via the im paired cysteine residue  
(Cys257) in the transmembrane proximal dom ain (Tom N ightingale, D Phil thesis, 
U niversity of Oxford, 2004). The formation of dimers m ay g ive rise to a n ovel 
dom ain betw een the link m odules of the adjacent units, w hich  could  interact 
w ith  such a dim er on an adjacent cell. The lack of constitutive b inding b y  LYVE- 
1 of its glycosam inoglycan ligand, H A  is clearly suggestive of another function, 
yet to be elucidated, in addition to that of an H A  receptor.
6.3.4 C onclusion
Results described in this chapter have show n that the up-regulation of the  
leukocyte adhesion m olecules VCAM-1 and ICAM-1 that had been extensively  
characterised in vitro (chapter 5) also occurs in  a m ouse m odel of TN Fa-m ediated  
inflammation. A dditionally, the TNFa-mediated down-regulation of LYVE-1 in  
intact lym phatic vessels in dermal tissue explants and in  the m ouse m odel of  
inflam m ation w as also show n, confirming data from three prim ary hum an LEC 
and tw o m ouse LEC lines described in chapters 4 and 5. Finally the up-  
regulation of JE/MCP-1 w as also detected in inflam ed m ouse derm is. Thus, data
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from the in vivo studies in this chapter has confirmed m any of the in vitro 
findings, w hich suggest that the lym phatic endothelium  responds to 
inflam m atory cytokines w ith  an expression programme to prom ote leukocyte 
m igration into the lymphatics.
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The lym phatic system  constitutes a network of h ighly perm eable absorbing  
vessels that is structurally distinct from the blood vasculature but functionally  
connected. Together these tw o circulatory system s act in  concert to maintain  
hom eostasis w ith in  the tissues, cell nutrition and rem oval of m etabolic by­
products (review ed by Mortimer, 1997). The initial lym phatic capillaries w ithin  
the skin originate as blind-ended endothelial-lined tubes and drain through a 
series of enlarging vessels, dim inishing in number until they reach the thoracic 
duct, w here the lym ph fluid is returned to the vasculature. Impaired lym phatic  
function can lead to the debilitating disease of oedem a (Berne et al., 1998) and  
cessation in  lym phatic flow  w ill result in death (Adair and Guyton, 1985).
The lym phatics provide a major exit route from the skin for circulating cells such  
as T-lym phocytes and macrophages, as w ell as professional antigen presenting  
cells (APCs) such as dendritic cells (DCs). A ntigens are transported to the 
regional lym ph node and a primary im m une response is initiated as naive  
lym phocytes are brought into contact w ith  APCs. Thus the lym phatics p lay  
critical roles in im m une surveillance and in the trafficking of APCs to the lym ph  
nodes, both constitutively and during inflammation, w here a dramatic increase 
in the num ber of trafficking events occurs (review ed by Randalph, 2001).
The elucidation of the molecular m echanism s behind lym phatic functioning  
relies upon the use of specific markers to discriminate betw een lym phatic vessels  
and blood vasculature in tissue sections and in cultured cells. O ne of the specific 
markers for the lym phatics is LYVE-1 (Banerji et al., 1999), the lym phatic H A  
receptor that forms the major subject of this thesis. D espite the w id e  use of this 
protein as a marker, its functions and the m echanism s b y  w hich  expression  is 
regulated have remained unknown. This PhD has sought to characterise the 
regulation of expression of LYVE-1 and to exam ine the response of the lym phatic  
endothelium  to inflammation.
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7.1 LYVE-1
7.1.1 Generation of monoclonal antibodies against mouse LYVE-1
To perm it investigations into m ouse tissue and com plem ent studies carried out 
using the hum an m onoclonal antibodies against LYVE-1 already raised by Dr. 
Remko Prevo in  the sam e laboratory, tw o m onoclonal antibodies (mAbs) against 
m ouse LYVE-1 Fc fusion protein w ere generated and characterised (chapter 3). 
The epitopes of both antibodies w ere show n to lie w ith in  the extracellular 
dom ain, in close proxim ity to the Link m odule, the H A -binding dom ain. O ne of 
the m Abs, (C l/8 )  proved a powerful tool for detecting lym phatics w ith in  m ouse  
tissue, particularly in w hole-m ount staining w hich perm itted a three- 
dim ensional perspective of lym phatic vessels and surrounding APCs (chapter 6). 
C l /8  w as also used extensively in the im m uno-selection of prim ary m ouse  
dermal LEC (chapter 5), w here it w as found to have a greater specificity for 
LYVE-l-positive LEC than rabbit polyclonal antisera and thus y ie lded  a purer 
population o f LEC.
Preliminary experiments w ere carried out to establish w hether either m A b  
induced functional effects on the LYVE-1 antigen. Curiously, the second m Ab  
(B l/1 0 ) w as found to reduce H A-binding by alm ost 70% in 293T-LYVE-1 
transfectants but only w hen  cells w ere exposed to the antibody during an  
incubation at 37°C: no such effect w as observed at 4°C. Furthermore a 33% loss  
of LYVE-1 surface expression w as detected by flow  cytom etry fo llow ing  
incubation of transfectants in the presence of B l/1 0  for 24h at 37°C. This m ost 
likely indicates that B l/1 0  m ediates loss of LYVE-1 surface expression through  
either shedding or internalisation. Further characterisation of this m Ab could  
include a tim e course to m easure the kinetics of the disappearance of LYVE-1 
surface expression from transfectants by flow  cytometry. To detect B l/1 0 -
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m ediated shedding, an ELISA could be em ployed to detect shed LYVE-1 in  the 
supernatant. The possibility of internalisation could be addressed u sing  confocal 
m icroscopy, double-staining w ith  polyclonal antisera to LYVE-1 and markers for 
the cell surface and subcellular compartments, to determ ine the intracellular 
location o f LYVE-1.
7.1.2 Factors regulating LYVE-1 expression
In order to define the limitations that LYVE-1 m ay have as a lym phatic marker, 
as w ell as shedding light on the roles it m ay play under physiological and  
pathological conditions, factors regulating LYVE-1 expression w ere investigated  
extensively, using commercially available primary hum an derm al LEC (chapter 
4). Follow ing incubation w ith  a panel of growth factors, cytokines and  
chem okines, LYVE-1 expression w as assayed by flow  cytom etry. W hereas the 
majority of factors d id  not significantly affect LYVE-1 surface expression, the 
pro-inflammatory cytokines TNFa and TNFp precipitated a dramatic loss of 
expression. This result w as confirmed by tw o similar studies in  this thesis, firstly  
using im m uno-selected podoplanin-positive hum an LEC w hich  w ere a kind gift 
from Dr. Ernst Kriehuber and secondly, a m ixed population of com m ercially  
available primary HDMEC. Furthermore, initial analysis of hum an tissue  
sections from squam ous cell carcinomas provides prelim inary evidence to 
suggest that LYVE-1 is down-regulated in vivo under pro-inflam m atory  
conditions (appendix III). The developm ent of this skin carcinoma is know n to 
by driven by  inflammation, up-regulation of TNFa and T N FR l-m ediated  
signalling (Lind et al., 2004). These observations, though based on a very  lim ited  
number of tissue sam ples, raise the possibility that LYVE-1 dow n-regulation  m ay  
play a role in the pathology of som e hum an cancers. Further substantial studies 
to pursue this observation w ill require staining of squam ous cell carcinoma 
tissue sam ples from m any more patients, to investigate the percentage of 
sam ples in w hich LYVE-1 is down-regulated and explore any correlation
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betw een the loss of LYVE-1 expression and other characteristics of the lesion, for 
exam ple invasiveness.
A s LYVE-1 can be so dramatically down-regulated under pro-inflam m atory  
conditions, the use of this marker alone could have lead to an underestim ation of 
tum our lym phatic vessel density in other previous studies.
7.1.3 The effect o f TNFa on LYVE-1 expression in primary LEC
TNFa and TNFp w ere both found to induce total loss o f surface expression of 
LYVE-1 in  the three sources of hum an LEC examined. Curiously, fo llow ing  
stim ulation of primary m ouse LEC w ith  TNFa, LYVE-1 surface expression w as  
significantly reduced but loss w as not absolute (chapter 5). M oreover, expression  
recovered w ithout the need to rem ove the cytokine-supplem ented m edium . 
W hether this discrepancy is due to differences betw een the species or betw een  
the cell lines remains unclear. The murine LEC w ere isolated from  post-partum  
derm is and such cells from neonates m ay not have developed  a full 
inflammatory response, whereas hum an LEC w ere isolated from you n g adult 
dermis. The primary cell lines also differ in passage num ber at w hich  the 
experim ents w ere carried, as hum an LEC could be cultured to m uch later 
passages than m ouse LEC. H ow ever a loss of LYVE-1 w as observed in  intact 
lym phatic endothelium  in  m ouse tissue, both in  ear tissue w hich  had been  
cultured in the presence of TNFa and in  TNFa-mediated inflam m ation w ith in  the 
ears of m ice in contact hypersensitivity (chapter 6), in  w hich  a loss o f LYVE-1 
expression w as recorded from alm ost 70% of vessels fo llow ing 18h o f elicitation  
of inflammation. D own-m odulation o f LYVE-1 has not been reported during  
chronic inflammation, such as that occurring follow ing bacterial infection (Baluk 
et al., 2005) and therefore w ould  appear to be only a feature of acute 
inflammation.
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The TNFa-induced loss of LYVE-1 surface expression w as further characterised  
in vitro in  primary HDLEC (chapter 4). The cytokine d id  not induce any  
apoptotic or necrotic response in primary HDLEC and upon rem oval of cytokine 
from the m edium , LYVE-1 expression com pletely recovered w ith in  72h. 
Subsequent experiments revealed that the cells had com m enced internalising  
LYVE-1 w ithin  3h of TNFa stim ulation and it w as associated w ith  the lysosom al 
compartment, accom panied by a decrease in the abundance o f LYVE-1 m R NA  
w ithin  12h of stim ulation and abolition of constitutive shedding, w hich  had been  
found to occur in unstim ulated cells. The m eticulous avoidance of the cells to  
shed any LYVE-1 could suggest potential biological activity of soluble LYVE-1. 
For exam ple, this m echanism  of rem oval o f cell surface LYVE-1 w as in  stark 
contrast to that m ediated by the phorbol ester, PM A w hich  has been sh ow n  in  
previous studies to induce M M P-dependent shedding via  activation o f the PKC 
pathw ay in  293T LYVE-1 transfectants and also in  this study in  primary HDLEC, 
w hich endogenously express LYVE-1. Whether this soluble LYVE-1 binds its 
glycosam inoglycan ligand, H A  (discussed in  section 7.1.4) or w hether it b inds  
another as yet unidentified ligand remains to be identified. The developm ent of 
arrays of im m obilized oligosaccharides could enable broad screening for 
potential sugar ligands and com parison of specificities of LYVE-1 binding, 
similar to the study recently carried out by  Guo et al. (2004), into ligand b ind ing  
of DC-SIGN and L-SIGN.
TNFa-stimulated internalisation of LYVE-1 in  hum an LEC, and cessation of 
constitutive shedding, w ere detected by the mAb 8C and LYVE-1 polyclonal 
antisera, all raised against the extracellular dom ain of LYVE-1. Thus, w h ilst the 
degradation of the extracellular dom ain w as show n conclusively b y  experim ents 
in this thesis, the fate of the transmembrane and cytoplasm ic dom ains rem ain to  
be explored. A s this dom ain is h ighly conserved, it m ay not prove sufficiently  
im m unogenic in rabbits if cloned into the pCDM 7Ig plasm id to y ield  a fusion
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protein w ith  hum an Fc (as w as found w ith  podoplanin Fc, described in  appendix  
II). A n alternative approach to raise polyclonal antisera in  rabbits m ay be to 
generate a rabbit IgG Fc-LYVE-l-cytoplasmic tail construct. Such a reagent 
w ould  perm it the subcellular localisation of the LYVE-1 intracellular dom ain to 
be determ ined follow ing TNFa-stimulation. It is possible that this dom ain m ay  
be cleaved from the internalised protein, and translocate to another part of the 
cell concurrent w ith  the degradation of the extracellular dom ain. For exam ple, 
the cytoplasm ic dom ain o f CD44, the more w idely  expressed hom ologue of 
LYVE-1, w as show n by Okamoto et al. (2001) to be involved  in  signal 
transduction follow ing phorbol ester-induced proteolytic release from  the 
ectodom ain of the m olecule by  membrane type 1 matrix m etalloproteinase. This 
intracellular dom ain (ICD) w as found to translocate to the nucleus and activate 
transcription through phorbol ester-responsive elem ents, found in  num erous 
genes involved  in diverse cellular processes, including CD44. The intriguing  
prospect that the cytoplasm ic dom ain of LYVE-1 could exhibit similar biological 
activity w ill be addressed in future experiments. Confocal m icroscopy could be  
used to identify whether the cytoplasm ic dom ain of LYVE-1 m ay translocate to  
the nucleus of hum an LEC follow ing stim ulation w ith  PM A or TNFa and  
m em brane/cytosol and nuclear fractions could be analysed b y  W estern blotting  
w ith  antisera against the LYVE-1 cytoplasm ic domain.
7.1.4 HA binding by LYVE-1
Previous w ork by Tom N ightingale in the Jackson laboratory (DPhil thesis, 
U niversity of Oxford, 2004) has show n that LYVE-1 expressed on  prim ary  
hum an and murine LEC does not constitutively bind HA. H ow ever, confocal 
m icroscopy and flow  cytometry carried out in  chapter 4 of this thesis provided  
som e evidence that H A  is internalised by lym phatic endothelial cells and a 
marginal increase in binding of H A  by these cells occurs fo llow ing  TNFa 
stimulation. That raises the question as to w hether LYVE-1 becom es activated to
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bind H A  sim ultaneous w ith  its internalisation or w hether som e other receptor is 
involved. Future experiments could distinguish betw een these possibilities. The 
hum an LYVE-1 blocking antibody 3A could be em ployed to investigate w hether  
this mAb reduces H A  uptake in primary HDLEC. A lso if the m ouse m A b B l/1 0  
generated in this PhD proves to induce loss of LYVE-1 surface expression, it 
could be used to establish a role for LYVE-1 in H A  internalisation in  prim ary 
m ouse LEC. A dditionally it w ould  be interesting to incubate H A  w ith  prim ary  
LEC isolated from the LYVE-1-/- knock-out m ouse, to determ ine b y  m icroscopy  
w hether they are capable of internalisation of HA. These experim ents w ou ld  test 
w hether a LYVE-l-dependent m echanism  is responsible, or either a LYVE-1- 
independent m echanism  or a second com pensatory m echanism  is em ployed.
7.1.5 A  putative role for LYVE-1 in regulating reverse transmigration
Observations from the w hole-m ount tissue sections of m ouse derm is fo llow ing  
elicitation of inflammation in a m odel of delayed contact hypersensitivity (CHS), 
(described in chapter 6) suggest that LYVE-1 m ay have another function besides  
that of an H A  receptor. Significant down-regulation of LYVE-1 w as observed in  
lym phatic vessels w ithin inflam ed tissue. Moreover, MHC class Il-positive APCs 
could be seen preferentially surrounding and presum ably reverse-transm igrating  
across lym phatic vessels upon w hich LYVE-1 had been either partially or fu lly  
down-regulated. A dditionally, both w hole-m ount staining of intact vessels and  
im m unofluorescence m icroscopy has show n that LYVE-1 is expressed  
preferentially at the cell-cell junctions. One possibility is that in  norm al non­
inflam ed tissue LYVE-1 m ay play a role in the maintenance of cell-cell junctions, 
perm itting only a low  level of constitutive migration. The microarrays 
performed in this PhD show ed that upon activation o f the lym phatic  
endothelium , junctional m olecules such as claudins and occludin are dow n- 
regulated as w ell as LYVE-1. This permits the increased num ber of 
transmigration events resulting from increased trafficking of n ew ly  extravasated
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m onocytes, w hich m ust gain entry into the lymphatics. To establish w hether the 
dow n-m odulation of LYVE-1 is a necessary pre-requisite for increased leukocyte 
trafficking, future experiments could include transmigration assays of hum an  
m onocyte-derived DCs through m onolayers of primary HDLEC, rem oving  
LYVE-1 expression by the use of siRNA. Alternatively (depending upon the 
efficacy of rem oval of surface expression induced by the m ouse m Ab B l/1 0 ) , a 
m ouse in vitro m odel of transmigration could be used, using  B l/1 0  to rem ove 
LYVE-1 expression in  place of sm all interfering RNAs (siRNA). A lso, the 
num ber of constitutive trafficking events in the LYVE-1-/- knock-out m ouse could  
be assessed. If LYVE-1 does indeed play the role of a "gate keeper", increased  
constitutive trafficking w ould  be expected in the knock-out m ouse, w hich  m ay  
exhibit higher numbers of DCs w ithin the lym ph nodes that w ou ld  be apparent 
in FACS analysis of lym ph node cell populations. This m ight also be m anifest as 
fewer DC resident w ith in  the dermis and perhaps a delay in  the onset of 
inflam m ation follow ing elicitation of delayed contact hypersensitivity.
7.2 The effects o f TNFa on  lym phatic endothelia l cells in vitro  and in  intact 
tissue
7.2.1 TNFa-mediated induction of key leukocyte adhesion molecules
Another major finding in  this PhD w as the induction b y  TNFa and TNFp of key  
adhesion m olecules, previously associated w ith  inflam ed b lood  vascular  
endothelium . Both cultured HDLEC and n ew ly  derived isolates o f m ou se LEC 
displayed marked up-regulation of ICAM-1, VCAM-1 and E-selectin. F low  
cytom etry studies revealed that both E-selectin and VCAM-1 w ere absent from  
unstim ulated LEC but w ere induced follow ing exposure to TNFa or TNFp. 
HDLEC w ere found to constitutively express ICAM-2, w hich  w a s d ow n -  
m odulated follow ing stim ulation w ith  TNFa, although not to the sam e  
pronounced extent as LYVE-1.
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In the TNFa-mediated CHS m odel in mice, over 50% of lym phatic vessels  
expressed VCAM-1 and ICAM-1 w ithin 18h of the elicitation of inflam m ation, 
and concurrent w ith  the loss of LYVE-1 from alm ost 70% of vessels (chapter 6). 
Furthermore, the change in expression of these receptors w as concom itant w ith  
the observation of MHC class II-positive APCs surrounding the lym phatics, 
apparently in preparation for reverse transmigration. 12h follow ing elicitation of 
inflammation, extravasation of n ew ly  recruited m onocytes from b lood capillaries 
w as observed. These differentiate in the derm is into either m acrophages w hich  
stay resident in the peripheral tissue or DCs, w hich transmigrate into the 
lym phatics to present their new ly  acquired antigen w ith in  the T cell-rich  
paracortical area of a regional lym ph node (Randolph et al., 1998). Thus the  
onset of inflam m ation heralds a m assive increase in the num ber of trafficking 
events and the up-regulation of know n leukocyte adhesion m olecules m ay be a 
necessary pre-requisite. Future experiments should  include triple 
im m unofluorescence staining of tissue w ith  antibodies against podoplanin , M HC  
class II and either VCAM-1 or ICAM-1, to establish w hether transmigrating cells 
are associated w ith  lymphatic vessel expression these leukocyte adhesion  
m olecules. A lso, future studies could use specific markers to d istinguish  subsets 
of MHC class II-positive APCs. A  recent study by  Q u et al. (2004) has sh ow n  that 
CCR8 can serve as a marker for m onocyte-derived DCs and therefore future 
experim ents could use this to distinguish constitutive trafficking from  the 
increased trafficking of DCs derived from new ly  recruited m onocytes from  the 
blood.
The involvem ent of VCAM-1 and ICAM-1 in leukocyte transmigration across 
lym phatic endothelium  w hich is suggested by the data in chapters 5 and 6 o f this 
thesis could also be elucidated more fully by  further experim ents in vitro. Effects 
of receptor neutralising antibodies on migration of m onocyte-derived D Cs could
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be investigated in  transmigration assays across an endothelial m onolayer. 
Randolph and Furie (1996) have previously show n that ICAM-1 neutralising  
antibodies totally block transmigration of m ononuclear phagocytes (w hich w ere  
in  the process of differentiating towards DC-like cells), from  basal to apical 
surfaces of a HUVEC monolayer. It w ould  be interesting to investigate w hether  
such antibodies have a similar effect on m onocyte-derived DC m igration across a 
primary LEC monolayer. To observe the localization of adhesion m olecules on  
lym phatic endothelium  during transmigration events, electron m icroscopy w ith  
im m uno-gold labeling could be used. If expression of the adhesion m olecules on  
the abluminal or lum inal surface of the endothelium  could be determ ined, this 
could provide evidence as to whether these receptors are involved  in  the initial 
transmigration into the vessel or during migration of the leukocyte through the 
lymphatics. Earlier studies have show n that ICAM-1 is expressed on  both  
surfaces of HUVEC whereas VCAM-1 expression is restricted to the apical 
surface (Oppenheimer Marks et al., 1991; Randolph and Furie, 1996), as VCAM-1 
is only involved  in adhesion w hereas ICAM-1 also plays a role in  transmigration. 
A  previous study by Xu et al. (2001) show ed that ICAM-1 deficiency on  
lym phatic endothelium  resulted in reduced migration of Langerhans cells from  
the skin into draining lym ph nodes. H ow ever, no accum ulation o f DC around  
lym ph vessels in the dermis of ICAM -l-deficient m ice w as observed, arguing  
that ICAM-1 is not required for DC entry to the lym phatic vessels in  the skin. 
This suggests that ICAM-1 m ay play a role in  events dow n-stream  of reverse 
transmigration, such as the trafficking of leukocytes through the afferent 
lymphatics. N evertheless, a role for ICAM-1 in  reverse transm igration cannot be  
dism issed as it is possible that in  the ICA M -l-deficient m ouse, other 
com pensatory m echanism s are involved, for exam ple ICAM-2 w hich  is an  
alternative ligand for LFA-1 (C D lla /C D 1 8  or aLp2, (Makgoba et al., 1988). 
M oreover, blood endothelial ICAM-1 and ICAM-2 have been sh ow n  to have  
redundant roles in lym phocyte recirculation through lym ph nodes (Lehm ann et
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al., 2003). A s on blood endothelium  (McLaughlin et al., 1998), ICAM-2 in  
primary HDLEC underwent a marginal but significant dow n-regulation in  
response to TNFa, suggesting that lymphatic endothelial ICAM-2 does not have  
a role in inflammation but rather is constitutively expressed in norm al tissue. 
H ow ever ICAM-2 on lym phatic endothelium  m ay play a role in  constitutive 
leukocyte migration across the lym phatic endothelium  and m ay com pensate for 
ICAM-1 deficiency during inflammation.
7.2.2 TNFa-induced change in morphology of lymphatic endothelial cells
A  striking change in  cell m orphology w as observed in both prim ary HDLEC and  
m ouse LEC follow ing TNFa-stimulation, from rounded to elongated. This 
suggests rearrangement of cytoskeletal elem ents, w hich could be assessed  b y  
confocal microscopy. It is tem pting to speculate that such reorganisation m ight 
facilitate leukocyte reverse transmigration across lym phatic endothelium  during  
inflammation.
7.2.3 Synthesis of pro-inflammatory chemokines by lymphatic endothelial cells
Both the microarray analyses and ELISA data revealed that in  addition to 
affecting expression of adhesion m olecules, TNFa induces synthesis o f a vast 
range of pro-inflammatory chem okines including RANTES, MCP-1, MIP-3a, 
MCP-3, Fractalkine, IL-8, ENA-78 and GROp w hich are chem otactic for 
m onocytes, DCs, T-cells and neutrophils (von Andrian and M ackay, 2000). This 
indicates that the lymphatics have the capacity to p lay an active role in  
recruitment of leukocytes from the tissues to the draining lym ph node. 
Alternatively, as lymphatic vessels lie close to b lood capillaries, these  
chem okines could be to aid extravasation of new ly  recruited inflam m atory cells 
from the blood. Another interesting possibility is these chem okines m ight be  
released into the lum en of the lym phatic vessel and transported through the 
afferent lym ph to the lym ph node cortex for presentation on the lum inal face of
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HEVs. Such a process has been described in a study by  Palframan et al. (2001), 
w hich follow ed  the path of MCP-1 secreted by unspecified cells w ith in  the 
derm is to the lum inal surface of HEVs by reticular netw ork fibres, triggering  
integrin-dependent arrest of rolling m onocytes and thus enhanced recruitment to  
the lym ph node. To investigate w hich chem okines are secreted from the 
abluminal surface into the surrounding extracellular matrix, and w hich  in  the 
basolateral direction for transport to the peripheral draining lym ph node, LEC 
could be cultured in Transwell™  assays and stim ulated w ith  TNFa. Supernatant 
from both the upper and low er chambers w ould  then be harvested and  
chem okine secretion detected by ELISA.
7.2.4 Induction ofMM Ps by lymphatic endothelial cells
The microarray data also indicated the induction of transcripts of matrix 
m etalloproteinases (MMPs) such as MMP-3 (Stromelysin-1), MMP-6, MMP-9 
(Gelatinase B), MMP-10 (Stromelysin-2) and MMP-19. The substrates o f MMP-3 
include E-cadherin and TGF-pi (reviewed by Parks et al., 2004). Therefore it is 
possible that MMP-3 m ay enhance m obilisation of Langerhans cells from  the 
epiderm is by breaking E-cadherin-mediated hom ophilic interactions w ith  
keratinocytes (Jakob et al., 1999) and inactivating TGFpl, w hich  m ediates  
retention of Langerhans cells by  up-regulating E-cadherin and blocking TNFa- 
induced up-regulation of CCR7, w hich is critical in the m igration of LC to the 
lym phatics (review ed by Jakob et al., 2001). MMPs such as MMP-9 m ay also  
contribute to the establishment of chem okine gradients by  releasing im m obilised  
chem okines from their heparan sulphate proteoglycan binding sites w ith in  the 
extracellular matrix and regulate chemotactic activity through proteolytic  
cleavage of chem okines (Parks et al., 2004; Van den Steen et al., 2003a; and Van  
den Steen et al., 2003b). MMP-9 has also been show n to regulate chem otactic 
activity of ENA-78, GCP-2, IL-8, MIG and IP-10 through proteolytic cleavage o f  
these chem okines (Van den Steen et al., 2003). These chem okines w ere all sh ow n
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to be induced in LEC follow ing stim ulation w ith  TNFa b y  the microarray 
analyses perform ed in this PhD. MMPs are know n to be responsible for the 
turnover and degradation of the extracellular matrix and therefore m ay facilitate 
extravasation of m onocytes from the b lood by degrading basem ent m em brane 
structures on inter-endothelial tight junctions of juxtaposed blood capillaries. 
Clearly expression of all of these transcripts m ust be confirm ed at the protein  
level in TNFa-stimulated primary LEC and in inflam ed tissue.
7.2.5 Synthesis ofTNF superfamily members by lymphatic endothelial cells
The microarray data from primary HDLEC further suggests an influence b y  the 
lym phatic endothelium  on other cells w ith in  its environs b y  expression of TNF  
superfam ily mem bers and their receptors. TNFa w as found to induce expression  
of 0X 40 (also know n as CD134, or by the system atic nam e TNFRSF4) and its 
ligand OX40L (CD134L or TNFSF4), as w ell as GITR ligand (glucocorticoid- 
induced TNFR family-related ligand, TNFSF18). These receptors and ligands 
prom ote the survival and perhaps prolong the im m une response o f CD4+ T cells 
at sites of inflam m ation (Godfrey et al., 1994) and interrupt apoptosis in  T cells 
(Nocentini et al., 1997). The effect of LEC in prom oting T cell survival could  be  
assessed in vitro by  inducing apoptosis on T cells artificially and then incubating  
these cells in the presence of a TNFa-stimulated LEC m onolayer. A nnexin  V  
could be used as a marker for apoptosis to compare the num ber of apoptosing T 
cells incubated w ith  unstim ulated LEC w ith  that of T cells incubated w ith  the 
TNFa-stimulated monolayer. A n increase in transcript abundance of CD137  
(TNFRSF9) w as also observed in the data generated b y  the microarray and as 
ligation of this receptor is reported to interrupt T cell apoptotic program s 
associated w ith  activation-induced cell death (Hurtado et al., 1997), this w ou ld  
suggest that the lym phatic endothelial cells are also capable o f protecting  
them selves from apoptotic signals during inflammation, as w ell as synthesising  
ligands to ensure the survival of neighbouring T cells.
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7.2.6 A model for the inflammation-induced expression programme in lymphatic 
endothelium
Experiments detailed in chapters 4, 5 and 6 have show n that the lym phatic  
endothelium  responds to inflammatory cytokines w ith  an expression program m e  
w hich w ould  suggest that it is responsible for actively prom oting leukocyte  
migration into the lymphatics. The follow ing m odel is proposed (figure 7.1), 
although clearly in vitro studies are required to establish the roles of individual 
m olecular interactions betw een m igrating leukocyte and endothelium .
In normal non-inflam ed lym phatic endothelium , ICAM-2 and lo w  levels of 
ICAM-1 are expressed to permit low  levels of constitutive m igration and LYVE-1 
is localised primarily at cell-cell junctions (figure 7.1). Follow ing the activation of 
endothelium  by stim ulation w ith  TNFa or TNFp, LYVE-1 is internalised and  
degraded concurrent w ith  the up-regulation of E-selectin, w hich it is  tem pting to  
speculate, could perm it the initial loose capture of neighbouring leukocytes. 
Increased expression of ICAM-1 and VCAM-1 w ould  perm it m ore h igh  affinity  
interactions to form betw een the endothelium  and leukocyte via counter 
receptors, w hilst the secretion of new ly  synthesised chem okines from  basolateral 
and lum inal faces of the endothelium  w ould  chemoattract leukocytes, not only  
from the im m ediate vicinity but also across distant lym ph nod e HEV, by  a 
m echanism  of remote control. Increased synthesis of M M Ps contributes b y  
m odulating chem okine activity, m obilising Langerhans cells and degrading  
basem ent membranes to enhance extravasation of more inflam m atory cells from  
the blood. Thus lym phatic endothelial cells p lay dynam ic roles in  influencing  
both neighbouring leukocytes and the b iology of the interstitium  surrounding  
them.
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Figure 7.1 Schematic representation of lymphatic endothelium during inflammation. This 
figure depicts a model in which resting lymphatic endothelium expresses abundant LYVE-1 at cell­
cell junctions as well as ICAM-2 and low levels of ICAM-1 which may participate in constitutive 
trafficking of leukocytes. Upon activation by pro-inflammatory cytokines, E-selectin, VCAM-1 and 
ICAM-1 are up-regulated, bringing about capture, activation and ultimately transmigration of 
leukocytes through interactions with their counter receptors. The up-regulation of these adhesion 
molecules may be necessary to support the increased number of trafficking events which occur 
during inflammation. ICAM-2, involved only in constitutive migration, is down-regulated and LYVE- 
1 is internalised, degraded and thus removed from the cell-cell junctions. The endothelium 
secretes high levels of inflammatory chemokines as well as other soluble factors, thus radically 
affecting its environment to promote further leukocyte transmigration into the lumen of the 
lymphatic vessels for transport to a regional lymph node.
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7.3 C onclusion
The data presented in this thesis have show n that the expression of the lym phatic  
vessel H A  receptor LYVE-1 on lymphatic endothelium  is tightly regulated and  
radically dow n-m odulated follow ing stim ulation w ith  the pro-inflam m atory  
cytokine TNF, both in cultured primary dermal LEC and in  an allergen-induced  
m ouse m odel of skin inflammation. This thesis has also show n that lym phatic  
endothelium  responds to key inflammatory cytokines by instigating a distinct 
expression programme characterised by up-regulation of the key leukocyte  
adhesion receptors ICAM-1, VCAM-1 and E-selectin, chem okines and other 
potential regulators of leukocyte entry. The major com ponents of this program  
w ere found to be induced in  dermal lym phatic vessels in v ivo , sim ultaneous 
w ith  the transmigration of leukocytes into the lym phatic lum en. Thus these  
results provide the first evidence that lym phatic endothelial cells p lay  an active 
role in inflammation and indicate that parts of the sam e address code for specific 
vascular targeting are found in both the lym phatics and blood vascular system .
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Preliminary characterisation of the LYVE-1 gene
A l.l Introduction
The generation of a LYVE-1-/- knock-out mouse to study the phenotype and 
establish the physiological role of LYVE-1 was part of the original project 
undertaken in this PhD. However, when it became known that such a transgenic 
mouse was in the later stages of being produced by Regeneron, this aspect of the 
project was terminated. Instead, preliminary mapping of the LYVE-1 promoter 
was performed and this may provide a basis for further studies.
A1.2 Results
Al.2.1 Identification of LYVE-1 genomic clones from a mouse PAC library
To isolate clones containing LYVE-1 sequence, a mouse 129 strain genomic 
library, spotted on seven separate filters was used. This library (from the UK 
Human Genome Mapping Centre) had been prepared from female 
129/SvevTACfBr mouse spleen and uses a pPACi vector based on a PI plasmid, 
a large single-copy plasmid containing large inserts averaging in size at 147Kb.
The DNA sequence used to probe this PAC library was derived by PCR 
amplification of embryonic (E13.5) balb/c cDNA using the primers 157F 
(GAACTCTCCATCCAGCTTGGTG) and 471R(CTGCGCTGACTCTACCTGGTC) 
and comprised mouse LYVE-1 exon 1, part of exon 2 and the intervening intron. 
This DNA was used as a probe for Southern blotting of the filters. Of the seven 
filters probed, three displayed positive results and a total of five clones were
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identified as containing the desired sequence. These were named 457P18, 
493010,530D13,565L9 and 497B1, each over 20kb.
The intended strategy was to knock-out exon 1 which encodes the leader peptide 
and ideally also exons 2 and 3, which together encode the Link domain. PCR 
analysis of the clones selected from the library revealed that they all contained 
sequences from exon 1 through exon 5 and were therefore appropriate for the 
preparation of the knock-out construct.
Further studies proceeded with mapping one of the clones, 457P18 using a range 
of 6-base cutter restriction endonucleases in single digests. The fragments 
generated were separated by agarose gel electrophoresis and transferred to 
nitrocellulose membrane for Southern blotting using LYVE-1 probes generated 
by PCR amplification of balb/c genomic DNA by the primers 290F 
(CTAGGCACCCAGTCCAAGG) and 471R (CTGCGCTGACTCTACCTGGTC); 
and 451F (GACCAGGTAGAGTCAGCGCAG) and 528R 
(GATGACAGAGAACTGTTCTCCAAC), as probes for exon 1, (figure A l.l) and 
exon 2, (figure A1.2) respectively.
The results (figures A l.l and A1.2) showed that each probe hybridised to the 
same 7-kb Kpnl fragment, which was therefore selected for cloning into 
pBluescript. However, this was not used for the knock-out construct as at this 
stage it became known that Regeneron were generating such a mouse and the 
emphasis of this part of the PhD changed to characterising the LYVE-1 gene.
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Figure A1.1 Southern blotting of fragments of PAC clone 457P18 with a LYVE-1 exon 1 
probe. Fragments were generated by a panel of restriction enzymes and separated by agarose 
gel electrophoresis prior to transfer onto Hybond N+ membrane and probing using a DNA probe 
generated by PCR of LYVE-1 exon 1.
Ill
Appendix I Preliminary Characterisation of the LYVE-1 Gene
— 8
— 2
Figure A1.2 Southern blotting of fragments of PAC clone 457P18 with a LYVE-1 exon 2 
probe. Fragments were generated by a panel of restriction enzymes and separated by agarose 
gel electrophoresis prior to transfer onto Hybond N+ membrane and probing using a DNA probe 
generated by PCR of LYVE-1 exon 2.
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Al.2.2 Mapping of the LYVE-1 transcription start site by primer extension 
analysis
To map the 5' end transcription start site of LYVE-1, primer extension was 
performed whereby oligonucleotides complementary to sequence at the 5' of 
exon 1 were radiolabeled at the 5' end and used to prime synthesis of cDNA 
within the 5' UT of the LYVE-1 mRNA, extending from the primer to the 5' 
terminus of the LYVE-1 mRNA. Products were subjected to polyacrylamide 
electrophoresis and the length of product from each primer was used to 
determine the distance of the primer from the transcription initiation site of the 
mRNA.
As a positive control for the primer extension reaction, the 5'UT of CD44 was 
extended using a CD44 primer designed previously for primer extension analysis 
of the human CD44 gene (Shtivelman and Bishop, 1991) on commercially 
available human spleen RNA (Clontech). The reaction yielded a product of the 
expected size of 163 nucleotides from the initiation site (figure A1.3). As 
expression of LYVE-1 is mostly restricted to lymphatic endothelium, only a small 
number of tissues proved abundant sources of RNA. This experiment pre-dated 
the availability of commercially available HDLEC from PromoCell (chapter 4 of 
this thesis) and due to lack of human tissue readily obtainable, primer extension 
analysis was performed on RNA isolated from mouse lung tissue, which was 
shown to contain abundant LYVE-1 message by reverse-transcriptase PCR (data 
not shown). To define the most suitable primers for primer extension analysis, 5 
different primers were used (shown in figure A1.4), which all yielded products 
(figure A1.5) and enabled the 5' end transcription start site of mouse LYVE-1 to 
be mapped, as indicated in figure A1.4.
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Figure A1.3 Positive control: primer extension analysis of the CD44 transcriptional start site.
The CD44 primer used by Shtivelman and Bishop (1991) was used to generate a product of the 
expected size of 163 nucleotides from the primer to the initiation site, from commercially available 
human spleen RNA (Clontech), 30pg, detected by autoradiography.
TAGAACTCTCCATCCAGCTTGGTGATTGAACATCTGTCTCCCTTACTGCGG 
GTGGCCAGCCACAGTGCCCCGGAGGGATCTGCACAATGCCCAGCACAC 
TAiGCCTGGTGTTACTCCTCGCCTCTATTTGGACCACTAGGCACCCAGT2 
CCAAGGTGCCGACCTCGTGCAAGACCTTTCCATTTCTACATGCAGAATC 
ATGGGCGTTGCCCTFGTGGGCAGAAACAAAAACCCACAGATGAATTTC 
ACAGAAGCCAACGAGGCCTGTAAGATG4CTGGGACTGACTCTGGCCAG 
CAGGGACCAGGTAGAGTCAGCGCAGAAATCTGGCTTTGAGACT5TGC... 
....Exons 3, 4, 5 and 6.
Figure A1.4 Positions of primers (1-5) used for primer extension to map the transcription 
site of mouse LYVE-1 sequence. Complementary primer sequence is underlined, untranslated 
sequence is shown in black, exon 1 in red and exon 2 in blue. Sequence commences with the 
transcription initiation site mapped by primer extension (figure A1.5). The intron between exons 1 
and 2 is not shown.
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Figure A1.5. Mapping the transcription initiation site of mouse LYVE-1 mRNA. Primer 
extension analysis was performed using 40pg of total RNA from mouse lung using primers 1-5. 
Products were electrophoresed in the corresponding lanes and detected by autoradiography. The 
sizes of each are indicated (bases). Lower molecular weight, feint bands which migrated faster 
than the main bands of products and are thus visible lower down the gel represent incomplete 
extensions caused by premature dissociation of the reverse transcriptase enzyme. The over­
exposure at the bottom of the gel represents unextended primers.
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Al.2.3 Identification of putative promoter sequences in human LYVE-1
Cloning potential upstream regulatory sequences into luciferase reporter 
constructs
To identify promoter sequences upstream of the LYVE-1 gene, segments of the 
human gene immediately upstream of the transcription start site were cloned 
into reporter constructs. Studies were performed on the human gene due to 
greater availability of sequence data. The transcription start site in the human 
gene was assumed to be the same as in the mouse gene, identified through 
primer extension, as the two genes share similar organisation of exons and 
introns (data not shown). The two reporter vectors, pGL3Basic and 
pGL3Enhancer, encoding the luciferase gene, downstream of a multiple cloning 
site were used (figure A1.6). One construct, pGL3 Enhancer, also contained an 
additional downstream SV40 enhancer element, to increase the activity of the 
promoter. As a positive control, a chicken p-actin promoter was excised from 
pBR-p-actin-Luc (a kind gift from Dr. Katya Simon) using Xhol and Hmdlll, and 
cloned into both constructs for transfection efficiency, for the validation of the 
luciferase assay. Initially a sequence of 2.0 kb was amplified from human 
genomic DNA using the primers HuLYVEl-91561FX/zoI 
(GACTACTGCTCGAGTAGAGAGCTCTGCTTGAGCC) and 93610RHmdIII 
(GTCATCAGAAAGCTTCCAGGCTGAAGCACCTGGCCATC), with TaqPlus 
polymerase, a mixture of high fidelity polymerase and high efficiency 
polymerase. Following digestion with Xhol and Hmdlll the 2-kb product was 
cloned into the two Xhol/Hmdlll-cut luciferase reporter constructs, for 
transfection in to cell lines.
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Figure A1.6 pGL3 luciferase vector maps. Sequence indicated luc+ (shown in yellow) represents 
cDNA encoding the modified firefly luciferase; Ampr, the gene conferring ampicillin resistance in E. 
coli; ori, origin of replication in E. coli. Arrows within luc+ and the Ampr gene indicate the direction 
of transcription. (Adapted from the Promega catalogue).
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Analysis of LYVE-1 promoter activity in transfected cell lines 
To assay for LYVE-1 promoter activity of genomic DNA upstream of the LYVE-1 
coding sequence, reporter constructs were transfected into a range of cell lines. 
Ideally the choice of candidate cell line should endogenously express LYVE-1 
and be readily transfectable. However, primary lymphatic endothelial cells 
(LEC) only became available at a later stage of this thesis and therefore could not 
be used for these experiments. Therefore in these preliminary studies, the first 
cell line selected for transfection was the human embryonic kidney fibroblast 
cells 293T. These have the advantage of high transfection efficiency by calcium 
phosphate, although they do not express LYVE-1. The second cell line used was 
the mouse monocyte-macrophage cell line RAW264.7. LYVE-1 expression has 
been detected on a subpopulation of macrophages isolated from mouse 
peritoneal cavities (for example, see figure A1.7) and although no basal LYVE-1 
expression was detected in RAW264.7 (data not shown), it was considered 
possible that these cells might have the necessary transcription factors to 
recognise the human LYVE-1 promoter. Finally transfection of the endothelial 
cell line HUVEC was performed because these cells represented the closest 
lineage to LEC available at the time these assays were performed. Indeed LYVE- 
1 was originally cloned from a HUVEC cDNA library (Banerji et al., 1999) and 
LYVE-1 is expressed on blood vasculature in the embryo.
293T
The luciferase constructs generated were used to transfect 293T by calcium 
phosphate, alongside negative controls of empty vector. Luciferase activity was 
observed in cells transfected with p-actin positive controls but the LYVE-1 
constructs displayed luciferase activity that was not significantly greater than 
that of the negative controls (empty vectors), (table A l.l). In fact, both basic and 
enhancer constructs containing the 2kb fragment actually induced less luciferase 
activity than the vector alone. The lack of a positive result from the 2kb
X
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constructs could be due to either this sequence lacking promoter activity or, more 
likely due to an inability of 293T cells to transcribe LYVE-1, a protein that has 
never been shown to be expressed in these cells.
RA W 264.7
The luciferase constructs were used to transfect RAW 264.7 by lipofectin and 
lysates were assayed for luciferase activity. Results showed that the 2kb 
constructs displayed less luciferase activity than that of empty vectors, although 
both data from empty vectors and LYVE-1 constructs showed very low activity 
in comparison to that from p-actin constructs (table A1.2).
H U VEC
The endothelial cell line, HUVEC were transfected with the luciferase constructs 
by Nucleofector™ electroporation (Amaxa). However, as with the other cell 
lines, transfection with the 2kb LYVE-1 construct displayed luciferase activity 
that was not significantly greater than that of the empty vectors, although the 
positive controls indicated that transfection had been efficient in parallel samples 
(table A1.3).
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Figure A1.7 Expression of LYVE-1 in a subpopulation of mouse peritoneal macrophages.
Slides of cells obtained by peritoneal lavage were prepared by cytospin and stained using the anti- 
mannose receptor mAb, F4/80 (a kind gift from Prof. Simon Gordon, Sir William Dunn School of 
Pathology, Oxford) and rabbit anti-LYVE-1 antisera. The appropriate AlexaFluor® 488 and 594- 
conjugated goat antibodies were used for secondary detection and nuclei counter-stained with 
DAPI. Images were captured at magnification: x 32.
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Construct Mean luciferase activity 
(arbitary units)
Standard error
pGL3Basic 78.72 3.56
pGL3Basic+2kb 24.44 18.36
pGL3Basic+p-actin >9999 -
pGL3Enh 45.98 9.92
pGL3Enh+2kb 23.58 19.06
pGL3Enh+p-actin >9999 -
Table A1.1 Luciferase activity from 2kb LYVE-1 sequence in 293T transfectants. Cells in 6- 
well dishes were transfected with 1 pg/well DNA by calcium phosphate precipitation, in duplicate 
for each construct. Following 24h incubation, cell lysates were prepared using reporter lysis buffer 
(Promega) and luciferase assays were performed using luciferase substrate and buffer (Promega) 
in a luminometer. Values >9999 indicate activity beyond the detection range of the luminometer.
Construct Mean luciferase activity 
(arbitary units)
Standard error
pGL3Basic 0.24 0.10
pGL3Basic+2kb 0.07 0.01
pGL3Basic+p-actin 781.90 3.90
pGL3Enh 1.42 0.17
pGL3Enh+2kb 0.113 0.01
pGL3Enh+p-actin 674.20 4.10
Table A1.2 Luciferase activity from 2kb LYVE-1 sequence in RAW 264.7 transfectants. Cells 
in 6-well dishes were transfected with 1 pg/well DNA by lipofectin reagent (Life Technologies), in 
duplicate for each construct. Following 72h incubation, cell lysates were prepared using reporter 
lysis buffer (Promega) and luciferase assays were performed using luciferase substrate and buffer 
(Promega) in a luminometer.
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Construct Mean luciferase activity 
(arbitary units)
Standard error
pGL3Basic 0.123 0.059
pGL3Basic+2kb 0.077 0.001
pGL3Basic+p-actin 229.0 57.8
pGL3Enh 0.288 0.181
pGL3Enh+2kb 0.334 0.051
pGL3Enh+p-actin 250.8 108.5
Table A1.3 Luciferase activity from 2kb LYVE-1 sequence in HUVEC transfectants. Cells in 
6-well dishes were transfected with 5 pg/well DNA by electroporation (Amaxa), in duplicate for 
each construct. Following 72h incubation, cell lysates were prepared using reporter lysis buffer 
(Promega) and luciferase assays were performed using luciferase substrate and buffer (Promega) 
in a luminometer.
The lack of promoter activity shown with these cells indicates the promoter 
elements in the LYVE-1 gene most likely lie further upstream than the 2kb 
segment analysed. For this reason, a larger fragment of 5kb was amplified from 
the LYVE-1 5TJT region in human genomic DNA, using the primers 88361XM 
(GACTACTGCTCGAGAGTTATGGAGAGCTCCTGCAC) and 93610HmdIII 
(detailed earlier) and following digestion with Xhol and HindUl, cloned into the 
the Xhol/Hindlll-cut luciferase reporter pCL3Enhancer. Transfection of HUVEC 
was then performed (table A1.4).
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Construct Mean luciferase activity 
(arbitary units)
Standard error
pGL3Enh 0.338 0.052
pGL3Enh+5kb 0.121 0.040
pGL3Enh+p-actin 445.45 99.85
Table A1.4 Luciferase activity from 5kb LYVE-1 sequence in HUVEC transfectants. Cells in 
6-well dishes were transfected with 5 pg/well DNA by electroporation (Amaxa), in duplicate for 
each construct. Following 72h incubation, cell lysates were prepared using reporter lysis buffer 
(Promega) and luciferase assays were performed using luciferase substrate and buffer (Promega) 
in a luminometer.
However, the results (table A1.4) revealed that this larger fragment of sequences 
displayed no luciferase activity significantly greater than that of the negative 
controls. Although this indicated that the promoter may be further upstream, 
the possible presence of a repressor element in the 2kb and 5kb segments also 
had to be considered. Therefore, smaller sequences of 0.4, 0.7 and 1.1 kb were 
amplified from human genomic DNA using 93610HmdIII (detailed earlier) and 
the primers 92991¥Kpnl (GACTACTGGACTACTGGGTACCGGAAGGCAGAAG 
GTTCTAGACTC); 92731¥Kpnl (GACTACTGGACTACTGGGTACCAGGTGGA 
GTCTGACTTGAATTCTG) and 92369¥Kpnl (GACTACTGGACTACTGGGTAC 
CGTGCTCACCCAGATCATGAGGTC) respectively. The amplified sequences 
were digested with Hmdlll and Asp718 (a more efficient isoschizomer of Kpnl), 
cloned into the HmdIII/Asp718-cut pCL3Enhancer vector and transfected into 
HUVEC (table A1.5). However no promoter activity was detected in any of the 
LYVE-1 fragments cloned into the luciferase reporter construct.
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Construct Mean luciferase activity 
(arbitary units)
Standard error
pGL3Enh 0.116 0.101
pGL3Enh+0.4kb 0.000 0.000
pGL3Enh+0.7kb 0.025 0.005
pGL3Enh+l.lkb 0.000 0.000
pGL3Enh+2kb 0.029 0.005
pGL3Enh+5kb 0.008 0.008
pGL3Enh+p-actin 247.55 98.05
Table A1.5 Luciferase activity from LYVE-1 sequence in HUVEC transfectants. Cells in 6-well 
dishes were transfected with 5 pg/well DNA by electroporation (Amaxa), in duplicate for each 
construct. Following 72h incubation, cell lysates were prepared using reporter lysis buffer 
(Promega) and luciferase assays were performed using luciferase substrate and buffer (Promega) 
in a luminometer.
A1.3 Discussion
Despite initial success in identifying a PAC clone containing the LYVE-1 gene, 
efforts towards generating a LYVE-1 knock-out mouse were abandoned upon 
discovering that the US company Regeneron were at an advanced stage of 
creating such a mouse. Consequently efforts were diverted to characterisation of 
the promoter.
The 5' end of mouse LYVE-1 was successfully mapped using primer extension of 
five independent primers. However, the mapping of promoter elements proved 
to be more problematic as the luciferase assays employed rely on LYVE-1 being 
actively transcribed within a transferable cell line. It is possible that the 
promoter sequences in LYVE-1 lie much further upstream from the transcription 
start site than those sequences of up to 5kb which were cloned into the reporter
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constructs. Another possibility is that a repressor element is present. An 
example of this lies within the VCAM-1 gene, in which upstream sequences 
contain negative regulatory activity (Neish et al., 1992). Future experiments 
would require cloning of defined segments of 5'UT region into the reporter 
constructs. The HDLEC cell line from PromoCell, Heidelberg may prove a better 
candidate as these cells constitutively express LYVE-1 (described in Chapters 4,5  
and 6). However methods for transfecting these cells must be optimised before 
such experiments could be successful. Detection of DNase hypersensitivity sites 
would also be an effective method to identify regions of the gene involved in 
active transcription of LYVE-1 in HDLEC. The main advantage of such a 
technique is that it involves no assumptions as to where putative promoter 
sequences and enhancer elements may lie.
As a footnote, the LYVE-1-/- mouse developed by Regeneron has proved not to 
be embryonic lethal and thus far exhibits no obvious phenotypic characteristics 
or reductions in life-span. However, the ability of the mouse to perform under 
certain physiological challenges such as inflammation may well be compromised 
and is the subject of current research in the Jackson laboratory.
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Appendix II
Expression of Podoplanin-Fc for the Generation of 
Antisera
The aim of this work was to clone the extracellular domain of human podoplanin 
into pCDM7Ig and transfect the construct into human 293T cells using calcium 
phosphate prior to purifying the secreted protein from the supernatant by 
protein A-Sepharose chromatography. This was then used to generate 
polyclonal antisera in rabbits, as a stable marker for lymphatic endothelium in 
tissue samples (see appendix III) and in LEC. The fusion protein was also used 
to screen for reactivity of the mAb D2/40. The latter was carried out as a 
collaboration with Prof. Michael Detmar's laboratory in the Cutaneous Biology 
Research Centre, Harvard.
A2.1 RT-PCR and Preparation of Podoplanin cDNA
RNA was isolated from commercially available cultured human dermal 
microvascular endothelial cells, PromoCell, Heidelberg (described in chapters 4 
and 5) and first strand synthesis performed. The podoplanin coding sequence 
was amplified by PCR with the primers hPodol56FHmdIII 
(GTCAGCAGGAAGCTTCCAGGAGAGCAACAACTCAAC) and hPodo 570R 
BamHl (TCGGCTCCGGATCCACTGTTGACAAACCATCTTTCTC) using 
Pyrococcus furiosus (Pfu) DNA polymerase. Following digestion with Hmdlll and 
BamHl the product was cloned into a Hindlll/BamHl cut IgFc vector pCDM7Ig, 
to yield a construct encoding podoplanin fused at the COOH terminus to the Fc 
region of human IgGl.
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A2.2 Expression of Podoplanin as a Soluble IgFc Fusion Protein
For expression and purification of podoplanin-Fc fusion protein, the construct 
was transfected into 293T cells using calcium phosphate and the secreted fusion 
protein purified from the supernatant by affinity chromatography on a column 
of protein A-Sepharose.
A2.3 Detection of Podoplanin Fusion Protein by D2/40 in ELISA
To identify the antigen of the mAh D2/40 as podoplanin, an ELISA was 
performed. Microtitre plates were coated with 5pg of either human podoplanin- 
Fc or human LYVE-l-Fc (included as a negative control). The mouse mAb anti­
human podoplanin, D2-40 was applied at a series of dilutions and bound 
antibody was detected by incubation for lh  with horseradish-peroxidase- 
conjugated goat anti-mouse IgG followed by O-phenylenediamine (OPD) 
substrate and quantitated by spectrophotometry at 490 nm (see also Schacht et 
al., 2005).
A2.4 Detection of Podoplanin Fusion Protein by Western Blot
To further confirm the specificity of D 2/40 for podoplanin, a Western blot was 
performed. 200ng human podoplanin-Fc and human LYVE-l-Fc were subjected 
to SDS-PAGE and transferred to nitrocellulose membrane. The blot was 
incubated with D2-40 and developed with horseradish peroxidase-conjugated 
goat anti-mouse IgG, using chemiluminescent detection and exposing to Kodak 
BioMax MR film, (see also Schacht et al., 2005).
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Figure A2.1 Specificity of D2/40 for podoplanin in ELISA. Microtitre plates were coated with 
5pg of either the putative human podoplanin-Fc or human LYVE-1-Fc (included as a negative 
control). The mouse mAb anti-human podoplanin, D2-40 was applied at a series of dilutions and 
bound antibody was detected by incubation for 1 h with horseradish-peroxidase-conjugated goat 
anti-mouse IgG followed by O-phenylenediamine (OPD) substrate and quantitated by 
spectrophotometry at 490 nm.
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Figure A2.2 Specificity of D2/40 for podoplanin by Western blotting. The putative podoplanin 
Fc protein was subjected to polyacrylamide gel electrophoresis in parallel with LYVE-1 Fc, included 
as a negative control, then transferred to Hybond C+ membrane. The anti-podoplanin mAb D2-40 
and HRP conjugated goat anti mouse IgG were applied, prior to detection using ECL reagent 
(Pierce) and X-ray film. Molecular weight standards (kDa) are shown on the left.
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A2.5 Generation of podoplanin antisera in rabbits
To generate human podoplanin antisera, podoplanin Fc fusion protein was used 
to immunize two rabbits. Two test bleeds were taken one week after consecutive 
boost immunizations and antibody responses of the rabbits were monitored by 
ELISA. A microtitre plate was coated with either podoplanin Fc or LYVE-1 Fc, as 
an irrelevant fusion protein to assess the proportion of immune response which 
had been raised against the Fc domain of the immunogen. Serum prepared from 
animals following immunisation and also from the same animals before the 
immunisation schedule had commenced (as preimmune controls), were applied 
to the microtitre plate. Bound antibody was detected by peroxidase-conjugated 
goat anti-rat IgG and O-phenylenediamine (OPD) substrate and quantitated by 
spectrophotometry at 490 nm. As shown in figure A2.3, the antiserum from both 
rabbits showed reactivity against both fusion proteins and hence was directed 
towards the Fc region. Therefore neither could be used as a podoplanin 
polyclonal antibody although proved useful in detecting the Fc portion of human 
IgG (Branwen Hide, PhD student).
Future attempts to generate antibodies against podoplanin should either involve 
cloning into a vector that permits efficient cleavage and thus removal of the Fc 
portion. Alternatively rabbit, mouse or rat (depending on the host species) Fc 
could be used in the fusion construct in place of human Fc.
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Figure A2.3 Test bleed of rabbit podoplaninFc immunised rabbits. Sera from both animals, 
from either the preimmune test bleed as negative controls or from the two test bleeds were diluted 
1:50 and applied to a microtitre plate precoated with either LYVE-1 Fc or podoplanin Fc at 5 pg/ml. 
Bound antibody was detected with HRP-conjugated goat anti-rat antibody and OPD substrate, 
measuring the absorption at 490nm. Values are the mean ± standard deviation for triplicate wells.
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Appendix III
Heterogeneity of LYVE-1 Expression by Tissue 
Lymphatics
Squamous cell carcinoma is known to have a considerable inflammatory 
infiltrate associated with it and the development of such lesions in mice has been 
shown to be mediated through TNFR1 signalling, as well as an up-regulation of 
TNFa (Lind et al., 2004). Experiments described in chapter 4 of this thesis 
showed that TNFa induces marked down-modulation of LYVE-1 in primary 
lymphatic endothelial cells derived from three different sources. Therefore to 
investigate whether such a decrease in expression occurs in vivo, lymphatic 
vessels within frozen sections of squamous cell carcinoma tissue were stained 
using podoplanin, a stable marker for lymphatic endothelium and LYVE-1. 
Frozen sections of squamous cell carcinomas and surrounding healthy tissue 
were prepared from 5 patients and kindly donated by Abigail King and Dr. 
Graham Ogg, MRC Human Immunology Unit, Weatherall Institute of Molecular 
Medicine, Oxford for this preliminary study.
Whereas the normal skin surrounding the lesion showed colocalisation of LYVE- 
1 with podoplanin and strong expression of LYVE-1, tissue from the lesions 
showed numerous podoplanin-positive vessels which were LYVE-1 negative 
(figure A3.1). Although some LYVE-1 expression was detected in squamous cell 
carcinoma tissue (for example in patient 5), it was feint and only on a minority of 
vessels. A study by Schacht et al. (2005) has shown that although podoplanin is 
absent from normal human epidermis, it can be strongly induced in squamous 
cell carcinoma. Therefore, some of the podoplanin-positive structures shown in
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figure A3.2 which do not appear to have typical lymphatic vessel morphology, 
may be epithelial tissue and hence LYVE-l-negative. Further studies into this 
potentially interesting avenue were restricted by patient numbers.
Many human cancers are associated with pre-existing chronic infectious or 
inflammatory conditions (Schacter et al., 2002). Inflammatory infiltrates of 
tumour-associated macrophages, DCs and T cells result in the high concentration 
of pro-metastatic cytokines, MMPs and reactive oxygen intermediates and 
although squamous cell carcinoma is not highly metastatic, a substantial 
inflammatory infiltrate has been reported. The apparent down-regulation of 
LYVE-1 observed in squamous cell carcinoma may be in response to the pro- 
inflammatory infiltrate and cytokines such as TNFa, shown in chapters 4 and 5 of 
this thesis to reduce expression of LYVE-1 dramatically in vitro and in chapter 6 
to down-regulated LYVE-1 in intact lymphatic vessels in vivo. Although hypoxia 
was also shown to reduce LYVE-1. expression in cultured HDLEC (chapter 4), the 
effect was marginal in comparison to that induced by TNFa and the images 
captured by immunofluorescence microscopy suggest a more significant loss of 
LYVE-1 in tissues than that precipitated by hypoxia. Immunofluorescence 
microscopy could be used to indicate whether or not the tissue is hypoxic and 
expressing CA9, known to be up-regulated on endothelium under conditions of 
low oxygen tension, or whether TNFa could be detected. Clearly if the down- 
regulation of LYVE-1 apparent in this preliminary study is borne out in an 
extended investigation examining more samples of human tissue, the use of 
LYVE-1 as a marker in conditions of inflammation could have led to an 
underestimation of lymphatic vessel density in previous studies.
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Figure A3.1 Reduced expression of LYVE-1 on podoplanin-positive lymphatic endothelial 
vessels in squamous cell carcinoma tissue. Frozen tissue sections were stained with anti- 
LYVE-1 mAb and rabbit anti-podoplanin, with AlexaFluor® conjugates 488 (green) and 594 (red) 
respectively. Nuclei were counterstained with DAPI. Immunofluorescence microscopy of normal 
healthy geriatric skin tissue from patient 1 is shown in the upper panels whilst a representative 
image from the carcinoma lesion of that patient is shown in panels beneath, as well representative 
images from the lesion of a second patient. Images were captured at magnification: X 320.
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